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In addition, because of development-specific differences in pharmacoki-
netics (pk) and/or pharmacodynamics (pd), the relationships between drug 
action and drug exposure in children cannot be understood fully by simply 
extrapolating information from adult patients. For example, pk can differ con-
siderably between children and adults as a result of physiological differences, 
differences in the maturity of enzyme systems, and differences in clearance 
mechanisms16. Age-related differences in pk can lead to differences in the 
blood concentration of a drug even when the same dose is given to a child 
and an adult, or to a young child and an older child, as reported for methyl-
phenidate17. The brain-to-serum concentration ratio of a drug can also vary 
with age, potentially leading to age-dependent differences in concentration 
at the drug’s site of action. For example, children with bipolar disorder have 
been reported to have lower lithium brain-to-serum ratios than adults18. In 
addition, several aspects of drug therapy may be related to brain develop-
ment. Neural development in childhood and adolescence involves a highly 
coordinated sequence of events that is characterized by both progressive and 
regressive processes. As a result of this sequence of events, the development 
of gray matter, white matter, total brain volume, and neuronal connecti-
vity is age-dependent19, and perturbations in these developmental patterns 
may play a central role in the pathogenesis of several childhood neuropsy-
chiatric and neurodevelopmental disorders, including autism, adhd, fragile 
x syndrome, 22q11 deletion syndrome, Williams syndrome, Down syndrome, 
and Turner syndrome20. On the other hand, far less is known regarding the 
changes in brain function that result from these age-dependent and dis-
order-related changes in brain structure. However, a growing body of data 
suggests that healthy children have differential trends in the development 
of task performance in distinct functional areas of the central nervous sys-
tem (cns)21-24, and children with neuropsychiatric disorders may have 
impaired neuropsychological function in several domains, as reported for 
adhd25. Brain development can also affect drug efficacy and pharmacoresis-
tance13. For example, monoaminergic systems, the target for most cns drugs, 
undergo considerable plasticity and rearrangement during childhood and 
Until approximately 15 years ago, pharmaceutical companies rarely con-
sidered the needs of children when developing medicines, even though 
the majority of active substances licensed by the European Agency for the 
Evaluation of Medicinal Products (ema) were considered to be relevant for use 
in children. Thus, fewer than half of all licensed active substances considered 
relevant for use in children had a pediatric indication in at least a subset of 
the pediatric population1; moreover, the off-label or unlicensed use of drugs 
in pediatric pharmacotherapy was highly prevalent among many European 
countries2-4. Although off-label use does not necessarily reflect off-know ledge 
use5, off-label use can be a frequent cause of adverse events among hospital-
ized children6. In addition, the availability of several classes of medicines with 
a pediatric indication was limited, as pediatric medicines may not be age-ap-
propriate (for example, they may not be dose-applicable or come in a suitable 
formulation), even if their use is authorized7. These issues are pertinent to 
pediatric pharmacology in general8, but they may be even more pertinent to 
children and adolescents with a psychiatric9 or neurological disorder (such as 
epilepsy10 or pain11).
differences between children and adults with cns disease
The pharmacological treatment of children and adolescents with psychiatric 
disorders, as well as several neurological disorders, has traditionally followed 
the development program in adults, without cross-age validation or recogniz-
ing the inherent differences between children and adults with respect to their 
neuropsychopathology and neuropsychopharmacology12,13. For example, 
unlike in adulthood, the manifestation of schizophrenia in childhood and ado-
lescence carries a particularly poor prognosis, and this poor outcome may be 
due to the disease’s effect during a highly susceptible time in the development 
and neurobiological maturation of children and adolescents14. Moreover, 
in contrast to adults who experience seizures, many newborn infants and 
children who experience seizures remain refractory to therapy15. Finally, 
some disorders such as certain epilepsy syndromes are specific to children 
and have therefore been largely neglected, particularly with respect to drug 
development. 
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aspects of judgment and decision-making in children and adolescents with 
neuropsychiatric disorders such as cognitive immaturity and impaired cog-
nitive processing are also unique to pediatric neuropsychopharmacology 
research40. Unlike other fields within pediatric pharmacology (such as pedi-
atric oncology), child and adolescent psychiatry and pediatric neurology have 
not been tightly integrated into psychopharmacological networks, and profes-
sional societies for child and adolescent psychiatry have only recently begun 
to establish their own networks for psychopharmacology research41 ,42. 
The situation has been complicated even further by a decrease in the num-
ber of new drug registrations for psychiatric and neurological indications in 
adults. Such research is generally considered to be too risky, as the subjective 
nature of endpoints in psychiatry and neurology makes it difficult to determine 
whether a drug is effective, even using large-scale trials. As a result, the major 
changes in cns drugs over the years have focused primarily on pharmacolog-
ical modifications (such as improving the drug’s intrinsic efficacy, selectivity, 
and/or kinetic properties43) rather than developing novel treatments.
Despite the relative paucity of scientific data to support the safe and effi-
cacious use of cns drugs in children and adolescents, and despite a lack of 
novel treatments, the number of treated children and adolescents, as well as 
the duration of exposure to cns drugs, has increased substantially over the 
past few decades44-46. To close this gap, researchers need to acquire evidence 
regarding the adequate dosing, efficacy, and safety of these treatments47. 
Recent European legislation (the eu Pediatric Regulation) will likely drive an 
increase in pediatric trials and specific label changes, dosing recommenda-
tions, and age-appropriate formulations. Unless a specific waiver or deferral 
is granted, the Regulation requires the industry to plan clinical trials in chil-
dren early in the development of new medicines for treating adults or for line 
extensions for on-patent medications. Several challenges have emerged 
when working within the framework of this new legislation48. For example, 
performing randomized, controlled trials in children can raise specific tech-
nical, logistic, legal, and financial difficulties that are not usually associated 
with trials performed in adults. In addition, even studies that are performed 
adolescence26-28, and animal studies have revealed age-related differences in 
the drug responses of several psychostimulant drugs such as amphetamine29, 
cocaine30,31, and methylphenidate32,33. In addition, a-aminobutyric acid 
(gaba) – the activity of which is affected in many neurological and neurodeve-
lopmental disorders34  –  excites immature neurons but inhibits neurons in the 
normal adult brain35. As a result of these age-dependent differences in pk and 
pd, children may respond differently than adults to cns drugs. Unfortunately, 
our understanding of age-dependent differences in pk and pd is based almost 
entirely on animal models, and remarkably few clinical trials in humans have 
focused on understanding the age-dependent differences in response to cns 
drugs.
drug development for children with cns disease 
In addition, the registration of cns drugs for use in children and adolescents 
has lagged behind new developments in adults36. In particular, the steps 
involved in recognizing, classifying, and treating psychiatric disorders gener-
ally proceed much more slowly in children and adolescents than in adults12. 
In fact, the field of clinical psychopharmacology has only recently begun to 
include children and adolescents on a relatively large scale. This delay is the 
result of a combination of factors, including concerns regarding drug safety 
and tolerance in this vulnerable population, diagnostic uncertainties, and 
the pharmaceutical industry’s reluctance to seek pediatric registration and to 
perform labeling studies for diagnoses that are not traditionally considered to 
be predominant disorders of childhood and adolescence (for example schizo-
phrenia and bipolar disorder)37. In terms of clinical research, several areas 
within the field of pediatric neuropsychopharmacology have been neglected, 
including – but not limited to – eating disorders, early-onset schizophrenia, 
mental retardation38, and pediatric critical care settings39. With respect to 
epilepsy, the most prevalent severe neurological disease among children, 
extremely few trials have been performed in children compared to adults; 
moreover, most antiepileptic drug trials in children are performed only once, 
whereas the majority of adult trials are replicated13. The developmental 
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no clear functional relationship with psychosis, anxiety, or depression. It is very 
likely that a clear concentration-dependent effect of a highly specific com-
pound is mediated by the drug’s mechanism of action, even if the functional 
relationship itself is not clear43, thereby enabling researchers to compare dif-
ferent drug formulations and age-dependent differences in drug profiles. 
To relate drug-related changes in cns functional activity to changes in pk, 
drug concentrations must be measured. Traditional pk protocols – with mul-
tiple samples and indwelling catheters or multiple venipunctures – are 
undesirable in therapeutic pediatric drug research, and they are strictly 
unacceptable in non-therapeutic pediatric drug research. To overcome some 
of these limitations, other sample collection methods for determining drug 
concentration (for example, saliva sampling) have been developed and vali-
dated. Studies have reported that patients and parents prefer saliva sampling 
over venous blood drawing50, and some drugs can be detected in the saliva 
relatively soon after administration, enabling the researcher to compile a con-
centration-time profile. This method has the added benefit of allowing on-site 
testing without the need for medical personnel or complicated post-collec-
tion sample processing, thereby further decreasing the burden placed on the 
children. 
A drug’s secretion and distribution in the saliva is dependent upon its 
physico-chemical properties. Lipophilicity, degree of ionization, and protein 
binding are the major determinants of the saliva:plasma concentration (s/p) 
ratio51. For example, drugs that are heavily protein bound and drugs that are 
extremely hydrophilic and positively charged at physiological pH (for example, 
aminoglycosides) can be undetectable in saliva. The transition of drugs to the 
cns is favored by low molecular weight, a lack of ionization at physiological 
pH, and lipophilicity52, all of which theoretically favor the drug’s secretion into 
the saliva. In certain cases, saliva concentration may even be preferred over 
total plasma concentration, particularly for highly protein-bound drugs, as 
saliva concentration can reflect the free fraction of a non-ionized drug (and 
thus reflects the intracellular concentration in target tissues). For example, 
the concentration of phenytoin in cerebrospinal fluid correlates more closely 
successfully in children are not necessarily maximally informative, as many 
studies measure pk only or perform a single post-dose pd measurement. 
Because of these challenges – even in fields with extensive pediatric research 
such as adhd – it can be difficult to reach valuable and relevant conclusions 
regarding pharmacological profiles and/or dose-dependent effects based 
solely on currently available studies. 
need for non-invasive measurement methods 
Therefore, there is an urgent need for validated assessment tools that are 
suitable for evaluating the efficacy and safety of cns drugs in the pediatric 
population49. In addition, because clinical research in pediatric patients is 
generally hampered by interrelated logistic and ethical constraints (including 
the limited number, scope, and invasiveness of study-related interventions 
that can be performed if they fall outside the realm of routine clinical care), 
researchers should attempt to reduce the burden placed on participating 
children and adolescents by using non-invasive or minimally invasive mea-
surement methods. Changes to these methods that are designed to reduce 
patient burden (for example, implementing a change in the sampling pro-
cedure) have been reported to increase patient enrollment in studies of rare 
pediatric diseases48.
The most accessible and non-invasive means to measure drug activity 
in the brain is to measure drug-related cns functional activity using meth-
ods that provide sufficient sensitivity and specificity43. Although validated 
biomar kers are rare in neurology and psychiatry, many neuropsychiatric drugs 
affect a variety of cns functions in a dose-dependent and concentration-de-
pendent manner, particularly drugs that affect neurotransmitter activity. This 
provides the opportunity to quantify cns effects, even in situations in which 
the activity measured is not an essential step in the pathogenic cascade. 
The affected functions can often be roughly or partially linked to the specific 
pharmacological mechanism (for example, linking gabaa-ergic activation to 
reduced saccadic peak velocity). Thus, these physiological functions can be 
useful biomarkers for measuring a pharmacological effect, even if they have 
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non-invasively. We evaluated the feasibility of using saliva as an alternative 
to plasma for measuring drug concentration in two studies. For this purpose, 
caffeine was chosen as an example of a basic cns drug that is primarily 
non-ionized in human saliva, and methylphenidate was chosen as a typical 
basic cns drug that is primarily ionized in human saliva. This thesis concludes 
with the report of two clinical trials that were designed to develop age-appro-
priate formulations for potential use in children. 
In chapter 2, the impact of the Pediatric Regulation on the development of 
pediatric drugs – including cns drugs – is evaluated. In this study, we evaluated 
for which drug classes and therapeutic subgroups pediatric development was 
agreed by (or waived by) the Regulation. In addition, we evaluated whether the 
Regulation is likely to increase the development of drug classes for pediatric 
conditions for which there exists an unmet pediatric need based on usage and 
availability data.
The psychostimulant methylphenidate (mph) is the most commonly 
prescribed medication for treating pediatric attention-deficit/hyperactivity 
disorder (adhd). However, previously published studies investigating the 
effects of immediate-release methylphenidate (mph-ir) have yielded con-
tradictory results due to several sources of variability, including a lack of 
standardized biomarkers and drug-effect measurements. Despite its wide-
spread use, and despite extensive research, researchers still lack useful, 
validated biomarkers for studying the effect of mph in children with adhd. 
In chapter 3, we identified generally applicable, non-invasive biomarkers 
for monitoring the acute effects of mph-ir in children and adolescents with 
adhd. The presence of unexplained variations in the s/p ratio during the time 
course of both mph-ir and extended-release mph can interfere with the 
further exploration of saliva as an alternative method for determining mph 
concentration in children. Therefore, a liquid chromatography-tandem mass 
spectrometric method that uses a hydrophilic interaction liquid chromatogra-
phy column (hilic) was validated and is presented in chapter 4. This analytical 
tool provides an accurate and precise quantification of mph in both plasma 
and saliva samples. Chapter 5 describes a study in which we attempted to 
with the saliva concentration than the blood concentration53. Saliva sampling 
is also recommended over plasma sampling for the therapeutic monitoring 
of several other anti-epileptic drugs54. Unfortunately, however, the use-
fulness of determining the saliva concentration of several other drugs has 
been questioned because of variability in the s/p ratio. Interpreting the saliva 
drug concentration of neutral, weakly acidic (pKa > 8.5), or weakly basic (pKa 
< 5.5) drugs with negligible protein binding (such as ethanol, antipyrine, and 
paracetamol) is relatively easy, as the s/p ratio is approximately 1. In contrast, 
interpreting the saliva drug concentration of drugs with other properties can 
be challenging, as the s/p ratio can be low for acidic drugs (pKa < 8.5) and drugs 
with high protein binding (such as caffeine and phenobarbital), and the con-
centration can be influenced by active transport mechanisms (such as lithium) 
or the occurrence of an alkaline reaction in aqueous solutions, for example 
in the case of basic drugs (pKa > 5.5) with low protein binding (such as meth-
ylphenidate, procainamide, amphetamine, and lidocaine). Therefore, the use 
of saliva sampling for measuring concentration of several drug types has been 
limited. In addition, because many drugs are administered orally, buccal con-
tamination can affect the s/p ratio at early time points after administration. 
Nevertheless, if the sources of variability in the s/p ratio can be minimized or 
quantified, measuring the saliva drug concentration might be a meaningful 
alternative to measuring plasma drug concentration, particularly for the 
aforementioned drug types. 
scope of this thesis 
In this thesis, we explored non-invasive methods for monitoring the phar-
macokinetics and pharmacodynamics of commonly used cns stimulants 
(methylphenidate and caffeine) and depressants (ethanol and melatonin) 
in children and/or adolescents. Neuropsychological and neurophysiological 
functions were measured longitudinally using the NeuroCart, a battery of 
tests developed at the Centre for Human Drug Research that includes tests for 
alertness, visuomotor coordination, motor control, memory, and subjective 
drug effects. Drug concentrations in children and adolescents were measured 
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including the need to develop an age-appropriate sustained-release formula-
tion and the need to collect data regarding melatonin’s pk, efficacy, and safety 
in children with autism and a sleep disorder. The study described in chapter 8 
is part of a Pediatric Investigation Plan (pip) under the Pediatric Regulation 
and was a cross-over ascending dose study of Circadin (1 mg mini-tablets), a 
prolonged-release melatonin formulation. In this study, the pk profile, safety, 
and acceptability of Circadin mini-tablets were evaluated in 16 children and 
adolescents with autism and a sleep disorder. Whole-saliva samples were col-
lected non-invasively from passive drool, and melatonin concentration was 
measured.
Because of its rapid onset and rapid recovery profile, midazolam is the 
medication of choice for providing conscious sedation and management of 
epileptic seizures. Nasal delivery of midazolam is a patient-friendly alter-
native to parenteral delivery routes. Nasal delivery offers several practical 
advantages; for example, it allows for direct, easy, needle-free administration, 
and it can be administered safely without professional assistance. However, 
previous formulations for delivering midazolam nasally have not been very 
successful due to the lack of solvents that can dissolve midazolam at therapeu-
tic dosages without causing nasal mucosa damage. Therefore, in chapter 9, 
we evaluated the pk, efficacy, and tolerability of a new, highly concentrated 
aqueous midazolam formulation (Nazolam) in healthy adult volunteers. This 
new formulation has potential for use in providing conscious sedation and 
epilepsy management in children and adolescents.
In chapter 10, the feasibility and applicability of saliva sampling in pedia-
tric populations will be discussed based on data obtained from pediatric 
clinical studies of caffeine, methylphenidate, and melatonin described in this 
thesis. In addition, the (potential of) pharmacological profiling of pharmaco-
dynamics in children and adolescents will be discussed based on literature 
review and clinical studies of methylphenidate, caffeine, alcohol and mid-
azolam. This chapter concludes with potential practical applications of this 
approach and suggestions for future directions.
identify sources of variability in mph concentration and to determine the cor-
relation between mph concentration in the saliva and plasma in healthy adult 
volunteers using a population-based pk approach. 
Chapter 6 describes a study of the effect profile of low-dose caffeine in 
healthy adolescents. Caffeine concentration was measured non-invasively 
in saliva samples. Because saliva can be contaminated by residual caffeine 
after drinking a caffeinated beverage, a second study was performed in young 
adult subjects in order to measure contamination after drinking a caffeinated 
beverage compared to swallowing a caffeine capsule. In addition, previous 
studies in adults related caffeine effects to changes in plasma concentration; 
therefore, simultaneous saliva and plasma samples were collected, and the s/p 
ratio of caffeine was measured. Based on the data obtained from this kinet-
ics study, a population-based pk model was built in order to obtain estimated 
plasma drug levels in adolescents; this model could prove useful in the devel-
opment of a caffeine pharmacokinetics-pharmacodynamics (pk/pd) model in 
adolescents. 
Chapter 7 describes a study to measure the acute effects of low-dose 
alcohol on sensitive biomarkers for alcohol effects in healthy adolescents. To 
correlate the measured effects with concentration, alcohol concentration was 
measured non-invasively using end-expired breath sampling. A pk/pd model 
was then developed using data from this study with adolescents as well as 
data collected from previous alcohol studies performed in adults in order to 
characterize alcohol pk, the effects on objective and subjective biomarkers, 
and sources of variability in pk and pd, including age. 
Sleep problems are highly prevalent among children with neurodevelop-
mental disorders and can have a substantial impact on the child and the child’s 
family. Melatonin is effective for treating sleep problems in these children, 
and melatonin appears to have a favorable short-term and long-term risk 
profile, which has led to the increasingly widespread clinical use of melatonin 
as an off-label medicine. However, no commercially available, age-appro-
priate prolonged-release melatonin preparation is currently available. 
Melatonin was identified by the ema as having a pediatric therapeutic need, 
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currently high (which reflected extensive adult use). For 
these drug classes, there appeared to be relatively little need 
for research and development based upon Dutch pediatric 
usage and availability data or based on the ema Needs Lists. 
Dutch physicians working in pediatric healthcare were not 
convinced that medicines for which pediatric development was 
agreed were needed for clinical practice. Given the substantial 
public health investment and the potential negative effects 
of the Regulation on research in areas with bona fide needs, 
key improvements in the Regulation’s implementation are 
recommended in order the ensure that the Regulation provides 
children with medicines they actually need.
abstr act  
 
The eu Pediatric Regulation requires the pharmaceutical 
industry to plan clinical trials in children at an early 
development stage in adults. The aim of this study was to 
evaluate whether this initiative is likely to provide medicines 
that children need. We evaluated the drug classes for which 
pediatric development was either agreed for development 
or was waived by the ema from 2007 until March 2012. We 
questioned if the scope of drug classes for which pediatric 
development was agreed reflects trends in Dutch pediatric 
usage and availability data, the relative distribution of drug 
classes included in the ema Pediatric Needs Lists, or drug 
expenditure data. Dutch pediatricians were asked if they 
perceived these pediatric medicines as being necessary. 
Allergens were excluded from the analysis. Approximately 
two-thirds of the medicines were agreed for pediatric 
development; deferral was granted for 83% percentage of 
these medicines. The majority of medicines agreed for pediatric 
development belonged to the drug class antineoplastic and 
immunomodulatory drugs, anti-infectives for systemic 
use, and drugs that act upon the blood and blood-forming 
organs. The majority of agreed research and development 
occurred for drug classes for which drug expenditure is 
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to determining the number of development plans by therapeutic area covered 
by the planned indication. In addition, some important issues were not con-
sidered in the report, including the Regulation’s impact on the development of 
age-appropriate formulations, despite the specific emphasis placed upon this 
aspect by the Regulation. 
Therefore, the objective of our study was to determine in further detail 
whether the initiative is likely to provide medicines that children need. First, we 
determined the drug classes and age groups for which pediatric development 
was either agreed or waived by the pdco from 2007 until March 2012. We also 
evaluated whether the scope of drug classes for which pediatric development 
was agreed matched the trends in Dutch pediatric pharmaco-epidemiological 
prescription and availability data or drug expenditure data. Finally, we evalu-
ated whether Dutch pediatricians believe that pediatric medicines developed 
and researched under the Regulation are actually needed. 
Methods 
Drug classes with agreed or waived pediatric development 
A publicly available database on the ema website8 was searched in March 
2012 for pdco opinions and ema decisions on company proposals for PIPs, 
waivers or modifications for the pediatric development of active substances. 
The Regulation includes a system for waiving medicines that are unlikely to 
benefit children and for deferring the start or completion of measures in the 
pip until after authorization for adults in order to ensure that medicines are 
tested in children only when safe and to prevent unnecessary delays in the 
authorization for adults. After the pdco has agreed to the pip, the pip can be 
modified by the company at a later stage by adding new knowledge or if the 
company encounters difficulties with its implementation that render the 
plan untenable or no longer appropriate. In these situations, the company 
may propose changes to the pip or may request a deferral or waiver – based on 
Introduction
The Pediatric Regulation, introduced by the European Medicines Agency (ema) 
in early 2007, changed the European regulatory environment for the develop-
ment of pediatric medicines. One of the Regulation’s strategies is to require 
industry to plan clinical trials in children in an early stage during drug develop-
ment in adults or in case a new indication, formulation or administration route 
is investigated for adults for on-patent medicines. Marketing authorization 
applications for this type of medicines must contain the results of all previous 
studies and information described in the company’s pediatric investigation 
plan (pip) previously agreed by ema’s Pediatric Committee (pdco). Prior to the 
Regulation’s implementation, the lack of appropriate pediatric formulations in 
a large number of therapeutic areas1 was an important reason for off-label and 
unlicensed drug use and was a major obstacle to the study of drugs in children. 
This situation was complicated further by a general lack of overlap between 
areas in which pediatric drug research was conducted and both pediatric 
therapeutic needs2 and pediatric disease burden3. The Regulation  – which 
is based upon unmet pediatric needs and establishes clear obligations and a 
system of incentives aimed at pharmaceutical companies – was expected to 
result in research more focused on children’s needs and to drive fundamental 
changes in therapeutic options for treating pediatric patients2. In addition, the 
Regulation was expected to provide early access to newer, safer, more targeted 
treatments4,5, and to lead to more options in terms of age-appropriate formu-
lation types6. 
In July 2012, the ema submitted a five-year interim report to the European 
Commission7 in which they reflected on the experience acquired as a result of 
the Regulation. From 2008 through 2011, 13 new medicines, 30 new indications, 
and 9 new formulations of existing medicines were authorized for use in chil-
dren based on pips that were agreed by the pdco. Importantly, some pediatric 
therapeutic areas that predominantly affect children had been neglected in 
terms of pharmaceutical research7. However, the assessment of concordance 
between agreed pediatric drug development and pediatric needs was limited 
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atc code assignment
Generic names of active substances in the study database were searched in a 
searchable version of the World Health Organization Collaborating Centers 
(whocc) database9. If the generic name was not included in the pip, Thomson 
Reuters’ Integrity database10 was searched for this information. The who 
Anatomical Therapeutic Chemical (atc) Classification anatomical main group 
and therapeutic subgroup retrieved from the whocc database (2013) were 
added to each active substance in the study database using a standardized 
approach. Medicinal products are classified according to the main thera-
peutic use of the main active ingredient, on the basic principle of only one 
atc code for each route of administration. For active substances with only 
one entry in the whocc database, this unique atc code was included in the 
study database. A medicinal product can be given more than one atc code if 
it is available in two or more strengths or administration routes with clearly 
different therapeutic uses. Pharmaceutical forms for topical and systemic use 
are also given separate atc codes. For active substances with multiple entries 
in the whocc database, planned pediatric indication and formulation were 
taken into account while choosing the most appropriate code. Combination 
products contain two or more active ingredients. Fixed combination products 
(e.g., amlodipine/valsartan) have a unique atc code. For other atc combination 
levels, not all active ingredients are searchable in the whocc database, but atc 
code is based on the code of the main ingredient. Unique atc codes for combi-
nation products in the study database were added if present. If no unique atc 
code could be identified, general who guidelines were followed, i.e., different 
combination products sharing the same main active ingredient are usually 
given the same atc, or the atc code of the main ingredient was included (as 
the classification of combination products is decided by the main therapeutic 
use). 
The atc code for combination products and active substances with multiple 
entries in the whocc database were assigned based on the consensus of two 
researchers (authors A.D.M. and L.S.). For active substances that did not have 
an entry in the who database, the temporary atc code given at the 2013 meet-
ing of the who International Working Group for Drug Statistics Methodology11 
specific grounds from the pdco. The types of ema decisions that are posted on 
the ema website therefore include decisions that (1) agree on a pip proposed 
by the company, either with or without a partial waiver and/or deferral (‘p’); (2) 
grant a waiver proposed by the company in all age groups for the listed con-
dition or conditions (‘W’); (3) are based on an application by the company for 
modifying an agreed pip (‘pm’); (4) refer to a refusal of a pip proposed by the 
company (‘rp’); (5) refer to a refusal of a waiver requested by the company in all 
age groups for the listed condition or conditions (‘rw’); and (6) refer to a refusal 
of an application by the company to modify an agreed pip (‘rpm’). In our analy-
sis, active substances with one or more pips with a decision type p, pm, or rpm 
were considered as active substances for which pediatric development was 
agreed by the ema (referred to hereafter as ‘medicines with agreed pediatric 
development’). Active substances with one or more pips with a decision type W 
were considered as active substances for which the ema agreed to waive pedi-
atric development (referred to hereafter as ‘medicines with waived pediatric 
development’).
data retrieval
Data were extracted using a pre-established study database (in a Microsoft 
Excel workbook) and included pdco decision number, active substance, con-
dition, therapeutic area, pharmaceutical form(s), route(s) of administration, 
company name, decision type, the date of the initial decision or last updated 
decision in the case of a request for modification, the age range of the pedi-
atric population covered by the pip, the type and number of required studies, 
waiver type, deferral (yes or no), invented name (if available) and the pip’s 
expected completion date. The pharmaceutical forms under each pip were 
categorized into: peroral, topical/transdermal, ocular, nasal, parenteral, auric-
ular, rectal, pulmonary, and vaginal. The oral pharmaceutical form was further 
subdivided in: solution/drops, emulsion/suspension, powder/multiparticulate, 
tablet, chewable tablet, and capsule. The pediatric subset was categorized 
into: younger than 2 years of age (infants and toddlers), 2-11 years of age (chil-
dren), and 12-18 years of age (adolescents). If the researched age range included 
ages that fell within a specific age subgroup, this subgroup was listed as ‘yes’. 
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also holds ‘temporal’ duplicate applications (e.g., an ema decision regarding 
a refused waiver for a particular active substance that is later followed by an 
agreed pip for the same indication). Currently, duplicate pips are not identified 
on the ema website. Because duplicate pips share a single pediatric develop-
ment, all pips were checked manually for duplicate status (by reviewing the 
conditions, subset of the relevant pediatric population, administration route, 
formulation, and agreed studies). In the event of a duplicate application, only 
one pip was considered in our analysis. In the event of a temporal duplicate 
(waiver followed by agreed pip for same indication), only the ema’s most recent 
decision was included in the analysis. The input from the ema was sought in 
case of unclarity regarding duplicate status. 
data assessment
All medicines for which pediatric development had been agreed and all active 
substances for which development was waived were listed according to drug 
classes and therapeutic subgroups. The number of formulation types and 
number of formulations were assessed by drug class. 
Drug classes with an established or potential pediatric need
Data extracted from the ema Pediatric Needs Lists12 (published through July 
2012) included the active substance, therapeutic area, authorized indication, 
and specified needs. Needs were categorized as ‘formulation only’ (research 
need for an age-appropriate or disease-appropriate formulation only), ‘pediat-
ric studies only’ (only need to expand the indication to other indications or age 
groups, need for study, or definition of age limit), or ‘full pediatric development’ 
(the need for age-appropriate formulations and studies). Medicines for which 
there was only a need for the availability of the indication or age-appropriate 
formulation in all eu member states were not included in the analysis. Medi-
cines were listed by drug class and evaluated for their specified needs type. 
was used if available. For the remaining substances, a ‘fictitious’ atc code was 
assigned based on the atc of a reference drug with the same target and indica-
tion (if available) or based on the drug target, therapeutic group, product class 
listed in the Thomson Reuters’ Integrity database10 (accessed in March 2014), 
or indication. For these active substances, an additional pharmacist (author 
r.r.) reviewed all of the collected data and the atc proposed by the first two 
authors and provided input; based on this input, a final atc was chosen.
data merging
Pediatric development was analyzed for each active substance. All of the data 
from various pips for a given active substance were merged, except for allergen 
products. pips for allergen products were left out of the analysis, as the infor-
mation in the Decisions and Opinions was not specific enough to distinguish 
different active substances or pediatric development. For all other active 
substances, if a therapeutic area was addressed by multiple indications for a 
given active substance, it was considered only once in the analysis. If the same 
formulation type was considered in multiple pips, it was counted only once. If 
the pharmaceutical form in the pip was intended for several administration 
routes, was constituted in several different ways, or if the pharmaceutical form 
was packaged in several different delivery devices, the pharmaceutical form 
was counted twice. 
The ema’s online database includes several duplicate applications that 
share pediatric development. ema decisions can be split or merged, and until 
2010, duplicate applications could be submitted by a company for a given 
active substance that had – or planned to have – more than one marketing 
authorization and for which the scope of the development was the same (e.g., 
the same conditions, route of administration, and/or formulation). For exam-
ple, one marketing authorization holder can have two or more authorizations 
in order to have different trade names, and two pharmaceutical companies 
can be joint holds of a global marketing authorization. The ema database 
non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 30 –
 
chapter 2 – pediatric regul ation: will it provide children with the medicines they need? 
– 31 –
Project; in English: the Medicines and Aiding Devices Information Project) 
databank17, an information system used by the Dutch Healthcare Insurance 
Board. Drug classes were listed by expenditure data (both overall and per user). 
Survey of Dutch physicians working with children
All medicines for which a development plan was agreed by March 2012 were 
listed by ema therapeutic area using an online survey that included informa-
tion regarding agreed clinical studies in children. Fifty medical specialists and 
residents in the fields of pediatrics or child and adolescent psychiatry com-
pleted one or more surveys in which they were asked to indicate whether they 
need the medicine in their practice (‘yes’ or ‘no’); if ‘yes’, would they (intend to) 
use the drug in their practice for treating the study population described in the 
clinical study and do they find the information obtained from the trials useful; 
if ‘yes’, would they prescribe the medicine. 
Data analysis
Descriptive data were analyzed using Microsoft Excel 2007. Data from the 
pharmo Database Network were analyzed using sas programs organized 
within sas Enterprise Guide version 4.3 (sas Institute Inc., Cary, nc, usa) and 
conducted under unix using sas version 9.2.
Results 
Research and development under the Pediatric Regulation
765 ema decisions were extracted from the ema database, of which 117 deci-
sions concerned allergens (which were excluded from the analysis). Of the 
remaining decisions, 9% were (temporal) duplicates. Thus, a total of 590 ema 
decisions were included in our analysis. Consensus regarding atc was reached 
Trends in the prevalence of drug use in Dutch children 
Data were obtained from the pharmo Database Network, a population-based 
network of healthcare databases that combines data from various healthcare 
settings within the Netherlands. These data sources are linked on a patient 
level using validated algorithms13-15. For this study, drug dispensing data from 
2005 through 2011 extracted from the pharmo Out-patient Pharmacy Database 
were used. The Out-patient Pharmacy Database includes healthcare products 
prescribed by a general practitioner or specialist and dispensed by an out-pa-
tient pharmacy (coded according to the who atc Classification System). The 
dispensing records include the type of product, date, strength, dosing regimen, 
quantity, route of administration, the prescriber’s specialty, and the cost. Within 
each year from 2005 through 2011, a separate patient selection was performed; 
accordingly, we selected all children who were 0-18 years of age in a given cal-
endar year and had at least one drug dispensed from the pharmo out-patient 
pharmacy database (excluding vitamin K, as this is given to all children who are 
breast-fed)16. For each calendar year, age was assessed by subtracting the year 
of birth from the calendar year. Patients were grouped into specific age groups 
(see above). For each year in the study period, the number of children for whom 
any drug was dispensed was measured and then extrapolated to the general 
population of the Netherlands. Specifically, we multiplied the number of chil-
dren counted by the number of inhabitants in the Netherlands; we then divided 
by the number of residents in the pharmo catchment area (standardized for 
calendar year, age, and gender). Prevalence of use was reported per 10,000 chil-
dren and was stratified by calendar year and age group. In addition, we counted 
and extrapolated the number of children for whom different anatomical classes 
of the atc classification scheme (first level atc code) were dispensed. 
Trends in Dutch pharmaceutical expenditure 
Drug volume consumed and drug prices for the years 2007 through 2011 were 
extracted by drug class from the gip (Genees- en hulpmiddelen Informatie 
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Trends in the prevalence of drug use in Dutch children 
From 2005 through 2011, the prevalence of using any medicine was highest 
among adolescents, infants, and toddlers. Whereas the prevalence increased 
in adolescents, the use of medicines in infants and toddlers decreased after 
2008. Use in children remained relatively stable in any calendar year after an 
initial increase from 2005 to 2006. The prevalence of medication use per age 
group is shown in Figure 4. 
Trends in pharmaceutical expenditure data 
Pharmaceutical expenditure for all drug classes was generally stable in the 
Netherlands from 2007 through 2011. Notable exceptions included a clear 
decrease in the cost of cardiovascular drugs, a clear increase in the cost of anti-
neoplastic and immunomodulating drugs, and varying costs for neurological 
agents and drugs that act on the alimentary tract. The per-user and the total 
(volume times per-user) costs are shown in Figure 5. 
Survey of Dutch physicians working with children
The majority of respondents (19 out of 32 who provided basic information) 
worked (at least part-time) at a non-academic center. The survey related to 
ophthalmology was the only one not completed once. Incomplete surveys 
included surveys with a large number of medicines, for example the sur-
vey related to cardiovascular disease. Surveys completed by at least 10% of 
respondents included those related to neonatology/pediatric intensive care, 
cardiovascular diseases, diagnostics, anesthesiology, and pain. These surveys 
included a total of 36 different active substances, five of which (chloroprocaine, 
perflubutane, fentanyl citrate, morphine, and dopamine) were perceived as 
useful by all respondents. In most cases, if the respondents identified the med-
icine as being useful, they also found research to be useful and would use the 
for anatomical main group for each medicine that did not have a unique entry 
in the whocc database. For two medicines (Eritoran and Clazosentan), no 
therapeutic subgroup could be assigned.
Pediatric development was agreed for 358 medicines and waived for 173 
medicines (Figure 1). Antibacterials for systemic use, antihemorrhagic agents, 
antineoplastic agents, drugs used in diabetes, immunosuppressants, sys-
temic antivirals, and vaccines accounted for half of all medicines for which 
pediatric development was agreed. In all drug classes, fewer medicines were 
researched in infants and toddlers than in older age groups, with the excep-
tion of antiparasitic agents, which was an extremely small drug class in the 
analysis. Medicines were researched at the same frequency in children and 
adolescents for nearly all drug classes, with the exception of drugs that act on 
genitourinary system and sex hormones, which were studied more frequently 
in adolescents. Deferral of one of the measures described in the PIP was grant-
ed for 83% of medicines with agreed pediatric development.
The majority of medicines were formulated for parenteral (48%) or oral 
(43%) use (allergens not considered). Oral formulation types are shown in 
Figure 2. Multiple dosage formulations were listed for 124 medicines, covering 
a range of 2-7 dosage formulations. Age-appropriate formulations were con-
sidered for 210 medicines for infants and toddlers, for 327 medicines for young 
children 327, and for 331 medicines for adolescents.
Drug classes with an established or potential pediatric need
A total of 323 active substances in 51 different therapeutic subgroups had a 
recognized need for pediatric research or development; full pediatric develop-
ment was indicated for half of these active substances (Figure 3). Drugs used 
in diabetes, drugs for cardiac therapy, antineoplastic agents, immunosup-
pressants, anesthetics, analgesics, antiepileptics, psycholeptics and drugs for 
obstructive airway disease accounted for half of all medicines for which a need 
for pediatric research or development was recognized.
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and antiparasitic agents, and lowest for genitourinary drugs, sex hormones, 
dermatologicals, and cardiovascular drugs1. Although future studies should 
attempt to determine whether the low availability of these drug classes for 
children is a problem in clinical practice1 , combining these availability data 
with our outpatient usage data suggests the possible presence of an unmet 
pediatric need for research and development of dermatological agents in all 
ages and genitourinary drugs and sex hormones in adolescents; although 
these medicines are frequently prescribed to these age groups, they are not 
always readily available. Unfortunately, these drug classes are researched 
relatively rarely under the Regulation. Based on prescription and availability 
data, there is no apparent pediatric need for anti-infectives (which are pre-
scribed frequently and are readily available), a drug class that is researched 
frequently under the Regulation. However, current availability data may not 
be the best indicator of the potential need for anti-infectives, as the need for 
drug availability may exceed regulations in the near future due to microbial 
(antibiotic resistance) and viral (pandemic flu) threats. Therefore, the devel-
opment of new anti-infectives for use in children should not lag behind the 
development for use in adults.
The need to develop more age-appropriate formulations for younger age 
groups1 appears to be addressed by the Regulation, as infants and toddlers 
are considered with respect to more than 200 medicines. In contrast to expec-
tations6, in most cases only one formulation type will be developed. Despite 
the inclusion of younger age groups, there seems to be no shift in the types of 
formulations that may be available for children following the implementation 
of the Regulation; similar to the situation in 20091 , most pediatric medi-
cines that are developed are intended for oral (mostly tablets) or parenteral 
administration. 
The Regulation may lead to newer, safer, or more targeted treatments, as 
our study database included several novel drug types which may also become 
available for use in children, including tissue transglutaminase inhibitors22, 
soluble guanylate cyclase activators23, and toll-like receptor 4 receptor anta- 
gonists24. In addition, several protein-based drugs have agreed pediatric 
medicine in clinical practice. Another 13 active substances were perceived as 
not useful by all of the respondents for the proposed indication, nearly all of 
which were listed for treating cardiovascular disease. 
Discussion 
More than five years have passed since the Pediatric Regulation was imple-
mented; in this period, the eu budget’s contribution to operational costs totaled 
more than 39 million euros, in addition to the contribution of resources in-kind 
by European national competent authorities18. Despite this substantial public 
health investment, it is unlikely that (future) pediatric authorizations will be 
focused more on pediatric needs. Drug classes and therapeutic subgroups with 
a high need for pediatric research and development on the ema Needs Lists 
(including drugs that act on the cardiovascular or nervous system and drugs for 
treating obstructive airway disease) or for which a pressing pediatric need has 
been expressed in the literature (e.g., ophthalmological agents19) are either 
researched rarely or often waived from pediatric development. In addition, 
despite the diversity of therapeutic subclasses listed on the Needs Lists, pediat-
ric research agreed under the Regulation was dominated by seven therapeutic 
subgroups (allergens not considered).
Ideally, drug research in children should be prioritized based on current 
trends in medication use20 and frequent pediatric use of medicines that are 
not readily available or age-appropriate may indicate an important unmet 
pediatric need1. Our analysis of Dutch outpatient pediatric use revealed that 
the use of any medicine was highest among Dutch adolescents, infants, and 
toddlers, which suggests a shift in the highest use of medication towards ado-
lescents, as previous studies found the highest prevalence of medication use 
among younger children16,21. Consistent with this notion, adolescents were 
rarely waived from pediatric development under the Regulation. In 2009, the 
percentage of medicines that were authorized and commercially available 
for use in Dutch children was highest for anti-infectives, respiratory drugs, 
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It should be noted that our evaluation was limited by the cross-sectional 
nature of the collected data, as agreed pips may have been modified after our 
search. In addition, some data in the ema database cannot be readily used for 
scientific analyses such as our study. For example, although duplicate appli-
cations and shared pediatric development among pips cannot be identified 
easily, this information is important for reliably assessing the impact of the 
Regulation on pediatric research and development. Our evaluation of the per-
ceived usefulness of medicines researched under the Regulation among Dutch 
physicians working in pediatric healthcare should be regarded as preliminary, 
as it included fifty physicians only. In addition, it may be valuable to evaluate 
the perceived usefulness in expert groups as well.
In conclusion, progress has been made regarding the (planned) inclusion 
of adolescents in pediatric research and the development of more age-ap-
propriate formulations for younger age groups. However, the Regulation’s key 
strategy does not necessarily lead to the increased pediatric development of 
drug classes for which there may be a unmet pediatric need and physicians are 
unlikely to have more options in terms of formulation types for the majority 
of pediatric medicines. Instead, the Regulation’s output is in line with expen-
diture data, most likely as a result of the ‘adult-driven’ approach. Pediatric 
research in actual needs areas may be hampered as a result of the Regulation, 
as the number of agreed pediatric development plans is high and the number 
of children available for research is low. Given the substantial public health 
investment and the potential negative effects of the Regulation on research 
in actual needs areas, important refinements in implementation are needed 
in order to ensure that the Regulation will provide children with the medicines 
they actually need. 
development plans and may provide additional options for meeting unmet 
pediatric needs25. It remains to be seen whether these drugs will be developed 
successfully for children, as some developments have already been discon-
tinued10. In addition, as more than 80% of the medicines in our database had 
at least one deferred measure in the agreed development plans, children are 
likely to have late rather than early access to new medicines. As a result, it is 
possible that no effect of the Regulation will be seen regarding the total off-la-
bel use in the pediatric population – even though this is one of the Regulation’s 
intended aims – as has been demonstrated for triptans, which were labeled for 
pediatric use with delay; pediatric treatment remained dominated by off-label 
use, despite labeling the product in an age-appropriate formulation for the 
most relevant age group26. 
Finally, relatively few medicines in the fields of neonatology/pediatric 
intensive care, cardiovascular disease, diagnostics, pain, and anesthesiology 
were considered to be needed by a small contingent of Dutch physicians work-
ing in pediatric healthcare. 
It is not surprising that the drug classes in our evaluation with the lowest 
number of medicines with agreed pediatric development have the lowest 
pharmaceutical expenditure. Under the Regulation, only medicines for which 
the adult indication also exists in children and for which no important rea-
son exists to waive pediatric development will be considered for pediatric 
development. It has been argued that many children are denied access to 
innovative medicines because of this ‘adult-driven’ approach, for example in 
the field of oncology27. It has therefore been argued that implementation of 
the Regulation should be guided instead by the biology of pediatric tumors 
and the medicine’s mechanism of action. We argue that this approach should 
be expanded beyond pediatric oncology, as this approach is relevant to other 
therapeutic areas as well. Indeed, in a recent publication, the pdco explained 
that it tends to ask for research based on the medicine’s mechanism of 
action28. However, whether this request for additional research will be volun-
tary or mandatory is currently unclear. In addition, new incentives should be 
considered for first-in-children indications.
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figure 2 Oral formulation types developed or researched under the Pediatric Regulation, 
based on published ema decisions through March 2012. 
figure 1 Number of active substances per drug class for which pediatric research and 
development was agreed (with or without deferral of one of the measures in at least one 
development plan) or waived under the Pediatric Regulation, based on published ema 
decisions through March 2012. Octocog alfa (B02), cyclosporin (S01), budesonide (R03), ulipristal 
acetate (G03), everolimus (L01, L04), and afamelanotide (D02) had agreed as well as waived pediatric 
development plans. Antineoplastic agents, immunosuppressants, antihemorrhagic drugs, antiviral 
agents for systemic use, and vaccines were the largest therapeutic subgroups for which pediatric 
development was agreed (each subgroup contained >20 active substances). In the main drug classes 
for which pediatric development was waived, drugs that act on the renin-angiotensin system, 
lipid-modifying drugs, antineoplastic drugs, drugs used in diabetes, sex hormones and modulators 
of the genital system, and ophthalmological drugs were the largest therapeutic subgroups (each 
subgroup contained >10 active substances).
           Agreed Pediatric Development                           Agreed Pediatric Development                  Waived Pediatric Development                    









































































































































non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 42 –
 
chapter 2 – pediatric regul ation: will it provide children with the medicines they need? 
– 43 –
figure 4 Average number of users per 10,000 children by anatomical class and age group 
from 2005 through 2011. In all pediatric age groups, the most frequently used medications were 
drugs that act on the alimentary tract, dermatologicals, anti-infectives for systemic use, and respi-
ratory drugs. With respect to infants and toddlers, drugs that act on the sensory organs were also 
used frequently; among adolescents, drugs that act on the genitourinary system and sex hormones 
were used frequently (predominantly among females). In all pediatric age groups, a decrease in 
prevalence was observed with respect to the use of anti-infectives, and an increase in prevalence 
was observed with respect to drugs that act the alimentary tract and dermatological agents. Among 
children and adolescents, an increase in the use of neurological agents was observed, with the larg-
est increase among antidepressants (including antidepressants combined with psycholeptics) and 
stimulants. Among adolescents, an increase in the use of respiratory drugs and drugs that act on the 
genitourinary system was also observed. 
figure 3 Number of active substances per drug class listed in the Pediatric Needs Lists 
published through July 2012 for which a pediatric need for research was indicated. For three 
neurological agents, no specific need was specified on the Neurology Needs List. Drugs that act on 
the sensory organs were not included in any of the Pediatric Needs Lists. Drugs that act on the senso-
ry organs were not included in any of the Pediatric Needs Lists. Most of the active substances with a 
need for pediatric research or development were drugs used in patients with diabetes, antithrombic 
agents, cardiac therapy drugs, diuretics, anti-viral agents for systemic use, antineoplastic agents, 
immunosuppressants, anesthetics, analgesics, anti-epileptics, psycholeptic agents, and drugs for 
treating obstructive airway disease (each therapeutic subgroup contained 10-38 active substances).
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figure 5 Total pharmaceutical expenditure data of active substances per drug class from 
2007 through 2011; data were retrieved from the gip databank and are expressed as the fraction of 
total costs of all drug classes for overall medicinal costs (total medicinal costs) and per user (individ-
ual medicinal costs).
            Total Medicinal Costs                              Ind. Medicinal Costs
Biomarkers of acute 
methylphenidate effects in 





Lenneke Schrier1, Margreke JE Brill1, Jacobus Burggraaf1 
Rám N Sukhai2 , Adam F Cohen1, Joop MA van Gerven1
1. Centre for Human Drug Research (chdr), Leiden


















































































































non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 46 –
 
chapter 1 – introduction
– 47 –
attention, divided attention, and impulsivity (inhibitory 
control), indicating that mph has acute effects on all three core 
symptoms of adhd among mph-responsive children with adhd. 
These candidate biomarkers should be investigated further in 
future studies to obtain a more thorough evaluation of dose-
response relationships, including their effect size and potential 
applicability for predicting the response to mph.
abstr act  
 
Despite the extensive use of methylphenidate (mph) and 
considerable research, suitable validated biomarkers for 
monitoring the effects of mph are not currently available. 
Here, we performed a systematic literature review to identify 
generally applicable biomarkers for monitoring the effects of 
immediate-release mph (mph-ir) in children and adolescents 
with attention-deficit/hyperactivity disorder (adhd). We 
identified 78 randomized placebo-controlled clinical studies  
that investigated central nervous system effects following 
a single dose of mph-ir in pediatric adhd patients. Neuro-
cognitive clusters and individual tests that were used in five 
or more studies were evaluated for reporting consistent 
mph effects. The following outcomes showed a consistent 
response to a therapeutic mph dose across studies based on 
different cohorts: Continuous Performance Test, Go/no-go 
Task, Visual Evoked Potentials, and several observation scales 
(including Following Rules Observations, Oppositional 
Behavior Observations, On-Task Behavior Observations, and 
Impulsivity Behavior Observations). A closer inspection of the 
Visual Evoked Potentials revealed that mph mediates increases 
in late potential amplitudes. mph’s effect was best detected 
in tests and observations regarding motor control, sustained 
non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 48 –
 
chapter 3 – biomarkers of mph effect in pediatric adhd  
– 49 –
an onset of action within 30-60 minutes and reaching peak clinical effect 1-2 
hours after administration; the effects typically last 2-5 hours. The relation-
ship between mph’s pk and biological effects is complex and not completely 
understood; however, recent studies suggest that the drug’s principal clinical 
effects closely follow its predicted pk profiles8,9. The autonomic, psychomo-
tor, and neurocognitive effects of mph-ir in pediatric adhd have been studied 
extensively. However, previous published studies of the effects of mph-ir have 
yielded conflicting results due to several sources of variability, including a 
lack of standardized biomarkers and effect measures for mph10,11. Despite 
the widespread use of mph and extensive research, no validated or generally 
accepted biomarkers for mph’s effects in children and adolescents with adhd 
have been identified. Identifying suitable biomarkers will help researchers 
develop a more efficacious and specific treatment regimen for children with 
adhd; for example, biomarkers could be used for the early identification of 
responders versus non-responders, to identify patients with an increased 
risk of developing adverse side effects, and to monitor treatment outcome. 
Biomarkers could also facilitate future research regarding the core pathology 
of adhd, mph’s mechanism of action, and the effects of stimulants in children. 
The following operational criteria have been used in the search for a suitable 
biomarker12-16: 1: a clear, consistent response across studies using different 
study cohorts; 2: a clear change in the biomarker in response to a therapeutic 
dose of mph; 3: a measurable dose-response and/or concentration-response 
relationship; and 4) a plausible relationship between the biomarker, the phar-
macology of mph, and the pathogenesis of adhd.
Here, we performed a systematic review of the literature to investigate 
generally applicable outcome measures in response to mph-ir treatment of 
children and adolescents with adhd. Our research group and other groups 
have successfully used this approach in healthy volunteers to identify suitable 
functional biomarkers for antipsychotic drugs12, benzodiazepines13, selective 
serotonin reuptake inhibitors14, tetrahydrocannabinol15, mdma (i.e., ecsta-
sy)16, and alcohol17. 
Introduction
Attention-deficit/hyperactivity disorder (adhd) is the most common neurobe-
havioral disorder among children and adolescents. adhd is characterized by 
the childhood onset of symptoms that include inattention and impulsivity/
hyperactivity1,2. The psychostimulant methylphenidate (mph) is the most 
commonly prescribed medication for treating the symptoms associated with 
pediatric adhd3,4. This treatment has been validated by numerous controlled 
studies that show the efficacy of low-dose oral mph at reducing the behavioral 
symptoms associated with the disorder; the effects are usually reported by the 
child’s parents and teachers and include both the cognitive (inattention and 
impulsivity) and non-cognitive (hyperactivity) domains. In controlled clinical 
trials, approximately 60-70% of treated children show clinical improvement5, 
although the response rate is lower (approximately 50%) and less predictable 
in clinical practice. The clinical use of mph is usually based on a trial-and-er-
ror approach before optimal therapy is achieved; this approach is often used 
because mph’s effects vary widely between individuals in terms of clinical 
response6 and pharmacokinetics (pk). More than 30% of patients do not 
respond favorably to mph at any dose6 and therefore must switch to an alter-
native medication after the initial titration phase. As a consequence of this 
lack of response, a significant percentage of adhd children either experience a 
considerable delay in receiving adequate treatment or stop seeking treatment 
altogether. Therefore, there is a need for a more sensible, personalized thera-
peutic approach to adhd. 
Despite its long history of use, mph’s precise mechanism of action remains 
poorly understood, complicating the assessment of treatment efficacy or 
the timely identification of non-responders. mph is available in several for-
mulations, with a variety of delivery mechanisms that result in changing pk 
and effect profiles throughout the day7. Immediate-release mph (mph-ir) 
has been on the market for more than 50 years, whereas other formulations 
have only recently become available. mph-ir is a short-acting compound, with 
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Data analysis
Outcome measures were clustered to groups of related tests or test variants 
(referred to as ‘clusters’) in order to generate a reasonable degree of stan-
dardization across studies and tests. For example, the Arrow/Sound (In)
Compatibility Task, Dichotic Listening Task, Divided Attention Task, and Dual 
Task were clustered under ‘Divided Attention’, which is part of the functional 
domain ‘Attention’. This approach enabled us to preserve individual study data 
in the early stages of our analysis, thus enabling us to evaluate individual fre-
quently used tests using uniform outcome measures. We then performed a 
progressive condensation of the results into logical clusters, thus providing a 
more general assessment of the drug’s effects on groups of comparable tests 
or functional domains. This approach enabled us to evaluate the practical 
suitability of using a test as a biomarker in small-to-medium size studies. 
No effort was made to further quantify the level of statistical significance. 
Neurocognitive and neurophysiological tasks were categorized into clusters 
of related tests or test variants12 using the compendiums of Strauss18 and 
Lezak19. 
The clusters were further divided into six domains (referred to as ‘domains’) 
in accordance with the Strauss compendium18, including executive functions, 
memory, attention, motor function, language, and perception. Physiological 
measurements (e.g., heart rate, blood pressure, pupil size, and electrodermal 
activity) were not included in this review. Event-related potentials (erps) and 
neuroendocrine measurements (e.g., cortisol, growth hormone, and prolactin) 
were also grouped into clusters and domains. 
With respect to erps, the following clustering method was used. A potential is 
evoked using a standard visual or auditory stimulus and an infrequent deviant 
stimulus (the ‘target’ in the Continuous Performance Task, Go/no-go task, and 
Oddball task). If the pattern of the potential evoked by the standard stimulus 
was significantly altered following mph treatment, the event was classified as 
a significant effect of mph on the neurophysiologic parameter (drug condition 
Methods
Search strategy and data collection
To identify studies that investigated the acute effects of mph in pediatric 
patients with adhd, the databases PubMed, embase, and Psycinfo were 
searched (for the search queries, see Table 1). All returned citations were 
imported in a Reference Manager database, and duplicate records were 
removed from this database. Potentially relevant studies were selected by 
viewing the titles and abstracts. Non-relevant reports were discarded, and 
the full-length articles of all relevant or potentially relevant reports were 
obtained. The following inclusion criteria were then applied to this pool of 
potentially eligible studies: studies that were randomized, double-blind, pla-
cebo-controlled clinical trials; studies that compared the effects of an acute 
dose of mph-ir versus placebo in previously mph-treated or mph-naïve chil-
dren and/or adolescents with adhd; studies with a minimum washout period 
of five half-lives; studies with a minimum cohort size of ten subjects per treat-
ment arm; and studies that were published in English. To minimize population 
heterogeneity, studies that included subjects with mental retardation (iq <70) 
and studies in which adhd patients were selected for a specific comorbidity 
were excluded.
Data were extracted from the studies to a pre-established database tem-
plate (Microsoft Excel). The extracted data included information regarding the 
study details (e.g., study design, number of subjects, wash-out period), subject 
characteristics (e.g., gender, age, adhd type, comorbidity, previous exposure to 
mph), medication given (e.g., formulation, dose), and outcome measures (e.g., 
the type of test, time interval between drug administration and the test, over-
all effect). Because effect measures and mph doses varied among the studies, 
each effect measure at a certain mph dose was considered an independent 
effect measure. Thus, the total number of effect measures evaluated was the 
combined sum of the number of studies, tests, and mph doses. 
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clustered separately in secondary clusters. However, if a secondary param-
eter could be categorized in the same functional domain as the primary test 
parameter, it was not included separately, and only the primary item was 
added to the database.
For each outcome measure and functional cluster, we calculated the per-
centage of improved (+) or impaired (-) test outcomes relative to the total 
number of tests. Secondary outcome measures/clusters and erp-related clus-
ters were evaluated separately. Consistent mph-induced improvement in task 
performance, rating, or observation was defined as an increase in >60% of the 
tests.
Dose-effect relationships 
On average, the clinical dosing range for mph is linearly correlated with the 
reduction in adhd symptoms22. The likelihood that a given test will detect 
a difference in effect between mph treatment and placebo is expected to 
increase with increasing dose. Therefore, to investigate mph’s dose-effect rela-
tionship, the doses were categorized as ‘low’, ‘medium’, or ‘high’. The ‘low’ dose 
was defined as 0.1-0.25 mg/kg (i.e., the recommended daily therapeutic start-
ing dose), the ‘medium’ dose was defined as 0.25–0.59 mg/kg, and the ‘high’ 
mph dose was defined as *0.6 mg/kg23. Dose-effect relationships were mea-
sured for clusters and for effect measures that were used in *3 studies (per dose 
category) and/or across *15 studies. Dose-related changes in the average per-
centages of improvement were reported without formal statistical analyses.
Results
Identified studies
The literature search included all scientific articles that were published 
through December 31, 2009. The search yielded a total of 1,973 hits, from which 
x standard stimulus), regardless of the direction of the effect (i.e., a positive 
or negative wave, increased or decreased amplitude, or a change in time). In 
addition, if the pattern of the potential evoked by the deviant (or target) stimu-
lus was altered significantly after mph and compared to the standard stimulus 
(drug condition x standard stimulus x deviant stimulus), the response was con-
sidered to reflect an effect of mph in the task-related neurocognitive domain 
(for example, sustained attention in the event of an erp with the Continuous 
Performance Task) and was clustered as such in the database. 
In several studies, subjective measures and rating scales were used to 
assess the effect of mph in children with adhd. Clustering of these mea-
sures was guided by a review of classification methods in published rating 
scales (the Conners Rating Scale20 and scales derived therein, and the add-h 
Comprehensive Teacher Rating Scale21) and the clusters and domains that are 
used to classify the neurocognitive tasks18,19. This subdivision is described in 
the Results section. 
In our analysis, we assumed that in most cases, no single consistent quan-
titative outcome parameter could be recorded for an individual test due to the 
large variation in methods and parameters. Therefore, the ability of a test to 
reveal a statistically significant difference between placebo and baseline was 
scored as ‘+’ (an improvement or increase), ‘=’ (no significant effect), or ‘–’ (an 
impairment or decrease). Different parameters of a single test were grouped 
if they provided information regarding a common functional cluster. Several 
tasks yielded different outcome parameters, in some cases showing opposite 
effects of mph. If these opposite responses were part of the same neurocogni-
tive cluster, two items were scored for the same test (e.g., one ‘+’ and one ‘-’). In 
cases in which one of the improved parameters was part of a different func-
tional cluster than the parameter that did not improve, both items were scored 
separately (i.e., as belonging to separate clusters). Items that were considered 
to be secondary test parameters were marked with an asterisk in the database. 
For example, in the Continuous Performance Task, the level of commission 
errors (which evaluates impulsivity) is secondary to the level of omission errors 
(which evaluates sustained attention). These secondary parameters were 
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Oppositional Behavior, On-Task Behavior, and Impulsive Behavior. The only 
scale that did not improve consistently across the studies was Social Behavior. 
None of the outcome measures that were used in at least 5 studies showed 
impairment following mph treatment. 
Table 5 reports on the functional clusters (following categorization of 
outcome measures; see Methods) that contain all of the most consistent 
individual outcome measures identified above. Nearly half of the functional 
clusters that were assessed showed consistent improvement (i.e., >60% con-
sistency) following mph compared to placebo; these clusters include Divided 
Attention, Secondary Reaction Time, Sustained Attention, Motor Control, 
Evoked Potentials, and the following scales: Attention, Oppositional, adhd, and 
Impulsivity. The highest consistency was seen for Evoked Potentials, Sustained 
Attention (Vigilance), and the Oppositional and Attention Scales. The observa-
tion-related outcome measures and functional clusters (‘scales’) were more 
sensitive at detecting the effects of mph than task-related measures and 
clusters. Moreover, executive functioning-related clusters had relatively low 
improvement ratings. 
With respect to evoked potentials, mph-related changes in outcome mea-
sures and/or clusters were evaluated regardless of the direction of change 
(e.g., positive or negative, increased or decreased). Visual evoked potentials 
were measured in ten studies28-37, and late potential amplitudes (*300 msec) 
increased in approximately 70% of cases following mph treatment. In contrast, 
we found no consistent change in early potentials or evoked potential laten-
cies following mph treatment. Auditory evoked potentials were measured in 
three studies29,30,38 and showed a similar change following mph treatment. 
Dose-response relationships
We next investigated the dose-response relationship of the outcome mea-
sures and functional clusters that had a consistent mph-induced response 
(>60% consistency). Specifically, we examined the dose-response curve of 
each outcome that was used in *3 studies per dose level (low, medium, or high; 
78 articles were identified that met the inclusion criteria for this review. Ten 
of these articles did not explicitly mention dsm or icd criteria when describ-
ing the study population; however, these studies did mention the use of other 
diagnostic methods (for example, questionnaires, interviews with parents, 
etc.) to confirm the presence of a hyperactivity disorder. The majority of studies 
included boys ranging from 5-13 years of age, and the majority of studies inves-
tigated a ‘medium’ dose of mph (defined as 0.25-0.59 mg/kg; see Methods). The 
study characteristics are summarized in Table 2.
Clustering of outcome measures
The identified outcome measures – categorized by functional cluster and 
domain – are summarized in Table 3. Results from domains and clusters that 
were used only once or twice could not be generalized, and will not be discussed 
further. In total, 151 separate outcome measures (i.e., tasks and observations) 
were used to assess the effect of mph; 104 of these measures were used only 
once. Only 11 measures were used more than five times, with Visual Evoked 
Potential and the Go/no-go Task being the most frequently used measures 
(each was used in ten studies). Progressive condensation of outcome mea-
sures resulted in 49 clusters.
Following mph treatment, task performance and observations generally 
improved. Only four of the 78 studies reported performance impairment or 
decreased hormone serum levels following mph; these four outcomes were 
the Math Cheating Task24, the Behavior After Failure Task25, the Tachistoscopic 
Task26, and Prolactin levels27.
The outcome measures that were used in at least five studies (Table 4) were 
reasonably consistent (>60%) at detecting mph’s effects across studies (with 
the exception of the Arithmetic Task and the Reaction Time Task). The tests with 
the highest consistency were Visual Evoked Potentials and the Continuous 
Performance Task (with 84.2% and 76.2% consistency, respectively). With 
respect to the observational outcome measures, the following observation 
scales had the highest consistency, ranging from 68.4-100%: Following Rules, 
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groups. We also observed consistent mph-induced improvement at the clus-
ter level for Divided Attention, Sustained Attention (Vigilance), Reaction Time, 
Motor Control, Evoked Potentials, and several scales (Attention, Oppositional, 
adhd, and Impulsivity). 
In order to be useful in a clinical setting, a biomarker should be sufficiently 
sensitive to detect the effect of a therapeutic dose of mph; moreover, a plausible 
relationship between the biomarker, mph pharmacology, and/or adhd patho-
genesis should also exist. Several neurotransmitters have been implicated in 
the pathophysiology of adhd (and by extension, mph’s mechanism of action). 
Compelling evidence suggests that dysfunctional dopamine and norepineph-
rine neurotransmission, as well as dysregulation of dopaminergic pathways, 
are involved in the pathogenesis of adhd39,40. mph appears to stimulate the 
dopaminergic and noradrenergic systems in the fronto-striatal region of the 
brain, thereby improving symptoms associated with impaired motor and cog-
nitive function. Other neurotransmitters (such as histamine, and serotonin) 
and nicotine have also been suggested to play a role in the pathophysiology 
of adhd41-45, and both animal and human studies have reported increased 
levels of these neurotransmitters in the prefrontal cortex following mph treat-
ment. However, the evidence collected to date does not necessarily support 
the putative relationship between mph-induced neurochemical modulation 
and the clinical improvements observed in adhd patients following mph treat-
ment39,46. In our study, all of the mph-sensitive outcome measures – and most 
of the functional clusters – were associated with the core symptoms of adhd. 
Other functional clusters that were previously associated with adhd patho-
genesis and were measured in >5 studies (e.g., working memory, reasoning, 
and set shifting)47 failed to show consistent mph-induced improvements. This 
finding seems to correspond with the clinical finding that a single therapeutic 
dose of mph selectively improves some of adhd’s core features (in particular, 
attention, impulsivity, and hyperactivity), whereas learning, planning, and 
organization improve only following chronic mph treatment (possibly as an 
indirect consequence of mph’s acute cns effects). adhd has also been associ-
ated with various deficits in event-related potentials. In the auditory modality, 
see Methods) or *15 studies (Table 6). The outcome measures Go/no-go Task 
and Scale – adhd showed reasonably high consistency for all dose levels. The 
functional cluster Sustained Attention (Vigilance) had a robust dose-response 
relationship in the medium and high dose levels. The cluster Motor Control 
also showed an increasing response in the high dose level; in contrast, the low 
and medium doses gave similar response rates across the studies. 
Discussion
The clinical use of methylphenidate (mph) for treating children with adhd is 
currently based on a trial-and-error approach. The availability of mph effi-
cacy biomarkers may help clinicians determine the optimal type and dose of 
medication, thus providing the most efficacious treatment regimen. Here, we 
performed a systematic literature review in order to identify potential bio-
markers for assessing the acute effects of a single dose of immediate-release 
mph in children and adolescents with adhd. Using this approach, we expected 
to identify the most sensitive outcome measures for the effect of mph, provid-
ed that a change in task performance, rating, or observation can be detected 
after administering a single low dose of mph; moreover, the responses that 
were consistently detected in multiple studies should reflect the most robust 
biomarkers. Outcome measures were clustered into groups of related tests 
and/or test variants in an attempt to standardize the results across studies and 
tests, and this was followed by a progressive condensation of results into 20 
clusters of related cns tests. Although 151 different outcome measures were 
used to assess the effects of mph, fewer than one-third (47 measures) were 
used in more than one study. The Continuous Performance Test, Go/no-go Task, 
and Visual Evoked Potentials, as well as several observation scales – includ-
ing Following Rules Observations, Oppositional Behavior Observations, 
On-Task Behavior Observations, and Impulsivity Behavior Observations – were 
identified as outcome measures that showed a clear, consistent response 
to therapeutic mph doses in several studies performed by various research 
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pressure)52, and baseline brain activity (eeg theta power)52, and the contin-
gent negative variation (cnv, a slow negative shift in the eeg that can occurs 
between a warning signal and an imperative stimulus during a reaction time 
task)53.
Ideally, a suitable research biomarker should have a clear dose-response 
relationship with mph and should preferably be sensitive to a low therapeu-
tic dose of mph, criteria that were not addressed in previous reviews. Here, we 
predefined three discrete dose ranges. The majority of studies in our review 
used the medium dose range (0.25-0.59 mg/kg), which limited our ability to 
assess a putative dose-response relationship. The cut-off values for the dose 
categories were based on clinically relevant ranges. Alternatively, we could 
have determined the cut-off values based on the distribution of dose levels in 
our dataset, thereby balancing the number of studies in each dose category. 
However, this approach would have been post hoc (rather than a priori) and 
would not have reflected true clinical practices. In our data set, dose-response 
relationships were determined for the outcome measures and functional 
clusters that were sensitive to the effects of mph in a minimum number of 
studies. Because our method merely determined the statistical significance 
of test results following treatment, it did not enable us to detect effect sizes; 
rather, we could only determine consistency in the measured outcomes across 
studies. This approach may have masked the identification of a dose-response 
relationship, particularly for biomarkers that showed a clear response at all 
dose levels, including the lowest level (for example, with outcome measures 
from the Go/no-go Task, the functional cluster Motor Control, and outcome 
measures of the scale adhd). 
Our analysis has several limitations. Firstly, the basic concept of adhd as a 
disorder changed several times in terms of both nomenclature and classifica-
tion in the past few decades. As a result, potentially eligible studies may have 
been missed. In addition, although differences in the response to mph have 
been described between the inattentive/hyperactive and combined subtypes 
of adhd54-56, we did not attempt to differentiate between adhd subtypes, 
due in part to an insufficient number of studies. Also, publication bias might 
adhd-related differences are apparent in all components from the auditory 
brain-stem response to the late slow wave. Although relatively few studies 
have investigated the visual attention system, similar differences have been 
reported for a range of components; for example, the visual p3 component has 
been reported to differ between children with adhd and control subjects48. 
Late evoked potentials are associated with stimulus evaluation and matching 
procedures that are related to attention37,49. Our findings show that mph con-
sistently induces a change in late evoked potential amplitudes. 
Previously reported mph-induced improvements include improvements in 
impulse control, learning, short-term memory, and activity10, with the largest 
improvements in activity level, attention, and inhibition50. Pietrzak and col-
leagues11 used an approach similar to ours, but their search was limited to 
cognitive tasks, and they included both non-controlled trials and chronic mph 
trials, which may explain the differences between their results and our results. 
For example, Pietzrak and colleagues reported that saccadic eye movement, 
planning/cognitive flexibility, attention/vigilance, and inhibitory control were 
improved by mph in *70% of the studies they reviewed. In contrast, only 50% 
of the studies they reviewed reported improvements in working memory and 
divided attention following mph treatment. In our study, tasks and/or obser-
vations that evaluate learning and planning could not be reviewed in our 
study, as they were not used frequently enough in the studies we reviewed. A 
recent systematic review and meta-analysis of the effects of mph on cognitive 
function51 found that mph improves executive and non-executive memory, 
reaction time, reaction time variability, and response inhibition in children 
and adolescents with adhd. In contrast to our study, they included studies with 
additional non-pharmacological interventions (as long as these interventions 
were applied to both placebo-controlled randomized study groups); in addi-
tion, for studies that included several doses of mph, they included only the 
data regarding the highest mph dose, which may explain their positive find-
ings with respect to memory. Other potentially sensitive biomarkers for mph 
effect not included in our database include cognitive performance (sustained 
attention/vigilance)52, baseline autonomic arousal (heart rate and blood 
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adolescence with respect to the response and tolerance to mph64. Because rel-
atively few published studies specifically examined the moderating effect of 
gender, and because sample sizes were questionable in some studies, no clear 
conclusions can be drawn regarding whether gender affects the response to 
treatment64,65. Pietrzak and colleagues11 reviewed several other factors of 
influence related to intra-individual and inter-individual differences in med-
ication response, including the study design and repeated neuropsychological 
assessments. Our dose-response analysis was complicated further by several 
additional factors. For example, effect profiles can differ among outcome mea-
sures, including the effect’s time of onset, duration, and time to reach maximal 
effect. The stimulant-induced reduction in motor activity can persist for up to 
7-8 hours, whereas the drug’s effects on attention last for only 2-3 hours39,66. 
Because most studies did not include repeated effect measurements, it is con-
ceivable that in some studies the time points of specific measurement did not 
coincide with the time of maximal effect, thereby missing potentially signifi-
cant improvements. In addition, previous studies reported evidence of acute 
tolerance to mph67,68. mph pharmacokinetics and/or pharmacodynamics also 
vary among children with adhd. Thus, it is possible that some studies lacked 
a sufficiently large sample size to detect a significant effect. Although this 
might have been overcome by performing a formal quantitative meta-ana-
lysis, in nearly all cases this would have been hampered by the lack of uniform 
quantitative outcome parameters. The change from baseline following mph 
treatment can also depend on the individual patient’s baseline value (i.e., 
intrinsic state) and is estimated to account for approximately half of the vari-
ability observed in mph’s effects69. 
Nevertheless, despite these limitations, we identified several tests that 
could potentially serve as biomarkers for monitoring the acute effects of a sin-
gle dose of mph-ir in pediatric adhd. The most reliable tests were related to 
adhd’s core features of motor control, attention and impulsivity, and event-re-
lated potentials. These potential biomarkers might help identify responders 
versus non-responders following a test dose of mph. Because dose-effect 
relationships could not be quantified, these tests and clusters should be 
have played a role57, potentially increasing the publication success of studies 
that report significant mph effects. Moreover, although grouping the tests 
into functional clusters and domains provided a degree of standardization, it 
also reduced the level of detail with respect to the information collected. Thus, 
potentially suitable biomarkers might have been missed, given that infre-
quently used outcome measures were excluded from further analysis. 
Other limitations are inherent to the nature of the studies that have been 
published. Studies with a period of *5 half-lives between placebo and mph 
occasions were included to ensure complete washout; however, in some 
studies, the effects of mph on withdrawal – rather than mph’s effects on the 
condition itself – may have been measured. In addition, several studies used 
different criteria for selecting subjects, leading to potential differences in base-
line impairment and subsequent differences in the magnitude of the response 
to treatment. Our search also returned studies in which subjects received prior 
treatment with mph. Differences between adhd patients who were previously 
treated with mph and ‘mph-naïve’ patients have been reported in networks 
associated with executive control58 and dopaminergic metabolism84, and 
this difference may have influenced our findings. In addition, several studies 
used a titration scheme; rather than controlling the mph dose given before the 
study period, the children were stabilized with an optimal mph dose (deter-
mined by the treating clinician) before evaluating the effect of the treatment. 
Patients receiving a high dose of mph (i.e., 60 mg) have been reported to exhibit 
smaller changes in clinical measures during placebo treatment, suggesting 
that patients who require a higher dose of mph are likely to have a worse out-
come if left untreated. These subjects also exhibited higher sensitivity to drug 
treatment, reflected in smaller estimated ec50 values59, consistent with pre-
vious reports that children with more behavior problems at baseline tend to 
respond better to mph9,60,61. Moreover, the majority of studies included boys 
5-13 years of age. Only a few studies (primarily the more recent studies) also 
included preschoolers and adolescents with adhd and/or included a reason-
able numbers of girls. A limited body of evidence suggests that aside from the 
preschool period62,63, few age-related differences exist during childhood and 
non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 62 –
 
chapter 3 – biomarkers of mph effect in pediatric adhd  
– 63 –
references
1  World Health Organization. icd-10; Interna-
tional Statistical Classification of Diseases 
and Related Health Problems. 1999.
2  American Psychiatric Association. dsm-iv: 
Diagnosic and Statistical Manual of Mental 
Disorder. 4th ed. Washington, dc: The Asso-
ciation; 1994.
3  Greenhill LL, Pliszka S, Dulcan MK, Bernet W, 
Arnold V, Beitchman J, et al. Practice param-
eter for the use of stimulant medications in 
the treatment of children, adolescents, and 
adults. J Am Acad Child Adolesc Psychiatry. 
2002;41:26S-49S.
4  Arnsten af. Stimulants: Therapeutic actions 
in adhd. Neuropsychopharmacology. 
2006;31:2376-2383.
5  Greenhill LL, Pliszka S, Dulcan MK, Bernet W, 
Arnold V, Beitchman J, et al. Summary of the 
practice parameter for the use of stimulant 
medications in the treatment of children, 
adolescents, and adults. J Am Acad Child 
Adolesc Psychiatry. 2001;40:1352-1355.
6  Markowitz JS, Straughn AB, Patrick KS. 
Advances in the pharmacotherapy of atten-
tion-deficit-hyperactivity disorder: focus on 
methylphenidate formulations. Pharmaco-
therapy. 2003;23:1281-1299.
7  Swanson J, Volkow N. Pharmacokinetic and 
pharmacodynamic properties of methyl-
phenidate in humans, in stimulant drugs 
and adhd: Basic and clinical neuroscience. 
259-82. 2001. New York: Oxford University 
Press 2001, Solanto MV, Arnsten AF, Castel-
lanos FX, Eds. 
8  Swanson JM, Wigal SB, Wigal T, Sonu-
ga-Barke E, Greenhill LL, Biederman J, et al. A 
comparison of once-daily extended-release 
methylphenidate formulations in children 
with attention-deficit/hyperactivity dis-
order in the laboratory school (the Comacs 
Study). Pediatrics. 2004;113:e206-e216.
9  Sonuga-Barke EJ, Swanson JM, Coghill 
D, DeCory HH, Hatch SJ. Efficacy of two 
once-daily methylphenidate formulations 
compared across dose levels at different 
times of the day: preliminary indications 
from a secondary analysis of the comacs 
study data. bmc Psychiatry. 2004;4:28.
10  Oettinger L, Jr., Majovski lv. Methylpheni-
date: a review. South Med J. 1976;69:161-163.
11  Pietrzak RH, Mollica CM, Maruff P, Snyder 
PJ. Cognitive effects of immediate-release 
methylphenidate in children with atten-
tion-deficit/hyperactivity disorder. Neurosci 
Biobehav Rev. 2006;30:1225-1245.
12  de Visser SJ, van der Post J, Pieters MS, Cohen 
AF, van Gerven JM. Biomarkers for the 
effects of antipsychotic drugs in healthy vol-
unteers. Br J Clin Pharmacol. 2001;51:119-132.
13  de Visser SJ, van der Post JP, de Waal PP, 
Cornet F, Cohen AF, van Gerven JM. Bio-
markers for the effects of benzodiazepines 
in healthy volunteers. Br J Clin Pharmacol. 
2003;55:39-50.
14  Dumont GJ, de Visser SJ, Cohen AF, van 
Gerven jm. Biomarkers for the effects of 
selective serotonin reuptake inhibitors 
(ssris) in healthy subjects. Br J Clin Pharma-
col. 2005;59:495-510.
15  Zuurman L, Ippel AE, Moin E, van Gerven JM. 
Biomarkers for the effects of cannabis and 
thc in healthy volunteers. Br J Clin Pharma-
col. 2009;67:5-21.
16  Dumont GJ, Verkes RJ. A review of acute 
effects of 3,4-methylenedioxymeth-
amphetamine in healthy volunteers. J 
Psychopharmacol. 2006;20:176-187.
17  Zoethout RW, Delgado WL, Ippel AE, Dahan 
A, van Gerven JM. Functional biomarkers for 
the acute effects of alcohol on the central 
nervous system in healthy volunteers. Br J 
Clin Pharmacol. 2011;71:331-350.
18  Strauss E, Sherman EMS, Spreen O. A 
Compendium of Neuropsychological Tests; 
Administration, Norms and Commentary. 
3rd ed. New York: Oxford University Press, 
Inc.; 1998.
19  Lezak MD hdld. Neurosphychological 
Assesment. 4th ed. New York: Oxford Univer-
sity Press; 2004.
investigated further in order to thoroughly evaluate the dose-response rela-
tionships, including effect size and, and establish clinically relevant changes. 
Our study revealed that these studies would benefit greatly from a certain 
degree of standardization. Ideally, these studies should include concentra-
tion- (in addition to dose-) effect relationships at several time points in order 
to profile the effect of mph treatment in children and adolescents with adhd. 
Short-term data is generally inadequate for assessing a long-term treat-
ment response, as large-scale studies have shown that short-term response 
rates – which can be as high as 75-80% – often drop to 55-60% over the long 
run. Therefore, the predictive value of these candidate mph biomarkers should 
be tested in long-term trials. In addition, performing multiple tests – rather 
than one test – may be preferred in such a long-term trial, as multiple tests can 
yield a more precise and stronger prediction of the response to mph treatment 
and can account for the heterogeneity of adhd52. This research should also 
include biomarkers for mph tolerance, as many children who respond posi-
tively to mph also experience adverse side events70,71, potentially reducing 
treatment compliance or causing the patient to discontinue treatment alto-
gether70-72. Finally, these putative mph biomarkers could help guide future 
research regarding the core pathology of adhd, mph’s mechanism of action, 
and the effects of stimulant use in children in general, as distinct classes of 
drugs can elicit distinct effect profiles12-17. 
non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 64 –
 
chapter 3 – biomarkers of mph effect in pediatric adhd  
– 65 –
37  Verbaten MN, Overtoom CC, Koelega HS, 
Swaab-Barneveld H, van der Gaag RJ, 
Buitelaar J, et al. Methylphenidate influenc-
es on both early and late erp waves of adhd 
children in a continuous performance test. J 
Abnorm Child Psychol. 1994;22:561-578.
38  Winsberg BG, Javitt DC, Silipo GS. Elec-
trophysiological indices of information 
processing in methylphenidate responders. 
Biol Psychiatry. 1997;42:434-445.
39  Solanto MV. Dopamine dysfunction in 
ad/hd: integrating clinical and basic 
neuroscience research. Behav Brain Res. 
2002;130:65-71.
40  Volkow ND, Wang GJ, Fowler JS, Ding YS. 
Imaging the effects of methylphenidate 
on brain dopamine: new model on its 
therapeutic actions for attention-deficit/
hyperactivity disorder. Biol Psychiatry. 
2005;57:1410-1415.
41  Barrickman L, Noyes R, Kuperman S, Schum-
acher E, Verda M. Treatment of adhd with 
fluoxetine: a preliminary trial. J Am Acad 
Child Adolesc Psychiatry. 1991;30:762-767.
42  Milberger S, Biederman J, Faraone SV, Chen 
L, Jones J. adhd is associated with early 
initiation of cigarette smoking in children 
and adolescents. J Am Acad Child Adolesc 
Psychiatry. 1997;36:37-44.
43  Davids E, Zhang K, Tarazi FI, Baldessarini RJ. 
Animal models of attention-deficit hyper-
activity disorder. Brain Res Brain Res Rev. 
2003;42:1-21.
44  Horner WE, Johnson DE, Schmidt AW, Rolle-
ma H. Methylphenidate and atomoxetine 
increase histamine release in rat prefrontal 
cortex. Eur J Pharmacol. 2007;558:96-97.
45  Wilens TE. Effects of methylphenidate on 
the catecholaminergic system in atten-
tion-deficit/hyperactivity disorder. J Clin 
Psychopharmacol. 2008;28:S46-S53.
46  Prince J. Catecholamine dysfunction in 
attention-deficit/hyperactivity disor-
der: an update. J Clin Psychopharmacol. 
2008;28:S39-S45.
47  Bush G. Attention-deficit/hyperactivity 
disorder and attention networks. Neuropsy-
chopharmacology. 2010;35:278-300.
48  Barry RJ, Johnstone SJ, Clarke AR. A 
review of electrophysiology in atten-
tion-deficit/hyperactivity disorder: ii. 
Event-related potentials. Clin Neurophysiol. 
2003;114:184-198.
49  Zillessen KE, Scheuerpflug P, Fallgatter AJ, 
Strik WK, Warnke A. Changes of the brain 
electrical fields during the continuous 
performance test in attention-deficit 
hyperactivity disorder-boys depending on 
methylphenidate medication. Clin Neuro-
physiol. 2001;112:1166-1173.
50  Kavale K. The efficacy of stimulant drug 
treatment for hyperactivity: a meta-analy-
sis. J Learn Disabil. 1982;15:280-289.
51  Coghill DR, Seth S, Pedroso S, Usala T, Currie 
J, Gagliano A. Effects of Methylphenidate on 
Cognitive Functions in Children and Adoles-
cents with Attention-Deficit/Hyperactivity 
Disorder: Evidence from a Systematic 
Review and a Meta-Analysis. Biol Psychiatry. 
2013.
52  Hermens DF, Cooper NJ, Clark CR, Debrota 
D, Clarke SD, Williams LM. An integrative 
approach to determine the best behavioral 
and biological markers of methylphenidate. 
J Integr Neurosci. 2007;6:105-140.
53  Linssen AM, Vuurman EF, Sambeth A, Nave 
S, Spooren W, Vargas G, et al. Contingent 
negative variation as a dopaminergic bio-
marker: evidence from dose-related effects 
of methylphenidate. Psychopharmacology 
(Berl). 2011;218:533-542.
54  Barkley RA, DuPaul GJ, McMurray MB. 
Attention deficit disorder with and without 
hyperactivity: clinical response to three 
dose levels of methylphenidate. Pediatrics. 
1991;87:519-531.
55  Beery SH, Quay HC, Pelham WE, Jr. Differ-
ential Response to Methylphenidate in 
Inattentive and Combined Subtype adhd. J 
Atten Disord. 2013.
56  Grizenko N, Rodrigues Pereira RM, Joober R. 
Sensitivity of scales to evaluate change in 
20  Conners CK, Sitarenios G, Parker JD, 
Epstein JN. Revision and restandardiza-
tion of the Conners Teacher Rating Scale 
(CTRS-R): factor structure, reliability, and 
criterion validity. J Abnorm Child Psychol. 
1998;26:279-291.
21  Ullmann RK, Sleator EK, Sprague RL. A new 
rating scale for diagnosis and monitoring 
of add children. Psychopharmacol Bull. 
1984;20:160-164.
22  Pliszka S. Practice parameter for the 
assessment and treatment of children and 
adolescents with attention-deficit/hyper-
activity disorder. J Am Acad Child Adolesc 
Psychiatry. 2007;46:894-921.
23  Farmacotherapeutisch Kompas Nederland. 
yearly ed. College voor Zorgverzekeringen; 
2009.
24  Hinshaw SP, Heller T, McHale JP. Covert anti-
social behavior in boys with attention-deficit 
hyperactivity disorder: external validation 
and effects of methylphenidate. J Consult Clin 
Psychol. 1992;60:274-281.
25  Pelham WE, Hoza B, Kipp HL, Gnagy EM, 
Trane ST. Effects of methylphenidate and 
expectancy of adhd children‘s perfor-
mance, self-evaluations, persistence, and 
attributions on a cognitive task. Exp Clin 
Psychopharmacol. 1997;5:3-13.
26  Malone MA, Kershner JR, Siegel L. The effects 
of methylphenidate on levels of processing 
and laterality in children with attention 
deficit disorder. J Abnorm Child Psychol. 
1988;16:379-395.
27  Overtoom CC, Verbaten MN, Kemner C, Ken-
emans JL, Van EH, Buitelaar JK, et al. Effects of 
methylphenidate, desipramine, and L-dopa 
on attention and inhibition in children with 
Attention Deficit Hyperactivity Disorder. 
Behav Brain Res. 2003;145:7-15.
28  Jonkman LM, Kemner C, Verbaten MN, 
Van EH, Camfferman G, Buitelaar JK, 
et al. Attentional capacity, a probe erp 
study: differences between children with 
attention-deficit hyperactivity disorder 
and normal control children and effects 
of methylphenidate. Psychophysiology. 
2000;37:334-346.
29  Jonkman LM, Kemner C, Verbaten MN, Koele-
ga HS, Camfferman G, vd Gaag RJ, et al. Effects 
of methylphenidate on event-related poten-
tials and performance of attention-deficit 
hyperactivity disorder children in auditory 
and visual selective attention tasks. Biol 
Psychiatry. 1997;41:690-702.
30  Klorman R, Salzman LF, Bauer LO, Coons HW, 
Borgstedt AD, Halpern WI. Effects of two 
doses of methylphenidate on cross-situa-
tional and borderline hyperactive children‘s 
evoked potentials. Electroencephalogr Clin 
Neurophysiol. 1983;56:169-185.
31  Michael RL, Klorman R, Salzman LF, Borg-
stedt AD, Dainer KB. Normalizing effects of 
methylphenidate on hyperactive children‘s 
vigilance performance and evoked poten-
tials. Psychophysiology. 1981;18:665-677.
32  Miller DC, Kavcic V, Leslie JE. ERP changes 
induced by methylphenidate in boys with 
attention-deficit hyperactivity disorder. 
Journal of Attention Disorders. 1996;1:95-113.
33  Novak GP, Solanto M, Abikoff H. Spatial 
orienting and focused attention in attention 
deficit hyperactivity disorder. Psychophysiol-
ogy. 1995;32:546-559.
34  Pliszka SR, Liotti M, Bailey BY, Perez R, III, 
Glahn D, Semrud-Clikeman M. Electrophys-
iological effects of stimulant treatment on 
inhibitory control in children with atten-
tion-deficit/hyperactivity disorder. J Child 
Adolesc Psychopharmacol. 2007;17:356-366.
35  Sunohara GA, Malone MA, Rovet J, Hum-
phries T, Roberts W, Taylor MJ. Effect of 
methylphenidate on attention in children 
with attention deficit hyperactivity disorder 
(adhd): erp evidence. Neuropsychopharma-
cology. 1999;21:218-228.
36  Jonkman LM, Kemner C, Verbaten MN, 
Van EH, Kenemans JL, Camfferman G, et al. 
Perceptual and response interference in 
children with attention-deficit hyperactivity 
disorder, and the effects of methylphenidate. 
Psychophysiology. 1999;36:419-429.
non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 66 –
 
chapter 3 – biomarkers of mph effect in pediatric adhd  
– 67 –
table 1 Literature search queries  




(‘Attention Deficit Disorder with Hyperactivity’[Mesh] or ‘attention deficit hyperactivity disorder’[all fields] 
or ‘attention deficit disorder’[all fields] or ‘adhd’[all fields] or ‘minimal brain disfunction’[all fields] or ‘atten-
tion-deficit/hyperactivity disorder’[all fields]) and (‘methylphenidate’[Mesh Terms] or ‘methylphenidate’ 
[All Fields] or (‘methylphenidate’[Mesh Terms] or ‘methylphenidate’[All Fields] or ‘dexmethylphenidate’ 
[All Fields]) or (‘methylphenidate’[Mesh Terms] or ‘methylphenidate’[All Fields] or ‘ritalin’[All Fields]) or 
‘stimulant medication’[all fields] or ‘stimulant medications’[all fields]) and (‘humans’[Mesh Terms] and 
English[lang] and (Clinical Trial[ptyp] or Randomized Controlled Trial[ptyp] or Clinical Conference[ptyp]  
or Clinical Trial, Phase I[ptyp] or Clinical Trial, Phase ii[ptyp] or Clinical Trial, Phase iii[ptyp] or Clinical Trial, 
Phase iv[ptyp] or Comparative Study[ptyp] or Consensus Development Conference[ptyp] or Consensus 
Development Conference, nih[ptyp] or Evaluation Studies[ptyp] or Research Support, Non us Gov’t[ptyp]  




(*attention deficit disorder/ or attention deficit hyperactivity disorder.ti,ab. or attention deficit disorder.
ti,ab. or adhd.ti,ab. or minimal brain disfunction.ti,ab.) and (methylphenidate.ti,ab. or *methylphenidate/ or 
dexmethylphenidate.ti,ab. or Ritalin.ti,ab.) and (biomarker*.mp. or biological marker/ or biological marker*.






(de ‘Attention Deficit Disorder with Hyperactivity’ or de ‘Attention Deficit Disorder’ or tx adhd or tx attention  
deficit disorder or tx attention deficit hyperactivity disorder or tx minimal brain disfunction) and (de ‘Methyl-
phenidate’ or tx methylphenidate or tx dexmethylphenidate or tx Ritalin) and (de ‘Biological Markers’ or  
tx biological marker* or tx biomarker* or de ‘Treatment Outcomes’ or tx treatment outcome* or tx treatment 
response* or tx treatment effect* or tx predictor*
table 2 Characteristics of studies included in the analysis 
Tests n (%) Observations n (%) Total n (%)
Number of studies 72 31 78
Sex Male 1769 (91%) 1423 (93%) 2695 (92%)
Female 168 (9%) 100 (7%) 234 (8%)
mph dose High (*0.60 mg/kg) 26 (36%) 12 (39%) 29 (37%)
Medium (0.25-0.59 
mg/kg)
66 (92%) 28 (90%) 72 (92%)
Low (0.1-0.25) 15 (21%) 6 (19) 16 (21%)
Wash-out period > 1 week 9 (13% 0 (0%) 9 (12%
> 5 half-lives 63 (88%) 31 (100%) 69 (89%)
Age 5-13 years 58 (81%) 27 (87%) 64 (82%)
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table 4 Improvement following mph for each individual test or observation that was used 
in at least five studies














Go Task 7 11 63.6 7
Reaction Time Task 9 18 50.0 6
Continuous Performance Task 16 21 76.2 9
Go/No-Go Task 13 21 61.9 10
Arithmetic Task 11 28 39.3 6







Following Rules Observation 15 15 100.0 5
Oppositional Behavior Observations 12 14 85.7 6
On-task Behavior Observation 12 12 100.0 7
Impulsivity Behavior Observation 13 19 68.4 6
Social Behavior Observation 12 32 37.5 6
table 5  Effect of mph for each functional cluster that was used across at least five studies









Attention Divided Attention Test - 28.6 71.4 7 5
Focused/Selective 
Attention
Test 1.9 54.7 43.4 54 26
Reaction Time Test - 50.0 50.0 28 9
Reaction Time* Test* - 25.0 75.0 8 6
Sustained Attention 
(Vigilance) 
erp - 60.0 40.0 10 6
Sustained Attention 
(Vigilance)
Test - 23.9 76.1 50 22
Scale - Attention Observation - 16.7 83.3 30 13
Behavior Scale - Oppositional Observation 2.0 12.2 85.7 49 10
Disease 
Intensity
Scale - adhd Observation - 19.5 80.5 41 9
Executive Impulsivity Test - 50.0 50.0 46 16
Impulsivity* Test* - 43.6 56.4 39 13
Reasoning/Association/
Problem Solving
Test - 61.0 39.0 41 11
Set Shifting Test - 57.1 42.9 14 7
Working Memory/
Immediate Recognition
Test - 69.5 30.5 82 8
Language Production Test - 83.3 16.7 18 6
Spelling/Grammar/
Semantics
Test 6.7 46.7 46.7 15 7
Scale - Impulsivity Observation - 21.2 78.8 33 9
Motor Motor Control Test - 28.1 71.9 32 8
Neuro-
physiologic
Evoked Potential Test - 13.0 87.0 23 11
Social 
behavior
Scale - Social 
Interaction
Observation - 64.9 35.1 32 8
‘+’ reflects an improvement or increase, ‘=’ reflects no significant effect and ‘-’ reflects an impairment 
or decrease as measured by the corresponding test. Whenever tests provided different parameters 
with information on more than one functional domain, effects were scored separately, and the 
secondary effects were marked (*). 
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table 6 Dose-response relationship for outcome measures and functional clusters that 





Low Dose Medium 
Dose
High Dose





Test - 100 0 2 - 28 72 22 - 11 89 6
Motor 
Motor Control Test - 33 67 5 - 33 67 5 - 18 82 3
Disease Intensity
Scale - adhd Observation - 11 89 4 - 27 73 9 - 0 100 4
Individual test
Go/No-go Task Test - 20 80 5 - 50 50 6 - 25 75 3
n is the number of studies in which the cluster was evaluated (for each dose)
Determination of 
methylphenidate in plasma 
and saliva by liquid 
chromatography/tandem 
mass spectrometry   
Journal of Chromatography B, 923–924 (2013) 22–28
 
 
Ahmet Seçilir1, Lenneke Schrier2, Yuma A Bijleveld1, Jan H Toersche1, 
Sona Jorjani1, Jacobus Burggraaf2, Joop MA van Gerven2, Ron aa Mathôt1
1. Academic Medical Center (amc), Amsterdam 
2. Centre for Human Drug Research (chdr), Leiden
chap ter 4
non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 76 –
 
chapter 1 – introduction
– 77 –
and saliva at room temperature and 5°C. Samples were stable 
at -20°C for at least 4 weeks. The method was successfully 
applied for the determination of mph concentrations in 
plasma and saliva samples from an adult healthy volunteer. 
Using protein precipitation and hydrophilic interaction liquid 
chromatography coupled to tandem mass spectrometry, this 
method allows fast, accurate and precise quantification of mph 
in both plasma and saliva.
abstr act  
 
Methylphenidate (mph) is a phenethylamine derivative used 
in the treatment of attention-deficit hyperactivity disorder 
(adhd). In adults, clinical monitoring of mph therapy is usually 
performed by measuring plasma mph concentrations. In 
children blood sampling is however undesirable. Saliva may 
be an alternative matrix for monitoring mph concentrations 
with the advantage that it can be obtained non-invasively. 
Therefore, we developed an analytical method for the 
quantification of mph in both plasma and saliva.  
We present the validation of a liquid chromatography-
tandem mass spectrometric method using a hydrophilic 
interaction liquid chromatography column (hilic). In 100 µl 
sample, proteins were precipitated with 750 µl acetonitrile/
methanol 84/16 (v/v) containing d9-methylphenidate as the 
internal standard. Standard curves were prepared over the 
mph concentration range of 0.5-100.0 µg/l. The total analysis 
time was 45 seconds. Accuracy and within- and between-run 
imprecision were in the range of 98-108% and less than 7.0%, 
respectively. Matrix effects were greater for plasma than saliva 
with 46% and 8% ionization suppression. The matrix effects 
were adequately compensated by the use of deuterated mph 
as internal standard. mph significantly degraded in plasma 
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hydrophilicity of the compound. This may produce a significant loss in sensi-
tivity due to the co-elution with matrix interference and the high percentage 
of water at the chromatographic elution time. Recent research however has 
shown that for hydrophilic compounds the sensitivity, precision and accura-
cy of a quantitative analytical chromatographic method may be improved by 
using hydrophilic interaction liquid chromatography (hilic)19. In addition, 
the use of hilic has advantages in sample preparation when measuring polar 
compounds. Because of the high organic modifier content, usually acetonitrile, 
used during chromatography, proteins can be precipitated using organic sol-
vents without the loss of chromatographic integrity, as is often the case when 
used with polar compounds in combination with rp chromatography. A high 
organic modifier concentration is also ideal for compound ionization by elec-
trospray ionization mass spectrometry (esi-ms), resulting in higher sensitivity. 
The aim of the present study was to develop a method to determine mph 
concentrations in human plasma and saliva for potential use in therapeutic 
drug monitoring. We present the development and validation of an analytical 
method using hilic chromatography coupled to tandem mass spectrometry. 
The stability of mph in plasma and saliva was investigated at different tem-
peratures. The applicability of the method was demonstrated with plasma and 
saliva data from one healthy adult volunteer obtained before and after intake 
of 10 mg immediate release (ir) mph and 18 mg mph – osmotic controlled-re-
lease oral delivery system (oros) – on different occasions.
Materials and methods
Chemicals
Methylphenidate was purchased from Bufa (Uitgeest, Netherlands). As an 
internal standard (i.s.) a 1 mg/ml solution of deuterated methylphenidate hcl 
(d9-mph) in methanol was obtained from lgc-Standards (Teddington, United 
Introduction
Methylphenidate (mph) is a psychostimulant widely used in the treatment 
of attention-deficit hyperactivity disorder (adhd). adhd is a neurobehavior-
al problem mostly encountered in school-aged children at a prevalence of 
5-10% of the general population1,2. mph is a piperidine-derived molecule that 
contains two chiral centers and exists as four stereoisomers (Figure 1). The 
pharmacological activity resides entirely with the dl-threo-methylphenidate 
racemic (50:50) mixture3.
The major metabolic pathway of mph is the hydrolysis of the methyl ester 
linkage by esterases to form ritalinic acid4-5. Minor metabolic pathways for 
both these compounds include parahydroxylation of the aromatic ring, oxida-
tion to 6-oxo-dervatives and glucuronide formation6-7. Ritalinic acid and the 
other metabolites are pharmacologically inactive8-10. 
There is a clinical need to perform therapeutic drug monitoring (tdm) in 
patients who are undergoing mph therapy. mph exhibits wide inter-individual 
variability in both pharmacokinetics and clinical response11-12. tdm can be 
applied when the patient remains unresponsive to therapy, exhibits unexpect-
ed adverse events or to check adherence. In adults, clinical monitoring of mph 
therapy is usually performed by measuring plasma mph concentrations. In 
children, monitoring of drug levels should be performed with minimal discom-
fort for the patient. Monitoring of mph concentrations in saliva may therefore 
be an interesting non-invasive alternative to blood sampling as demonstrated 
earlier by Marchei and coworkers13.
Several methods have been developed for quantification of mph in plasma, 
urine and hair, using high-performance liquid chromatography (hplc) with 
ultraviolet detection6,14, capillary electrophoresis-mass spectrometry15, gas 
chromatography-mass spectrometry8,9,16 and liquid chromatography–tan-
dem mass spectrometry7,13,17-18. The determination of mph concentrations 
by standard reversed-phase (rp) chromatography coupled to ms/ms detection 
is particularly challenging since retention times may be short due to the high 
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Analytical procedures
preparation of stock solutions, calibration standards  
and quality control solutions
Two stock mph solutions (5.0 mg/l and 50.0 mg/l) were prepared by dissolv-
ing mph in water/methanol 1/1 (v/v). The stock internal standard (10 µg/l) was 
prepared by diluting the 1 mg/ml d9-mph standard solution with acetonitrile/
methanol 84/16 (v/v). All stock solutions were stored at 5°C until use.
Four mph calibration standard solutions (5.0, 10.0, 25.0 and 50.0 µg/l) were 
prepared by diluting 10, 20, 50, and 100 µl of the 5.0 mg/l stock solution in 10 
ml of water/methanol 1/1 (v/v). Three mph calibration standard solutions (100, 
400 and 1000 µg/l) were prepared by diluting 20, 80 and 200 µl of the 50.0 mg/l 
stock solution in 10 ml of water/methanol 1/1 (v/v). Quality control (qc) solu-
tions were prepared in a similar manner as the calibration standard solutions. 
The mph concentrations of the qc solutions were 5.0, 100 and 1000 µg/l. The 
calibration standard and qc solutions were stored at 5°C until use. 
sample preparation
Calibration standards and qc samples were prepared just prior to analysis. 
Calibration standard and qc solutions were shortly vortexed and a volume 
of 10 µl was pipetted into a 1.8 ml vial. Subsequently, 100 µl saliva or plasma, 
depending on the composition of the calibration line, was added and shortly 
vortexed. Final concentrations of the plasma and saliva calibration line were 
0.5, 1.0, 2.5, 5.0, 10.0, 40.0 and 100.0 µg/l and final concentrations of the quality 
controls were 0.5 (qc1 (lloq)), 10.0 (qc2) and 100.0 µg/l (qc3). Patient plasma 
and saliva samples were thawed and shortly vortexed and 100 µl of each sam-
ple was pipetted into a 1.8 ml vial. Subsequently, 10 µl of water/methanol 1/1 
(v/v) was added and shortly vortexed. In all samples proteins were precipitated 
by adding 750 µl of the internal standard solution. After vortexing for 1 minute, 
Kingdom) (Figure 1). Water was purified and deionized using an elga purelab 
Optron q (Veolia Water; Saint Maurice, France). Drug free, non sterile, k2 edta 
human plasma was obtained from Equitech-Bio (Kerrville-tx, usa). OraFlx syn-
thetic saliva was obtained from Dyna-Tek (Lenexa-ks, usa).
Instrumentation
The lc-ms setup comprised of a Thermo Scientific Surveyor lc (Waltham-ma, 
usa) system coupled to a Maylab Mistraswitch column oven (Spark Holland, 
Netherlands Emmen), and a Thermo Scientific tsq Quantum Access ms system 
with an esi source. The Xcalibur 2.0.7 sp1 (Thermo Scientific) software package 
was used for controlling the lc-ms system and for data processing.
lc-ms/ms conditions
Isocratic elution was applied using A: 2% formic acid in water (v/v) and B: 
acetonitrile 100%. A was set at 10% and B at 90%. Analytical separation was 
accomplished on a SeQuant zic-hilic column (Merck, Darmstadt, Germany) 
with a length of 50 mm, an internal diameter of 2.1 mm and 5 µm particle size. 
The flow rate was 1.00 ml/min giving a total chromatographic run time of only 
45 seconds. To minimize carry-over effects the lc injection system was washed 
with 20% formic acid in water (v/v) after every injection. The autosampler tem-
perature was maintained at 10°C, the column oven at 30°C. The analytes were 
detected in positive ion mode using multiple reaction monitoring (mrm). The 
ion spray voltage was 5000 V and the ion transfer tube temperature was 250°C. 
Sheath and auxiliary gas pressure were 50 and 20 psi, respectively. Collision gas 
(argon) pressure was 2.0 mTorr. mph and d9-mph were measured as [M+H]
+ 
using the mass transitions 234.1 A 84.1 and 243.1 A 93.1 respectively. Tube lens 
voltage and collision energy were 90 and 21 V, respectively. Dwell time was 300 
ms for mph and 50 ms for d9-mph.
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single sample of each level was analyzed (between-run imprecision). Mean 
accuracy and within-run imprecision (coefficient of variation) were calculated 
from the results (n=6) of the first run. Between-run imprecision was calculated 
from the results (n=6) of the first sample of the first run and the samples of run 
two through six. According to the us Food and Drug Adminstration guideline 
for bio-analytical method validation the mean accuracy should be within 
85-115% and the within-run and between-run imprecision should be less than 
15%19. Furthermore, the limit of quantification of the assay was defined as the 
lowest concentration of mph that could be detected with a mean accuracy 
within 80-120% and within-run and between-run imprecision not exceeding 
20% of the coefficient of variation20.
Since plasma and saliva may be diluted to obtain concentrations in the 
calibration range, the accuracy of diluted samples was determined as well. 
Plasma and saliva samples were prepared with concentrations of 100 µg/l 
(qc3) and 1000 µg/l. All samples were diluted ten times with commercially 
acquired saliva and plasma (10 µl sample + 90 µl plasma/saliva) in six fold and 
the accuracy was determined. Mean accuracy of the diluted samples should be 
within 85%-115% and imprecision should be less than 15%.
process efficiency and matrix effects
Plasma, saliva and solvent components in the ionization chamber may cause 
batch specific ion suppression or enhancement, leading to inter-patient 
and intra-patient signal variability21-22. Assay recovery and matrix effects 
were quantified for both plasma and saliva using the strategies proposed by 
Matuszewski et al23. In short, chromatograms were obtained from plasma and 
saliva samples that were spiked pre-precipitation, plasma and saliva samples 
spiked post-precipitation and spiked aqueous solutions. In total, six batches of 
plasma and saliva were spiked in duplicate; the mph and d9-mph concentra-
tions were 10 µg/l. Recovery (re) was defined as the relative signal of samples 
spiked post-precipitation versus pre-precipitation. Matrix effects (me) were 
similarly defined as the relative signal of post-precipitation spiked plasma 
and saliva samples versus spiked aqueous samples. A value of 100% for me 
samples were stored at -20°C for 30 minutes to enhance protein precipitation, 
vortexed again and centrifuged for 5 minutes at 480xg. Two microliter of the 
supernatant was injected.
quantification
ms response was expressed as integrated area of the chromatographic peak. 
For calibration, the concentration of prepared calibration standards was the 
known variable (x), the ratio of analyte ms response divided by internal stan-
dard ms response per calibration level was the unknown variable (y). Patient 
samples were back-calculated using the calibration line by their respective 
ratio of analyte / internal standard ms response.
Method validation
selectivity
One lot of blank, commercially acquired saliva and plasma, together with sali-
va and plasma samples from five different patients, not receiving mph, were 
tested for interferences. Proteins were precipitated using acetonitrile/meth-
anol 84/16 (v/v) without i.s. The data of the chromatograms were processed 
and the integrated response should not exceed 10% of the average integrated 
response of the lloq of mph and 1% of the integrated response of d9-mph.
calibration
A total of six calibration lines, consisting of seven different concentrations, 
were prepared in commercially acquired saliva and plasma and measured 
during six runs. Calibration curves were obtained by fitting the peak area ratios 
to a weighted (1/x) least squares regression model. 
accuracy and imprecision
The accuracy and imprecision of the method were determined for the qc sam-
ples during six consecutive runs. In the first run all qc concentration levels were 
analyzed in six fold (within-run imprecision); during the following five runs a 
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Clinical application
The developed assay was applied to saliva and plasma samples from a healthy 
adult volunteer participating in a pharmacokinetic study. The study was 
approved by the local Institutional Ethics Committee. Saliva and blood sam-
ples were collected at t=-30, -15 (saliva only), 20, 40, 60, 80, 100, 120, 150, 180, 210, 
240, 300, 360 minutes following the intake of 10 mg mph-ir (Ritalin). Following 
ingestion of 18 mg mph-oros (Concerta), samples were collected at t=-30, -15 
(saliva only), 20, 40, 60, 80, 100, 120, 150, 180, 210, 240, 270, 300, 330, 360, 390, 420, 
450, 480, 600 and 720 minutes. Study days were separated by at least 5 days to 
ensure complete wash-out. Blood samples were collected in edta tubes and 
put on ice immediately for 30 min. Saliva samples were obtained using the 
polyester Salivette swab system (Sarstedt ag, Nümbrecht, Germany). Samples 
were directly centrifuged at 2000xg for 10 minutes at 4˚C and the plasma and 
saliva were stored at -80°C until analysis.
Results and discussion
Chromatography
Using electrospray in the positive mode ms parameters were tuned to produce 
maximum responses for mph and the internal standard d9-mph. The proton-
ated molecular ions [M+H]+ were m/z 234.1 and 243.1, respectively. The ms2 
spectra of both methylphenidate and d9-methylphenidate are given in Figure 
2; the corresponding most abundant product ions were m/z 84.1 and 93.1.
The chromatographic results after injection of drug free plasma and saliva, 
a lloq sample and a patient receiving mph are shown in Figure 3. The chro-
matography shows excellent peak shape and symmetry, with a peak baseline 
indicated that signals in plasma/saliva samples and aqueous samples phase 
were similar. A me value greater than 100% indicated ionization enhance-
ment, whereas a value less than 100% indicates ionization suppression.
Process efficiency (pe) was defined as the product of re and me, i.e. the over-
all signal of spiked plasma and saliva versus an aqueous standard solution. 
Average values and coefficients of variation of re, me and pe were calculated 
over the six plasma and saliva batches.
stability 
The stability of mph in saliva and plasma qc1 (lloq) and qc3 samples was 
determined for several storage conditions. The freeze-thaw stability in plas-
ma and saliva was determined by comparing freshly prepared samples with 
samples that underwent three freeze-thaw cycles (24 hours at -80°C). The mph 
concentration of plasma and saliva samples stored at -20°C and -80°C was 
determined weekly and compared with freshly prepared samples. The stability 
of mph in plasma and saliva at 5°C was assessed after 2, 5 and 7 days of storage. 
The time course of mph degradation in plasma and saliva was studied at room 
temperature by determination of the mph concentration at the start of the 
experiment and 1, 4, 8, 21.5, 24 and 48 hours after the start. The esterase medi-
ated decay of mph in plasma and saliva was described by a first-order process. 
Data were log-transformed and rate constants were obtained by linear regres-
sion. Half life was calculated by dividing 0.693 by the rate constant.
The mph concentration of processed samples stored in the autosampler 
(10°C) was determined after 24 hours and compared with the initial concen-
tration. The analyte was considered stable in the biological matrix or extracts if 
80%-120% (qc1 (lloq)) or 85%-115% (qc3) of the reference concentration was 
recovered. 
All stability experiments were performed in triplicate and results were 
expressed as mean ± sd.
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calibration 
The calibration curves provided a linear response for the interval 0.5 – 100.0 
µg/l. Un-weighted and weighted linear regression 1/x and 1/x2 were compared 
by means of statistical and graphical methods. A weighting factor of 1/x pro-
vided the best fit. The value of each calibration standard was within 90-110% 
of the nominal value. The correlation coefficients (r2) of the 1/x-weighted 
calibration curves were in the range of 0.9997-1.0000 (n=6, mean 0.9999) for 
plasma and in the range 0.9995-1.0000 (n=6, mean 0.9980) for saliva. The stan-
dard curves were y = 0.00791 (0.00130) x + 0.00235 (0.00306) for plasma and y 
= 0.00807 (0.00130) x + 0.00051 (0.00043) for saliva (mean (95% ci); n=6). For 
plasma the intercepts with the y-axis was not significantly different from zero, 
whereas a small but constant error was present for saliva.
accuracy and imprecision
The lower limit of quantification (lloq) for mph was arbitrarily set at 0.5 µg/l 
(=qc1) in both plasma and saliva. Only noise was detected when blank plasma 
and saliva samples were injected following the injection of the highest calibra-
tion standard; carry-over was less than 0.1%. 
The mean accuracy in both saliva and plasma was within the acceptance 
criteria of 85 – 115% for all qc levels (Table 1). For both plasma and saliva with-
in-day and between-day imprecision were acceptable with values less than 
7.0% in all qc samples. The mean accuracy of ten times diluted samples was 
acceptable as well. Accuracy was 110.5% and 100.2% for plasma samples with a 
concentration of 100 µg/l (qc3) and 1000 µg/l, respectively; the mean accuracy 
in saliva was 105.0% and 102.2% at similar concentrations. 
process-efficiency and matrix effects
The process efficiency of the used method for the quantification of mph in 
plasma was influenced by the occurrence of matrix effects. The matrix effects 
determined at plasma and saliva concentration of 10 µg/l were 53.9 ± 8.7% and 
resolution of less than 10 seconds. Under the chromatographic conditions 
employed, the retention times were 24 s for both mph and internal standard 
d9-mph. The total runtime was 45 s. The reproducibility of the retention times 
was good for the several columns used during the development and validation 
of the method and the analysis of several thousand clinical samples (data not 
shown). The lifetime of the column was acceptable; more than 1000 injections 
could be made before chromatographic performance became unacceptable. 
Total runtimes of reversed-phase chromatographic ms/ms methods for mph 
quantification have been reported to range from 5 to 15 min18, 24-25. When 
using reversed phase chromatography, a short retention time of mph may be 
unfavorable since sensitivity may be reduced due to co-elution of matrix com-
ponents. In the present study application of the hilic column allowed a total 
runtime of 45 s, which was at least 6-fold shorter than published reversed-
phase methods18, 24-25.
Methods have been developed for the simultaneous determination of mph 
and its inactive metabolite ritalinic acid18, 24-25. Assesment of the latter may 
be particularly useful in forensic studies or compliance studies since ritalinic 
acid concentrations are generally 10- to 50- fold higher than methylphenidate 
concentrations and ra may be detected longer following ingestion due to its 
longer elimination half-life26. In case of therapeutic drug monitoring detec-
tion of ritalinic acid has no value, since the individual dose is adjusted on basis 
of determined concentrations of methylphenidate only. 
Validation
selectivity
There were no discernable interfering components in commercially available 
and patient plasma and saliva. Figure 3 shows chromatograms from blank 
plasma and saliva, plasma and saliva spiked with mph at lloq and d9-mph and 
a patient sample. 
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The degradation of qc3 plasma and saliva samples after 3 freeze/thaw cycles 
was acceptable; corresponding values were 6.4 ± 4.2% and 12.4 ± 9.3% (mean 
± sd, n=3). For qc1 samples significant degradation was observed in plasma 
after the second cycle (38.4 ± 9.2%) and in saliva after the third cycle (18.4 ± 
6.2%). This indicates at lower concentrations the number of freeze/thaw cycles 
should be limited to 1. 
The processed plasma and saliva samples were stable in the autosampler 
(10°C) for 24 hours, suggesting that all esterase activity is eliminated after pro-
tein precipitation. 
Little information is available in literature on the stability of mph in plasma 
and saliva. Considering the present results, plasma and saliva samples should 
be immediately frozen at -20°C after collection from the patient. Protein pre-
cipitation should be performed directly following thawing of the sample. 
Clinical application
The developed method was successfully applied for the assessment of mph 
concentration profiles in plasma and saliva in an adult healthy volunteer 
taking 10 mg mph as ir preparation and 18 mg as oros (Figure 5). The time 
profile of mph concentration in saliva followed more or less the plasma time 
profile. During the first hour after ingestion of the ir preparation, saliva con-
centrations were approximately two-fold higher than plasma concentrations. 
This may be caused by some degree of dissolution of the ir formulation in the 
mouth, as this was given in its commercially available tablet form. Two-fold 
higher saliva concentrations were also observed following ingestion of the 
oros formulation, which is a capsule, indicating that another mechanism 
influencing the distribution between plasma and saliva may be involved as 
well. mph is an ampetamine-like compound that has low plasma protein bind-
ing (approximately 15%), and low molecular weight (233 Da) and shows the 
characteristics of a weak base (pKa = 8.9). Based on these characteristics, ion 
trapping may occur, as has also been described for methylenedioxymetham-
phetamine (mdma)28. The free mph fraction passively distributes in its ionized 
92.5 ± 10.2% (mean ± sd, n=6), respectively, corresponding to 46.1% and 7.5% 
ion suppression. Matrix effects for d9-mph were comparable: 55.7 ± 11.2% for 
plasma and 98.0 ± 12.2% for saliva. Notably, the matrix effect for d9-mph in 
plasma was comparable, indicating the beneficial effect of using a deuterat-
ed internal standard. Recovery of mph was 116.6 ± 6.3% in plasma and 103.4 ± 
6.6% in saliva; corresponding values for d9-mph were 113.8 ± 7.7% and 99.8 ± 
7.7% (mean ± sd, n=6). Wang and colleagues reported that a slight difference 
in retention time between analyte and an internal standard labeled with a 
stable isotope may cause a different degree of ion suppression between the 
analogues and, consequently, influence the accuracy of the method27. In our 
method retention times of mph and d9-mph were similar and >90% of the peak 
areas were overlapping. As a result, patient- and time-dependent variability in 
ion suppression will not affect the accuracy of our method.
stability
At -80°C mph concentrations in plasma decreased with 6.4 ± 3.1% (qc1 (lloq)) 
and 2.2 ± 1.9% (qc3) after having been stored for 4 weeks (mean ± sd, n=3). The 
corresponding values in saliva were 2.4 ± 1.0% and 0.3 ± 0.7%. Degradation at 
4 weeks at -20°C was 7.3 ± 4.2% for plasma and 7.8 ± 2.8% for saliva in qc1; cor-
responding values for qc3 were 2.4 ± 3.4% and 0.3 ± 0.5%. At -80°C and -20°C, 
stability was not studied for more than 4 weeks of storage. In qc1 plasma and 
saliva samples stored at 5°C, 43.8 ± 6.1% and 42.7 ± 3.1% was degraded after 
two days, respectively. In qc3 plasma and saliva samples decay was 39.1 ± 2.7% 
and 53.0 ± 3.7%. Apparently, degradation of mph, caused by the catalytic activi-
ty of esterases, is still present at 5°C. 
Figure 4 presents the degradation profile of mph in plasma and saliva for 
qc1 and qc3 at room temperature. After 8 hours of storage the mph concen-
tration of mph was decreased with 5.4 ± 4.2% and 7.0 ± 4.9% (mean ± sd, n=3) 
in the qc1 and qc3 plasma samples, respectively. After 1 hour saliva concen-
trations were reduced with 13.2 ± 3.5% and 6.9 ± 1.7%, respectively. Half-life in 
plasma was 81 ± 7h and 68 ± 6h for qc1 and qc3, respectively; corresponding 
saliva values were 24 ± 4h and 23 ± 3h (mean ± sd, n=3).
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form from blood to saliva (which is more acidic than blood) and then cannot 
diffuse back into plasma, leading to higher mph concentrations in saliva com-
pared to those in plasma.
Alternative biological matrices (hair, oral fluid, sweat) have been studied 
earlier for monitoring therapeutic use or misuse of methylphenidate18, 29. 
Marchei and coworkers demonstrated that the overall patterns of concentra-
tion-time profiles of plasma and saliva mph agreed reasonably well following 
the administration of fast- and extended-release formulations13. They report-
ed higher saliva concentrations than plasma concentrations, which is in 
accordance with the result of the present study. In the referred study however 
the saliva/plasma ratio proved to be time- and formulation dependent, which 
may have hampered clinical application of saliva monitoring so far.
Conclusion
An lc-ms/ms method using hydrophilic interaction liquid chromatography 
has been successfully developed for determination of mph concentrations in 
plasma and saliva. The method has proven to be rapid, sensitive, accurate and 
precise. Due to matrix effects of plasma, the use of deuterated mph as an inter-
nal standard was essential. Stability experiments demonstrated that samples 
should be stored at temperatures of -20°C or below directly after sampling, 
and that samples should be processed immediately after thawing. The assay 
allows further investigation of therapeutic monitoring of mph concentrations 
in saliva.
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figure 2 Product ion mass (ms2) spectra of [m+h]+ for methylphenidate (top) and  
[m+h]+ for d9-methylphenidate (bottom). 
table 1 Accuracy, within-day and between day imprecision for the determination of  
mph in plasma and saliva (n=6) 
qc sample Concentration 
(µg/L)







a qc1 (lloq) 0.5 107.8 5.0 6.9
qc2 10 101.1 7.0 1.6
qc3 100 101.3 4.5 1.7
Sa
liv
a qc1 (lloq) 0.5 106.2 5.9 5.4
qc2 10 99.3 2.2 4.2
qc3 100 98.3 3.4 2.9
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figure 4 Degradation of methylphenidate in plasma (squares) and saliva (circles) at room 
temperature. Closed and open symbols represent the concentration at 0.5 µg/L (qc1 (lloq)) and 100 
µg/L (qc3), respectively (mean ± sd, n = 3). The fitted lines represent the fitted first-order decay for a 
concentration of 0.5 µg/L (dashed line) and µg/L (solid line).
figure 3 Chromatograms of blanco plasma (a), spiked plasma with a methylphenidate 
concentration of 5 µg/l (lloq) (b) and patient plasma (c). Chromatograms of blanco saliva (d), 
spiked saliva with a methylphenidate concentration of 0.5 µg/l (lloq) (e) and patient saliva (f).
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figure 5 Time profiles of methylphenidate concentration in plasma (closed squares) and 
saliva (open squares) in a healthy adult volunteer after intake of 10 mg methylphenidate (mph) 
in an immediate release formulation (Ritalin; top) and 18 mg mph in a sustained release prepa-
ration (Concerta; bottom) on different occasions.
Population pharmaco kinetics 
modeling of 
two methylphenidate 
formulations in plasma and 
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abstr act
and first-order elimination provided the best description 
of estimated mph plasma pk. The estimated clearance was 
6.0 liters/hour and the volume of distribution was 7.5 liters. 
The derived terminal half-life was 0.9 hours. Inter-individual 
variability was identified on clearance, the volume of 
distribution, and the absorption rate constant for mph-oros. 
The saliva-to-plasma mph (s/p) ratio was 2.44 from 2.5 hours 
onward. Inter-individual variability was identified in the s/p 
ratio. With proper allometric scaling techniques, we expect that 
this pk model can used in children to predict the concentration-
time profile in the plasma using mph concentrations measured 




Monitoring methylphenidate (mph) concentrations can 
help determine whether a lack of observed efficacy and/or 
the presence of unexpected adverse effects are related to 
pharmacokinetic (pk) or pharmacodynamic (pd) factors.  
Saliva sampling is a promising non-invasive alternative 
to blood sampling, particularly in children. However, the 
challenges associated with reliably predicting mph plasma 
concentration from a saliva sample has limited the feasibility 
of using saliva sampling to monitor mph plasma concentration. 
Here, we investigate and quantify putative sources of variability 
in mph plasma and saliva concentrations and describe the 
saliva-to-plasma relationship using nonlinear mixed-effect 
population pk modeling. In this randomized, open-label study, 
immediate-release mph (mph-ir) and osmotic release oral 
system mph (mph-oros) were administered in a crossover 
design to 12 healthy adult subjects (six men and six women). 
Paired blood and saliva samples were collected pre-dose and 
at regular intervals for 6 (mph-ir) or 11 (mph-oros) hours 
following drug administration. Population pk analysis was 
performed using nonlinear mixed-effect modeling. A one-
compartmental structure model with first-order absorption 
(with separate compartments for mph-ir and mph-oros) 
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alternative to blood sampling, as it allows for the determination of concen-
tration-time profiles of both mph and the ritalinic acid metabolite. However, 
several potential complicating factors have been encountered in previous 
studies, including indications of oral contamination in the first few saliva sam-
ples after taking mph tablets and considerable – yet unexplained – variation in 
the saliva-to-plasma (s/p) ratio throughout the time course of both tablet and 
capsule formulations7. Nevertheless, if the sources of variability in the s/p ratio 
could be minimized or quantified, saliva drug sampling has the potential to 
become a reliable alternative to plasma drug sampling.
Here, our primary objective was to use population-approach modeling 
techniques to describe the concentration-time profile of mph in plasma and 
saliva after oral administration of mph-ir and mph-oros in healthy adult sub-
jects. Our secondary objective was to quantify the degree of contamination in 
the early saliva samples and to determine the effect of saliva pH on mph saliva 
measurements, as mph’s ionized free fraction may be incorporated into saliva 




This trial was a randomized, open label, two-way crossover study performed 
in 12 healthy adult subjects (6 men and 6 women). Based on our previous 
experience, we expected that a sample size of 12 subjects would be sufficient 
for determining the pk parameters and s/p ratio. The study was conducted in 
accordance with the International Conference on Harmonisation’s Guidelines 
for Good Clinical Practice and in accordance with the tenets of the Declaration 
of Helsinki. The study was performed at the Centre for Human Drug Research 
in Leiden, the Netherlands, and approved by the local ethics committee of 
Leiden University Medical Center (Leiden, the Netherlands). The subjects 
Introduction
Methylphenidate (mph) is currently the medication of choice for treat-
ing patients with attention-deficit/hyperactivity disorder (adhd), a highly 
prevalent neurodevelopmental disorder that places significant burdens on 
social development and can impede academic performance. Although con-
trolled trials have found that 60-70% of children respond to mph, actual 
clinical experience has revealed a much lower and less predictable response 
rate of approximately 50%. The clinical use of mph is usually based on a tri-
al-and-error approach before optimal therapy is achieved, as mph has wide 
inter-individual variability in terms of both plasma concentrations1,2 and clin-
ical response3,4. Approximately 20-30% of patients do not respond favorably 
to mph at any dose5, and these so-called ‘non-responders’ must switch to an 
alternative medication after this initial attempt at treatment. Therefore, a sig-
nificant subset of children with adhd experience a delay in receiving adequate 
treatment, and patients may stop taking medication altogether. A clear view 
of mph concentration-time profiles is needed in order to understand whether 
a lack of observed efficacy and/or the presence of unexpected adverse effects 
is related to pharmacokinetic (pk) or pharmacodynamic (pd) factors. However, 
measuring circulating mph concentration in children is extremely challenging 
due to the need for repeated intravenous blood sampling.
Collecting samples for measuring drug concentrations should be per-
formed with minimal discomfort to the patient, particularly in pediatric 
patients. Because mph is a weak base (with a pKa of 8.9) and has a relatively 
low molecular weight (233 Da)6, it diffuses readily across cell membranes and 
other lipid layers, quickly entering tissues and biological substrates that are 
more acidic than blood, thus enabling its detection in other matrices at rel-
atively higher concentrations. Moreover, because of its low protein binding 
saturation (10-33%), nearly all of the total mph available in the plasma can 
diffuse to extravascular compartments. Several non-invasive biological matri-
ces for measuring mph have been proposed, including urine, breath, sweat, 
hair, and saliva. Saliva sampling is currently the most promising non-invasive 
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subject randomly received either 10 mg of mph-ir (Ritalin) or 18 mg mph-
oros (Concerta) on different study days separated by a minimum of five 
days. The potential effects of the estrous cycle on mph pharmacokinetics has 
not been evaluated in humans14. Therefore, female subjects who took oral 
contraceptives were studied while taking their contraceptive but not in the 
stop week. Subjects were required to refrain from consuming xanthine- and/
or alcohol-containing products and from smoking within 12 hours of mph 
administration until the end of each study day. On study days, the subject 
was questioned regarding his/her intake of medication, alcohol, and/or illegal 
drugs, and a urine drug screen, a urine-based pregnancy test, and an alcohol 
breath test were performed before any study-related procedures began. The 
mph dose was taken with 240 ml water after an overnight fast of *10 hours. 
Subjects were instructed not to chew the medication and to swallow the tab-
let or capsule whole. Subjects were confined to the clinical research unit for 
approximately six (mph-ir) or 12 (mph-oros) hours after drug administration. 
Water (250 ml) was provided every two hours after the mph dose to maintain 
all subjects on a consistent hydration schedule. A standardized lunch (mph-
ir) or lunch and dinner (mph-oros) was provided 4 and 10 hours, respectively, 
after the mph dose.
To measure the pk of mph-ir, saliva and blood samples were collected pre-
dose and at t=20, 40, 60, 80, 100, 120, 150, 180, 210, 240, 300, and 360 minutes 
after the dose. To measure the pk of mph-oros, saliva and blood samples were 
collected at the same time points as well as at the following additional time 
points: t=270, 330, 360, 390, 420, 450, 480, 600, and 720 minutes. Saliva samples 
were obtained actively using the Polyester Salivette swab system (Sarstedt ag, 
Nümbrecht, Germany), a commercially available product designed specifical-
ly for collecting saliva specimens. The system contains a roll of polyester that is 
held in the oral cavity for several minutes. Three swabs were collected per time 
point. Saliva was collected actively in order to minimize variability in saliva 
pH. After collection and weighing the saliva (to assess salivary flow), the swabs 
were immediately centrifuged at 2000xg for 10 minutes at 4˚C. Subsequently, 
the saliva collected from the three swabs was pooled, and pH was measured 
provided written informed consent after receiving a full explanation of the 
study. Subjects had to be healthy, 18-35 years of age, with a body mass index 
of 18-30 kg/m2 and body weight of 50-90 kg. Subjects had to use a medically 
approved method of contraception throughout the entire study period and for 
three months after the study was completed.
We excluded subjects with a clinically relevant abnormal history of physical 
or mental health determined from the subject’s medical history and physical 
examinations (obtained during the screening visit and/or prior to receiving the 
first dose of the study drug); clinically relevant abnormal laboratory results, 
ecg, vital signs, or physical findings; current breast-feeding; and/or a history of 
alcohol and/or substance abuse within three years of screening. Subjects who 
habitually consumed more than 21 or 14 units of alcohol per week, respectively, 
and subjects who smoked >5 cigarettes/day or used nicotine or nicotine-con-
taining products within three months of screening were excluded. We also 
excluded subjects who tested positive for hepatitis B, hepatitis C, or hiv, female 
subjects with a positive urine-based pregnancy test, and subjects who tested 
positive for drug and/or alcohol at screening. Subjects with previous exposure 
to pharmaceutical stimulants (including – but not limited – to mph, mdma, 
methamphetamine, amphetamine, ephedrine, and cocaine) in the past six 
months were excluded, as were subjects who took any medication other than 
ibuprofen, paracetamol, oral contraceptives, or topical medication within one 
week of their first mph dose. Subjects who participated in an investigational 
drug study within 90 days of the first dose and/or participated in more than 
four clinical trials in the past year were not allowed to participate. Finally, 
subjects who donated blood or lost >500 ml of blood within three months of 
screening were not allowed to participate.
mph-ir (immediate release mph) and mph-oros (osmotic controlled-re-
lease oral-delivery system mph) formulations were chosen as interventions, as 
most Dutch children with adhd begin their treatment by taking Ritalin (mph-
ir, Novartis Pharmaceuticals uk Ltd.), and Concerta (mph-oros, Janssen-Cilag 
Ltd.) was the most commonly used extended-release formulation at the time 
of the study (gip database 2011, Genees- en hulpmiddelen Informatie). Each 
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modeling strategy
Population pk analysis was performed by nonlinear mixed-effect modeling 
using nonmem version 7.2.0 (Icon Development Solutions, Ellicott City, md, 
usa). The model was developed using advan6 with First-Order Conditional 
Estimation with Interaction (focei). Different models were compared with 
increasing complexity in the structural model and by increasing the number of 
random effects. The objective was to obtain the simplest model that described 
the data adequately. nonmem reports an objective function value (ofv), which 
is the -2 times log likelihood (-2ll). Models were compared using the likeli-
hood ratio test, with the assumption that the difference in -2ll is Chi-square 
distributed, with degrees of freedom determined by the number of additional 
parameters in the more complex model. Hence, with a decrease in ofv of at 
least -6.63 points (p<0.01), the model with one additional parameter was pre-
ferred over its parent model. We also used graphical analyses to help assess the 
differences between models. These analyses included: (1) predicted concentra-
tion versus observed concentration; (2) Conditional Weighted Residuals with 
Interaction (cwresi) versus predicted concentration, as well as cwresi versus 
time; (3) frequency distribution of the cwresi; (4) frequency distributions of the 
post hoc individual estimates of etas; and (5) correlation plots of post hoc indi-
vidual estimates of etas of all parameters with a random effect. The statistics 
software package r was used for graphical representations to evaluate of the 
goodness of fits, to select covariates, and to evaluate the models.
population pk model development
The population pk analysis focused on identifying structural (e.g., 2 and 3 com-
partmental) models with appropriate absorption and elimination processes 
(e.g., linear or nonlinear) to best describe and explain all of the collected data. 
The population parameter estimates were incorporated using ln-normal dis-
tributions. Additional, proportional or combined additive and proportional 
residual error distributions were drawn using parameters from a normal dis-
tribution to describe the residual variability. The random effects structure was 
incorporated using ln-normal distributions for the inter-individual variability 
using a Symphony pH meter (model sp70P, vwr Scientific) fitted with a pH/
Redox electrode (pH range: -2.000 to 19.999; relative accuracy: ± 0.002). Finally, 
the sample was divided in two, transferred to 2-ml tubes (Sarstedt), and imme-
diately stored at -80˚C. One stored sample was used for analysis, and the other 
sample was stored as a back-up. Blood samples were collected in 6-ml edta 
tubes to inhibit plasma esterases, which metabolize mph to ritalinic acid. 
The blood samples were cooled in an ice bath and centrifuged at 2000xg for 
10 minutes at 4˚C within 30 minutes of collection. The plasma fractions were 
collected, aliquoted into two transport tubes (containing approximately 1 ml 
of plasma per tube) and stored at -80˚C. 
Quantification of saliva and plasma mph concentration
mph (and the internal standard d9-mph) was analyzed in plasma and saliva 
samples by liquid chromatography–tandem mass spectrometry (lc-ms/ms) 
using the positive ionization mode of a Thermo Scientific (Waltham, ma, usa) 
Surveyor lc coupled to a Thermo Scientific Quantum Access ms. The develop-
ment and validation of this lc-ms/ms method using hydrophilic interaction 
liquid chromatography for mph analysis and for assessing mph stability in 
plasma and saliva at various temperatures have been described previously15. 




Exploratory individual and summary concentration-time profiles were gener-
ated in order to identify potential outliers, to understand the possible effect of 
censoring concentrations below the lloq, and to provide indications regard-
ing the base structural model. All concentrations below the lloq after Tmax 
were excluded from the analysis. All concentrations below the lloq prior to 
Tmax were set to zero. 
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m2 (range: 19.7–26.6 kg/m2). All subjects tested negative for pre-dose drugs 
of abuse in the urine. Concomitant medication used during the study period 
included ibuprofen (400 mg orally four days prior to the study day) and parac-
etamol (500 mg orally eight days after the last dose). All 12 subjects completed 
the study. 
Pharmacometrics analysis
population pk plasma model development
A total of 764 plasma samples were obtained from the 12 subjects. Fewer than 
20% of the samples had pk data below loq. Based on the exploratory plots, 
one outlier (a plasma sample taken five hours after the administration of an 
mph-ir dose) was excluded from the analysis. After the administration of mph-
ir and mph-oros, the concentration-time profiles of subject 8 and subject 9 
deviated from the profiles of the other subjects; however these data remained 
in the dataset. 
development of the population pk plasma model
The plasma pk data were described best by a one-compartment pk model 
with separate absorption compartments for the two drug formulations. The 
best model is depicted schematically in Figure 1. We estimated the lag time 
between administration of the drug and the onset of absorption (alag). For the 
mph-oros formulation, absorption was divided into two first-order absorp-
tion processes; one standard oral absorption process reflecting the capsule’s 
immediate-release component, with its own lag time and the same ka1 as 
the ir formulation (orosir), and an additional absorption process reflecting 
the capsule’s slow-release component (orossr), which was defined as a con-
tinuous infusion with a distinct lag time and ka2. This approach required the 
estimation of an infusion rate (r3). To parse the mph-oros dose into the orosir 
and orossr components, the fraction of the dose corresponding to orosir was 
modeled in terms of bioavailability (F), and the remaining fraction of the dose 
(corresponding to orossr) was defined as (1-F). The central compartment was 
(iiv) of the pk parameters. The iiv of the pk parameters were established by 
applying an exponential transformation of a normal random effects distri-
bution. Various types of variance-covariance matrices were tested for iiv. The 
estimated population values (both fixed and random effects) were used to 
determine individual empirical Bayes‘ estimates (post hoc estimates) of the pk 
parameters. The best structural pk model was determined before any covari-
ate (e.g., sex, weight, or height) was evaluated for incorporation into the model. 
To visualize potential correlations, scatter plots were created for each pair of 
covariates with a variance-covariance ellipse, the Pearson correlation coeffi-
cient, and its significance. This approach was performed to assess correlations 
between covariates, correlations between post hoc individual estimates of eta 
for each parameter and the covariate, and between estimated pk parameters 
and covariates. Confounding covariates were grouped following an evaluation 
of their correlation structure. The covariate in each variable cluster that had 
the highest correlation with the empirical Bayes’ estimates of the parame-
ters – and which was also clinically relevant – was implemented in the model. 
Continuous covariates were included by centering on a reference value; the 
median of the observed covariate values was selected as the most informative 
reference value.
The model was developed using a sequential approach in which plasma 
mph pk was modeled first. Subsequently, a saliva mph pk model was devel-
oped in which all plasma pk parameters were fixed to the individual estimates 
derived from the plasma pk model. 
Results
Subjects
Twelve healthy adult subjects (6 men and 6 women) met the selection crite-
rion and were enrolled in the study. The mean age of the subject was 23 years 
(range: 19-31 years), and the subjects had a mean body mass index of 22.1 kg/
non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 108 –
 
chapter 5 – popul ation pk model of mph in healthy subjects  
– 109 –
The saliva pk data were described best as a linear relationship between mph 
concentration in the plasma and mph concentration in the saliva. The individ-
ual plasma mph drug concentrations at each time point were used to drive the 
saliva model, with the following equation:
Y  = _  x  Cp 
where Y is the saliva mph concentration, Cp is the plasma mph concentration, 
and _ is the estimated parameter (s/p ratio). 
The estimated s/p ratio (_) was 2.44 (± standard error 26.9%). The residual 
error was described best by a proportional error structure (0.171 ± standard 
error 1.3%). iiv could be identified for _ (0.14 ± standard error: 2.9%). No covari-
ate relationships could be identified (for example, saliva pH or flow were not 
identified as covariates). 
As with the best pk plasma model, the predicted concentrations in the best 
pk saliva model were accurate with a small – albeit acceptable – bias in the low 
concentration range (Figure 4). The first samples also had a time-dependent 
bias (Figure 4). cwresi was distributed normally, with 0 lying within the 1.5 
interquartile range, despite the presence of some outliers at the extremes of 
the distribution (Figure 5); these outliers remained when the data were sep-
arated by formulation (data not shown). The outliers at the extremes were 
more evident for mph-oros than for mph-ir. With the exception of the data 
collected from subjects 8 and 9 following mph-ir administration, the model 
describes the data adequately (Figure 6).
Discussion
Reliabe prediction of plasma mph concentrations based on saliva sampling is 
challenging. As a result, the feasibility of this method has been questioned16. 
Minimizing and quantifying sources of variability in the saliva/plasma (s/p) 
ratio could improve the acceptance of serial saliva sampling as an alternative 
to therapeutic drug monitoring using (invasive) serial plasma sampling, which 
defined in terms of distribution volume (v) and clearance (cl). Ultimately, we 
abandoned our attempts to model ir and orosir as one compartment, as this 
resulted in worse fit and a non-normal distribution of the individual cl param-
eters (in which cl was formulation-dependent) and conditional weighted 
residuals. iiv was identified for cl, v, and ka2. Based on the correlation scatter 
plots, age and sex were considered as covariates for cl, v, and ka2; these were 
not incorporated in the model as they did not result in an improvement in 
ofv. Covariance between v and ka2 improved the model’s performance and 
was therefore kept in the model. The estimated pk parameters of the best pk 
plasma model are summarized in Table 1. Parameter estimations are accurate 
given the relatively low standard deviations, except for the absorption rate 
constants that show higher, but acceptable standard deviations. With regard 
to the goodness-of-fit plots (Figure 2), the observations versus population pre-
dictions indicate that the structural model is appropriate, as inclusion of the 
iiv (individual predictions) improves the goodness-of-fit, e.g. the observations 
are closer to the line of unity. In general, the conditional weighted residuals 
versus the population prediction and versus time are symmetrically distrib-
uted around zero indicating good model performance. However, there is a 
small  – albeit acceptable – bias in the low concentration range near time=0. 
Overall, the conditional weighted residuals are normally distributed (Figure 
2). The individual plasma mph concentration versus time after administration 
of mph-ir and mph-oros are well described by the model, with exception for 
subjects 8 and 9 (Figure 3).
development of the population pk saliva model
A total of 612 saliva samples were obtained from the 12 subjects. Fewer than 
20% of the samples had pk data that was below loq. The saliva samples 
collected after administration of mph-ir (tablet formulation) had clear indica-
tions of contamination, and efforts to correct for this contamination resulted 
in major bias in the description of the terminal pk phase. Based on previous 
experience in similar studies (our unpublished data), we excluded all post-
dose mph-ir data collected prior to the 2.5-hour post-dose time point. 
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to increase over time due to the drug’s concentration gradient that is incorpo-
rated into the two layers22. Therefore, the model’s descriptive properties might 
be improved further by incorporating previously published data – for example, 
the average release profile of mph-oros capsules – into the model. 
Given mph’s physicochemical characteristics, it is likely that mph is incor-
porated into the saliva by passive diffusion of the free ionized drug fraction, 
which will become ionized in saliva and therefore cannot diffuse back into 
the plasma23. A small – but acceptable – bias in the low concentration range 
was observed in saliva, which was likely due to the similar bias in the plasma 
pk model and oral contamination in the saliva samples collected early after 
mph-ir administration. Our data set included some subjects who had con-
tamination in their early samples (i.e., some or all of the subjects after taking 
mph-ir) and subjects who had no contamination (i.e., all of the subjects after 
taking mph-oros); by inference information collected after taking mph-oros 
could theoretically provide information regarding possible contamination 
after taking mph-ir. Such contamination would be the strongest – and there-
fore would have the highest impact on pk parameters – at earlier time points. 
Our efforts to correct for oral contamination resulted in a large bias in the 
description of the terminal phase. Therefore, a pragmatic approach was cho-
sen: all saliva data collected in the first 2.5 hours after administration were 
excluded from analysis. 
Obtaining an accurate s/p ratio is essential for realizing the full potential of 
using saliva sampling to monitor plasma mph concentrations. The theoretical 
s/p ratio based on the modified Henderson-Hasselbalch equation has previ-
ously been calculated as 3.124. In our study, the model-based s/p ratio for mph 
at time points beyond 2.5 hours after administration averaged 2.44. This value 
is lower than the average s/p ratios reported in previous studies7,25, which 
may be explained by study-related differences in saliva stimulation. Because 
stimulating saliva secretion increases the saliva’s pH to values that approach 
plasma pH, the apparent drug concentration of basic drugs can be reduced, 
and resulting s/p ratios will have less variability, for example as described pre-
viously for mdma and cocaine26,27. Therefore, we obtained the saliva samples 
is of particular interest in pediatric populations. Here, a first attempt was made 
to quantify sources of variability in mph plasma and saliva concentrations, and 
to describe the relationship between mph concentration in saliva and mph 
concentration in plasma using a population pk modeling approach. The data 
were comprised of paired plasma and saliva mph concentrations from healthy 
adults, following a single dose of mph-ir (through 6 hours post-dose) or mph-
oros (through 24 hours post-dose). 
A one-compartment model with first-order absorption (separate absorp-
tion compartments for mph-ir and mph-oros) and first-order elimination 
best described the plasma pk for mph. The population parameter estimates 
for clearance was 403 liters/hour with a distribution volume of 1808 liters 
and a derived terminal half-life (ln2/ke) of 3.15 hours, which is consistent with 
previously published estimates17,18. The population parameter estimates for 
clearance, distribution volume, and lag time (for the ir formulation) had low 
uncertainty; however, the standard errors of the population values for the 
absorption rate constants of both mph-ir and mph-oros, as well as the stan-
dard error for the lag time of the sustained release phase of mph-oros, were 
relatively high, albeit still within an acceptable range. Absolute bioavailability 
after oral dosing has been reported to be both low and variable19. The level of 
uncertainty for ka’s and lag time may be explained – at least in part – by the 
relatively low number of subjects, lack of data points in the upward part of 
the concentration time profile and the seemingly aberrant pk profiles of two 
subjects, particularly after receiving the mph-ir formulation. For example, 
the post-mph-ir dose plasma concentrations in subject 9 had an extremely 
long absorption phase, which may be attributed to extended gastric emptying 
time, which is the primary factor controlling mph absorption for ir formula-
tions20. Because gastric emptying time can be prolonged in both clinical and 
research settings, we did not exclude these data from our analysis. In addition, 
large differences between subjects have been reported with respect to the 
release profile of mph-oros21. Finally, our model described absorption during 
the osmotic release phase of mph-oros capsules as a continuous, stable infu-
sion. In contrast, the rate of release rate from oros capsules has been reported 
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and formulation will likely work best in each child with adhd. In addition, our 
pk model could be used to simulate a clinical trial in order to determine the 
optimum sampling schedule for future studies. 
Despite its advantages, several issues may limit the potential applica-
bility of our method. In our study, concomitant medication shortly before 
and/or during study days was limited to the use of only a few medications, 
including ibuprofen and paracetamol. Children with adhd often use med-
ications that are related – either directly or indirectly – to adhd treatment or 
the treatment of psychiatric comorbidities; such medication include tricyclic 
antidepressants and other antidepressants, clonidine, antipsychotics, antie-
pileptic agents, anxiolytics, melatonin, and other hypnotics32. Thus, validation 
studies are needed to in order to determine the predictive performance of our 
model in patients who use these medication types.  
In conclusion, we report that the relationship between plasma and saliva 
mph concentrations in healthy adult subjects can be described as a constant 
s/p ratio, but only 2.5 hours after administration of two distinct oral formula-
tions of mph. With proper allometric scaling (using body size to account for 
developmental changes in mph clearance and distribution volume), this pk 
model may also be suitable for predicting the concentration-time plasma 
mph profile in children using non-invasive saliva sampling. Further studies are 
needed to determine the predictive performance of the model in children with 
adhd.
actively using a mechanical stimulus (which can stimulate saliva flow of 1-3 
ml/min28). In contrast, in a previous study12 samples were collected by hav-
ing the subject spit, which usually produces little stimulation, thus leading to 
higher apparent drug concentrations and higher s/p ratio variability. As basal 
(i.e., unstimulated) salivary flow is generally lower in children with adhd than 
in children without adhd29, stimulating salivary flow with active sampling 
may be even more important in this patient population in order to ensure 
adequate sample volume for analysis. The s/p ratios in our study had inter-in-
dividual variability. For strong basic drugs such as methamphetamine, the s/p 
ratio can be highly sensitive to small changes in saliva pH, and inter-individ-
ual variability in saliva pH is the likely explanation for inconsistent s/p ratios 
with these drugs types30. However, both saliva pH and saliva flow could not be 
identified as covariates in the current dataset. 
Our results serve as the impetus for exploring further the feasibility using 
saliva as a non-invasive method for monitoring mph concentrations in 
patients, particularly children. Because this method has the added benefit 
of allowing on-site testing without the need for medical personnel or com-
plicated sample processing, the burden of collecting samples from children 
is decreased even further. Using saliva sampling to measure mph concen-
tration is currently limited to confirming treatment compliance or testing 
for treatment misuse. However, monitoring mph saliva concentrations in 
children with adhd could have several important clinical and research appli-
cations. For example, the time course of clinical efficacy parameters in 
children can be simulated based on the time course of mph concentration in 
adults31. If our model is validated for children using pediatric pk data, the true 
parameters of the pediatric pk-pd relationship could be estimated, and the 
model could be used to estimate target mph concentrations > 2.5 hours after 
administration in the pediatric population. Such a result would represent an 
important step towards using non-invasive therapeutic drug monitoring to 
provide customized treatment to children with adhd. Ultimately, the ability 
to differentiate between responders and non-responders – ideally at the onset 
of mph treatment – would help clinicians determine which medication, dose, 
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figure 2  Goodness of fit plots of the plasma pk model. Upper left: observed (dv) versus 
population predicted (pred) plasma mph concentrations (black line is the line of unity); upper 
right: dv versus individual predicted concentrations (ipre (black line is the line of unity); lower left: 
conditional weighted residuals (cwresi) versus pred; lower right: cwresi versus time (time).
table 1 Parameter estimates of the best plasma mph pk model.  
Parameter Estimate* (standard error) iiv (standard error)
cl (L/h) 5.951 (8.0) 0.065 (3.7)
V (L) 7.484 (9.8) 0.043 (2.3)
ka1 (h-1) 1.075 (26.3)
alag1 (h) -1.208 (2.4)
R3 (mg/h) 15.184 (8.8)
F2 (*100%) 0.272 (2.6)
alag2 (h) -1.338 (12.3)
alag3 (h) 0.487 (19.1)
ka2 (h-1) -1.081 (23.0) 0.244 (20.4)
Covariance 0.0851 (7.1)
Proportional error 0.1 (0.99)
iiv, inter-individual variability.
figure 1 Schematic representation of best pk plasma model of mph-ir and mph-oros. 
alag, lag time between administration and onset of absorption; central, central compartment; ka, 
absorption rate constant; ke, elimination rate constant; ir, absorption compartment of immediate 
release methylphenidate; orosir, absorption compartment of immediate release part of osmotic 
controlled-release oral-delivery system methylphenidate; orossr, absorption compartment of 
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figure 3  Individual plasma mph concentration versus time after administration of  
mph-ir (above) or mph-oros (under), plotted on a log-linear scale. Dashed lines represent the 
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figure 5  Pooled distribution of mph-ir and mph-oros cwresi results, visualized as a  
frequency histogram (left; the line represents a normal distribution), a box plot (middle), and  
a qq plot (right).
figure 4  Goodness of fit plots of the saliva pk model. Upper left: observed (dv) versus 
population predicted (pred) plasma mph concentrations (black line is the line of unity); upper 
right: dv versus individual predicted concentrations (ipre (black line is the line of unity); lower left: 
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figure 6  Individual saliva mph concentration versus time after administration of  
mph-ir (above) or mph-oros (under), plotted on a log-linear scale. Dashed lines represent the 
population prediction, continuous lines represent the individual prediction, and circles represent 
the observations.
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abstr act
develop a pk/pd model. In adolescents, caffeine had significant 
effects on task parameters related to attention and visuomotor 
coordination (adaptive tracking task) and alertness (saccadic 
peak velocity). The cognitive effects of caffeine included an 
increase in error rate in the attention switch task. Plasma 
caffeine concentrations in adults were described best as 
a two-compartment model with a dose depot, first-order 
absorption kinetics, and first-order elimination kinetics. Lean 
body mass-dependent variability was identified for the volume 
of the central compartment. This pk model was expanded to a 
population model that described saliva caffeine concentrations 
in adults >1 hour after administration as a fraction (0.68) of 
plasma concentration. Caffeine’s early effects in adolescents 
(i.e., within one hour) were not suitable for inclusion in a pk/
pd model. In conclusion, in healthy, alert adolescents, low-
dose caffeine has significant effects on parameters regarding 
alertness and reaction speed. Whether these effects observed in 





Despite the highly prevalent use of caffeine among adolescents, 
remarkably little research has been conducted regarding the 
physiological and behavioral effects of caffeine in this age 
group. Data obtained from animal studies suggest that the 
effects of caffeine reported in adults cannot be extrapolated 
simply to adolescents. Therefore, we evaluated the effect 
profile of caffeine on central and autonomic nervous system 
parameters following the consumption of a low dose 
caffeinated beverage by healthy adolescents; the results were 
compared with data obtained following the consumption of 
a non-caffeinated beverage. Caffeine concentrations were 
measured from saliva samples. In a separate study using adult 
volunteers, we determined the extent of oral contamination 
with caffeine after consuming a caffeinated beverage versus 
swallowing a caffeine capsule. In addition, because previous 
studies in adults correlated caffeine’s effects with changes 
in plasma concentration (but not saliva concentration), both 
saliva and plasma samples were collected simultaneously in 
order to measure the saliva-to- plasma (s/p) ratio of caffeine 
concentration. Based on the data collected from this kinetic 
study, a population pk model was built to estimate plasma 
drug levels in adolescents; this model could prove useful to 
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tamine9, cocaine10,11, and methylphenidate12,13 – potentially due to the 
functional inhibition of dopamine D1 receptors at young age11. Based on these 
findings, the effects of caffeine that have been reported in adults likely cannot 
be extrapolated simply to adolescents. 
Here, we measured the effect profile of caffeine on both central and auto-
nomic nervous system parameters after consuming two cups of espresso by 
adolescents who usually infrequently consume caffeine. Saliva samples were 
collected in order to measure caffeine concentration. Because the saliva can 
be contaminated by residual caffeine after drinking a caffeinated beverage, 
we performed a second study in young adult volunteers to compare the extent 
of contamination between drinking a caffeinated beverage and swallowing a 
caffeine capsule. In addition, although caffeine’s effects have been correlated 
to changes in plasma caffeine concentrations14,15, the relationship between 
caffeine’s effect and saliva concentrations has not been studied. Therefore, 
we collected saliva and plasma samples simultaneously in order to measure 
the saliva-to-plasma (s/p) ratio for caffeine concentration. Based on the data 
obtained from this kinetic study, a population pharmacokinetic (pk) model was 
developed to estimate plasma drug levels in adolescents, and this model could 




Healthy male and female adolescents (15-18 years of age) were included. The 
subjects were non-smokers and consumed )14 units of alcohol per week. After 
providing written informed consent (plus consent from a parent or legal guard-
ian for subjects <18 years of age), the subjects were medically screened within 
three weeks of the start of the study; subjects who presented with relevant 
clinical abnormalities were excluded. We also excluded subjects who used 
Introduction
Caffeine (1,3,7-trimethylxanthine) is the most commonly used psychoactive 
substance worldwide1; caffeine is widely available in foods, dietary supple-
ments, chewing gum, beverages, and many over-the-counter combination 
analgesics. Many adolescents use caffeine as a way to enhance their aca-
demic or athletic performance2 and to intentionally postpone sleep during 
nighttime leisure activities3. Given that some caffeine-containing products 
are marketed directly to children and adolescents, and given that caffeine 
use among children and adolescents has increased by 70% since 19774, it is 
important to understand better the potential effects – both positive and neg-
ative – of caffeine use within this particular population2 . An extensive body 
of research regarding the behavioral and psychomotor effects of caffeine in 
adults shows that caffeine produces behavioral effects that are similar to the 
effects of ‘classic’ central nervous system (cns) stimulants such as cocaine and 
amphetamine. However, despite its high incidence of use among adolescents, 
remarkably little research has been conducted regarding the physiological 
and behavioral effects of caffeine in this specific age group2,5. 
Caffeine’s effects in adolescents can differ from its effect in adults2. To date, 
no studies have compared the effects of caffeine between adolescents and 
adults. However, prepubescent children experience more objective effects of 
caffeine than adults at doses of 3-10 mg/kg; these effects include increased 
motor activity, increased speech rate, and decreased reaction time. After 
ingesting caffeine, adults generally report side effects that children do not 
appear to experience; however, autonomic measures of arousal are affected 
similarly in both age groups6. A relatively limited number of animal studies 
regarding the correlation between age and caffeine’s effects have shown that 
caffeine-induced locomotor stimulation is higher in adolescent rats than in 
adult rats7, and adolescent rats may respond more robustly than adult rats 
to adaptive changes associated with chronic caffeine consumption8. These 
age-dependent effects are likely not limited to caffeine, as age-dependent 
effects have been reported for other cns stimulants – including amphe-
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approximately 135 mg caffeine (according to the manufacturer) or two cups 
of decaffeinated espresso coffee containing <10 mg caffeine on two separate 
study days. To increase palatability, sucrose and dehydrated milk were avail-
able. This dose of caffeine (135 mg) was expected to block adenosine receptors 
and – to a small extent – phosphodiesterases16, while minimizing undesired 
adverse events. Decaffeinated coffee was chosen as a placebo to make the 
two intervention arms as comparable as possible with respect to expectancy, 
sensory effects (due to the similar taste of caffeinated and decaffeinated cof-
fee) and the presence of biologically active substances other than caffeine17. 
The beverages were administered following a minimum fasting period of four 
hours. A standardized light breakfast and a standardized lunch were offered 
2.5 hours and 4.5 hours after coffee consumption, respectively. Water was pro-
vided ad libitum. The subjects were confined to the clinical research unit for 
approximately six hours after caffeine consumption.
Based on previous studies conducted at chdr, a sample size of 16 subjects 
was sufficient to detect a 10% in adaptive tracking and a 5% change in saccadic 
peak velocity with 80% power (two-sided test, alpha = 0.05) using a random-
ized Williams square design.
kinetic adult study
This study was a randomized, open-label, two-way crossover study. Each sub-
ject received two cups of espresso coffee containing approximately 135 mg 
caffeine or one capsule containing 200 mg coffeine (Pharmaline, Oldenzaal, 
the Netherlands) on two separate study days. The dose of 200 mg in capsule 
form was chosen based on a pk model using data from the study in healthy 
adolescents and reported data in adults (Figure 1). The capsule was admin-
istered with approximately two cups of water. Where applicable, female 
subjects were studied while taking their oral contraceptive (i.e., not during 
the stop week). The caffeinated beverage or capsule was administered follow-
ing a minimum fasting period of four hours. A standardized light breakfast, 
lunch and dinner were offered 2 hours, 4!/3 hours and 9 hours after caffeine 
administration. Water (200 ml) was given every two hours after the caffeine 
medications and/or agents known to affect caffeine metabolism and/or cns 
performance; urine drug screens were performed during the selection process 
and prior to each test day. The study was approved by the Central Committee on 
Research involving Human Subjects. 
kinetic adult study
The inclusion criteria for this study included healthy male or female volunteers 
18-35 years of age with a body mass index of 18-30 kg/m2 and body weight of 
50-90 kg. Exclusion criteria included a personal history of impaired physical or 
mental health; a history of drug, substance, and/or alcohol abuse; and abnor-
mal findings with respect to medical history, physical examination, ecg, vital 
signs, and/or blood and urine laboratory results. The subjects were instructed 
not to use any medications, dietary supplements, or food products that would 
potentially affect the metabolism of caffeine within one week of the start of 
the study. The subjects were instructed not to consume more than five units of 
xanthine-containing products, to smoke more than five cigarettes per day or to 
consume more than 21 (male subjects) or 14 (female subjects) units of alcohol 
per week. The subjects had to refrain from consuming xanthine-containing 
products (within days of caffeine administration and throughout the study 
day) or alcohol and cigarettes (within 12 hours of caffeine administration and 
throughout the study day). On study days, the subject’s use of medications, 
alcohol, and/or drugs was questioned, and a urine drug screen, pregnancy test 
(where applicable), and alcohol breath test were performed prior to the start of 
any study-related procedures. This study was approved by the Medical Ethics 
Committee of the Leiden University Medical Center, Leiden, the Netherlands.
Study design
adolescent study
This study was a randomized, double-blind, placebo-controlled, two-way 
crossover study. Each subject received two cups of espresso coffee containing 
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Redox electrode (range: -2.000 to 19.999; relative accuracy: ±0.002). The saliva 
was then transferred to 2-ml tubes (Sarstedt) and immediately stored at -80°C. 
For pk analyses, venous blood samples were obtained from the adult sub-
jects via an indwelling catheter four minutes after the start of each saliva 
sample collection. Blood samples were collected in 6-ml edta tubes and kept 
on ice. The samples were centrifuged (2000xg for 10 minutes at 4°C) as soon as 
possible after collection, but within 30 minutes of collection. The saliva super-
natants and plasma samples were stored at -20°C until analysis. 
Caffeine concentrations in the saliva samples obtained during the ado-
lescent study were measured at Erasmus Medical Center (Rotterdam, the 
Netherlands). Caffeine concentrations in the saliva and plasma samples 
obtained during the adult study were measured at the Academic Medical 
Center (Amsterdam, the Netherlands). In both laboratories, a validated 
high-performance liquid chromatography method was used19. Samples were 
either analyzed immediately upon arrival at the laboratory or stored at 4°C 
until analysis (within 24 hours). The limit of quantification was 0.2 mg/l in a 
sample volume of 100 µl. 
Pharmacodynamics
An extensive cns battery was implemented to determine which functional 
cns domains are affected by caffeine. All pharmacodynamics (pd) measure-
ments – with exception of the visual and verbal learning task (vvlt) – were 
performed at the same time points as the saliva collection time points (see 
above). vvlt was administered approximately 45 and 150 minutes after caf-
feine administration in order to assess immediate and delayed recall. The pd 
measurements were performed in a quiet room with ambient lighting, with 
only one subject in the room per session. Prior to the first study day, the sub-
jects were familiarized with the experimental procedure and performed a 
practice testing session to minimize potential learning effects during the 
study days. The tests were performed as described below.
administration to maintain all subjects on a consistent hydration schedule. 
The subjects were confined to the clinical research unit for approximately 11 
hours after caffeine administration.
For this study, no formal power calculation was performed. However, based 
on previous experience, we expected that a sample size of six subjects would 
be sufficient for determining the pharmacokinetic parameters and the sali-
va-to-plasma ratios.
In both the adolescent and adult studies, the wash-out period between 
study days was *3 days, and caffeine (or placebo) was administered at the 
same time of day to minimize any confounding effect of circadian rhythm.
Pharmacokinetics
In adolescents, saliva was collected in Salivette tubes (Sarstedt, Numbrecht, 
Germany) prior to caffeine administration (to confirm compliance) and 
every 15 minutes thereafter for 120 minutes, then every 60 minutes until the 
240-minute time point, then every two hours until the 360-minute time point. 
In the adult study, the post-caffeine sampling time points were determined 
based on a pk model using data from the study in healthy adolescents and 
reported data in adults (see Figure 1); samples were collected prior to caffeine 
administration, 10, 30, and 60 minutes after administration, and 2, 4, 7, and 11 
hours after administration. Because caffeine saliva pk can be complicated by 
pH partitioning, saliva was collected actively, as stimulated saliva flow leads 
to a stronger correlation between plasma and saliva caffeine levels18,19. At 
each time point, the subjects were instructed to insert three Salivette in their 
mouth and move it around the oral cavity for two minutes. Both saliva pH 
and saliva flow rate were measured to determine whether any fluctuation in 
these parameters might account for any remaining variability in the s/p caf-
feine ratio. Immediately after collecting and weighing the saliva (to measure 
salivary flow), the swabs were centrifuged at 2000xg for 10 minutes at 4˚C. 
The three saliva samples per subject were then pooled, and pH was measured 
using a Symphony pH meter (model sp70P, vwr Scientific) equipped with a pH/
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methylphenidate30,31. The average performance during a 3-minute testing 
period was used for statistical analysis.
left/right distraction task
A parametric version of the color-word response conflict task34 was used to 
measure intervention-induced inhibition35. This task has been used previous-
ly to measure the effects of several compounds, including antipsychotics36. In 
this task, the word ‘Left’ or ‘Right’ was displayed on either the left or right side of 
a computer screen. The subject was instructed to respond quickly by pressing 
the button corresponding to the location of the word, irrespective of the word’s 
meaning. The output parameters included response time and response accu-
racy as a function of task difficulty. 
finger tapping
The finger tapping test evaluates motor activation and fluency and was adapt-
ed from the Halstead-Reitan Neuropsychological Battery37. During the test, 
the rate of tapping the index finger on the dominant hand was measured; a 
session comprised five 10-second tests. The subject was instructed to tap the 
index finger as rapidly as possible on the space key of a computer keyboard. 
The output measure was mean tapping rate and standard deviations were 
used for statistical analysis. 
visual and verbal learning task 
The vvlt has been used previously to identify the cns effects of various com-
pounds, including benzodiazepines38, antidopaminergic agents32, and 
cannabinoid drugs29. This task was performed as described previously32. The 
primary outcomes for the immediate and delayed word-recall tasks were the 
numbers of correct responses; the primary outcomes for the delayed word rec-
ognition task were the number of correct items and the mean response time 
for correct responses. Learning was measured using the change in reproduced 
words with three consecutive memorization trials, decay from the change in 
reproduced words after a time delay (delayed word recall versus the last trial 
saccadic and smooth pursuit eye movement 
Saccadic and smooth pursuit eye movements were recorded as described pre-
viously20-22; in adults, these movements can be affected by many drugs that 
act upon the cns, including gabaergic23, serotonergic24, noradrenergic25,26, 
and dopaminergic drugs. For this test, we use a computer-based system for 
data recording and analysis (Cambridge Electronics Design, Cambridge, uk), a 
Nihon Kohden device for stimulus display, signal collection, and signal ampli-
fication (Nihon Kohden Corporation, Tokyo, Japan), and single-use surface 
electrodes (Medicotest N-oo-s, Olstykke, Denmark). The average values for 
latency (i.e., response time), peak saccadic velocity, and the inaccuracy of all 
artifact-free saccades were used as parameters for quantifying saccadic eye 
movements. Saccadic inaccuracy was calculated as the absolute difference 
between the stimulus angle and the corresponding saccade, expressed as a 
percentage of the stimulus angle. A higher percentage reflects poorer perfor-
mance on the eye movement test. For smooth pursuit, the target moved in a 
sinusoidal pattern over 20 degrees of eyeball rotation at a frequency ranging 
from 0.3–1.1 Hz. The primary parameter was the percentage of time that the 
eyes pursued the target smoothly.
body sway
The body sway metric records body movements in a single plane, thus pro-
viding a measure of postural stability. A variety of cns-active drugs induce a 
change in body sway, including gabaergic drugs27,28, cannabinoids such as 
tetrahydrocannabinol29, and cns stimulants such as methylphenidate30,31. 
Body sway was measured as described previously32.
adaptive tracking
Adaptive tracking measures visuomotor coordination and vigilance and 
was performed as originally described by Borland and Nicolson33. This test 
was adapted for use on a personal computer. The adaptive tracking test has 
been used previously to measure the cns effects of alcohol, sleep depriva-
tion, and a wide range of cns-active drugs, including stimulants such as 
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assessed only once for each treatment arm, the raw test scores were evaluat-
ed. Data analyses included an analysis of variance with baseline correction. 




Exploratory individual and summary concentration-time profiles were 
generated in order to identify potential outliers, to understand the influence 
of censoring concentrations below the limit of quantification (loq), and to 
yield information regarding the base structural model. Concentration-time 
curves were plotted for the plasma and saliva samples in order to identify 
indirect relationships (e.g., time shifts). Samples below loq before Tmax were 
set to zero. 
modeling strategy
Pharmacometrics were performed using nonlinear mixed-effect modeling 
(nonmem version 7.2.039, Icon Development Solutions, Ellicott City, md, usa, 
2009). First-order conditional estimation with interaction (focei) was used 
for the estimation, with a convergence criterion of five significant digits in the 
parameter estimations. nonmem reports the objective function value (ofv), 
which is the -2 times log likelihood (-2ll). Models were compared using the 
likelihood ratio test with the assumption that the difference in -2ll is Chi-
square distributed, with degrees of freedom determined by the number of 
additional parameters in the more complex model. Therefore, with a decrease 
in ofv of at least 6.63 points, a model with one additional parameter is con-
sidered superior to its parent model (p<0.01). Different models with increasing 
complexity were compared to identify the simplest model that described the 
data adequately. Graphical analysis was used to assess model performance 
while developing the model. 
 
of immediate word recall), and retrieval (the difference between delayed word 
recognition and delayed word recall).
attention switching task
This task was used to measure executive control. chdr uses an adaptive ver-
sion of a task-switching design with a Go/no Go task as described by Wylie and 
colleagues (2003). The output parameters are response time and error-rate. 
pupil size measurement
Measurement of the pupil size was done by taking a picture from both eyes 
simultaneously while the subject was seated on a chair with his head fixed in 
the head support system. From the pictures the ratio between the pupil - and 
iris diameter was calculated
blood pressure and heart rate
Blood pressure was measured using a Nihon Kohden bsm-1101K automated 
oscillometric monitor, a Pressmate bp 8800 (Colin), or a Dash 4000 monitor. 
Heart rate was measured using oscillometry.
Statistical analysis and pharmacometrics
pharmacodynamics 
The pd endpoints of the adolescent study were analyzed using mixed-mod-
el analyses of variance (using the sas proc mixed program). Subject, subject 
by treatment, and subject by time were random effects; treatment, test day, 
time, and treatment by time were fixed effects; and the average baseline value 
was a covariate. Contrasts were estimated within the overall treatment effect, 
and contrasts between treatments >360 min were calculated. Body sway and 
attention switch task variables were log-transformed, analyzed, and then 
back-transformed (the results are presented as percent change). The atten-
tion switch error rate was transformed by adding 1 to all data points in order 
to avoid log-transforming a value of 0. Because the vvlt parameters were 
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<30% was considered acceptable42. Proportional and combined error struc-
tures were evaluated to best describe the residual error. Based on graphical 
identification, the most promising covariates were tested in the model; these 
covariates were then included based on a decrease in ofv in a stepwise man-
ner (forward inclusion of covariates, followed by a backward elimination step). 
A plasma-saliva pk model for caffeine was then developed using the saliva 
data collected from the study in adults. All plasma pk parameters were fixed to 
the individual estimates that were derived from the best plasma pk model. The 
simulated individual plasma concentration-time profiles consequently drive 
the saliva caffeine concentrations, for which different model structures were 
explored (e.g., a linear effect model or an effect compartment). The model was 
developed as described for the best pk plasma model (e.g., by incorporating iiv, 
residual error, and covariates). The best model was validated by performing a 
vpc of the simulated saliva concentrations in adolescents.
Results
Subjects
A total of 16 adolescent subjects (10 males, 6 females) 15-18 years of age (mean: 
16.8 years) were enrolled in 2009, and a total of 7 adult subjects (5 males, 2 
females) 19-24 years of age (mean: 21.4 years) were enrolled in 2012. All ado-
lescent subjects were attending pre-university secondary education (in Dutch, 
Voortgezet Wetenschappelijk Onderwijs or vwo). One of the male adult volun-
teers discontinued the study after the first study day (a caffeine capsule) for 
reasons unrelated to the study and was replaced. The mean weight and height 
of the adolescent subjects were 69 kg (range: 50-85 kg) and 1.80 m (range: 1.65-
1.93 m), respectively; the mean weight and height of the adult subjects were 77 
kg (range: 58-90 kg) and 1.82 m (range: 1.70-1.98 m), respectively. None of the 
adolescents reported using cigarettes; one adult subject reported smoking 
four cigarettes per day. One female adult subject used an oral contraceptive 
The following goodness-of-fit plots were prepared: observed concentration (the 
dependent variable, or dv) versus population concentration (pred); dv versus 
individual predicted concentration (ipred); weighted residuals with interaction 
(cwresi) versus ipred; cwresi versus time after dose; combined pred, ipred, 
and dv versus time (per individual) and distribution of inter-individual variabil-
ity (iiv) estimates (eta). Covariates were analyzed using a stepwise approach. 
For the visual predictive check (vpc), dosing regimens were simulated as per-
formed in the adolescent and adult studies based on the distribution of lean 
body mass (lbm40) in the data sets. The best pk and pk/pd models were selected 
based on the likelihood ratio test, diagnostic plots, vpc, parameters, and preci-
sion in parameter estimates. The relative standard error (rse) was calculated 
and used to derive the uncertainty in the parameter estimates; rse <10% was 
considered acceptable. Preparing the nonmem input file and processing of the 
model results (i.e., preparing tables and graphs) was performed using r version 
2.12.041. vpc was performed using the lsoda function from the deSolve library 
(version 1.8.1) and the function mvrnorm from the mass library (version 7.3-8) by 
simulating 1000 replications of the best models and a simulation data set (up to 
12 hours). The median prediction and 95% prediction interval were calculated 
for each simulated time point and compared to the observations.
population pk model development
First, a population plasma pk model for caffeine was developed using 
the plasma data obtained from the adult study. One-compartment and 
two-compartment structural models, as well as different compartmental 
and elimination sub-models, were tested. All models used a first-order pro-
cess to describe the oral absorption of caffeine. Interindividual variability (iiv) 
was assessed separately for each pk parameter using a stepwise bottom-up 
approach. Correlations between the iiv of each parameter were determined 
graphically. When a correlation was found to be significant (either by shape or 
Pearson’s correlation coefficient), covariance between the terms was assessed 
by applying an omega block on selected parameters and accepted based on 
the results of a likelihood ratio test. For the parameter estimation, shrinkage 
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oral administration (alag1) was fixed at a value of 0.23 hours (the time point 
before the first pk sample), as this parameter was needed in order to describe 
the absorption phase; however, the number of data points in the absorption 
phase was not sufficient to accurately quantify the two necessary absorption 
parameters (ka and alag). For the beverage treatment group, v2 (the distri-
bution volume for the central compartment) was corrected by the fractional 
bioavailability, as bioavailability differs between beverage and oral treatment. 
To facilitate fitting of the model, the initial parameter estimates and boundar-
ies for the parameters estimates were selected based on published values. The 
residual error model included combined proportional and additive errors. iiv 
was identified on ka (the absorption rate constant) – with different variabil-
ity between the two treatments – on clearance, on ke and on the correction 
fraction of v2 for the beverage group. Two parameter estimates with large con-
fidence intervals (ka and q) were modeled as an exponent in order to prevent 
negative – and thus physiologically impossible – values for these parameters. 
lbm was implemented in the model as a covariate of v2 in normalized power 
function (Eq. 1).
Pi   =  Pp  x  (cov/covmedian)k               Eq. 1 
where pi; individual parameter estimate, pp; typical (population) value, cov; 
individual covariate value, covmedian; normalization value for covariate, k; 
parameter estimate for the exponent.
In the best pk model, the population concentrations and individual predicted 
concentrations were close to the observed values. In addition, we observed no 
apparent concentration-dependent or time-dependent bias (Figures 5 and 6). 
population pk saliva model development
A total of 614 pk observations from saliva samples were obtained from 6 adult 
and 16 adolescent subjects. All data points collected prior to Tmax and below 
loq were set to zero. 
The adult data were described best by a pk model that described saliva con-
centration as a fraction of the plasma concentration. However, this model was 
during the study. In addition, one adolescent subject used paracetamol during 
the study (a single 500-mg dose taken 2.5 hours prior to dosing on the first 
study day.) The mean daily consumption of xanthine-containing products in 
the preceding months was 2.6 (range: 0-5) standard units for the adolescents 
and 1.7 (range: 0-4) standard units for the adults. 
Pharmacodynamic results
neurophysiological parameters 
Caffeine administration significantly increased adaptive tracking perfor-
mance and saccadic peak velocity and accelerated saccadic reaction time 
(Table 1, Figure 2 and Figure 3). No significant effect was observed with respect 
to body sway, saccadic eye movement (response latency), and tapping. In addi-
tion, no significant effect was observed with respect to parameters related to 
memory (Table 2).
Attention switch task error rate and response time (pre-switch trial, #3) 
were both significantly affected by caffeine (Table 3, Figure 4). In the distrac-
tion task, the response times for incorrect responses were shorter than the 
response times for correct responses (Table 3).
Neither systolic blood pressure nor pupil size differed significantly between 
the caffeine and placebo groups (Table 4). 
Pharmacometrics analysis
population pk plasma model development
A total of 90 pk observations from plasma samples were collected from six 
adult subjects. One data point obtained prior to Tmax was below loq and was 
set to zero. 
A two-compartment model with a dose depot and first-order absorption 
and elimination kinetics described the caffeine plasma concentrations in the 
adult subjects best. The parameter estimates, relative standard error (rse) 
and iiv are summarized in Tables 5 and 6. The parameter for lag time after 
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a pk study in adults and determined the s/p ratio for caffeine concentration. 
Plasma caffeine concentration in adults was described best as a two-compart-
ment model with a dose depot, first-order absorption kinetics, and first-order 
elimination kinetics. Although some published reports suggest that caffeine 
pk in plasma can be described using a one-compartment model48, some 
individual concentration-time profiles suggested two-compartment prop-
erties. Therefore, a two-compartment model was tested and was found to be 
superior to the one-compartment model. The apparent clearance and distri-
bution volume were consistent with published values in adults48-50 and were 
estimated here with high precision. For the caffeinated beverage, the dose 
identified by the model was lower (by a factor of 0.67) than the dose indicated 
by the manufacturer (135 mg) and varied among the subjects. With respect to 
ka, the relative standard error of the population values was high, which could 
be attributed – at least in part – to the inclusion of pk data obtained after the 
administration of different formulation types, the low number of observa-
tions collected during the absorption phase, and caffeine’s moderately fast 
absorption rate. Two iiv terms were required for the absorption rate (one for 
each formulation), and an arbitrarily fixed lag time of 0.23 hours was needed 
in order to stabilize the model. iiv for the absorption rate was large for both 
formulations compared to iiv terms for other pk parameters, and this likely 
contributed to unexplained variability in the plasma Cmax and Tmax values. 
In addition, this high degree of variability necessitated the use of a relative-
ly large number of parameters in order to describe the data accurately. Thus, 
although this population pk model adequately describes the variability in data 
obtained in this study population, it should be used with caution when used 
for predictive purposes. Consistent with previous studies in adults50, we also 
observed iiv in the apparent clearance and apparent distribution volume (in 
the beverage group only). Additionally, iiv was identified in inter-compart-
mental clearance in the beverage group only (as this parameter is related to 
the apparent distribution volume) and the elimination rate constant. Lean 
body mass-dependent variability was identified for the volume of the central 
compartment. Other potential covariates, including smoking status50 and 
valid only for observations made >1 hour after the dose. Prior to the 1-hour time 
point, the relationship between the plasma and saliva concentrations was too 
complex to develop a physiologically plausible model, regardless of whether 
the caffeine was delivered as a beverage or capsule (Figure 7). Therefore, only 
saliva concentrations measured >1 hour after dosing were included in the 
analysis. The estimated parameter was the s/p ratio (_; 0.68). Because incorpo-
rating iiv into the estimated ratio did not improve the model, the relationship 
between saliva pH or flow and the s/p ratio could not be evaluated adequately. 
The residual error model included an additive error. The best model accurate-
ly described saliva concentrations for both capsule and beverage dosages in 
adults for >1 hour after dosing (Figures 8 and 9). The best model also accurate-
ly described saliva concentrations in adolescents from >1 hour after dosing, 
although the saliva concentrations in adolescents were slightly under-pre-
dicted (Figure 10).
Discussion
Although the behavioral and psychomotor effects of caffeine have been stud-
ied extensively43-45, they have not been investigated in adolescents. Because 
caffeine can affect adolescents and adults differently2, results obtained in 
adults cannot necessarily be translated to adolescents. This is the first study 
to examine the cns effect profile of a single oral dose of caffeine (a caffeinated 
beverage) specifically in adolescents. In adolescents, caffeine had significant 
effects on task parameters related to attention, visuomotor coordination 
(adaptive tracking task), and alertness (saccadic peak velocity). Caffeine also 
induced cognitive effects, including an increase in error rate in the attention 
switch task. 
Because previous studies have demonstrated that saliva is an appropriate 
matrix for estimating caffeine concentration in plasma46,47, we measured 
caffeine concentration in saliva samples. To correlate caffeine’s effects in ado-
lescents with the estimated plasma caffeine concentration, we performed 
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15 years of age55. Finally, other factors could be related to differences between 
adolescents and adults, although an age-dependent difference in the s/p ratio 
is unlikely, as reports suggest similar ratios across various ages19,20. Relative 
under-prediction of adolescent saliva concentrations may reflect differences 
in pk variability between adolescents and adults. A pubertal stage dependent 
decrease in cyp1A2-mediated caffeine clearance has been described in healthy 
adolescents56, and weight-normalized clearance values of caffeine’s active 
metabolite theophylline in sexually mature adolescents have been reported 
to be lower (¾45%) than those in prepubescent individuals57. Finally, because 
adolescents of the same age range can have different levels of physiological 
maturation, caffeine clearance is likely to vary widely among adolescents, 
resulting in a broader 95% prediction interval (and thus also higher concentra-
tions at the highest percentile) than previously estimated using data obtained 
from adults. 
Because the s/p ratio for caffeine could only be described accurately 
>1 hour after administration, the resulting pk model was not sufficient for 
developing a pk/pd model using adolescent data alone. Significant effects in 
adolescents were seen one hour of administration as well as 3-4 hours after 
administration. For example, caffeine’s effects on the adaptive tracking task 
peaked soon after administration, which may be explained by caffeine’s low 
ec50 (half-maximal effective concentration). Alternatively, caffeine could facil-
itate task learning (learning effects) rather than task performance. Caffeine’s 
effects that occurred within one hour were not suitable for developing a pk/
pd model based on simulated plasma caffeine concentration; however, these 
effects could be included in a pk/pd model that is based on measured saliva 
caffeine concentration. With compounds that diffuse freely, including caf-
feine, the salivary concentration provides a better estimate of the drug’s 
cellular concentration in organs than in peripheral venous blood54; thus, sali-
va concentrations may be superior to plasma concentrations for developing a 
model. However, such a model must be corrected for possible contamination 
(particularly in individual samples collected directly after administration of a 
caffeinated beverage). Unfortunately, contamination could not be estimated 
oral contraception51, could not be evaluated, as only one subject smoked and 
only one female subject was taking birth control pills at the time of the study. 
The population pk model for plasma caffeine was extended by including 
a population model that described caffeine saliva concentration in adults >1 
hour after administration; the model showed that saliva concentration was 
a fraction (0.68) of plasma concentration, which is consistent with previous 
studies in neonates19 and adults20. The relationship between plasma and 
saliva caffeine concentrations could not be described as linear at earlier time 
points. Several studies in healthy adults reported a time-dependent s/p ratio 
for caffeine concentration, with a higher initial ratio that was followed by a 
decrease in ratio at later time points52-54. This time-dependent phenomenon 
has been attributed to fluctuations in the arteriovenous blood concentra-
tion54 and pH partitioning53. In our pk study in adults, although saliva pH and 
flow were measured at each sampling time point, they could not be quantified 
as covariates in our model. 
A slight under-prediction was observed with respect to simulations of sali-
va concentration in adolescents. This may have been due to several factors in 
addition to the abovementioned limitations in the plasma pk model. Possible 
study-related factors include a variable – and therefore potentially slightly 
higher – dose in the adolescent study. Contamination also likely played a role 
in the early time points; however, this was likely not a factor at time points 
>1 hour after administration. In addition, the simulations were based on the 
distribution of lbm in the adolescent data set, which included more male 
subjects (with generally higher lbm) than female subjects, perhaps explain-
ing why the observed saliva concentrations were in the upper half of the 
95% prediction interval for the majority of female subjects. The formula that 
we used to calculate lbm18 may have caused an under-estimation of lbm in 
some of the male adolescents. This formula uses weight and body mass index 
(height/weight2) and is based on data from adults, as no validated equation 
has been developed for adolescents *15 years of age. However, in a recent 
study, an equation for lbm that included only height and weight resulted in 
the systematic under-estimation of lbm in male adolescents between 13 and 
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responses in the distraction task, which may suggest that impulsivity increas-
es after caffeine intake in adolescents. Neuroimaging studies have shown that 
task switching involves an extensive neural network, including lateral prefron-
tal and parietal cortical regions, the pre-supplementary motor area, and the 
anterior cingulate cortex64-69, neural regions that functionally mature during 
adolescence70. In addition, animal studies suggest that the dopaminergic 
system undergoes major changes during adolescence (for review, see71); in 
addition, other cns stimulants (for example, amphetamine) can have age-de-
pendent effects on impulsivity72. However, as the switch trial is not designed 
to evaluate impulsivity, it remains to be determined if caffeine indeed increas-
es impulsivity in adolescents.
In conclusion, we report that a low dose of caffeine induces significant effects 
on parameters regarding alertness and reaction speed in adolescents, despite 
an expected ceiling effect on several parameters among this healthy, alert 
population. Whether these low-dose effects of caffeine are stronger in ado-
lescents than in adults remains to be determined. Caffeine did not improve 
task-switching performance, but it may increase impulsivity. Finally, because 
the s/p ratio for caffeine in adults could only be described accurately >1 hour 
after receiving the dose, and because the level of contamination after con-
suming the caffeinated beverage could not be quantified, the early effects of 
caffeine in adolescents were not suitable for developing a pk/pd model. 
in one of the sub-models due to the limited number of observations. Caffeine’s 
effects that occur >1 hour after administration could be used to develop a pk/
pd model. For example, caffeine’s effects on saccadic peak velocity occurred 
3-4 hours after administration, and several of caffeine’s effects occur with a 
time delay relative to changes in plasma concentrations, with an equilibration 
half-life of 20-50 minutes14,15. However, whether these late effects can be 
attributed to caffeine’s distribution time into tissues, post-receptor changes, 
or the formation of active metabolites (such as theophylline, which acts as an 
adenosine receptor antagonist58) remains unclear. 
In our study of adolescents, a low to moderate dose of caffeine of approxi-
mately 135 mg was chosen because this dose can significantly block adenosine 
receptors16. However, the actual dose of caffeine that was absorbed from 
the beverage was likely lower than 135 mg, as the plasma model identified 
a dose of 90 mg in the adults who ingested the same caffeinated beverage. 
Despite this decreased effective dose, caffeine-related effects were observed 
in parameters regarding alertness and reaction time in adolescents, effects 
that are more commonly observer following a low to moderate dose of caf-
feine in adults59,60. It is therefore likely that larger changes would occur 
at higher caffeine doses for some outcome parameters such as body sway, 
response times (of saccadic eye movements and the distraction task), and 
blood pressure; parameters that changed slightly but did not reach statistical 
significance. For example, a dose-dependent increase in diastolic blood pres-
sure was reported in a recent study in adolescents61. In contrast to previous 
findings in adults, caffeine’s effects on parameters in the attention switch task 
included an increase in error rate, but no effect on response time in the switch 
trial. Performance in repeated-task trials is typically better than performance 
in ‘switch’ trials. Caffeine has been shown to reduce switch error rates and/
or response time relative to placebo62,63, and coffee consumption has been 
suggested to improve task-switching performance by enhancing anticipatory 
processing (e.g., task set updating), presumably via caffeine’s neurochemical 
effects on the dopaminergic system62. In addition, in our study the response 
time for incorrect responses was shorter than the response time for correct 
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table 3  Mean reaction times and error rates of attention switch task, adaptive tracking, 
tapping and distraction task
Parameter Least-square means Estimate of difference 
(95% CI)
p-value
placebo caffeine caffeine vs. placebo
Attention switch error rate (#1) 0.7 1.1 19.11% (1.61/39.62%) 0.0338
Attention switch reaction time 
(#3)
19525 17929 -8.17% (-11.0/-5.25%) <0.0001
Adaptive tracking 26.55 28.06 1.50 (0.60/2.41) 0.0031
Tapping (taps/10s) 63.6 65.1 1.5 (-0.3/3.4) 0.0975
Left/right distraction number 
correct
31 31 -0 (-1/0%) 0.1137
Left/right distraction number 
incorrect
1 1 0 (-0/1%) 0.1137
Left/right distraction reaction 
time correct (ms)
17649 17036 -613 (-1261/34) 0.0611
Left/right distraction
Reaction time incorrect (ms) 558 704 146 (-56/347) 0.1395
95% ci = 95% confidence interval; # = trial number
 
table 4  Least-square means, estimates of difference and confidence intervals of effects  
of caffeine on autonomic nervous system
 
Parameter Least-square means Estimate of difference 
(95% CI)
p-value
placebo caffeine caffeine vs. placebo
Left pupil/Iris ratio 0.5640 0.5582 -0.006 (-0.020-0.0084) 0.3528
Right pupil/Iris ratio 0.5561 0.5598 0.0037 (-0.007/0.0147) 0.4682
Heart rate (beats per minute) 65.3 66.4 1.0 (-4.6/6.7) 0.6842
Diastolic blood pressure 
(mmHg)
63.7 65.1 1.4 (-0.8/3.6) 0.1857
Systolic blood pressure (mmHg) 117.2 120.8 3.6 (-0.2/7.5) 0.0611
95% ci = 95% confidence interval
table 1  Least-square means, estimates of difference and confidence intervals of  
neurophysiological effects of caffeine 
Parameter Least-square means Estimate of difference 
(95% CI)
p-value
placebo caffeine caffeine vs. placebo
Body Sway (mm) 272 248 -8.85% (-18.5/1.96%) 0.098
Saccadic Inaccuracy (%) 6.3 6.4 0.1% (-0.3/0.6%) 0.559
Saccadic peak velocity (deg/sec) 517 526 8.5% (2.0/15.0%) 0.014
Saccadic Reaction Time (sec) 0.197 0.193 -0.005% (-0.009/0%) 0.068
Smooth pursuit (%) 49.4 49.2 -0.3% (-3.1/2.6%) 0.842
95% ci = 95% confidence interval; statistically significant differences (i.e., p<0.05) are indicated in 
bold
table 2  Least-square means, estimates of difference and confidence intervals of effects  
of caffeine on cognition 
Parameter Least-square means Estimate of difference 
(95% CI)
p-value
placebo caffeine caffeine vs. placebo
Immediate word recall number 
correct (#3)
19.4 19.9 0.5 (-1.5/2.5) 0.6023
Delayed word recall number 
correct
17.5 18.1 0.6 (-1.9/3.0) 0.6330
Delayed word recognition  
number correct
27.1 26.4 -0.7 (-2.1/0.7) 0.3025
Response time of correct 
responses (word recognition)
880.2 847.0 -33.3 (-82.2/15.7) 0.1676
 95% ci = 95% confidence interval; # = trial number
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figure 1 pk model simulation of caffeine saliva concentration using data from adolescents 
study (dots) and previously published studies (straight continuous lines:15,46,49,50 ).  
The final measurement time in the adult study is indicated by the vertical dashed line; the assay  
loq is indicated by horizontal dashed line. 
figure 2  Saccadic Peak Velocity change in least-square mean from baseline profile  
with 95% ci as error bars. Rhombus: placebo; circles: caffeine. 
table 5  Population parameter estimates of the best plasma pk model (caffeinated 
beverage) 
Parameter (units) Median rse (%) iiv (%)
ka (hr-1) 180 73.3 319
ke (hr-1) 0.153 12.4 27
v2/f (l) 50.7 12.7 25
q (l/hr) 240 28.1 nd
v3 (l) 12.3 11.3 nd
alag1 (hr) 0.23 nd nd
cl (l/hr) 7.73 10.4 37
k23 (hr-1) 4.72 35.7 25
k32 (hr-1) 19.6 22.8 nd
lbm cov 0.665 11.6 nd
_ 0.678 6.38 nd
Parameter uncertainties and inter-individual variability (iiv) are provided when applicable.  
nd, not determined; rse, relative standard error.
table 6  Population parameter estimates of the best plasma pk model (caffeine capsule) 
Parameter Median rse (%) iiv (%)
ka (hr-1) 180 73.3 2549
ke (hr-1) 0.153 12.4 27
v2/f (l) 30.8 4.0 nd
q (l/hr) 240 28.1 nd
v3 (l) 12.3 11.3 nd
alag1 (hr) 0.23 nd nd
cl (l/hr) 4.71 10.4 27
k23 (hr-1) 7.79 30.3 nd
k32 (hr-1) 19.6 22.8 nd
lbm cov 0.665 11.6 nd
_ 0.678 6.38 nd
Parameter uncertainties and inter-individual variability (iiv) are provided when applicable.  
nd, not determined; rse, relative standard error.
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figure 5 Goodness-of-fit plots for the plasma pk model. Upper left: observed (dv) versus 
population predicted (pred) plasma caffeine concentrations, using fixed effects only (continuous 
line represents the line of unity); upper right: observed (dv) versus individual predicted (ipred), using 
individual specific empirical Bayes‘ estimates (continuous line represents the continuous line of 
unity); lower left: conditional weighted residuals (cwresi) versus individual predicted (ipred); lower 
right: conditional weighted residuals (cwresi) versus time after dose (tad). Continuous line represents 
the Loess fit through the data; horizontal lines represent the mean (0) and +/- 2 standard deviations.
figure 3  Adaptive Tracking Performance change in least-square mean from baseline  
profile with 95% ci as error bars. Rhombus: placebo; circles: caffeine.
figure 4  Switch Costs error rate (#3) change in least-square mean from baseline  
profile with 95% ci as error bars. Rhombus: placebo; circles: caffeine.
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figure 7 Normalized difference between caffeine plasma concentration and corre-
sponding caffeine saliva concentration for the capsule treatment for all subjects. Saliva 
concentrations were divided by an estimated fraction from the relationship (0.70) in one of the 
sub-models. Resulting values were then subtracted from the corresponding plasma concentration, 
then divided by the plasma concentration. This value was then plotted against time after dose. 
figure 6 Individual caffeine plasma concentration versus time plots on a log-linear scale. 
Dashed lines represent the population prediction, continuous lines indicate the individual predic-
tion, and circles represent the individual observations. S, subject number; trt 1, treatment 1 (capsule, 
200 mg caffeine); trt 2, treatment 2 (beverage, estimated dose 90 mg caffeine)
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figure 8 Goodness-of-fit plots for the saliva model. Upper left: observed (dv) versus 
population predicted (pred) saliva caffeine concentrations, using fixed effects only (continuous 
line represents the line of unity); upper right: observed (dv) versus individual predicted (ipred), 
using individual specific empirical Bayes‘ estimates (continuous line represents the line of unity); 
lower left: conditional weighted residuals (cwresi) versus individual predicted (ipred); lower right: 
conditional weighted residuals (cwresi) versus time after dose (tad). Continuous line represents the 
Loess fit though the data; horizontal lines represent the mean (0) and +/- 2 standard deviations.
figure 9 Individual caffeine saliva concentration versus time plots on a log-linear scale. 
Continuous lines represent the individual prediction and black circles the observations. Dashed line 
represent the plasma concentration prediction of the model and grey circles the plasma observa-
tions. S, subject number; trt 1, treatment 1 (capsule, 200 mg caffeine); trt 2, treatment 2 (beverage, 
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figure 10 Visual predictive check for the saliva concentration after the beverage treatment 
in (left) adults and (right) adolescents after simulation of 1000 subjects based on the distri-
bution of lbm in the adult and adolescent datasets. Circles represent the observations; black 
line represents the median prediction; dashed lines represent the 95% prediction interval. Vertical 
dotted line represents the 1h time point after dose; the saliva model was only based on data from 
this time point onwards. S, subject number; trt 1, treatment 1 and trt 2, treatment 2 (beverage, 
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abstr act  
 
Although the acute effects of alcohol consumption on the 
central nervous system (cns) have been studied extensively 
in adults, these effects have not been studied in adolescents. 
It is likely that the effects of alcohol reported in adults cannot 
simply be extrapolated to adolescents, as animal studies 
have shown that adolescent and adult animals have different 
sensitivities to alcohol. Here, we used a pharmacokinetics-
pharmacodynamics (pk/pd) modeling approach to compare 
the objective and subjective responses to alcohol between 
adolescent and adult subjects. The acute effect of consuming 
a socially accepted dose of alcohol (two standard units) was 
determined in 16-18-year-old adolescents. Blood alcohol 
concentration was measured non-invasively using end-
expired breath samples. A pk/pd model was then developed by 
combining the data obtained from this study in adolescents 
with data obtained from previous alcohol studies performed 
in adults. This model was used to characterize alcohol’s 
pharmacokinetics and effects on an objective biomarker and 
a subjective biomarker and to explore potential sources of 
variability, including age. A two-compartment structural model 
with first-order absorption and Michaelis-Menten elimination 
provided the best description of estimated plasma alcohol pk. 
Inter-individual variability was identified for several kinetics 
parameters, with lean body weight-dependent variability in 
peripheral compartment volume and maximum elimination, 
weight-dependent variability in central compartment volume, 
and height-dependent and age-dependent variability in 
intercompartment clearance. The relationship between alcohol 
concentration and the effect on baseline smooth pursuit 
performance and the Visual Analogue Scale (vas) Alertness 
score was described best as a dose-dependent effect without 
indications of delay or tolerance. Higher baseline performance 
in smooth pursuit was correlated with a larger absolute 
decrease in performance. No covariates were identified for 
the relationship between alcohol concentration and effect 
with respect to baseline smooth pursuit performance or vas 
Alertness score. Whether sensitivity to other alcohol-related 
pharmacodynamics effects changes with age remains to be 
determined. 
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In addition, because motor impairment and sedation are direct effects of mod-
erate alcohol intake14, lower sensitivity to these effects in adolescence may 
contribute to increased alcohol use among this age group27. Conversely, if ado-
lescents develop severe ataxia or sedation after only a relatively low dose of 
alcohol, this could impair their ability to ride a bike or drive a car safely. Thus, it 
is important to determine whether ingesting a ‘socially acceptable’ quantity of 
alcohol affects the nervous system with a different time course in adolescents 
than in adults. 
Here, we studied the effect profile of consuming two standard alcohol 
units by 16-18-year-old adolescent subjects. The acute effects of alcohol were 
determined using a limited number of well-characterized, sensitive bio-
markers11, and the effects of alcohol on the autonomic nervous system were 
assessed by measuring systemic blood pressure and heart rate. To determine 
the correlation between the measured effects and alcohol concentration, 
blood alcohol concentration was measured non-invasively using end-expired 
breath samples. A pharmacokinetics-pharmacodynamics (pk/pd) model was 
developed by combining the data obtained from this study in adolescents 
with data obtained from alcohol studies in adults performed previously by our 
research group28-35. The purpose of this model was to characterize alcohol 
pharmacokinetics and alcohol’s effects on one objective biomarker and one 
subjective biomarker and to explore potential sources of variability, including 
age. Objective and subjective biomarkers for pk/pd modeling were selected 
based on an exploratory meta-analysis of all relevant alcohol data.
Methods
Clinical trial in healthy adolescents
subjects
Healthy male and female subjects aged 16-18 years were included. The subjects 
had to be non smokers. They had to be current users of alcohol (i.e., use of at 
Introduction
Ethyl alcohol (ethanol; referred to hereafter as simply ‘alcohol’) is the most 
commonly used recreational compound among adolescents1-3. In most West-
ern countries, adolescents experiment with alcohol, and alcohol consumption 
usually becomes ‘normal’ during adolescence. In 2009, approximately 85% 
of 15-16-year-old Dutch adolescents reported having consumed alcohol, and 
more than 60% were current users2,4. Concerns regarding the deleterious 
effects of early or excessive alcohol consumption on brain development and 
the increased risk of alcohol abuse in adulthood has led to a plethora of exper-
imental animal studies and observational human studies of adolescents with 
alcohol abuse/dependency or binge drinking (for reviews, see5-7). However, 
although a small subpopulation of adolescents use alcohol with high frequen-
cy and are exposed to the risks of heavy drinking, most adolescents ultimately 
establish a drinking pattern that is considered socially acceptable2,8-10. 
Although adolescents cannot legally purchase alcohol in the Netherlands, 
alcohol consumption by adolescents is – in itself – not prohibited by Dutch law. 
Nevertheless, the social and legal acceptability of moderate underage alcohol 
consumption has no scientific basis, as the functional effects of alcohol in ado-
lescents have not been investigated in a placebo-controlled study. 
The effects of acute alcohol consumption on the central nervous system 
(cns) have been quantified extensively in adults, and consistent effects on 
tests that evaluate divided attention and visuomotor control have been 
reported after a relatively low dose (e.g., bac <0.5 g/l)11. Adolescence is a period 
of intense development, and animal studies have revealed differences in sen-
sitivity to the acute effects of alcohol between adolescents and adults12-26. 
Therefore, it is conceivable that the effects of alcohol that have been reported 
in adults cannot simply be extrapolated to adolescents. If human adolescents 
and adults also have differential sensitivities to the acute effects of alcohol, 
adolescents may experience functional cognitive impairments at lower alco-
hol doses than adults, which is a serious issue given the substantial cognitive 
demands that adolescents face in school and early in their developing careers. 
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(e.g., coconut milk mixed with orange juice and vanilla aroma) on different 
study days. The total alcohol dose of 20 gram was anticipated to lead to a peak 
blood concentration of 0.3 g/l. Intervention arms were made as comparable 
as possible regarding expectancy, sensory effects and the presence of biologi-
cally active substances other than ethanol. To avoid confounds from circadian 
variability, alcohol was administered at the same time of day in all subjects. 
Subjects were instructed to drink one beverage at a time during a 5 minute 
interval.
pharmacokinetics
Breath alcohol concentrations (Brac) were determined through a breath test, 
using a hand-held Alco-Sensor iv meter (Honac, Apeldoorn, The Netherlands). 
Subjects were instructed how to properly use the device during a training 
session and 2 breath tests were taken prior to alcohol or placebo intake. To 
eliminate residual alcohol in the mouth, subjects were instructed to rinse their 
mouths thoroughly with water directly after alcohol intake. The first breath 
test after intake was taken at 17 minutes after alcohol intake to avoid residu-
al alcohol contamination of the mouth despite mouth washing. Breath tests 
were taken every 20 minutes (until 1 hour after intake), every 30 minutes (until 
2 hours after intake) and then at hourly intervals (until 5 hours after intake). 
pharmacodynamics
The NeuroCart is a test battery of sensitive tests for a wide range of cns 
domains that has been developed at the Centre for Human Drug Research 
(chdr, Leiden, The Netherlands) to examine different types of cns-active 
drugs. This test battery was incorporated to provide background information 
on general cns performance and functional cns domains, which could be 
affected by alcohol based on previous findings in adults11. 
All pharmacodynamic measurements (pd) measurements, with exception of 
the visual verbal learning task (vvlt), were performed at t= 30, 60, 90, 120, 180, 
and 300 minutes after alcohol intake. The vvlt was administered at approx-
imately 70 and 140 minutes after alcohol intake to assess immediate and 
least 4 units during the month preceding study participation), but were not 
allowed to use on average more than 7 units alcohol per week. After signing 
informed consent (in case age < 18 years, also by parents or legal guardian), 
subjects were medically screened within three weeks prior to study partici-
pation and excluded in case relevant clinical abnormalities were found. Use 
of medications and compounds known to affect cns performance (including 
nicotine, xanthines, drugs or alcohol) were not allowed and were screened 
during screening and prior to each study day. Ethical approval of the study pro-
tocol was obtained from the Central Committee on Research involving Human 
Subjects, the Netherlands. 
study design
This was a randomized, double-blind, placebo-controlled, two-way crossover 
study of 16 healthy, adolescent subjects with a wash-out period of at least 3 
days. Prior to the study days, subjects were instructed to remain fasted from 
midnight. Smoking and the use of alcohol and xanthine-containing foods or 
beverages were not allowed during the study days. A standardised light break-
fast and lunch were offered at approximately 1 hr prior and 2.5 hr after alcohol 
intake respectively. Water was allowed ad libitum. Subjects remained in house 
until 5 hr after alcohol intake.
The sample size of 16 was calculated (two-sided test, alpha = 0.05) for ran-
domization using Williams Squares. This sample size was estimated to have 
80% power of detecting a difference in means of -4.6 points for smooth pursuit 
eye movement assuming a standard deviation of differences of 6.1 (as found 
in a previous ethanol study by our group in which an effect of -3.9 points was 
found for an ethanol level of 0.3 g/l).
interventions
All subjects received 2 beverages (200 ml each) containing an oral dose of 
approximately 10 gram ethanol each (e.g., appropriate amounts of Malibu 
Coconut Rum, a rum with natural coconut extract with an alcohol percent-
age by volume of 21.0%, mixed with coconut milk and orange juice) or placebo 
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support placed opposite the target. The target consisted of an array of light 
emitting diodes on a bar, fixed at 50 cm in front of the head support. Saccadic 
eye movements were recorded for stimulus amplitudes of approximately 
15 degrees to either side. Fifteen saccades were recorded with interstimulus 
intervals varying randomly between 3 and 6 seconds. Average values of latency 
(reaction time), saccadic peak velocity of all correct saccades and inaccuracy of 
all saccades were used as parameters. Saccadic inaccuracy was calculated as 
the absolute value of the difference between the stimulus angle and the corre-
sponding saccade, expressed as a percentage of the stimulus angle. 
smooth eye pursuit  The same system as used for saccadic eye move-
ments was also used for measurement of smooth pursuit. For smooth pursuit 
eye movements, the target moves sinusoidally at frequencies ranging from 0.3 
to 1.1 Hz, by steps of 0.1 Hz. The amplitude of target displacement corresponds 
to 22.5 degrees eyeball rotation to both sides. Four cycles are recorded for each 
stimulus frequency. The method has been validated at the chdr by Van Steve-
ninck and colleagues39,41 based on the work of Bittencourt and colleagues42 
and the original description of Baloh and colleagues40. The time in which the 
eyes were in smooth pursuit of the target was calculated for each frequency 
and expressed as a percentage of stimulus duration. The average percentage 
of smooth pursuit for all stimulus frequencies was used as parameter. 
dual task test  The Dual Task (dt) can be used to measure mental work-
load, as multiple tasks should produce interference when they compete for the 
limited capacity resources. During this task, subjects were required to perform 
two separate tasks, each involving an unrelated mapping of a set of possible 
stimuli to a set of possible responses43 in an adapted version of the Pashler’s 
dt44-46. This adapted dt consists of 54 trials, with three blocks of 18 trials each. 
The subject was required to give a response as quickly and as accurately as 
possible indicating whether the tone is either low or high pitched and which 
letter is presented with a line below or above it. The subjects were instructed 
not to postpone their reaction for Stage 1 (s1) up until they knew the response 
delayed recall. The pd measurements were performed in a quiet room with 
ambient illumination with only one subject in the room per session. Prior to 
the first study day, subjects were familiarized with the experimental proce-
dure and given a practice session on the tasks to minimize learning effects 
during study days. The tests were performed as described below. In addition, 
a short questionnaire was taken at screening to evaluate the subjects’ current 
perceptions on alcohol use. 
adaptive tracking The adaptive tracking test as developed by Hobbs & 
Strutt, according to specifications of Borland and Nicholson36 was used. The 
adaptive tracking test is a pursuit-tracking task in which a circle of known 
dimensions moves randomly about a screen. The study subject was instructed 
to try to keep a dot inside the moving circle by operating a joystick. If this effort 
was successful, the speed of the moving circle was increased. Conversely, the 
velocity was reduced if the subject could not maintain the dot inside the circle. 
Performance was scored after a fixed period and the average performance and 
the standard deviation of scores over a 3.5-minute period was used for analysis. 
 
saccadic eye movements  Saccadic peak velocity is one of the most sen-
sitive parameters for sedation37-39. The use of a computer for measurement of 
saccadic eye movements was originally described by Baloh and colleagues40, 
and has been validated at chdr by Van Steveninck and colleagues39,41. 
Recording and analysis of saccadic eye movements was conducted with a 
microcomputer-based system for sampling and analysis of eye movements. 
The nystagmo stimulator used for stimulus display is from Nihon Kohden 
(Nihon Kohden Corporation, Tokyo, Japan), the program for signal collection 
and the ad-converter from Cambridge Electronic Design (ced Ltd., Cambridge, 
uk), the amplification by Grass (Grass-Telefactor, An Astro-Med, Inc. Product 
Group, Braintree, usa) and the sampling and analysis scripts are developed 
at the chdr. Disposable electrodes were applied on the forehead and beside 
the lateral canthi of both eyes of the subject for registration of the electro-oc-
ulographic signals. Head movements were minimised with the aid of a head 
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contentedness (often called mood; from five scores), and calmness (from two 
scores). To make the vas more age-appropriate, the words ‘incompetent’ and 
‘recalcitrant’ in the frequently used Dutch translation of this vas were replaced 
by ‘onbekwaam’ and ‘tegendraads’ respectively. In addition to this, a separate 
100 mm-line was added, asking the subject to indicate ‘how large is the effect 
of alcohol that you feel’ (alcohol effect)? 
blood pressure and heart rate Automated oscillometric blood press- 
ures were measured using a Nihon-Kohden bsm-1101K monitor, a Colin 
Pressmate bp 8800 or a Dash 4000 monitor. Pulse rates were determined by 
oscillometry.
Alcohol studies in adults
Pharmacokinetic and selected pharmacodynamic data from several alcohol 
studies in adults previously performed by our research group were included 
in the pk/pd model (see Table 1 for an overview). In these studies, the alcohol 
clamping method (according to the methods of Zoethout and colleagues49) 
was used in which the infusion rate is adjusted according to the estimated 
blood alcohol concentration. All studies were performed in healthy adults, 
with exception of one study in adult patients with essential tremor30. In all 
studies, subjects with a history of ethanol abuse were excluded from the study. 
In most studies subjects who drank regularly (up to 3-4 alcoholic beverages a 
day) were allowed to participate. In three studies28,29,31 familiarity with the 
use and effects of ethanol was required for inclusion of a subject. All subjects 
had a normal body mass index (bmi). 
Statistical analysis and pharmacometrics
pharmacodynamics
The pharmacodynamic end-points of the adolescent study were analysed by 
mixed-model analyses of variance (using sas proc mixed) with treatment, 
for Stage 2 (s2). At the end of each block, the subject was provided with feed-
back of percentage correct responses and mean correct rt for both s1 and s2. 
body sway The body sway meter allows measurement of body movements 
in a single plane, providing a measure of postural stability and was mea-
sured with an apparatus similar to the Wright ataxiameter37,47. With a string 
attached to the waist of the subject, all body movements over a period of time 
were integrated and expressed as mm sway on a digital display. Before starting 
a measurement, the subjects were asked to stand still and comfortable, with 
their feet approximately 10 cm apart and their hands in a relaxed position 
alongside the body. The subjects were instructed to keep the eyes closed. 
visual verbal learning task The visual verbal learning test (vvlt) is 
a comprehensive memory task for immediate and delayed recall and con-
tains three different subtests that cover merely the whole scope of learning 
behaviour. Subjects were asked to complete a training version of the vvlt 
within three weeks before study start. The subjects were presented 30 words 
in three consecutive word trials at approximately 75 minutes after alcohol/
placebo administration, i.e. word learning test (vvlt30). Each trial ended 
with a free recall of the presented words, i.e., immediate recall, to determine 
acquisition and consolidation of information. Approximately two hours after 
start of the first trial, the subjects were asked to recall as many words as pos-
sible, i.e. delayed recall, to measure active retrieval from long term memory. 
Immediately thereafter, the subjects underwent a memory recognition test, 
which consisted of 15 presented words and 15 ‘distractors’, i.e. delayed recog-
nition, to test memory storage. The subjects were not allowed to write words 
down at any time during the whole test procedure. 
visual analogue scores At various times, the subject indicated (with 
a mouse click on the computer screen) on sixteen horizontal Visual Analogue 
Scales how he/she felt. From these measurements, three main factors were 
the calculated as described by Bond and Lader48: alertness (from nine scores), 
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test under the assumption that the difference in -2ll is Chi-square distributed 
with degrees of freedom determined by the number of additional parameters 
in the more complex model. Hence, with a decrease in ofv of at least 10.8 points 
the model with one additional parameter is considered superior over its parent 
model (p<0.001). Different models with increasing complexity were compared 
to find the simplest model that described the data adequately. Graphical 
analysis was used to assess model performance during model development. 
The goodness of fit plots used included: observed concentration (dependent 
variable, dv) versus population predicted concentration (pred) and versus 
individual predicted concentration (ipred); weighted residuals (cwresi) 
versus ipred and versus time; combined pred, ipred and dv versus time, per 
individual, and distribution of interindividual variability (eta). Covariate anal-
ysis was performed using a stepwise approach. Selection of the best pk- and 
best pk/pd models was based on the likelihood ratio test, diagnostic plots, 
visual predictive check (vpc) and precision in parameter estimates. Calculation 
of the relative standard error (rse) was used to derive the uncertainty in the 
parameter estimates and was considered acceptable when less than 10%. 
nonmem input file preparation and processing (tables and graphs) of the 
model results was performed using R version 2.12.0 (V2.12.0, R Foundation for 
Statistical Computing, Vienna, Austria, 2010). 
population pk model development  First, a population pk model 
for oral and intravenous alcohol was developed. One and two compartment 
structural models, and different compartmental and elimination submodels 
were tested. All models used a first order process to describe the oral absorp-
tion of alcohol in the adolescent data set. Inter-individual variability (iiv) was 
assessed separately on each of the pk parameters using a stepwise bottom-up 
approach. Correlations between the iiv of the various parameters were graph-
ically explored. When correlations were significant, either by shape or Piersons 
correlation coefficient, covariance between the terms was assessed by appli-
cation of an omega block on selected parameters and accepted based on the 
likelihood ratio test. For the parameter estimation, shrinkage was considered 
study day, time and treatment by time as fixed effects, and subject, subject 
by treatment and subject by time as random effects and the average baseline 
value as covariate. Contrasts were estimated within the overall treatment 
effect and contrasts between treatments over 120 min and 300 min were 
calculated within the statistical model. Body Sway and vas alcohol scores 
variables were analysed after log-transformation and back-transformed after 
analysis (results may be interpreted as percentage change). vas alcohol scores 
were log transformed (10log) after 2 was added to each score to avoid log trans-
formation from zero. vvlt parameters were analyzed by mixed model analysis 
of variance with treatment and study days as fixed factors and subject as ran-
dom factor. The statistical hypothesis was ‘there is no difference between 
alcohol and placebo’. 
pharmacometrics
data pk data from study days in which only alcohol was administered of the 
adolescent study and several adult studies (see Table 1) were used. Exploratory 
individual and summary concentration-time profiles were generated to iden-
tify potential outliers, understand the influence of censoring concentrations 
below the limit of detection (blod) and give indications regarding the base 
structural model. As the device reports a value of zero when alcohol breath 
concentrations are blod, all pk observations with a value of zero after plasma 
peak concentrations were removed from the pk dataset. Blood alcohol concen-
trations were calculated according to the specifications of the manufacturer 
(using ratio (2300:1) between blood- and breath ethanol concentrations) and 
used to develop the pk model. 
modeling strategy  Pharmacometric analyses were performed using 
nonlinear mixed effect modeling (nonmem version 7.2.0 (Beal). First order 
conditional estimation with interaction (focei) was used for estimation with 
a convergence criterion of 5 significant digits in the parameter estimations. 
nonmem reports an objective function value (ofv) which is the -2 times log 
likelihood (-2ll). Model comparison testing was done using the likelihood ratio 
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Results
Clinical trial in healthy adolescents
subjects
In the adolescent study, a total of 17 subjects (8 males and 9 females) 16-18 years 
of age were enrolled in 2010 and 2011. All of the subjects attended pre-universi-
ty secondary education (vwo, Voortgezet Wetenschappelijk Onderwijs). One of 
the female subjects discontinued the study because of a migraine experienced 
following the first study day (an alcohol occasion); this subject was replaced by 
another female subject. Three of the female subjects used an oral contracep-
tive; other medications used during the study included levocetirizine 5 mg p.o. 
as needed (by one subject; stopped two days before the first study occasion), 
paracetamol 500 mg p.o. 2-6 times daily (by 1 subject during the first study 
occasion), terbinafine cream 10 mg/g and terbinafine 250 mg p.o. once daily (by 
one subject during both study occasions). The mean alcohol consumption by 
the subjects in the months preceding the study was 3 standard units per week 
(range: 1-6 units per week). The reasons cited by the subjects for drinking alco-
hol included: they liked it (n=13); ‘it is socially enjoyable’ (n=14); and it reduces 
inhibition (n=2). None of the subjects reported that they drank alcohol because 
their friends also drank alcohol or to become drunk. The subjects either had 
never been drunk (n=6) or were drunk only occasionally (n=11); nine subjects 
reported an occasional black-out episode after consuming alcohol. Most of the 
subjects considered the short-term effects of alcohol (n=7) or the dangers of 
alcohol consumption (n=11). The majority of subjects (n=11) reported that they 
considered the long-term effects of alcohol only when pointed out by others. 
The mean alcohol dose in the study was 0.29 g/kg (range: 0.24-0.34 g/kg) for 
males and 0.31 g/kg (range: 0.27-0.38 g/kg) for females. After ingesting the alco-
hol or placebo on the study day, the subjects were asked which of the two they 
thought they had received. After ingesting the placebo, 13/16 subjects believed 
they had taken the placebo, and the other three did not know whether they 
acceptable when below 30%50. Proportional, additive, and combined error 
structures were evaluated to best describe the residual error. After graphical 
identification, the most promising covariates were tested in the model and 
included based on decrease in ofv in a stepwise manner (forward inclusion 
of covariates, followed by a backward elimination step). All covariates were 
implemented in normalized power function (Eq. 1), where the normaliza-
tion values for lbw, wgt, age and hgt were 60, 70, 30 and 1.75 respectively. 
ei  =  exp (eTV + ¡)  x  ([COV] i / [COV]n) ̂  (ecov)  Eq. 1
where ei; individual parameter estimate, eTV; typical (population) value, ¡; 
interindividual variability, COVi; individual covariate value, COVn; normaliza-
tion value for covariate, eCOV; parameter estimate for the exponent.
pk/pd model development  After development of the pk model, explor-
atory pd and pk/pd profiles were generated to identify the most suitable 
objective- and subjective pd parameter for development of a pk/pd model. 
Only pd parameters that were measured in at least two different studies and 
more than once on a single occasion were included. Selection of pd parameters 
for pk/pd model development was based on strong response to alcohol and 
indications of presence of a direct relationship between alcohol concentration 
and effect. For the development of the pk/pd model, all pk parameters were 
fixed to the individual parameter estimates of the best pk model. The simu-
lated individual plasma alcohol concentration time profiles were used in the 
exploration of linear- and exponential concentration-effect relationships, to 
best describe the observed pd response. Model development was performed 
as described for the best pk model (e.g. incorporation of iiv, residual error and 
covariates). Model description of the data was considered acceptable if time-, 
concentration- or performance-dependent bias seemed absent.
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and iiv are presented in Table 4. A combined residual error structure was iden-
tified for the model. iiv could be identified with respect to vm (the maximum 
elimination rate parameter), v2 (the central compartment), v3 (the volume of 
the peripheral compartment), and q (intercompartment clearance). The sub-
sequent addition of an eta to the Michaelis constant (km) caused a significant 
decrease in ofv; however, this decrease (38%) was above the acceptance cri-
terion and this covariate was not incorporated in the model. The investigated 
covariates included age, gender, height, weight, bmi, and lean body weight 
(lbw51). The following five covariate relationships were implemented in the 
model: lbw on v3 and vm, weight on v2, and height on q, and age on q. For the 
covariate weight on v2, the exponent was fixed at 1, as the confidence interval of 
the estimated exponent overlapped 1.0. Backwards elimination was than per-
formed; however, this approach resulted in a significantly poorer model in all 
cases. Covariance was identified between vm and q, vm and v2, and v2 and v3. 
 In the best pk model, the predicted concentrations were accurate and no 
time-dependent bias was observed (Figure 4 and 5). The Loess regression curve 
of the conditional weighted residuals (cwresi) versus individual predicted 
concentration (Figure 5) suggested a slight bias at higher concentrations (>1.0 
g/l); this bias is likely due to the low number of observations at high concentra-
tions (there were only two observations between 1.5 and 2.0 g/l) reducing the 
reliability of the Loess curve, rather than to model misspecification. nonmem 
assumes that etas are normally distributed around zero. The estimated etas 
were distributed normally (Figure 6).
Because alcohol was administered orally in only one study (adolescent 
study), and because this study did not include crossover design with an intra-
venous group, oral bioavailability (f) could not be estimated reliably by the pk 
model. The individual parameter estimates of v2, v3, and vm of the subjects in 
the adolescent study actually represent v2/f, v3/f, and vm /f, which can affect 
parameter estimation and/or the best model structure. A sensitivity analysis 
was performed using the data set (excluding the oral data). Removal of the oral 
data from the analysis did not change any decisions made at key steps in the 
model development; the resulting best model structure was the same, and 
had taken placebo or alcohol. After alcohol intake, 14/17 subjects believed they 
had taken alcohol, two believed they had taken the placebo, and one did not 
know. 
pharmacodynamics results
The pharmacodynamics results are summarized in Table 2. Least Square 
Means graphs of the parameters that differed significantly between alcohol 
and placebo are presented in the Supplemental Data. 
pharmacometrics
An overview of the demographics for the studies from which data were used to 
develop the model is presented in Table 3.
pk model development A total of 3,112 pk observations were obtained 
from 27 adolescents (16-18 years of age) and 122 adult subjects (19 years of 
age and older). In general, the percentage of pk data that was below the level 
of detection was <15%, except for the adult study in healthy Caucasian and 
Japanese volunteers29 (34%, excluding pre-dose observations) and the adult 
study with the compound gsk59880932 (29%, excluding pre-dose obser-
vations). In these two studies, pk sampling continued relatively long after 
ethanol infusion had stopped, and during the last few pk measurements, most 
of the subjects’ alcohol concentrations were below detectable levels. None of 
the data points between the start of dosing and reaching peak plasma alco-
hol concentration were below detectable levels. The entire data set from one 
occasion from one adult subject was excluded because the subject was not 
‘well-rested’, and the occasion was repeated on a later day. Finally, data from 
four adult subjects were excluded due to the suspected presence of erroneous 
dosing information.
A two-compartment structural model with first-order absorption and 
Michaelis-Menten elimination provided the best description of estimated 
alcohol plasma pk. A schematic representation of the alcohol pk model struc-
ture is presented in Figure 3. Parameter estimates, relative standard error (rse), 
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pursuit tests as the baseline. Implementing an additional population value did 
not significantly improve the model (p>0.05). 
The data were described using the following equation:
 
smp  =  bl  x  ( 1 - (ke  x  c) )      Eq. 2
where smp is smooth pursuit performance (%), bl is baseline performance (%), 
ke is effect constant (l/g), and c (g/l) is the alcohol concentration simulated by 
the plasma pk model.
An additive error structure performed better than a proportional error 
structure in all models (including the best pk/pd model). A combined error 
structure did not improve the model and was abandoned. iiv could be identi-
fied for the baseline smooth pursuit performance (bl) and the effect constant 
(ke), with acceptable shrinkage in the eta on bl and ke (<20%). A covariate 
analysis of age and gender was performed. Including age as a continuous 
covariate did not improve model performance. Age was also implemented as 
a categorical covariate, parsing the subjects into the following three groups: 
adolescents (16-18 years of age), young adults (19-29 years of age), and older 
adults (>29 years of age). This approach did not reduce ofv, and the estimated 
age effect did not differ significantly from ‘no effect’. As a result, no covariate 
was included on the model parameters bl and ke. Implementation of covari-
ance between eta1 and eta2 did not improve the model and was therefore not 
added to the model. 
The parameter estimates of the best model are summarized in Table 5. 
The uncertainty of the parameter estimates was considered to be acceptable. 
As expected based on the exploratory plots, the iiv of ke was relatively high 
(60.7%). Both the shrinkage on the etas and the additive error were below 20% 
and were therefore considered to be acceptable. 
The ability of the pk/pd model to describe the effect of alcohol on smooth 
pursuit performance was acceptable (Figures 7 and 8). nonmem assumes a 
normal distribution of the etas around zero. In the best model, the etas follow 
this assumption, although the distribution of the eta1 suggests a slight skew 
(Figure 9).
none of the parameter estimates changed significantly. Therefore, we con-
clude that including oral data – without estimating oral bioavailability – did 
not have a negative impact on the model development.
population pk/pd model development Based on the exploratory 
plots of pd and pk/pd, smooth pursuit performance was chosen as the most 
suitable objective pd measure (3643 data points collected from 24 adolescent 
subjects and 64 adult subjects), and vas Alertness (2671 data points collected 
from 19 adolescent subjects and 68 adult subjects) was chosen as the most 
suitable subjective pd measure. For these parameters, the exploratory plots 
suggested a strong, dose-dependent alcohol effect with no placebo effect 
(Figures 1 and 2). The exploratory plots also suggested relatively large inter-in-
dividual differences in subject susceptibility to alcohol’s effects on smooth 
pursuit performance and vas Alertness.
Smooth pursuit was included as a pd measure in the adolescent study and 
in four of the adult studies28,29,32,35, and vas Alertness was included as a pd 
measure in the adolescent study and in four of the adult studies29,31,32,35. One 
of the adolescent pre-dose smooth pursuit measurements reflected extreme-
ly poor performance (5.2%), which was likely related to a technical or subject 
attention-related problem; this measurement was therefore excluded from 
the analysis.
smooth pursuit pk/pd model The relationship between alcohol con- 
centration and the effect on baseline smooth pursuit performance was 
described best as a direct, linear concentration-effect relationship. A con-
centration-effect relationship proportional to the baseline characterized the 
effects of ethanol on smooth pursuit performance better than an absolute 
effect independent of baseline (lower ofv and comparable parameter esti-
mates). Because our exploratory plots revealed no apparent placebo effect on 
smooth pursuit performance, we used a fixed baseline. We also attempted to 
estimate a population value for the baseline performance; however, the best 
results were obtained using the mean performance of the pre-dose smooth 
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the model (p<0.001), but because of high eta-shrinkage (42.7%), the model 
without iiv on bl was deemed superior. The occasion-specific mean of the pre-
dose measurements was used as a covariate on bl during the structural model 
development. Because none of the covariates showed a particularly strong 
correlation with the individual parameter estimates (based on Pearson’s 
correlation coefficient and a visual check of the scatterplot), no additional 
covariate relationships were included in the model. 
The parameter estimates are presented in Table 6. The uncertainty of the 
residual error was rather high, and the other parameters had a reasonable 
degree of uncertainty. As expected from the exploratory plots, the iiv of ke was 
high compared to the population estimate of ke. Both the shrinkage of eta and 
the error were <20%. 
The pk/pd model described the effect of ethanol on vas Alertness score 
relatively well, with an absence of both time-dependent and concentra-
tion-dependent bias (Figures 11 and 12). The Loess curve in the cwresi vs ipred 
plot suggests a bias towards overestimating the vas Alertness score at very 
low scores (<30 mm). However, given the relatively small contribution of these 
few values in the total number of observations and given the fact that the low 
cwresi values seemed to lie within acceptance limits (-2 to 2), this appar-
ent bias was not considered a factor in the model’s performance. nonmem 
assumes a normal distribution of the etas around zero. The iiv of ke followed a 
normal distribution, although the mean of eta was not significantly different 
from zero (Figure 13). Thus, it might not be appropriate to assume a normal dis-
tribution of eta when performing a simulation using this pk/pd model.
Discussion
This is the first study to use a pk/pd modeling approach to compare the objec-
tive and subjective responses to alcohol between adolescents and adults. Most 
previous observational studies of alcohol use in adolescent subjects focused 
on potential negative effects on the brain and the associated long-term 
Because the pk/pd model was developed by sequentially modeling pk and pd, 
mis-fitting of the pk can cause a bias in the predicted pd (for example, if the 
ethanol concentrations are overestimated, the predicted effect might be over-
estimated as well). Therefore, the conditional weighted residuals of the best 
pk model were plotted against the residuals of the best pk/pd model. We found 
no indication that the residual error in the best pk/pd model was caused by the 
residual error in the best pk model (Figure 10).
VAS Alertness PK/PD model
The relationship between alcohol concentration and vas Alertness score was 
described best as a direct, linear effect on baseline. An additional concentra-
tion-effect relationship characterized the effects of ethanol on vas Alertness 
best when compared to a proportional relationship. Because there were no 
indications of a placebo effect, a fixed baseline was chosen. We tested the 
following four baseline sub-models: (1) the estimated population value; (2) 
the occasion-specific mean of the pre-dose measurements; (3) the fraction of 
the occasion-specific mean of the pre-dose measurements, and (4) the occa-
sion-specific mean of the pre-dose measurements as a normalized, linear 
covariate on the estimated population value. Of these four sub-models, the 
fourth performed the best (p<0.001) and was therefore implemented in the 
structural model. A combined error structure provided the best characteriza-
tion of the residual error in the best model. 
The data were described using to the following equation:
vas Alert  =  bl  –  ( ke  x  c)     Eq. 3
  
where vas Alert is the vas Alertness score (mm), bl is the baseline score (mm), 
ke is the effect constant (mm*g/l), and c (g/l) is the predicted alcohol concen- 
tration.
Removing either the additive or proportional error component resulted in a 
significantly poorer model (p<0.001). Implementing iiv on ke significantly impro- 
ved the model (p<0.001). Implementing iiv on bl also significantly improved 
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standard error of the population km value in our pk model was rather high. 
Because the majority of data was collected during clamping experiments, 
a relatively low percentage of the data was in the low concentration range, 
thereby reducing the informative value of the data with respect to esti-
mating km. In the adolescent study, alcohol was given as a fixed dose of 20 
mg rather than being adjusted for weight (or total body water, which might 
have been preferred58). While this approach might reflect common drinking 
practices, it likely added variability. Interindividual variability was identified 
for various kinetic parameters, with lbw-dependent variability on periph-
eral compartment volume and maximum elimination, weight-dependent 
variability on central compartment volume, and height- and age-dependent 
variability on intercompartment clearance. Body composition is important for 
the equilibrium distribution of alcohol between the blood and various body 
compartments58. Because alcohol is distributed into the total body water, 
differences in age, gender, and body weight can affect alcohol’s concentra-
tion-time profile59-61. In our evaluation, gender per se was not identified 
as a potential covariate, but gender was factored indirectly into in the cal-
culation of lbw. The covariates that were identified in our pk model may be 
related – either directly or indirectly – to differences between adolescents and 
adults, as considerable age-related and maturity-related changes in body 
composition occur during adolescence, including changes in weight, height, 
and fat-free mass62. Because all of our subjects had normal bmi, differences in 
the prevalence of obesity between the adolescents and adults could not have 
accounted for the weight-related variability. The rate of alcohol distribution is 
dependent on factors that govern peripheral distribution58. In our pk model, 
age-dependent variability was found with respect to intercompartment clear-
ance; specifically, clearance increases with age. Changes in intercompartment 
distribution can be caused by changes in peripheral circulation (e.g., due to 
stress), muscle contraction, hormonal changes, vasoconstriction, changes in 
body and environmental temperature, and circulatory impairments in the 
cardiovascular system58. Moreover, it is conceivable that adolescent sub-
jects have different stress reactions to the testing environment than adults. 
risks of heavy drinking. Only a few clinical studies investigated the effects of 
acute alcohol in children and adolescents; however, these studies were not 
placebo-controlled and included relatively alcohol-naïve subjects52 or they 
evaluated responses in adolescents who had (or were at high risk for devel-
oping) an alcohol abuse disorder52,53. Data from these studies may not have 
direct implications for how alcohol interferes with psychomotor and cognitive 
abilities in more common situations, for example when relatively low, socially 
accepted doses are consumed by healthy adolescents with a limited history 
of drinking alcohol. In our study, a pk/pd model was developed by combining 
the adolescent data with adult data obtained from alcohol studies previously 
performed by our research group in order to investigate whether pk and/or pd 
has any age-related differences. The clamping method, which was used in pre-
vious adult studies, is best suited to evaluating potential sources of variance in 
pk, including age-related effects. Due to ethics considerations, ethanol clamp-
ing could not be performed in adolescents. We anticipated that the accuracy 
of the clamping method in adults would provide the basis for an accurate pk/
pd model, which would be robust enough to accommodate the more variable 
adolescent data collected after oral ingestion.
The pk model was built using a combination of estimated blood alcohol 
concentration in adolescents (following oral administration) and adults (using 
an infusion-based clamping method). A two-compartment structural model 
with first-order absorption and Michaelis-Menten elimination provided the 
best description of estimated alcohol plasma pk. The estimated combined 
volume of the central and peripheral compartments (46 liters) and estimates 
of elimination (maximum elimination rate and Michaelis constant) were 
consistent with published values54-57. The population parameter estimates 
of absorption and distribution had low uncertainties. Combining oral (low 
concentration range) and intravenous (higher concentration range) pk data 
provided an accurate estimate of the absorption rate, distribution parame-
ters, and Michaelis constant, thereby yielding accurate descriptions of the 
ascending and descending limbs of the alcohol concentration-time curve (the 
pk phases in which most of alcohol’s effects occur). In contrast, the relative 
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brain region-related differences in the expression nmda and gabaa receptor 
isoforms14. In our study, smooth pursuit performance and vas Alertness score 
were analyzed, as the data were likely to be described best using a simple pk/
pd model. Other sensitive functional biomarkers11 that were included in the 
adolescent study (for example, adaptive tracking, saccadic peak velocity, and 
vas alcohol effect) were less suitable for developing a pk/pd model, as the small 
effect in adolescents and the high number of non-responders precluded our 
ability to quantify the adolescent data and evaluate an age-dependent effect. 
Although a higher dose of alcohol would likely have yielded a quantifiable 
effect, using a higher dose in adolescents would have been prohibitive from an 
ethics perspective. Other age-dependent effects may have be seen at higher 
doses as well, including effects on memory, given that a placebo-controlled 
study73 found that 0.6 g/kg alcohol caused significantly more memory impair-
ment in 21-24-year-old subjects than in 25-29-year-old subjects. In addition, 
adolescents and adults may also differ with respect to the development of 
acute tolerance to alcohol effects, as has been reported for animals14. Tests 
that evaluate postural stability (for example, body sway) may also reveal an 
age-dependent effect and may reflect a difference in the threshold to the alde-
hyde metabolite rather than the alcohol itself. Age-related differences in the pk 
and/or pd of acetaldehyde, which can mediate physiological responses such as 
facial redness, pulse rate, and blood pressure63, may account for some of the 
differences observed between adolescents and adults64, although this topic 
needs further study.
Research into age-dependent differences in the effects of alcohol is poten-
tially complicated by differences in cumulative baseline drinking (affecting pk 
and/or pd) and age-related differences in motivation and expectations (affect-
ing pd). In all of the adult studies, alcohol was administrated intravenously 
using the clamping method, which provides precise control over blood alcohol 
content (and therefore the brain’s exposure to alcohol), thus minimizing varia-
tion between subjects. Due to ethics considerations, ethanol clamping was not 
performed in adolescents. The pk model adequately described both the oral 
and intravenous pk data. Adult subjects were exposed to alcohol longer than 
However, age-dependent factors unrelated to the testing environment may 
play a role as well, as equilibration can also reflect the development of other 
age-dependent processes, including alcohol- or metabolite-related changes 
in local muscle and/or cns blood flow. 
Although many studies have examined the acute effects of alcohol in 
adults11, to date no alcohol pk/pd model has been presented. This might 
be due to the complex pd of alcohol, as both acute tolerance and a lag in the 
recovery from alcohol-induced impairment have been observed for several 
biomarkers65-68, thus complicating the development of a pk/pd model. In our 
study, two biomarkers were selected based on an exploratory meta-analysis 
of several alcohol studies that were performed by our research group. Smooth 
pursuit performance and vas Alertness showed a clear response to alcohol 
with no indications of an indirect effect or acute tolerance. Thus, a relatively 
simple model would likely describe the data well, and the presence or absence 
of an age-related effect could be investigated. As expected, the relationship 
between alcohol concentration and the effects of alcohol on baseline smooth 
pursuit performance and vas Alertness score was described best as being 
dose-dependent, with no indications of delay or tolerance. Higher base-
line performance for smooth pursuit was correlated with a larger absolute 
decrease in performance. The best model accounted for 61% and 13% of the 
inter-individual variability in smooth pursuit performance and vas Alertness 
score, respectively, and the best model predicted the observed performance 
accurately. No significant covariates were identified, including no clear effect 
of age. However, vas alertness and smooth pursuit eye movements may not 
necessarily represent all of the alcohol-related effects on the cns, and we 
cannot exclude the possibility that sensitivity to other alcohol-related phar-
macodynamics effects change with age. Age-related differences between 
adolescents and adults with respect to acute sensitivity to alcohol are believed 
to reflect pd  – rather than pk  – factors72, and these differences may be related 
to the faster onset of acute tolerance and developmental changes that occur 
in the neural substrates underlying alcohol’s effects. For example, age-re-
lated differences in sensitivity and tolerance have been related to age- and 
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table 2  Summary of pharmacodynamic effects of alcohol compared to placebo 
(adolescent study) 
ls Means Contrast
Parameter Placebo Alcohol Alcohol vs Placebo
Estimates of difference,  
95% ci and p-value
Body sway (mm) 236.1 276.1 16.9% (5.2%, 30.0%) p=0.0069
Saccadic Inaccuracy (%) 6.22 6.27 0.05 (-0.65, 0.75) p=0.8728
Saccadic Peak Velocity (deg/sec) 454.1 452.5 -1.5 (-9.3, 6.2) p=0.6766
Saccadic Reaction Time (sec) 0.207 0.207 -.001 (-.006, 0.005) p=0.8502
Smooth Pursuit (%) 43.1 42.4 -0.7 (-2.3, 0.9) p=0.3744
Adaptive tracking (%) 26.36 25.48 -0.88 (-2.14, 0.39) p=0.1575
vas Alertness (mm) 53.4 52.3 -1.1 (-2.4, 0.2) p=0.0879
vas Calmness (mm) 55.5 55.4 -0.1 (-2.0, 1.8) p=0.9150
vas Mood (mm) 56.6 57.1 0.5 (-0.5, 1.4) p=0.2946
vas Alcohol effect (log(mm)) 0.329 0.464 0.135 (0.033, 0.237) p=0.0134
Heart rate (beats per minute) 68.5 72.7 4.3 (2.6, 5.9) p=<.0001
Diastolic blood pressure (mmHg) 61 61 -0 (-3, 2) p=0.6988
Systolic blood pressure (mmHg) 116 113 -3 (-6, -0) p=0.0377
Correct acoustic stimuli at 650 
msec
17.7 17.7 0.0 (-0.2, 0.2) p=0.8473
Average rt of visual stimuli 
(msec)
785.2 802.7 2.2 (-1.1%, 5.7%) p=0.1795
Correct visual stimuli at 650 msec 16.7 16.8 0.1(-0.2, 0.4) p=0.6275
Correct visual stimuli at 150 msec 17.1 17.1 0.1 (-0.2, 0.3) p=0.5380
Correct visual stimuli at 50 msec 17.2 17.1 -0.1 (-0.4, 0.2) p=0.4435
Average rt of acoustic stimuli at 
650 ms (msec)
638.64 644.21 0.9% (-7.3%, 9.8%) p=0.8296
Delayed word recall correct 15.9 15.1 -0.8 (-2.9, 1.2) p=0.3871
Word recognition correct 26.6 26.0 -0.6 (-2.1, 0.9) p=0.3917
Word recognition rt correct 
(msec)
857.1 837.3 -2.3% (-10.5%, 6.7%) p=0.5798
Word recall correct trial 1 11.0 9.4 -1.5 (-3.6, 0.6) p=0.1453
Word recall correct trial 2 15.9 14.3 -1.6 (-3.8, 0.6) p=0.1460
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table 4 Population parameter estimates of final pk model
Population parameters Estimate [%rse] iiv (cv%)
vm (e1) (g/hr) 9.21 [3.6] 27.5
Km (e2) (g/l) 0.051 [26.2] ne
v2 (e3) (L) 12.1 [3.0] 18.0
v3 (e4) (L) 33.8 [2.0] 29.3
q (e5) (hr-1) 56.8 [3.0] 14.5
ka(e6) (hr-1) 1.59 [7.6] ne
Power of lbw on vm (e7) 0.692 [8.3]
Power of lbw on v3 (e8) 0.407 [12.9]
Power of age on q (e9) -0.283 [25.7]
Power of height on q (e10) 2.29 [20.5]
Residual error, proportional (%cv) 2.87 [38.9]
Residual error, additive (g/l) 0.031 [11.6]
Parameter uncertainties and interindividual variability (iiv) are provided when applicable. ne=not 
estimated.
table 5  Parameter estimates of best pk/pd model for Smooth Pursuit Performance
Population parameters Estimate [%rse] iiv (cv%)
bl (mprd) ne 10.0
ke (e1) 0.304 [7.9] 60.7
Residual error, additive (smooth pursuit performance [%]) 5.40 [8.9]
Parameter uncertainties and interindividual variability (iiv) are provided when applicable. ne=not 
estimated.
table 6  Parameter estimates of vas Alertness pk/pd model
Population parameters Estimate [%rse] iiv (sd)
bl (mm) (e1) 53 [0.68]
mprd on bl (e2) 0.708 [10.0]
ke (mm / (g/l)) (e3) 9.4 [18.0] 13.23
Residual error, additive (mm) 4.29 [42.1]
Residual error, proportional (%cv) 6.67 [67.9]
rse, relative standard error; sd, standard error.
table 3  Overview of study demographics among studies from which data were used of 
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figure 2 Ethanol concentration versus change from baseline smooth pursuit performance 
of chdr071432, chdr1011 (adolescent study), chdr121435, chdr031328, and chdr050229.  
0.3 = target concentration of 0.3 g/l; 0.6 = target concentration of 0.6 g/l.
figure 3  Schematic representation of the final pk model structure of ethanol
figure 1  Individual change from baseline smooth pursuit performance over time of study 
chdr050229. Treatments: placebo (Placebo); ethanol clamping at 0.3 g/l (Clamp0.3); ethanol  
clamping at 0.6 g/l (Clamp0.6). The clamping was continued for 300 minutes. Similar effects  
of ethanol were seen in other studies. Open circles represent data; solid black lines represent  













































0.0 0.2 0.4 0.6 0.8
chdr0313 clamp0.6 chdr0502 clamp0.3
0.0 0.2 0.4 0.6 0.8
chdr0502 clamp0.6
chdr0714 clamp0.6





















non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 200 –
 
chapter 7 – comparison of alcohol pk and effects bet ween healthy adolescents and adults 
– 201 –
figure 5 Goodness of fit plots of final pk model with Loess curve. Conditional Weighted 
Residuals (cwresi) vs. individual predicted concentrations (ipred) (upper panel); cwresi vs. Time 
(lower panel).
figure 4  Individual predicted alcohol concentrations (ipred) versus observations (dv).  
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figure 6  Distribution of etas. The continuous line represents a normal distribution with the  
same mean and standard deviation as the eta. Corresponding parameters are: eta 1: Q, eta 2: Vm,  
eta 3: V2 and eta 4: V3.
figure 7 Individual predicted smooth pursuit performance (ipred) versus observations (dv).  
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figure 9 Distribution of etas. The continuous line represents a normal distribution with the 
same mean and standard deviation as the eta. Corresponding parameters are: eta 1: bl, eta 2: ke. 
 
figure 8 Goodness of fit plots of final pk/pd model for Smooth pursuit performance. Shown 
are conditional weighted residuals (cwresi) versus ipred (upper), time (middle) and ethanol 
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figure 10 pd cwresi over pk cwresi plots, per study. pk data was matched to the pd by 
closest time point (open circles). A Loess curve was drawn through the data points (solid black 
line). Studies: 502=chdr050229, 714= chdr 071432, 1011= chdr 1011 (adolescent study), 1214= 
chdr 121435, 313= chdr 031328.
figure 11 Individual predicted vas Alertness score (ipred) versus observations (dv). A linear 
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figure 13 eta distribution. The black line shows a normal distribution with the same mean 
and standard deviation as the eta. Corresponding parameter of eta 1 is ke.
figure 12 Goodness of fit plots of vas Alertness pk/pd model. Shown are conditional 
weighted residuals (cwresi) versus ipred (upper), time (middle) and ethanol concentration 
(lower). A Loess curve (solid black line) was drawn through the data points (open circles).
cwresi vs ipred
















0.2 0.4 0.6 0.8
cwresi vs time
time (hr)













predicted ethanol concentration (g/l)






















non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 210 –
 
chapter 7 – comparison of alcohol pk and effects bet ween healthy adolescents and adults 
– 211 –
figure 3  VAS alcohol effect LSMs change from baseline with 95% CI error bars.
figure 4  Body sway LSMs change from baseline with 95% CI error bars.
supplementary data
figure 1  Smooth pursuit LSMs change from baseline profile with 95% CI as error bars.
figure 2  vas alertness LSMs change from baseline profile with 95% CI as error bars.
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figure 5  Heart rate LSMs change from baseline with 95% CI error bars.
figure 6  Systolic blood pressure LSMs change from baseline with 95% CI error bars.
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abstr act
melatonin were estimated using non-compartmental 
modeling. All 16 subjects (age range: 7-15 years) had a clinical 
diagnosis of autism spectrum disorder (based on dsm-iv-tr 
criteria). Mini-tablets were found to be both safe (i.e., none 
of the children choked) and acceptable to the children. 
The melatonin concentration peaked within two hours of 
administration and remained elevated for several hours 
thereafter. Circadin exposure was dose-linear, and clearance 
(1,000 l/hr) was similar between the dose groups. The median 
apparent terminal half-life was comparable between dosages. 
All reported side effects were consistent with known side 
effects. The highest levels of sedation (assessed using the oaa/s) 
were observed between 2 and 3 hours after administration of 
Circadin 2 mg and between 2 and 6 hours after administration 
of Circadin 10 mg. In conclusion, this study demonstrates 
the short-term safety, acceptability, and prolonged-release 
profile of Circadin mini-tablets in 16 school-age children and 




Sleep problems are highly prevalent among children with 
autism spectrum disorder (asd), and these problems can 
significantly impact both the child and the child’s family. 
Because conventional therapies are generally unsatisfactory, 
there is currently an urgent need for an effective intervention. 
Melatonin is effective for ameliorating sleep problems 
in this pediatric population, and its favorable short-term 
and long-term risk profile has led to the increasingly 
widespread clinical use of melatonin as an off-label medicine. 
Currently, no age-appropriate prolonged-release melatonin 
preparation is commercially available. Here, we performed 
a pharmacokinetics crossover study of Circadin 1 mg mini-
tablets, a prolonged-release melatonin formulation, in 16 
children and adolescents with both asd and a sleep disorder. 
We tested 2 mg and 10-mg doses of Circadin based on the dose 
range we will use in an upcoming efficacy trial. Whole saliva 
samples were collected using passive drool collection, and 
melatonin concentration was measured in these samples. 
Adverse events were monitored throughout the study, and 
potential sedative effects were assessed using the Observer’s 
Assessment of Alertness/Sedation (oaa/s) scale for 10 hours 
after administration. Pharmacokinetics parameters for 
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necessarily manufactured in accordance with good manufacturing practice. 
In addition, no prolonged-release preparation for use in children is commer-
cially available, even though prolonged-release preparations are preferred 
over fast-release preparations; prolonged-released formulations provide sus-
tained blood levels18 and are more useful for maintaining sleep19. Importantly, 
although young children may be able to swallow small tablets, they cannot 
swallow large tablets, and children with asd can have difficulty swallow-
ing tablets at any age. Therefore, there is a need for a reliable, commercially 
available, age-appropriate prolonged-release melatonin preparation that is 
licensed for use in children with asd and sleep problems.
Circadin 2 mg is a prolonged-release melatonin formulation that is licensed 
in the eu for treating primary insomnia in patients 55 years of age and older. 
Previous studies demonstrated that Circadin 2 mg is both safe and efficacious 
in children and adolescents with neurodevelopmental and behavioral disor-
ders19-21. In order to provide its intended release profile, Circadin tablets must 
be swallowed whole. An age-appropriate formulation was developed in the 
form of mini-tablets, which have the same in vitro dissolution profile as reg-
ular-size Circadin tablets and should therefore produce a concentration-time 
profile that mimics the physiological rhythm (depending on the amount and 
timing of the dose). 
Here, we performed a pharmacokinetics (pk) crossover study in children 
with both asd and a sleep disorder. This initial study will be followed by a ran- 
domized, double-blind, placebo-controlled study to investigate the efficacy 
and long-term safety of Circadin mini-tablets in patients with a neuro - 
developmental disorder. To minimize study-related burden and risk, mela-
tonin concentration was measured non-invasively from saliva samples. Prior 
to the study, pk modeling and simulations were performed in order to deter-
mine the minimum number of sampling time points that would be needed and 
to adapt the sampling time points to accommodate the subjects as much as 
possible. 
Introduction
Sleep problems are highly prevalent among children with autism spectrum 
disorder (asd)1,2, a very common spectrum of neurodevelopmental disor-
ders that is characterized by impaired communication and social interaction 
together with restrictive and repetitive behaviors. Increased sleep latency, 
waking during the night, and difficulty awakening in the morning are among 
the most frequently reported problems in children with asd3-6. These sleep 
problems can become prominent as early as two years of age, and they can 
persist for many years. Sleep disorders in these children can place a significant 
burden on the child’s physical and mental health, thereby negatively affecting 
performance in school and creating stress for the child’s family7-12. In addi-
tion, these problems are usually resistant to conventional sleep medications 
(e.g., benzodiazepines) or antipsychotic agents12,13 – which in itself can cause 
adverse side effects or can lead to interactions with other drugs, and their use 
is contraindicated in some cases. Combining these drugs with behavioral 
approaches – which are generally difficult to apply, time-consuming, and usu-
ally require skilled expertise – is often unsatisfactory. Thus, there is an urgent 
need for an effective intervention3,14.
Chronic sleep-wake disorders in children with asd are associated with 
an inability to synchronize the circadian rhythm-generating biological sys-
tem with environmental zeitgebers, thus resulting in abnormal melatonin 
secretion15,16. Moreover, a shift in peak melatonin secretion may underlie 
sleep-onset problems, whereas reduced rhythm amplitude may underlie 
sleep interruptions and early morning awakening4. Melatonin’s efficacy in asd 
was recently classified as grade A17. These findings – together with the obser-
vation that melatonin has a highly favorable short-term and long-term risk 
profile – have led to the increasingly widespread clinical use of melatonin as 
an off-label medicine. However, the quality of many melatonin preparations 
is questionable, as these preparations are available as a health supplement 
in some countries (for example, in the United States) and are therefore not 
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release (like (in)direct beta-sympathicomimetic or -sympathicolytic drugs) or 
affect melatonin’s mode of action (like gabaa receptor modulators and antide-
pressants) were not allowed from one week to the first occasion, throughout 
the study. The subjects were allowed to continue the use of the antipsychot-
ics aripiprazole and risperidone, and of non-enzyme-inducing antiepileptic 
drugs. Stimulant drugs (methylphenidate, dexamphetamine) had to be dis-
continued at least 5 times the half-life of the specific drug to ensure complete 
wash-out during study days. On study days, the subjects had to refrain from 
aspirin use or drugs that contain ibuprofen. The subjects had to refrain from 
consumption of caffeine-containing products for 24 hours before each occa-
sion until the end of the study day. On study days, the subjects had to refrain 
from eating bananas and chocolate and from drinks containing articifical 
colorants, caffeine or alcohol during the entire day. In addition, administration 
of medication and caffeine was questioned and a urine drug screen and preg-
nancy test were performed before any study-related procedures were started. 
The Central Committee on Research involving Human Subjects approved the 
study protocol. 
Study design
This was an open label, single ascending dose, crossover study of 2 and 10 
mg Circadin mini-tablets. The first occasion included a 24-hour baseline 
measurement day. This study followed a staggered approach: the study was 
completed in at least four children aged 11-17 years before commencing in the 
group of children 10 years of age or younger. Pubertal stage was assessed at 
screening. Female subjects were not studied during the stop week of their oral 
contraceptives. The subjects were confined to the clinical research unit for 
approximately 24 hours after melatonin administration. Subjects were given 
a ‘paskaart’ (stopping card) which he or she could show to indicate a study 
related activity should be stopped. The use of this card was explained during 
the screening and start of each occasion. The ‘Gedragscode verzet minderjari-
gen’ (Code of conduct in case of resistance in minors) and ‘Gedragscode verzet 
Methods
Subjects
Sixteen children with a dsm-iv-tr diagnosis of autistic spectrum disorder 
(asd) with current sleep disorder were recruited from specialized child men-
tal health clinics in the Netherlands. Current sleep disorder was defined as 
difficulty initiating or maintaining sleep, or non restorative sleep, for at least 
1 month (dsm-iv 307.42). Subjects with an untreated medical or psychological 
condition that could be the etiology of sleep disturbances (e.g., restless leg syn-
drome) were not allowed to participate. The subject had to be able to comply 
with taking the study drug, collaborate freely with the study procedures and 
understand instructions in Dutch. Written informed consent was obtained 
prior to study initiation from parents having parental responsibility or from 
the legal guardian(s). In children aged 12 years or older, the written informed 
consent of the child was needed in addition to that of parents having respon-
sibility/legal guardian. We excluded subjects with a history of difficulty with 
swallowing or easy choking, current symptoms suggestive of obstructive 
sleep apnea syndrome or any breathing related sleep disorders or period-
ic limb movements, or non-stable epileptic attacks within 3 months prior to 
screening (in case of a history of epilepsy). Other exclusion criteria included 
known clinically significant disturbance(s) in hepatic and/or renal function, 
current asthmatic symptoms, clinically relevant periodontal disease and/or 
oral injuries, pregnancy (at time of screening), known allergy to melatonin, and 
unstable use of allowed medication within 2 months prior to the screening. The 
subjects were not allowed to use any form of melatonin within one week prior 
to dosing. In addition, other concomitant medication was also not allowed 
within one week prior to study days, except for paracetamol, oral contracep-
tives or some topical medication (i.e., creams, ointments, gels or lotions used to 
induce a local effect without systemic exposure). Drugs or dietary supplements 
that can cause pharmacokinetic interactions with melatonin (by inhibition or 
induction of involved cyp450 isoenzymes), can alter melatonin secretion or 
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ml) or water (10 ml). Melatonin has been shown to be stable in these common 
liquids and foods tested for up to 6 hours at room temperature (no degrada-
tion peak)22; hence it was unlikely that mixing the mini-tablets with these 
vehicles would affect melatonin dose. When mini-tablets were mixed in such 
a vehicle, it was recommended that it should be administered to the subject 
immediately. If immediate administration was not possible, the mixture 
was thrown away and a fresh dose was prepared using reserve mini-tablets. 
If the mini-tablets were administered mixed with a vehicle on the first occa-
sion, mini-tablets were also administered in the same vehicle on the second 
occasion. 
Swallowing was carefully observed. After deglutition the subject’s mouth 
was inspected by the investigator using a flashlight and outcome of drug 
administration was scored as following23: (1) swallowed (no chewing during 
deglutition and no solid residuals found during oral inspection); (2) chewed 
(swallowed most of the tablet pieces, but small residuals found during oral 
inspection); (3) spat out (no observed deglutition and no solid found during oral 
inspection); (4) choked on (the mini-tablet was inhaled or a cough was caused 
during swallowing), or (5) refused to take (all actions preventing the physician/
(co-)investigator/caretaker placing the mini-tablet in the mouth). In case of 
unsuccessful administration (e.g., spitting or visible chewing without other 
clear signs of obstruction), an attempt was made to administer a new dose 
using reserve mini-tablets available for the occasion. In case of visible chew-
ing, the occasion was terminated and the new dose was given at least 7 days 
later. In addition, a saliva sample was obtained two minutes after ingestion, for 
determination of elevated melatonin concentrations (compared to pre-dose 
levels) due to contamination.
Standardized meals were provided following drug administration. Water (200 
ml) was given every 2 hours post-dose to maintain all subjects on a uniform 
hydration schedule.
The wash-out period in-between occasions was at least 7 days and mel-
atonin was administered at the same time of day in all subjects to avoid 
confounds from circadian variability.
bij mensen met een verstandelijke handicap‘ (Code of conduct for physicians 
involved in the assessment of expressions of objection by people with mental 
disabilities) were to be followed in case a subject displayed resistance against 
any study related activity.
As this was an exploratory pharmacokinetic study in children and adolescents 
with asd, no formal power calculation was performed. However, based on 
previous experience, it was expected that a sample size of 16 subjects would 
suffice for determination of pk parameters in saliva.
Interventions
Circadin mini-tablets contain 1 mg of the active substance N-acetyl-5 methoxy- 
tryptamine, which is identical to endogenous melatonin. The mini-tablets 
were produced via traditional tableting methods, including dry-mixing and 
direct compression. A coating was applied to enhance palatability and reduce 
susceptibility to light (as melatonin is light sensitive). Most of the published 
studies as well as off-label use in clinical practice have shown that in the pedi-
atric population melatonin efficacy is achieved in a certain range of doses, 
mainly 2-12 mg. Therefore, a unit dose of 1 mg was chosen to allow maximal 
flexibility in dose modification. Based on the anticipated dose range in the sub-
sequent efficacy trial, dosages of 2 and 10 mg were included. In clinical practice, 
Circadin is taken in the evening, 1-2 hours before the child’s usual bedtime. 
However, in order to avoid sleep disturbance due to repeated nighttime saliva 
sampling after melatonin administration, it was decided to administer mela-
tonin during daytime (in the morning) instead of in the evening to minimize 
burden related to study participation. pk simulation indicated that the pk pro-
file could be accurately evaluated after daytime administration (see Figure 1). 
 Circadin was administered in the morning immediately after a standard-
ized breakfast. Administration was done in sitting position and in bright light 
(*2,500 lux). To ensure that the mini-tablets were ingested in whole, mini-tab-
lets could be taken together with standardized amounts of strawberry jam (5 
ml), strawberry yoghurt (5 ml), orange juice (10 ml), semi-skimmed milk (10 
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Subjects had to rinse their mouths out with water 10 minutes before each 
saliva collection and were instructed not to express mucus or sputum from 
the back of the throat into the collection tube. Saliva was collected in tubes 
wrapped in aluminum foil to protect the samples from light. After saliva col-
lection, saliva was transferred to duplicate transport tubes (also wrapped in 
aluminum foil; approximately 1 ml per tube) and stored within 2 hours after 
collection at a maximum temperature of -20°C. Saliva melatonin concen-
trations were determined by abl (Analytisch Biochemisch Laboratorium bv, 
Assen, The Netherlands) using a lc-ms/ms method (precision and accuracy, cv 
) 15%; validated range, 2 – 20,000 pg/ml).
urinary 6-sulphatoxymelatonin concentrations
Urine samples were collected for determination of 6-sulphatoxymelatonin 
(6-smt). Urine was collected after spontaneous voiding in potty-trained 
children or using a urine collection bag in prepubertal non-potty-trained 
children. All urine passed over 12 hour periods was collected into a standard 
urine bottle. The total volume was measured and recorded and approximate-
ly 5 ml was kept at -20°C. No preservative was required, as 6-smt is stable in 
urine for one day at room temperature, 2 days at 4°C and for at least 2 years at 
-20°C. 6-smt concentrations were determined by abl (Analytisch Biochemisch 
Laboratorium bv, Assen, The Netherlands) using a qualified radioimmunoas-
say (125i label) (Stockgrand Ltd.; validated upper limit of quantification, uloq 
2,500 pg/ml). 
Safety 
At screening, pregnancy testing was done in females who had a menstrual 
cycle using a qualitative, color immuno-chromatografic detection of hcg in 
urine using cards o.s. H.C.G.-urine test kits (Pacific Biotech, Inc., San Diego, ca 
92121, usa). Adverse events were monitored throughout the study. 
Pharmacokinetic methods
salivary melatonin collection and bioanalysis
For children who normally fall asleep before 12 hours prior to melatonin 
administration, saliva samples for baseline melatonin concentration determi-
nation were collected on the first occasion at t= -24, -20, -16 hrs, just before 
normal time of falling asleep, at a time point after falling asleep but before 
t=-5 hrs when the child wakes up on its own, -5 hrs, immediately after waking 
up, and 0 hrs pre-dose (not more than 10 min before dosing). For children who 
normally fall asleep after 12 hours prior to melatonin administration, baseline 
samples were collected at t= -24, -20, -16, -12 hrs, just before normal time of 
falling asleep, -5 hrs, immediately after waking up and 0 hrs pre-dose (not 
more than 10 min before dosing). Time points for pk sampling after administra-
tion were determined based on pk simulations (Figure 1). Whole saliva samples 
were collected by passive drool using the Saliva Collection Aid (Salimetrics 
Europe), a collection aid designed to simplify collection of whole saliva, hereby 
increasing subject compliance. The vented design helps avoid sample foaming 
and the device is constructed of polypropylene to avoid sample retention or 
contamination. Absorption loss and analyte degradation were further min-
imized by the use of low-protein binding storage cryovials (Salimetrics, uk), 
which are suitable for use with this collection aid. A minimum sampling vol-
ume of 1 ml was needed. Subjects and caregivers were trained prior to the first 
occasion on how to collect saliva using this collection aid. As bright light can 
suppress endogenous melatonin production, collection of saliva samples was 
done in dim light (< 8 lux). Plasma and salivary melatonin concentrations have 
been reported to increase when moving from a supine to a standing position 
and decrease when these positions are reversed, due to changes in plasma 
volume24. Therefore, saliva samples were collected after spending at least 15 
minutes in a sitting position. Deviations were allowed during the night in order 
to minimize the duration that subjects need to be awake for saliva sampling; 
in these cases, duration of time spent in sitting position was recorded as a note. 
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Comorbidities included 22q11 deletion syndrome, migraine, asthma, eczema, 
adhd, cystitis, and constipation. The medications that were continued during 
the study included propranolol (10 mg twice daily, by one subject), flixotide (250 
µg twice daily, by two subjects), ventolin (200 µg as needed, by one subject), 
desloratine (1 mg twice daily, by one subject), macrogol (6.9 g once daily, by one 
subject), and an antibiotic treatment (unspecified, for cystitis, by one subject). 
Antipsychotic agents (aripiprazole, 1-3 mg once daily, by two subjects; and 
risperidone, 0.5 mg once daily, by three subjects) were also continued during 
the study. Any disallowed concomitant medication was discontinued prior to 
the study in accordance with the protocol. Seven subjects had used melatonin 
prior to the study. During the study, all administrations were successful, and 
none of the subjects choked or visibly chewed on the study medication. All 
of the subjects completed the study. Subject 9 (a 45-kg 13-year-old boy with 
Tanner Stage 5) and subject 10 (a 58-kg 15-year-old boy with Tanner Stage 5) 
received an incorrect melatonin formulation that did not comply with the 
intended in vitro release profile. Thus, the data obtained from these two sub-
jects were excluded from the pk analysis and evaluation of the oaa/s scores; 
however, these two subjects were included in the safety analysis. Both of these 
subjects used melatonin prior to the study. In addition, it is suspected that 
three subjects (subjects 5, 6, an 11) held the tablets in their mouth for a long 
time after administration of 2 mg Circadin, resulting in measured melatonin 
levels at 1 hour which exceeded the levels of other subjects (up to 10-fold) prob-
ably because melatonin was released in their mouth before swallowing. These 
children were excluded from the sub-analysis pk population.
Concentration-time profiles of melatonin in saliva 
For the endogenous melatonin concentrations measured prior to administra-
tion of the Circadin mini-tablets, each individual had several observations that 
exceeded the assay’s lower limit of quantification (lloq; i.e., >2 pg/ml). For 14 
out of 16 subjects, no saliva samples were taken from 23:00 (11:00 pm) through 
7:00 am in order to minimize patient burden. 
Assessment of sedation
As Circadin was given in the morning, it was anticipated that daytime sleepi-
ness and slight lowering of body temperature could occur. As children with asd 
may be unable to verbally describe level of sedation, the Observer‘s Assessment 
of Alertness/Sedation (oaa/s) Scale was used pre-dose and 1, 2, 3, 6, and 10 hours 
after melatonin administration. This scale was developed to more objective-
ly measure the level of alertness in subjects who are sedated and has been 
shown to be reliable and valid and to be sensitive to the effects of for example 
midazolam25 and is comparable to the Ramsey scale which is commonly used 
in the pediatric intensive care unit to assess level of consciousness26.
Statistical analysis
pharmacokinetic analysis
Exploratory individual and summary concentration-time profiles of mela-
tonin and 6-smt were generated to identify potential outliers. Observations 
below the lower limit of quantification were excluded from the analysis. 
Saliva samples taken 2 minutes after dosing (’contamination samples’) were 
excluded from analysis, as these were unlikely to reflect actual (excreted) mel-
atonin saliva concentrations. pk parameters were estimated using r (v2.12.0, r 
Foundation for Statistical Computing, Vienna, Austria, 2010). 
Results
Subjects
A total of 16 subjects (12 male, 4 female) with asd were enrolled in 2013-2014. 
The average age was 10 years (range: 7-15 years), and the average weight 
was 40.6 kg (range: 26-67 kg). Most subjects were prepubescent (Tanner 
Stage 1, 50%), with fewer subjects having an intermediate pubescent stage 
(Stage 2, 19%; Stage 3 and 4, 6% each) or having adult features (Stage 5, 19%). 
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989.5 µg/12 daytime hours and 95.3 µg/12 nighttime hours. Following admin-
istration with Circadin 10 mg, many of the 6-smt values were above the uloq 
during the collection period 0-12 hours following dosing (further dilution of the 
samples was not validated). 
Sedation level
Shortly after waking up in the morning (at the time point of the first assess-
ment of the level of sedation), several subjects assessed by the Observer’s 
Assessment of Alertness/Sedation Scale transitory scored ‘drowsy/normal 
speech’; one subject was scored ‘drowsy’ just prior to the administration of 
Circadin 10 mg (Figure 4). Following morning administration of Circadin (2 mg 
or 10 mg), most subjects assessed by the Observer’s Assessment of Alertness/
Sedation Scale scored to have a mild increase in sedation. The highest levels of 
sedation were observed between 2 and 3 hours after administration of Circadin 
2 mg and between 2 and 6 hours after administration of Circadin 10 mg, with 
up to 6/14 (2 mg) and 7/14 (10 mg) of children scoring ‘drowsy to normal speech’ 
or a higher sedation score. 
Adverse effects
In the 16 subjects, the following adverse events were potentially or likely asso-
ciated with the administration of 2 and/or 10 mg Circadin: fatigue (in seven and 
eight subjects after 2 and 10-mg doses, respectively), a sensation of heaviness 
(in one subject after a 2-mg dose), somnolence (in three and two subjects after 
2 and 10-mg doses, respectively), falling asleep (in two subjects after both the 
2 mg and 10-mg dose), headache (in one and three subjects after 2 and 10-mg 
doses, respectively), and nausea (in one subject after a 10-mg dose). All of the 
adverse events were transient and mild, and no serious adverse events were 
reported. Nausea, fatigue and headache were more frequently reported fol-
lowing Circadin 10 mg compared with Circadin 2 mg.
In one subject (subject 4), the melatonin concentration measured in the saliva 
sample taken at t=3 hours exceeded the assay’s upper limit of quantification 
(uloq; i.e., >20,000 pg/ml). Because the number of freeze/thaw cycles for this 
sample exceeded the number of validated cycles, this observation was exclud-
ed from further analysis. None of the other pk samples had a concentration 
that exceeded uloq. Three and 8 samples that were taken two minutes after 
administration of 2 and 10 mg (‘contamination samples’) had a concentration 
that exceeded the uloq.
The apparent terminal elimination rate constant and its derived param-
eters – including the apparent terminal half-life, the area-under-the-curve 
(auc) from dosing to infinity (including extrapolated percentages), the appar-
ent drug clearance rate, and the apparent volume of distribution – were 
excluded for subject 6 (on the 2 mg dosing occasion) and subject 14 (on both 
occasions), as this parameter could not be accurately estimated for these 
occasions based on the regression plots.
The individual concentration-time profiles are presented in Figure 2. The mela-
tonin concentration peaked within two hours of administration and remained 
elevated for several hours thereafter (Figure 3). Circadin exposure (derived 
from the auc data) was dose-linear, and apparent clearance (approximately 
1,000 l/hr) was similar between the dose groups (Table 1). The median apparent 
terminal half-life was similar between the 2-mg and 10-mg dose groups. The 
apparent volume of distribution in the saliva decreased (with corresponding 
clearance) with increasing dose. 
Urine 6-sulphatoxymelatonin concentrations
Urine 6-sulphatoxymelatonin concentrations in samples collected during 
the first 12 hours of administration exceeded uloq (i.e., >2,500 pg/ml) for 1/14 
subjects following a 2-mg dose and for all 14 subjects following a 10-mg dose. 
The mean total 6-smt recovered from urine during the baseline period was 4.2 
µg/12 daytime hours and 13.5 µg/12 nighttime hours. Following administration 
with Circadin 2 mg, the mean amount of total 6-smt recovered from urine was 
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ingredient’s exposure to light. Previous studies showed that this type of for-
mulation is safe for use in healthy pre-school and school-age children up to six 
years of age28 23. In our study, this formulation was ingested safely (i.e., none 
of the children choked) and was acceptable to the children. However, children 
who had difficulty swallowing or had a history of choking easily were exclud-
ed from the study; therefore, the results may not be directly applicable to this 
population.
Because Circadin mini-tablets have the same in vitro dissolution profile as 
regular-size Circadin tablets, the melatonin concentration-time profile of the 
mini-tablets was expected to mirror the profile of regular-size Circadin tab-
lets. The pk properties of Circadin tablets have been investigated in both adults 
and children, as well as in children and adolescents with neurodevelopmental 
and behavioral disorders19-21. For our study, we chose 2-mg and 10-mg doses 
based on the anticipated dose range in an upcoming efficacy trial in which 
the children will initially receive 2 mg Circadin, after which they will have 
the option to modify the dose, first increasing to 5 mg, and then increasing to 
10 mg if the lower doses are not efficacious. Based on the results of a recent 
randomized clinical trial in which the long-term effects and safety of mela-
tonin were investigated in children29, we anticipate that some of the children 
in our upcoming study will need a dose of 10 mg. Other studies18,30 suggest 
that per kg body weight, children require a higher amount of melatonin than 
adults19; this difference may be due to the higher endogenous melatonin lev-
els in healthy children, as prepubescent children metabolize melatonin faster 
than adults31 32. Ideally, the in vivo release of Circadin mini-tablets should 
peak within 2-4 hours of administration, and the levels should remain ele-
vated for 4-5 hours thereafter. In our study, salivary drug concentrations were 
measured starting one hour after administration (and thereafter), and the oral 
cavity was rinsed after the mini-tablets were swallowed in order to minimize 
residual oral contamination. The melatonin concentration peaked within two 
hours following treatment with both 2 and 10 mg Circadin mini-tablets, and 
the concentration remained elevated for several hours thereafter. Circadin 
exposure in the saliva was dose-linear, and clearance in the saliva was similar 
Questionnaire regarding participation
Overall, the subjects and their caregivers were positive about the burden and 
duration of the study. Nearly all subjects (69%) and caregivers (88%) stated 
that they would consider (consent for) participating in a similar study again. 
Most of the children did not find the saliva sampling to be bothersome. The 
four subjects who indicated that saliva sampling was somewhat bothersome 
were 10, 11, 13, and 15 years old. The one child who would not participate again 
found participating in the study rather nice, but found the study day duration 
long and the urine sampling a bit bothersome. The one parent who would not 
consent for participation in similar research found the child’s participation 
very nice, but thought saliva and urine sampling were a bit bothersome, as did 
the child. The child itself found participating not so nice and did not know if it 
would participate again.
Discussion
This is the first study to investigate the pharmacokinetics (pk), acceptability, 
and short-term safety of a new prolonged-release melatonin formulation in 
children with asd. The ability to deliver pediatric medicines accurately and 
safely is essential in order to ensure that the correct dose is received and that 
the formulation is safe, easy to use, and acceptable from both the child’s and 
the caregiver’s perspective. Due to age-related differences in the anatomy of 
the buccal cavity27, young children may not be able to swallow a large tablet, 
and children with asd or other neurodevelopmental disorder might experi-
ence difficulty swallowing a tablet at any age. Therefore, Circadin mini-tablets 
were developed as an age-appropriate formulation for this patient population. 
These 3-mm diameter mini-tablets were produced using traditional tableting 
methods (i.e., dry-mixing and direct compression) that can be reproduced eas-
ily and do not require sophisticated manufacturing equipment. A coating was 
applied to the tablets to enhance their palatability and to reduce the active 
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relatively little research has been performed regarding melatonin metabolism 
in children with asd. A study in which serum melatonin and urine 6-smt were 
measured following an intravenous infusion of melatonin in prepubescent, 
pubescent, and adult subjects32 found that prepubescent children metabolize 
melatonin more rapidly than adults, and a second study found that mela-
tonin metabolism may be delayed in children with Asperger syndrome36. In 
our study, because the group size was relatively small, it was not possible to 
perform subgroup analyses in order to compare pk between pubescent and 
prepubescent children. Following morning administration of Circadin, most 
subjects were assessed by the Observer’s Assessment of Alertness/Sedation 
Scale to have a mild increase in sedation, with most scores indicating ‘drowsy/
normal speech’ or ‘slow reaction to verbal’. Sedation after the 2 mg Circadin 
dose peaked at (and after) 2 hours, which is around the Tmax time of the pk pro-
file, demonstrating pk/pd correlation.
Saliva melatonin concentrations at baseline were characteristic of day-
time sampling, being low in the morning and increased over 12 hours towards 
the evening yet showed overall low endogenous levels. These results were 
confirmed by baseline 6-smt measured in urine. This confirms the low levels 
found in earlier studies in children with asd. Children with asd can have an 
abnormal circadian melatonin profile, including lower nighttime melatonin 
levels15,37-39. Because nearly half of our subjects had used melatonin prior to 
the study, the study population may have been biased towards subject with 
lower baseline melatonin levels. However, because exogenous melatonin 
does not appear to affect the production of endogenous melatonin in terms 
of amplitude40, and because endogenous melatonin was not suppressed by 
the administration of Circadin tablets in previous studies (our unpublished 
data), it is unlikely that these subjects had low baseline endogenous levels 
due to negative feedback from taking exogenous melatonin prior to the study. 
On the other hand, endogenous melatonin profiles may be age-specific or 
disorder-specific. For example, healthy children show a progressive decline 
from pre-school age in both nocturnal serum melatonin31 ,41-43 and urinary 
metabolite excretion rate44, suggesting that circadian rhythm decreases with 
between the two dose groups. Determination of the melatonin metabolite, 
6-smt, in urine indicated extensive metabolism and excretion in the first 12 
hours following dose administration. Consistent with previous research33 34, 
melatonin pk in saliva varied widely. Given the fairly consistent shape of the 
individual saliva curves, and given the known variability of melatonin in plas-
ma33 34, this variability is likely due to variability in absorption and clearance, 
rather than variability in the saliva-to-plasma ratio. For example, considerable 
variability in bioavailability has been reported in healthy adults, with values 
ranging from 0.01 to 0.335. 
Following melatonin ingestion, melatonin saliva and plasma concentra-
tions are closely correlated34, and orally administered melatonin emerges in 
the serum and saliva with nearly parallel time courses33. Assuming that the 
average saliva-to-plasma ratio is 0.37 after the administration of melatonin 
(based on previous research33), the mean estimated maximum plasma con-
centration after administration of Circadin 2 mg mini-tablets in children with 
asd may actually be higher than the reported maximum plasma concentra-
tion in healthy adult volunteers with similar exposure (based on the estimated 
auc in plasma). After administration of Circadin 2 mg tablets, the average 
Cmax plasma value in adults was 483-1000 pg/ml. However, these results are 
difficult to interpret, as the groups varied in both age and gender, factors that 
can affect melatonin kinetics. For example, women generally have a Cmax 
value that is four-fold higher than men. If exogenous melatonin appears in the 
plasma with the same time course as in saliva, the maximum concentration 
in the plasma after taking Circadin 2 mg mini-tablets will be reached earlier 
in children with asd than in healthy adults after taking Circadin 2 mg tablets. 
This difference could be due to a faster absorption rate for mini-tablets com-
pared to conventional sustained-release tablets (due to the larger surface area 
of the mini-tablets). In healthy adults, a half-life of 6 hours has been reported 
after taking Circadin 2 mg tablets. In our study, the median apparent terminal 
half-life was approximately 4 to 5 hours, which may suggest that children – or 
children with asd – metabolize melatonin more rapidly than adults, or the 
volume of distribution may be smaller in children than in adults. To date, 
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figure 1  Graphs showing simulated concentration-time profiles in plasma (black line) after 
2-mg morning dose (upper left panel), 10-mg morning dose (upper right panel), 2-mg evening 
dose (lower left panel) and 10-mg evening dose (lower right panel) administered to a child of  
35 kg body weight in fed condition. In the current study, a morning dose was proposed. An allo-
metric scaling approach was used, assuming dose linearity from 2 to 10 mg, a smaller distribution 
volume (25 L instead of 50 L and higher metabolism rate (half-life of 0.42 hr) in a healthy child com-
pared to an average adult. Concentration-time profile of endogenous melatonin concentrations are 
shown in black and was fitted based on data from healthy children. The baseline profile (represented 
by grey line) in the study population can be different from this profile. Sampling time points after 
Circadin administration are indicated by vertical black lines. 
table 1 Summary pk parameters of melatonin per treatment 






2 mg 14 965 (1,170) 1.57 (0.762) 2,370 (1,240) 2,420 (1,100) 5.74 (3.31)
Circadin  
2 mg* 11 410 (210) 1.73 (0.792) 1,960 (1,030) 2,150 (960) 4.87 (1.87)
Circadin  
10 mg 14 3,970 (2,830) 1.37 (0.640) 12,300 (7,830) 13,00 (7,680) 4.44 (1.69)
Summary of melatonin pharmacokinetic parameters (mean and sd) in the pk population. Data from 
subject 9 and 10 were excluded from analysis as these subjects were dosed with a melatonin for-
mulation that erroneously did not comply with the desired in vitro release profile. *sub-analysis pk 
population. a. Area under the saliva concentration-time curve from the first to the last observation; 
b. Area under the saliva concentration-time curve from the first observation to infinity.
                children, plasma, 2 mg morning dose                children, plasma, 10 mg morning dose
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figure 3 Concentration-time profile of melatonin measured in saliva.figure 2 Individual concentration-time profile of melatonin measured in saliva on a 
semi-log scale. The continuous line represents the measured concentrations after 2 mg Circadin 
mini-tablets; the dashed line the concentrations after 10 mg Circadin mini-tablets. The assay’s lower 
limit of quantification (2 pg/ml) is plotted as a horizontal dashed line.
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figure 4  Observer’s Assessment of Alertness/Sedation Scale scores before and after admin-
istration of 2 mg Circadin or 10 mg Circadin, pk population. Number of subjects in pk population 
with score ‘awake/oriented’, ‘slow reaction to verbal, ‘drowsy/normal speech’ are presented per time 
point. None of the subjects scored ‘reacts to soft touch’.
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abstr act
mg intravenous midazolam, 47 minutes for 2.5 mg Nazolam, 
and 106 minutes for 5.0 mg Nazolam. Nazolam did not lead to 
nasal mucosa damage. 
Conclusions: This study demonstrates the nasal tolerance, 
safety and efficacy of Nazolam. When considering the 
preparation time needed for obtaining venous access, 
conscious sedation can be achieved in the same time span 
as needed for intravenous midazolam. Nazolam may offer 




Background: To evaluate the pharmacokinetics, safety, nasal 
tolerance and effects on sedation of a highly concentrated 
aqueous intranasal midazolam formulation (Nazolam) and 
to compare these to intravenous midazolam.Methods: In this 
four-way crossover, double-blind, double-dummy, randomized, 
placebo-controlled study, 16 subjects received 2.5 mg Nazolam, 
5.0 mg Nazolam, 2.5 mg intravenous midazolam or placebo 
on different occasions. Pharmacokinetics of midazolam and 
_-hydroxy-midazolam were characterized and related to 
outcome variables for sedation (Saccadic Peak Velocity, the 
Bond and Lader Visual Analogue Scale for sedation, the Simple 
Reaction Time Task and the Observer’s Assessment of Alertness/
Sedation). Nasal tolerance was evaluated through subject 
reporting and ent examination. 
Results: Nazolam bio-availability was 75%. Maximal plasma 
concentrations of 31 ng/ml (cv, 42.3%) were reached after 11 
minutes (2.5 mg Nazolam), and of 66 ng/ml (cv, 31.5%) after 14 
minutes (5.0 mg Nazolam). Nazolam displayed a significant 
effect on oaa/s scores. Sedation onset (based on spv change) 
occurred 1 minute after administration of 2.5 mg intravenous 
midazolam, 7 minutes after 2.5 mg Nazolam, and 4 minutes 
after 5 mg Nazolam. Sedation duration was 85 minutes for 2.5 
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swallowing and gastrointestinal absorption of excess fluid reaching the 
oropharynx, the maximal volume of nasal application is ideally restricted 
to approximately 100 µL1, requiring the efficacious dose of midazolam to be 
dissolved within this volume. Higher volumes lead to nasal drop-off or swal-
lowing, which in turn may lead to lower and unpredictable concentrations, 
and a relatively long onset of action. This in turn can cause overdosing, if a 
second dose is applied because the first one did not act fast enough. There-
fore, highly concentrated solutions with a high bioavailability are essential 
to achieve clinically relevant plasma concentrations after nasal application. 
Attempts to overcome this limitation by formulating midazolam in organic 
solvents or absorption enhancers that allow for dosing volumes as low as 100 
µl have largely failed due to the fact that these solvents are typically irritating 
to the highly sensitive and easily disrupted nasal mucosa tissue. 
Recently, a highly concentrated, aqueous midazolam formulation (Nazo- 
lam) that allows dosing of 100 µl or below has become available. Because of the 
aqueous nature of the midazolam formulation, nasal tolerance was expected 
to be good. If proven successful, this aqueous midazolam administration will 
be the first to address all limitations of currently intravenous and intranasal 
applications of midazolam. In this study, the pharmacokinetics (pk), efficacy 
and tolerability of this nasal midazolam formulation were evaluated and com-
pared to intravenous midazolam.
Methods
Study design
This was a randomized, double-blind, double-dummy placebo-controlled, 
four-way crossover study in 16 healthy volunteers. The study was conducted in 
adherence to the guidelines of the International Conference on Harmonisation 
Guideline for Good Clinical Practice and in accordance with the principles of 
the Declaration of Helsinki. The study was performed at the Centre for Human 
Introduction
Midazolam is a short acting benzodiazepine with anxiolytic, sedative, anti-
convulsant and skeletal muscle relaxant properties. Due to its fast onset and 
recovery profile, it is the preferred medication for obtaining conscious sedation 
and management of epileptic seizures. Midazolam is used in a wide range of 
indications for conscious sedation, including sedation for the majority of out-
patient diagnostic, therapeutic and endoscopic procedures and sedation for 
the preparation of general anesthesia in hospitalized patients. Administration 
of midazolam is generally intravenous as other administration routes such as 
oral, rectal, subcutaneous and buccal lead to a delayed onset of efficacy and to 
a large inter-individual variability in efficacy onset. The nasal route therefore 
appears to be a very convenient route of administration for conscious sedation 
and for the lay treatment of acute epileptic seizures. As conscious sedation is 
usually applied in time critical or logistically optimized hospital settings, intra-
venous administration is preferred over these other administration routes 
despite the disadvantages of requiring intravenous access and the intermit-
tent dosing protocol necessary to avoid high initial peak midazolam plasma 
concentrations. 
Nasal administration of midazolam is a simple, useful and reliable alternative 
to the parenteral route. It offers several practical advantages, as it allows for 
direct, easy and needle free administration, and can be safely administered 
without the need for professional assistance. Needle free sedation is partic-
ularly advantageous in children, patients with needle phobia, patients with 
varicose (difficult accessible) veins uncooperative patients and in emergen-
cy room settings, in dentistry and other non-hospital settings. In addition, 
it provides potential for rapid systemic drug absorption and quick onset of 
action without initial high peak concentrations, which may lead to respiratory 
depression. 
Unfortunately, nasal delivery of midazolam has not been very successful 
until now due to the absence of solvents that are able to dissolve midazolam 
at efficacious dosages without leading to nasal mucosa damage. To avoid 
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and intravenous solution containing 2.5 mg midazolam or saline. On each 
study day, subjects received both an intranasal and intravenous study drug 
administration. The subjects on each study occasion received one of four 
treatments: (i) 2.5 mg intranasal midazolam and intravenous placebo; (ii) 5 mg 
intranasal midazolam and intravenous placebo; (iii) intranasal placebo and 
2.5 mg intravenous midazolam, and (iv) intranasal placebo and intravenous 
placebo. The sequence of treatments was randomized, defined by a William 
Square Design, and study days were separated by washout periods of at least 6 
days. Doses were administered in the non-fasted state.
The recommended starting dose for conscious sedation is 2-2.5 mg2. The lowest 
dose administered intranasally was therefore 2.5 mg, based on the assumption 
of a high bioavailability. In addition, a 5-mg dose was tested because this dose 
is relevant in the treatment of epilepsy. Moreover, by studying both dosages, 
an indication of dose proportionality and dose-response relationships of the 
intranasal formulation could be obtained. The concentration of the aqueous 
midazolam spray was 55.6 mg/ml midazolam hcl (50 mg midazolam base per 
ml) and the volume was 50 µl for the 2.5-mg dose and 100 µl for the 5-mg dose. 
The spray was administered in the same nostril throughout the study by the 
supervising physician. 
The dosing regimen for the administration of 2.5 mg intravenous midazolam 
was 1 mg/30 seconds, which is in accordance with the smpc of midazolam for 
the indication of conscious sedation. 
Pharmacokinetic methods
Venous blood samples for pharmacokinetic analyses were obtained via an 
indwelling catheter before administration and at 1 minute and 15 seconds, 
and at every 3 minutes (until 30 minutes), every 10 minutes (until 60 minutes), 
every 30 minutes (until 2 hours), and at 3, 4, 6, 8 and 12 hours after drug admin-
istration. The Vacutainer tubes with lithium-heparin containing the blood 
samples were gently mixed by inversion (~8-10 times) and kept on wet ice 
thereafter. The samples were processed by centrifugation (10 minutes at 2-8 
Drug Research in Leiden, the Netherlands, and approved by the local ethics 
committee of Leiden University Medical Center (Leiden) (ref: P10.215) and reg-
istered with Eudract (ref: 2010-023425-38). The subjects consented in writing 
to the study after full explanation of what was involved.
Subjects
Inclusion criteria for this study were for healthy male or female volunteers 
aged 18-55 years, with a body mass index of 18-33 kg/m2. All subjects had 
to be willing and able to comply with study procedures. Exclusion criteria 
included history of central nervous system or psychiatric disease, history of 
drug, substance and/or alcohol abuse, and abnormal findings on screening 
medical history, physical examination, ecg, vital signs and/or blood and urine 
laboratory profile. Subjects with anatomical anomalies causing obstruction 
of the nares, recent (< 4 weeks) nose bleeds, or with a history of chronic nasal 
obstruction or clinically significant nasal surgery that could affect absorption 
of or tolerance to midazolam were excluded. Subjects with clinically signifi-
cant upper respiratory infection, common cold or flu-like symptoms and/or 
rhinitis at screening were also excluded. Subjects were not allowed to use any 
medication which could affect the metabolism of midazolam or the perfor-
mance of cns measurements from 2 weeks prior to the start of the study days. 
Subjects were not allowed to consume more than 8 units of xanthine-contain-
ing products per day. Subjects had to refrain from consumption of xanthine- or 
alcohol-containing products and smoking from 1 day prior to admission until 
the end of the study day. On study days, intake of medication, alcohol, or drugs 
was questioned and a urine drug screen and pregnancy test and an alcohol 
breath test were performed before any study-related procedures were started.
Study treatments
Study treatments were administered as a unit-dose nasal spray containing 2.5 
or 5.0 mg midazolam (Nazolam) or the same formulation without midazolam, 
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the subject’s individual variability in spv. Onset of sedation was defined as the 
(linearly interpolated) time point at which the spv reached minus 2 standard 
deviations (sd) of the pre-value (baseline) spv level for the occasion. Duration 
was defined as the total amount of time that the response was below the 
minus 2 sds threshold; this total time could be made up of a number of epi-
sodes if the threshold was crossed repeatedly before complete termination of 
the effect. 
visual analogue scales
Visual analogue scales as originally described by others12, have been previ-
ously used to quantify subjective effects of benzodiazepines13 and to evaluate 
sedative effect of both intranasal and intravenous midazolam14-26. In this 
study, by using vas Bond & Lader, the ‚directions‘ of different scales on a form 
were alternated, to avoid habitual scoring by subjects. 
simple reaction time task 
The Simple Reaction Time Task measures the attention and speed of informa-
tion processing of the subject. In this task, participants view a black computer 
screen. At random intervals (0.5 – 1.5 seconds), a white circle appears in the 
center of the computer screen. Subjects were instructed to press the space 
bar with the index finger of their dominant hand each time the circle appears. 
They were instructed to respond as quickly as possible after appearance of the 
circle. A total of 40 circles were presented, and the duration of the task was 
approximately 1 minute. The outcome of the task is the time between stim-
ulus display and response. It has been shown to respond to several classes of 
sedative drugs27. Several previous studies also showed the positive applica-
tion of srtt in the investigation of midazolam’s sedative effect28-30. The srtt 
can be regarded as a clinically relevant measure that represents the level of 
dysfunctioning that may be caused by sedation and was included in this trial 
to evaluate whether recovery from sedation was similar for intravenous and 
intranasal dosing.
°C at 2000xg) within 30 minutes after the sample was drawn and the plasma 
was stored -80 °C until analysis. Bioanalytical analysis was performed by abl 
(Analytisch Biochemisch Laboratorium bv, Assen, The Netherlands). Plasma 
concentrations of midazolam and its metabolite _-hydroxy-midazolam 
were determined using liquid chromatography coupled with tandem mass 
spectrometry. qc concentrations included qc-Low (target midazolam or 
_-hydroxy-midazolam concentrations in human heparin plasma of 0.300 ng/
ml), qc-Medium (target concentration of 3.00 ng/ml) and qc-High (target con-
centration of 75.0 ng/ml). Assay specifics included acceptable precision (total 
cvs of 15% for all qc target concentrations), good accuracy (mean absolute 
biases values for all qc target concentrations of 15%) and adequate incurred 
sample reproducibility (difference of ) 20% for all reanalyzed midazolam sam-
ples and 98% of reanalyzed _-hydroxy-midazolam samples). The analytical 
range of the assay for both the parent and the metabolite was 0.100 – 100 ng/
ml.
Pharmacodynamic methods
The ‘Neurocart’ is a battery of sensitive tests for a wide range of cns domains 
that was developed to examine different kinds of cns-active drugs including 
benzodiazepines3-6. All tests were performed twice at baseline, and repeat-
ed in the following order at the same time points as the pk blood sampling. 
Measurements were performed in a quiet room with ambient illumination 
with only one subject per session in the same room.
saccadic peak velocity
Saccadic peak velocity is one of the most sensitive parameters for sedation7-9 
and was therefore used to evaluate the onset and duration of pharmacologi-
cal effect of intranasal midazolam. The use of a computerized measurement 
of saccadic eye movements has been described elsewhere9-11. The definition 
of the onset and duration of pharmacological effect (sedation) was based on 
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and/or other visible abnormality). All observed or reported aes were recorded 
for all subjects and aes were classified as mild, moderate or severe and their 
relationship to study drug was assessed by the investigator.
Pharmacokinetic analysis
Pharmacokinetic parameters for midazolam and _-hydroxy-midazolam were 
estimated using non-compartmental modeling (WinNonlin 5.2; Pharsight, 
Mountain View, ca). The distributions of the dose-normalized pk parameters 
were compared using anova.
Statistical methods
Sample size was determined based on a presumed onset of sedative effect of 
midazolam as defined based on a decrease in saccadic spv of > 2sd from base-
line. In a previous study performed by our research group the inter-subject cv 
of the time of onset defined on the basis of a decline in spv was 62.5%. In this 
previous study the intra-subject cv could not be calculated, however, assum-
ing the intra-subject cv to be smaller than the inter-subject cv, an intra-subject 
cv of 50% was used for sample size calculations. Sample size calculations were 
performed in nQuery (version 7.0). It was determined that a sample size of 16 
would have 80% power to detect a difference in mean time of onset of sedative 
effect of 3.283 minutes, assuming a standard deviation of differences of 4.380, 
using a paired T-test with a 0.05 two-sided significance level.
srtt and oaa/s data were log-transformed prior to analysis to correct for 
the expected log-normal distribution of the data and analysis was performed 
on log transformed data. Repeatedly measured pharmacodynamic data (spv, 
vas, srtt, and oaa/s) were compared with a mixed model analysis of variance 
(using sas proc mixed) with fixed factors treatment, period, time and treat-
ment by time, random factors subject, subject by treatment and subject by 
time and the baseline value (average over all measurements at or before 
time=0) as covariate. The contrast between the midazolam treatments and 
observer’s assessment of alertness/sedation 
The Observer‘s Assessment of Alertness/Sedation Scale was previously devel-
oped to objectively measure the level of alertness in subjects who are sedated. 
The oaa/s Scale has been shown to be reliable and valid and to be sensitive to 
the level of midazolam administered 31. The oaa/s has been used extensively in 
studies with intravenous midazolam15,16,20,24-26,32.
Safety assessments
Safety assessments including adverse events (ae) monitoring, 12-lead ecgs, 
and laboratory safety tests were conducted at intervals throughout the study. 
Transcutaneous oxygen saturation levels were monitored during the first 6 
hours after administration and blood pressure and heart rate until discharge 
(12 hours after administration).
Nasal tolerance assessments
Nasal safety was monitored by inspection of the nasal mucosa by a physician 
trained by an ent medical specialist and by subject self assessment (subjec-
tive monitoring of congestion, irritation, pain, runniness and loss of smell). 
Nasal symptoms were assessed prior to and after nasal application and, if 
present, specified as (i) congestion or stuffiness; (ii) irritation or itchiness; 
(iii) runniness; (iv) pain or discomfort and/or (v) loss of or abnormal smell. In 
case of a nasal symptom, the severity was graded as (i) mild symptoms (minor 
awareness of symptoms, lasting up to an hour); (ii) moderate symptoms (mod-
erate awareness of symptoms, lasting up to 12 hours), or (iii) severe symptoms 
(strong awareness of symptoms, lasting more than 12 hours). In addition, local 
nasal tolerance was assessed by means of a regular nasal examination using 
the following scoring system: (i) no visible abnormality; (ii) mild abnormality (< 
1 cm of erythema and/or swelling and/or other visible abnormality); (iii) mod-
erate abnormality (1-2 cm of erythema and/or swelling and/or other visible 
abnormality), or (iv) severe abnormality (> 2 cm of erythema and/or swelling 
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2.5 mg intravenous midazolam). In- or exclusion of the data gathered during 
these occasions did not significantly change the pharmacokinetic parameter 
estimates. Doubling of the intranasal midazolam dose resulted in dose-pro-
portional increases in auc and maximum concentration (auc: mean increase, 
2.0-fold; Cmax: mean increase, 2.2-fold). Dose-normalized Cmax and auc(0-t) and 
auc(0-') were higher for the intravenous formulation than for the intranasal 
formulations. The overall concentration-time profiles of the intranasal formu-
lations showed no second peak and the formation of metabolite was low and 
the relative amounts formed compared to the parent compound were compa-
rable with the formation of metabolite after intravenous administration. Mean 
ratio of _-hydroxy-midazolam auc to midazolam auc after intranasal midaz-
olam administration was 0.2 for all formulations and dosages.
The midazolam intravenous administration displayed a nine-fold ratio be-
tween the highest and lowest observed Cmax value, whereas the ratio between 
the highest and lowest Cmax for the intranasal 2.5 mg administration was sev-
en-fold, and for the 5.0 mg intranasal administration three-fold, which led to 
the coefficients of variation (cv) in Cmax included in Table 1.
Pharmacodynamic results
saccadic peak velocity
A marked and time-dependent decrease in spv was seen after midazolam 
administration until three hours after administration (Figure 2). There was a 
statistically significant difference in spv between midazolam 2.5 mg intranasal 
and 5.0 mg intranasal (p < 0.001; 35.3, 95% ci = 20.6, 50.0). 
Onset of action of midazolam (as defined by a decrease in spv of more than 
2sd below baseline) occurred 7±4.4 minutes after administration of midaz-
olam 2.5 mg intranasal, 4±1.8 minutes after midazolam 5.0 mg intranasal. 
Onset of action after administration of midazolam 2.5 intravenous occurred 
on average 1±0.7 minutes after administration. There was a statistically 
significant difference between midazolam 2.5 mg intranasal and 2.5 mg intra-
venous (p < 0.001; 6.2, 95% ci = 4.2, 6,2), midazolam 5.0 mg intranasal and 2.5 mg 
placebo were calculated within the statistical model. For onset of sedation 
based on spv, the sd of the spv during the whole placebo period was calculated 
for each subject, and the threshold of sedation was determined as the base-
line value per period minus 2 sds. Onset and duration of sedative effect were 
compared between treatment groups, assuming that the effect sizes of the dif-
ferent treatment groups were comparable. As oaa/s is a categorical variable, it 
was not assumed to be normally distributed. Therefore, an additional analysis 
was performed using the glimmix procedure. In this procedure, all oaa/s data 
(including placebo) after dosing (time=0) followed a multinomial distribution 
and were compared with a mixed model analysis of variance with fixed factors 
treatment and period and random factors subject and subject by time. All cal-




16 healthy subjects (8 male, 8 female) were enrolled in this study. They were on 
average 26 years old (range 19-53 years), and had an average body mass index 
of 23.2 kg/m2 (range 19.6-28.1 kg/m2). All subjects had negative pre-dose urine 
tests for drugs of abuse, including benzodiazepines. Concomitant medication 
used during the study period included paracetamol (up to 1.0 g per day), nos-
capine, acetylsalicylic acid, and xylometazoline (one subject, stopped more 
than 1 day before study drug administration). All subjects completed the study.
Pharmacokinetic results
The pk parameters and mean concentration-time profiles of midazolam and 
_-hydroxy-midazolam are shown in Table 1 and Figure 1. The intravenous data 
of 2 subjects had to be excluded due to sampling failures on 2 occasions (both 
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0.0001; 95% ci = 1.92-3.75) for the contrast midazolam 2.5 mg intranasal vs 
midazolam 5.0 mg intranasal.
Safety
general
There were few adverse events. Adverse events were mild en transient and 
equally distributed over the 2.5 mg (17) and 5.0 mg intranasal (22) and intra-
venous (15) groups. The most common adverse events were somnolence and 
headache, which were reported 46 and 13 times in total and in 31-94% (somno-
lence) and 6-25% (headache) of subjects (including placebo) and reported in all 
treatment groups. Administration of a single dose midazolam did not result in 
clinically significant changes in physical findings or ecg recordings. 
In general, types of adverse events for the intranasal and intravenous 
formulations of 2.5 mg midazolam were similar. There were more cases of 
diplopia in the intranasal treatment groups (1 case in 2.5 mg group and 6 
cases in 5 mg group), which could be explained by midazolam’s characteristic 
(dose-related) benzodiazepine effects on gabaa-receptors in the central ner-
vous system. Since gabaa-receptors do not occur peripherally, it is unlikely that 
this is due to local effects of the intranasal formulation. The larger number of 
cases of sleep-related symptoms in the 5.0 mg intranasal midazolam group 
likely results from the higher auc in this treatment group. There were more 
cases of attention disturbances in the 2.5 mg intranasal midazolam treatment 
group compared to the 5.0 mg intranasal and 2.5 mg intravenous midazolam 
groups. Attention disturbance represents the lower end of the spectrum of 
gabaa -effects, and subjects in the low-dose intranasal treatment group may 
have not been sedated to such a level that somnolence occurred, but enough 
to experience attention problems. 
nasal
No significant abnormalities were found during nasal examination in any of 
the subjects. Mild and transient visible abnormalities (< 1 cm) were observed 
intravenous (p = 0.007, 2.7, 95% ci 0.8, 4.7) and midazolam 2.5 mg intranasal and 
5.0 mg intranasal (p = 0.001, 3.5, 95% ci = 1.5, 5.4)
Duration of action as defined by a 2sd decrease in spv was on average 
76±80.4 minutes after administration of midazolam 2.5 mg intranasal and 
145±104.9 minutes of midazolam 5.0 mg intranasal. Duration of action was on 
average 118±95.6 minutes after 2.5 mg intravenous midazolam. There was a 
statistically significant difference between 2.5 mg intranasal and intravenous 
midazolam (p = 0.03, -38.5, 95% ci -60.6, -3.9) and between the two intranasal 
dose levels (p = 0.001, -53.4, 95% ci -69.9, -28.0), but not between 2.5 mg intrave-
nous and 5.0 mg intranasal. 
visual analogue scales
Subjective alertness decreased after administration in a time-dependent 
manner in all midazolam groups. There was a statistically significant differ-
ence between the intranasal dose levels (p = 0.0009, 1.9, 95% ci 0.8, 2.9; see 
Figure 3). There were no effects on vas Calmness or vas Mood.
simple reaction time task 
Midazolam had a marked effect on the reaction time with a statistically signif-
icant difference between the intranasal dose levels (p = 0.0005, -10/8, 95% ci 
-16.2, -5.2; see Figure 4). 
observer‘s assessment of alertness/sedation 
Intranasal midazolam displayed a significant effect on sedation as measured 
using oaa/s. Levels of sedation after midazolam intranasal 2.5 mg and midazol-
am intravenous 2.5 mg administration were comparable, whereas midazolam 
intranasal 5.0 mg led to higher sedation levels (see Figure 5). The odds ratio 
(defined as the chance (odds) that a subject scored an oaa/s of 1 (awake/orien-
tated, indicating no sedation) during one treatment versus the other) was 2.3 
(p < 0.0001; 95% ci = 1.63, 3.18) for the contrast midazolam 2.5 mg intranasal vs 
midazolam 2.5 mg intravenous, 0.8 (p = 0.30; 95% ci = 0.62, 1.16) for the contrast 
midazolam 5.0 mg intranasal vs midazolam 2.5 mg intravenous, and 2.7 (p < 
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Single administration of Nazolam, however, was well tolerated and safe in 
healthy adult subjects. Nasal symptoms were mild and transient and only 
observed in two patients. Furthermore, the aqueous nature of the formulation 
allows for a pH driven transport into the buffered nasal mucosa constitution 
allowing for a fast onset of efficacy of midazolam in a similar time window 
as observed after intravenous administration of midazolam. Mean absolute 
bioavailability of Nazolam was high (approximately 75%) and clinically effec-
tive concentrations were reached within minutes after nasal administration. 
Observed maximal systemic midazolam concentrations were comparable to 
those observed after oral midazolam administration33,34. Lower (and thus 
more favorable) and less variable peak concentrations were seen after intra-
nasal compared to intravenous administration of midazolam. Nazolam 
showed dose proportional pharmacokinetics in the investigated dose range 
(2.5 – 5.0 mg). Several pharmacokinetic studies have been published using 
intranasal formulations35-42. Although some showed comparable phar-
macokinetic results, different nasal formulations were used, mainly using 
very large volumes, or high concentrations of organic solvents or absorption 
enhancers. There were no signs of important contribution of ingestion related 
intestinal absorption, as the overall concentration-time profiles of intranasal 
formulations did not show a second peak and the formation of metabolite was 
low and comparable with intravenous levels. The absence of clinically rele-
vant decreases in transcutaneous oxygen saturation parameters and blood 
pressure in this study indicate that the safety profile of nasal midazolam is 
comparable to that observed after oral midazolam administration.
Saccadic peak velocity is generally considered as a sensitive and reproduc-
ible biomarker for the sedative effects of benzodiazepines43 and was therefore 
used as a biomarker of pharmacological effect of midazolam in this study. 
spv has already been used as an outcome variable in several previous studies 
with intravenous midazolam44-51 and changes in saccadic eye movements 
allow the accurate recognition of the wake-sleep transition8,52. In this study, 
an attempt was made to compare the onset and duration of pharmacological 
effect of the different midazolam formulations as accurately and realistically 
for one subject almost 12 hours after administration of 2.5 mg intranasal mid-
azolam and for one subject 2 hours after administration of 5.0 mg intranasal 
midazolam, which all resolved spontaneously. Mild nasal symptoms were 
observed in 2 subjects 1 hour after administration of 5.0 mg intranasal midaz-
olam, which resolved within 1-2 hours. In one subject these symptoms may be 
related to mild runniness already observed before dosing. One subject report-
ed rhinorrhea, and one reported sneezing after 2.5 mg intranasal midazolam. 
After 5.0 mg intranasal midazolam, one subject reported cough, one reported 
irritation, one reported epistaxis (at the day after administration, where during 
the study day no nasal symptoms or visible abnormalities were observed), and 
two reported sneezing.
oxygen saturation
No clinically relevant decreases in transcutaneous oxygen saturation or blood 
pressure were observed.
Discussion
This study is the first to report on the pharmacokinetics and effects on sedation 
of Nazolam. Nazolam is a new aqueous nasal formulation of midazolam that 
does not lead to nasal tissue damage and delivers small enough volumes to 
be fully absorbed by the nasal mucosa, yet containing sufficiently high con-
centrations of midazolam to establish clinically relevant systemic midazolam 
concentrations. For all midazolam treatment groups, effects were seen on 
pharmacodynamic outcome variables of sedation and clinically relevant lev-
els of sedation as measured using oaa/s (* score 2, or drowsy/normal speech) 
were achieved within minutes after administration. It is therefore clear that 
use of Nazolam is an effective, convenient and safe method of inducing con-
scious sedation for a wide range of applications. 
Most previous studies used formulations that led to nasal run-off or nasal 
mucosal damage, or were hampered by flaws in the experimental design. 
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The effects on ssrt of both the intranasal and the intravenous formulation 
returned to baseline in almost 2 hours for all formulations. 
In conclusion, this study demonstrates that clinically effective concentrations 
can be reached within minutes after nasal application of a highly concen-
trated midazolam formulation with sedation profiles comparable to those 
observed after intravenous midazolam administration. When considering the 
preparation time needed for obtaining venous access, conscious sedation can 
be achieved in the same time span for nasal as for intravenous administration 
of midazolam. Potential applications of this new formulation are not limited 
to settings where midazolam is currently being used intravenously, but could 
also include settings in which intravenous access is not feasible such as in chil-
dren and patients with needle phobia, uncooperative patients and in urgent 
/ emergency room situations. With the demonstrated absence of initial high 
peak plasma concentrations, nasal delivery also allows for safe and efficacious 
conscious sedation out-side hospital settings such as the general practitioner 
office and dentistry settings. Finally, as the absorption capacity of the nasal 
mucosa is limited to 100 µl per nostril, nasal administration is relatively safe 
to overdosing. The immediate and non-invasive characteristics of this new 
formulation offer important advantages for clinical use in conscious sedation 
and in epilepsy.
as possible. In a recent review on biomarkers for the effects of benzodiazepines 
in healthy subjects, a relationship between spv reduction and clinical effica-
cy was described, as all reviewed benzodiazepines caused an impairment of 
saccadic peak velocity, which was closely related to the therapeutic dose43. 
Therefore, spv was used in this study to evaluate the onset and duration of 
pharmacological effect of intranasal midazolam. The definition of the onset 
and duration of pharmacological effect (sedation) was based on the subject’s 
individual variability in spv under placebo. As expected, intranasal midazolam 
led to a marked decrease in saccadic peak velocity at both investigated doses. 
Nazolam 2.5 mg led to conscious sedation in all individuals as reflected in 
the clear spv decline observed for all subjects, showing that spv is a sensitive 
biomarker and a good choice for a proof-of-pharmacology study such as the 
current one. 
The effects of intranasal midazolam on spv and subjective vas alertness 
increased in a dose proportional fashion. The time effect curves of spv and vas 
alertness were comparable, which supports the appropriateness of the use of 
spv as a surrogate marker for the sedative effect of midazolam. However, spv 
was clearly more sensitive to midazolam effects than vas alertness, as the 
observed effects of midazolam on spv started earlier and returned to baseline 
later than those on vas alertness. The use of spv to define onset of pharmaco-
logical effect is therefore supported by the current data. Onset and duration of 
sedation were compared between treatment groups. The duration of sedation 
was slightly shorter for intranasal than for the intravenous formulation, but 
this was not statistically significant. 
No effects were seen on subjective mood and calmness (as assessed by vas), 
but this was not unexpected as it is in accordance with our experience with 
studies in healthy non-anxious subjects and likely related to a floor effect in 
the assessment of subjective calmness.
To assess the impact of ongoing sedation due to midazolam on normal 
functioning, the effect on the simple reaction time task (srtt) was assessed. 
Reaction time was increased by midazolam for about as long as the other 
pharmacodynamic effects (slowing of spv and decrease in vas alertness). 
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table 1  Pharmacokinetic parameters of midazolam and _-hydroxy-midazolam in healthy 
subjects after administration of a single dose of 2.5 mg midazolam intravenous (i.v.) or 2.5 or 5 
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figure 2  Saccadic Peak Velocity LSMs change from baseline profile with 95% ci as error 
bars (first 3 hours after administration). Open rhombus represents placebo; grey closed circle 
represents midazolam 2.5 mg i.v.; black closed circle represents midazolam 2.5 mg i.n.; open circle 
represents midazolam 5.0 mg i.n.
figure 3  vas Alertness LSMs change from baseline profile with 95% ci as error bars (first 
3 hours after administration). Open rhombus represents placebo; grey closed circle represents 
midazolam 2.5 mg i.v.; black closed circle represents midazolam 2.5 mg i.n.; open circle represents 
midazolam 5.0 mg i.n.
figure 1  Geometric mean concentration-time profiles (log-linear) of midazolam and 
_-hydroxy-midazolam after intravenous (iv) (2.5 mg) and intranasal (in) (2.5 and 5.0 mg)  
midazolam administration in healthy subjects
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figure 4  Simple reactions time task lsms change from baseline profile with 95% ci as error 
bars (first 3 hours after administration). Open rhombus represents placebo; grey closed circle 
represents midazolam 2.5 mg i.v.; black closed circle represents midazolam 2.5 mg i.n.; open circle 
represents midazolam 5.0 mg i.n.
figure 5  Observation assessment LSMs profile with 95% ci as error bars (first 3 hours after 
administration). Grey closed circle represents midazolam 2.5 mg i.v.; black closed circle represents 
midazolam 2.5 mg i.n.; open circle represents midazolam 5.0 mg i.n. Score 1 = awake/oriented; score 2 
= drowsy/normal speech; score 3 = slow reaction to verbal; score 4 = inability 2 saccades
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reflected by an annual increase in out-patient use of neurologicals in Dutch 
children and adolescents from 2005 through 2011 (the end of the study period). 
The largest increase was among antidepressants (including antidepressants 
combined with psycholeptics) and stimulants. The in-patient use of cns drugs 
was not evaluated, but is also likely substantial, given that neonatologists, 
pediatricians, pediatric neurologists, and child and adolescent psychiatrists 
commonly prescribe neuropsychiatric drugs. 
Despite this high need for pediatric research and development, and 
despite the ongoing increase in the use of cns drugs among pediatric patients, 
cns drugs are researched only rarely under the Regulation. In addition, the 
Regulation is not likely to have a positive impact on the ability of children and 
adolescents to access new cns drugs, or on the delay in pediatric registration of 
cns drugs as described in the Introduction to this thesis. A total of 32 cns drugs 
were agreed for pediatric development, the majority of which (approximately 
80%) had a unique Anatomical Therapeutic Chemical (atc) code in the whocc 
(World Health Organization Collaborating Center) database (not reported in 
chapter 2), indicating that these drugs are currently marketed in at least one 
country. The newly developed cns drugs included several novel drugs; how-
ever, the development of some of these drugs had already been discontinued3. 
In addition, for the majority (81%) of cns drugs with agreed pediatric develop-
ment, one or more pediatric development plans included at least one measure 
for which deferral was granted until the drug was authorized for marketing to 
adults. The relatively low number of cns drugs with agreed pediatric develop-
ment is likely due to the reported decrease in research in adults. Because the 
adult indication is the starting point of the Regulation, and because pediat-
ric development plans are submitted as part of a development plan in adults, 
drug development for children with neuropsychiatric disorders still follows 
adult development, although some pediatric epilepsy syndromes (such as 
neonatal seizures, Lennox-Gastaut syndrome and Dravet syndrome) are being 
addressed specifically under the Regulation. 
To address some of these issues, in chapter 2 we suggested that the evalua-
tion of any proposal for a pediatric investigation plan (or request for a waiver) 
CNS drug research under the Pediatric Regulation:  
how can we move forward?
The 2007 eu Pediatric Regulation requires the industry to plan clinical trials 
in children early in the development of new drugs for use in adults, or for line 
extensions for on-patent drugs (unless a waiver or deferral has been granted). 
Because the Regulation is at the core of pediatric needs and establishes clear 
obligations and a system of incentives aimed at the pharmaceutical indus-
try, the Regulation was expected to result in research that would be focused 
more on the needs of children and would therefore drive important changes in 
therapeutic options available to pediatric patients1. Based on our evaluation 
presented in chapter 2, it is clear that under the Regulation, a higher percent-
age of medicines are considered for use in children. However, the Regulation 
does not necessarily lead to the increased pediatric development of drug class-
es for which there may be a unmet pediatric need based on pediatric usage and 
availability data. Importantly, only seven therapeutic subgroups accounted 
for half of all medicines for which pediatric development was agreed, and the 
drug classes that the European Medicines Agency (ema) Needs Lists identified 
as needing pediatric research and development were researched relatively 
infrequently under the Regulation. In addition, a small contingent of Dutch 
physicians working in pediatric healthcare are not convinced that medicines 
for which pediatric development was agreed are needed for clinical practice.
Our analysis confirms the increased need for researching and develop-
ing central nervous system (cns) drugs for use in pediatric patients, as drugs 
acting on the nervous system (the so-called neurologicals) had the highest 
number of off-label medicines for which the ema Needs Lists identified a 
need2. Nearly half of all cns drugs listed were indicated to need full pediat-
ric development. Anesthetics, analgesics, antiepileptics, and psycholeptics 
(such as antipsychotics, anxiolytics, hypnotics, and sedatives) were among the 
therapeutic subgroups with the highest number of active substances with a 
pediatric need. Our analysis also indicates that the percentage and number of 
children and adolescents who are treated using cns drugs continues to rise, 
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Non-invasive drug profiling in children and adolescents 
pharmacokinetics
In chapters 6 and 8, we evaluated the feasibility and applicability of sampling 
saliva from healthy adolescents and from children and adolescents with 
autism spectrum disorder (asd). Although the sample collection devices and 
techniques (for example active versus passive collection) are dictated by the 
characteristics of the drug of interest, the collection method must be tolerated 
by children and adolescents. As we expected, active sampling using a Salivette 
collection device was tolerated well by the adolescents who participated in the 
caffeine study (chapter 6). Children with asd can have particularly sensitive 
sensory systems7 that can cause the child to resist certain collection devices. 
In the study described in chapter 8, we collected whole saliva samples from 
children and adolescents with asd; whole saliva sampling is the preferred 
method for measuring melatonin concentrations in saliva8. A recent study of 
6-12-year-old (mostly male) children with asd found that passive saliva sam-
pling was an acceptable collection method (in terms of ease and comfort)9, 
and this method can also be used in young children10 without associated 
risks such as choking. In our study, we used the Saliva Collection Aid (available 
from Salimetrics Europe), a device that was recently developed to simplify the 
collection of whole saliva from passive drool. Importantly, the device is con-
structed of polypropylene, which resists sample retention and contamination, 
issues that can occur with amines such as melatonin. This collection method 
was tolerated well by the subjects in our study. 
Due to difficulties in reliably predicting plasma concentration using saliva 
measurements, determining the concentration of a drug in a saliva sample 
was limited for basic drugs (which undergo an alkaline reaction in aqueous 
solutions) and for acidic drugs and drugs that are highly protein-bound (these 
drugs can have an extremely low s/p ratio). However, if sources of variability 
in the s/p ratio can be overcome for these drug types, measuring saliva drug 
concentration might be a feasible alternative to measuring plasma drug 
concentration. The studies described in chapters 5 and 6 attempted to inves-
tigate and quantify the sources of variability (for example, contamination and 
should be based on the potential pediatric relevance of the mechanism of 
action or drug target, and new incentives should be considered for first-in-
children indications. In addition, given the high number of cns drugs with 
deferred pediatric studies, clinical trial strategies should be revised in a timely 
fashion. Deferrals under the Pediatric Regulation may be related in part to the 
need for extra time due to a lack of general expertise, as pediatric research in 
the eu is less extensive than in the United States. For example, in the field of 
child and adolescent psychopharmacology, the majority of publications and 
studies originate in the us4, and the ability to run early drug trials with innova-
tive therapies is significantly higher in the us than in Europe5. Because clinical 
research in pediatric patients is hampered by interrelated logistic and ethical 
constraints – including a limited number, extent, and invasiveness of study-re-
lated interventions that can be performed if they are not part of routine clinical 
care – researchers should attempt to reduce the burden placed on partici-
pating children and adolescents by using non-invasive or minimally invasive 
measurement methods. Changes in methods that are designed to reduce the 
patient’s burden (for example, changing the sampling procedure) have already 
been reported to increase patient enrollment in studies of rare pediatric dis-
eases that were performed under the Regulation6. Therefore, in this thesis, we 
explored the feasibility of using non-invasive monitoring of pharmacokinetics 
(pk) and pharmacodynamics (pd) for pharmacological drug profiling of com-
monly used cns stimulants and depressants in children and/or adolescents. 
Drug concentrations were measured non-invasively in either the saliva or 
exhaled breath, and neurocognitive and neurophysiological functions were 
measured longitudinally using the NeuroCart test battery. 
This chapter reviews how this approach was used in the preceding chapters 
of this thesis. We will first discuss the feasibility and applicability of saliva sam-
pling in pediatric populations based on data obtained from pediatric clinical 
studies of caffeine, methylphenidate, and melatonin. Then, we will discuss the 
(potential of) pharmacological profiling of pharmacodynamics in children and 
adolescents based on literature review and clinical studies of methylpheni-
date, caffeine, alcohol and midazolam. This chapter concludes with potential 
practical applications of this approach and suggestions for future directions.
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role when using saliva sampling. For example, remnants of syrup, uncoated 
tablets, or chewable tablets can contaminate saliva samples and can cause 
inappropriately high drug concentrations in samples measured early after 
administration. This source of contamination can be largely eliminated by 
thoroughly rinsing the mouth both after taking the drug and prior to obtaining 
a saliva sample16, as was done in the studies described in this thesis. However, 
even if the mouth is rinsed thoroughly, saliva concentrations can be higher 
than expected due to residual contamination, transient transmucosal absorp-
tion or deposition of the drug. Therefore, in the studies described in chapters 
5 and 6, we attempted to compare the magnitude of contamination after 
drinking a beverage (caffeine) or swallowing a tablet (an immediate-release 
mph tablet) with contamination after swallowing a sealed capsule. Using 
this approach, we anticipated that a contamination factor (the elimination 
rate constant) could be incorporated into the model equation describing the 
saliva pk data, and model-predicted saliva concentrations (and hence the s/p 
ratio) could be individually corrected for the level of contamination. In addi-
tion, the half-life of the elimination rate constant could be used to determine 
the time window in which considerable contamination could be expected, 
thus providing information regarding sampling time points for therapeutic 
drug monitoring in clinical practice. Unfortunately, our efforts to correct for 
oral contamination were largely unsuccessful, due in part to the relatively few 
observations measured at early time points following drug administration; 
therefore, this approach was abandoned.
Even in cases in which the saliva sample is not contaminated, the s/p ratio 
may not be consistent across pk phases. Several factors may account for this 
inconsistency17. First, the arteriovenous concentration ratio can vary between 
pk phases, particularly for compounds that diffuse easily. Second, even in the 
absence of this phenomenon, the s/p ratio may not be stable throughout all pk 
phases. If elimination is linear and proceeds at the same rate in plasma and sali-
va (i.e., parallel decline), the ratio will be inconsistent; however, if elimination 
proceeds exponentially, the ratio will remain constant, with a parallel decline 
in plasma and saliva drug concentrations. Third, concentration-dependent 
saliva pH) in the plasma and saliva mph and caffeine concentrations measured 
using a population pk modeling approach. In previous studies, the s/p ratios 
of mph11 and caffeine12-14 concentrations were time-dependent, possibly 
due to fluctuations in arteriovenous blood concentration12-14 and/or pH 
partitioning11,13. In addition, because many drugs are administered orally, 
contamination in the saliva can influence the s/p ratio at early time points 
after administration. In chapters 5 and 6, we showed that the relationships 
between plasma and saliva concentrations of both mph and caffeine are sta-
ble (i.e., not time-dependent or concentration-dependent) after 2.5 hours (for 
mph) and one hour (for caffeine) of administration. Prior to these time points, 
the relationship between plasma and saliva concentrations was not linear. 
Sample contamination due to residual drug levels is a general concern 
in pediatric clinical research, but this issue is rarely addressed or taken into 
account. For example, in oncology research, pk measurements are usually 
taken from samples obtained directly from the indwelling central venous line 
(cvl), which is the same line through which intravenous chemotherapeutics 
are administered. This is usually due to practical considerations (as the line 
is already in place) and prevents the need to collect samples from a periph-
eral catheter (which would need to be inserted), thereby increasing study 
enrollment. Although studies suggest that clearing the line can minimize the 
contamination of certain drugs, there is currently no universally accepted 
method to reliably address this issue. One exception is a recently published 
paper by Edwards and colleagues15, who developed a population pk model 
of actinomycin-D in children with cancer by incorporating expressions that 
account for drug contamination from samples obtained via an indwelling cvl. 
Compared to other models, their baseline contamination model – including 
a contamination factor proportional to the model-predicted concentration 
for samples obtained from a cvl – was chosen as the most conservative and 
accurate model. This contamination model assumed that drug contamination 
from the sampling catheter was included in the baseline concentration and 
was therefore factored into the level of each individual prediction. Because 
many cns drugs are delivered orally, sample contamination can also play a 
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mass spectrometry (lc-ms/ms), which can be costly and is currently not gener-
ally available for most cns drugs.
pharmacodynamics
The most accessible non-invasive method for assessing the effect of a cns drug 
is to measure drug-related cns functional activity with sufficient sensitivity 
and specificity19. In general, an excessive number of cns tests are currently 
used in psychopharmacological research to determine the effects of drugs 
that act on the nervous system. The sensitivity of these tests for assessing cns 
effects has not been determined fully for most drugs, and the reproducibility of 
these tests may be relatively low. Therefore, careful selection of pd parameters 
is essential. In the studies described in this thesis, useful cns tests (or func-
tional biomarkers) to measure the effects of several compounds (including 
alcohol20, benzodiazepines21, and others) in healthy subjects were selected 
based on previously published studies. These parameters were used to mea-
sure pd for alcohol and midazolam in studies of healthy volunteers; these 
studies are described in chapters 7 and 9, respectively. 
Selecting functional biomarkers for measuring drug effects in patients with 
neuropsychiatric disorders is likely to be more complicated than in healthy 
volunteers. A useful functional biomarker should be sensitive enough to detect 
a therapeutic drug dose; in addition, a plausible relationship between the bio-
marker, drug pharmacology, and/or disease pathophysiology should also be 
evident22-26. Because the precise mechanism of action of many cns drugs is 
not fully understood, and because many neuropsychiatric disorders are het-
erogeneous, these two criteria may be difficult to achieve. The review reported 
in chapter 3 describes a systematic literature search that used the same 
approach as previously published reviews in healthy subjects. The aim of our 
review was to assess the sensitivity and usefulness of functional biomarkers 
for demonstrating acute cns effects of immediate-release methylphenidate 
(mph-ir) in children and adolescents with attention-deficit/hyperactivity 
disorder (adhd). Pediatric adhd is an exception in the field of pediatric neuro-
psychopharmacology, as an extensive body of research has been performed 
protein binding can account for differences in the s/p ratio within an individu-
al subject. Finally, pH partitioning can play a role, particularly for basic drugs, 
which undergo an alkaline reaction in aqueous solutions. Many cns drugs 
are basic and reside in equilibrium between their charged and neutral states 
under physiological conditions. Thus, the free fraction of the ionized drug 
can be incorporated in saliva, as saliva is slightly more acidic than plasma18. 
Therefore, the s/p ratio is highly sensitive to small changes in saliva pH, which 
in turn can be influenced by saliva flow. In the studies described in chapters 
5 and 6, we measured saliva pH and saliva flow at each saliva sampling time 
point in order to determine whether changes in these parameters (despite 
active sampling) accounted for some of the residual variability in the s/p ratio. 
However, no significant covariates were identified for the s/p ratio.
The feasibility of using non-invasive saliva samples to measure pk is limited 
by the period of time needed by the subject between sampling time points to 
replace the saliva sampled. Thus, the number of samples that can be collected 
to measure the absorption phase of compounds with a short Tmax (such as mph 
and caffeine) is limited, thus hampering the ability to determine the magni-
tude of contamination, the s/p ratio, and sources of variability in the s/p ratio 
directly following administration. For these drug types, only cns effects that 
occur relatively late are suitable for developing a pk/pd model using measured 
saliva concentrations or predicted plasma concentrations. However, because 
the pharmacological cns action of most compounds is delayed relative to 
changes in plasma concentration, saliva sampling may still be a viable option 
for this type of research. Therefore, our results support the further exploration 
of using saliva as a non-invasive, feasible, and acceptable method for drug 
profiling cns drugs. Given the potential influence of saliva contamination and 
saliva pH on measured saliva drug concentration, standardizing the collection 
method (for example, by rinsing the mouth, choosing active versus passive 
sampling, etc.) will likely improve the applicability of using saliva for drug 
monitoring. On the other hand, the method is potentially limited by the fact 
that the relatively low volume of saliva in a sample necessitates the use of a 
highly sensitive bioanalytical method such as liquid chromatography-tandem 
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task. In addition, blood pressure and heart rate were measured at regular 
intervals after the administration of caffeine. Significant effects on parame-
ters regarding alertness (saccadic peak velocity) and reaction time (adaptive 
tracking) were observed after caffeine was administered, despite the rela-
tively low dose and the expected ceiling effect on several parameters in this 
cohort of healthy, alert adolescents. Improved postural stability and some of 
the response times approached the level of statistical significance; thus, it is 
likely that these functions will improve significantly at higher caffeine doses. 
Because caffeine has been reported to produce behavioral effects (including 
motor activation and arousal) similar to the effect of classic psychostimulants 
such as cocaine and amphetamine29, these tasks could be valuable in pedi-
atric studies using other cns stimulants. In the study described in chapter 
7, a low dose of alcohol induced significant changes in smooth pursuit eye 
movements, alertness score measured on the visual analog scale (vas), the 
vas alcohol effect score, body sway, systolic blood pressure, and heart rate. 
Given that animal studies have revealed developmental changes in the phar-
macological sensitivity of gabaa-receptor-mediated currents to several drugs 
(including diazepam30,31, pentobarbital30, and zolpidem32-35), these tasks 
could be used to study age-related differences in the cns effects of gaba-ergic 
compounds in pediatric drug research. The cns tests and their duration were 
tolerated by the majority of adolescent subjects in these clinical studies. These 
studies demonstrate the feasibility of collecting a rich dataset from this age 
group, and they show that neuropsychological and psychomotor tasks can 
be used as biomarkers of the acute effects of low-dose caffeine or alcohol in 
healthy adolescents. 
Potential practical applications 
In the introduction (chapter 1) of this thesis, we raised several issues with 
respect to pediatric neuropsychopharmacology. First, the differences in both 
neuropsychopathology and pharmacology between children and adults 
must be recognized. In addition, researchers need validated tools that are 
to study the effects of mph-ir (and other drugs) in this disorder. However, 
previously published studies investigating the effects of mph-ir yielded 
contradictory results due to several sources of variability, including a lack of 
standardized biomarkers and/or effect measures of mph27,28. The results of 
our review revealed that a wide variety of biomarkers are currently being used 
to evaluate the effect of mph-ir in adhd. In addition, our review revealed that 
these studies would benefit greatly from a certain degree of standardization. 
Because most tests were used relatively rarely, it was difficult to identify the 
most sensitive tests and drug–response relationships. Nevertheless, despite 
these limitations, our literature review revealed that the Go/no-go task, the 
Scale-adhd, and tests that assess motor control and/or sustained attention 
may be suitable candidate biomarkers to measure the acute effects of mph-ir. 
These tests may facilitate the identification of responders and non-responders 
following a test dose of mph-ir. Our evaluation shows that even in the context 
of extensive pediatric research, it is difficult to reach useful conclusions regard-
ing pharmacological profiles or dose-effect relationships based on currently 
available studies. For example, several studies in our analysis did not measure 
drug concentrations, or they performed only a single pd measurement follow-
ing the test dose. Future studies are needed in order to investigate effect size 
and to establish clinically relevant changes in cns test results. Ideally, these 
studies should include concentration-effect and dose-effect relationships 
measured at several time points in order to allow for drug effect profiling, simi-
lar to the approach used in the clinical studies described in this thesis.
The cns tests that are included in the NeuroCart battery are sensitive enough 
to detect low doses of caffeine and alcohol in adolescents, as shown by the 
studies described in chapters 6 and 7. In the study described in chapter 6, an 
extensive cns battery was incorporated in order to obtain information regard-
ing general cns performance and to identify the functional cns domains that 
are affected by caffeine. The cns tests included saccadic and smooth pursuit 
eye movements, body sway, adaptive tracking, the left/right distraction task, 
finger tapping, the attention switch task and the visual and verbal learning 
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differences may exist for functional biomarkers of acute tolerance (such as 
subjective intoxication) and/or for tests that evaluate postural stability, it is 
worth investigating whether sensitivity to other pharmacodynamic effects of 
alcohol change with age.
Several drug classes – including adenosine antagonists; noradrenergic and 
serotonergic reuptake inhibitors; gabaa-receptor agonists; ethanol; cannabi-
noid agonists and antagonists; dopamine antagonists; histamine antagonists; 
and muscarinic antagonists – have a unique cns ‘fingerprint’ (i.e. drug profile) 
on the NeuroCart test battery. This unique drug profile corresponds to the drug 
class’ mechanism of action36. These ‘‘fingerprints’ can be used to differenti-
ate a drug’s stimulant and sedative properties. For example, cns stimulants 
can exert a different – or even opposite – effect profile than cns depressants. 
cns stimulants temporarily increase mental and/or physical function and 
are believed to act primarily on the dopamine, noradrenaline, and serotonin 
systems or by disinhibiting adenosine. Thus, cns stimulants may have a com-
mon pharmacological profile. By analyzing the results of studies performed 
previously by our research group and by reviewing other studies (de Mol, 
unpublished data), we found previously that increased saccadic peak veloci-
ty is a typical sign of cns stimulation. In addition, increased adaptive tracking 
performance and elevated body temperature were also identified as likely 
signs of cns stimulation. Given that benzodiazepines – which are typical cns 
sedatives – and ethanol are reported to decrease saccadic peak velocity23,36, 
decrease adaptive tracking performance23, and induce hypothermia22,37-39, 
these functional biomarkers might be valuable for providing a better interpre-
tation of the cns stimulant or sedative effects of drugs that have a modified or 
novel mechanism of action. In addition, these biomarkers can be used to quan-
tify and compare these properties (including paradoxical side-effects such as 
agitation in the case of benzodiazepines) between children and adults. For 
example, functional biomarkers could be used to determine whether a specif-
ic drug exerts a pharmacological effect at a specific dose in children, and they 
could also be used to monitor unwanted sedative or stimulant properties of 
drugs in children. 
appropriate for assessing the efficacy and safety of cns drugs in children. 
Finally, special emphasis should be placed on formulation research. cns drug 
profiling has the potential to address all of these issues, as it enables research-
ers to evaluate age-dependent differences in pk and pd, and it can facilitate 
distinguishing between the drug properties of sedatives and stimulants in 
children. In addition, cns drug profiling can facilitate comparisons between 
profiles of drugs with different formulations. 
Because our current understanding of age-dependent effects and side-ef-
fects is based largely on data collected from animal studies, evaluating 
age-dependent differences in pk and pd in pediatric clinical trials will be 
an important step forward. Drug profiling enables researchers to evaluate 
age-dependent effects by drawing comparisons with existing data collected 
in adults, as demonstrated by the study described in chapter 7. In this study, 
we used a pk/pd modeling approach to compare the alcohol breath profiles of 
adolescents and adults, as well as the participants’ objective and subjective 
responses to alcohol. Oral data collected from adolescents were combined 
in a pk/pd model with previous intravenous data collected from adults. 
Inter-subject variability could be identified on the basis of various kinetic 
parameters, and all of the identified covariates were related – either directly 
or indirectly – to differences between adolescents and adults. Two function-
al biomarkers were selected based on an exploratory meta-analysis of all 
pd tasks that were performed several times during a single testing occasion 
(from several studies). Both smooth pursuit eye performance and vas alertness 
responded clearly to alcohol, with no indication of any indirect effects or acute 
tolerance; thus, it was likely that a relatively simple model would describe 
the data accurately, and the presence or absence of an age-dependent effect 
could be investigated. Although we successfully developed a pk/pd model for 
these functional biomarkers, we did not identify any significant covariates; in 
particular, we found no clear effect of age. However, vas alertness and smooth 
pursuit eye movements may not fully represent every effect of alcohol on 
the cns, and we cannot exclude the possibility that sensitivity to other phar-
macodynamic effects of alcohol changes with age. Because age-dependent 
non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 280 –
 
chapter 10 – gener al discussion 
– 281 –
10-mg Circadin, and the melatonin level remained elevated for several hours 
thereafter. Circadin exposure in saliva was dose-linear and clearance in saliva 
was comparable between dose groups. Sedation after the 2-mg Circadin dose 
peaked at 2 hours, which is around the Tmax time of the pk profile, demonstrat-
ing pk/pd correlation.
Non-invasive monitoring of an array of sensitive functional biomarkers can 
also be used to compare the effect profiles of different formulations, as was 
demonstrated in chapter 9. The ‘proof-of-pharmacology’ strategy described 
in this chapter may perhaps also be followed in pediatric studies on drugs for 
which extensive data exist on efficacy and safety, but for which there is only 
a need for an age-appropriate formulation. In the study described in chapter 
9, the pharmacokinetics of two doses of a novel highly concentrated aqueous 
intranasal midazolam formulation (Nazolam) was characterized in healthy 
adult volunteers and related to several outcome variables for sedation. In 
addition, the onset and duration of the pharmacological effect were evaluated 
and compared to intravenous midazolam using spv, as a relationship between 
spv reduction and clinical efficacy has been described21. Effects were seen on 
pd outcome variables of sedation and clinically relevant levels of sedation as 
measured using oaa/s were achieved within minutes after administration. In 
addition, single administration was well tolerated and safe. This new formu-
lation has potential for use in conscious sedation and epilepsy in children. A 
future study in children could include non-invasive measurement of midaz-
olam in saliva46 and repeated effect measurements on spv (in older children) 
and a clinically relevant biomarker of sedation (oaa/s). In addition, a previously 
validated anxiety score (Faces Pain Scale-revised)47 could be used to measure 
the effect on anxiolysis.
future directions
In parallel with further refining the methods described in this thesis, several 
other steps must be taken. First, non-invasive drug monitoring should be 
evaluated in younger age groups and in subjects with other neuropsychiatric 
disorders. The studies described in this thesis primarily involved adolescents, 
Finally, non-invasive monitoring of pk and pd could facilitate the evalua-
tion of age-appropriate formulations of cns stimulants and depressants for 
use in children, as illustrated by the studies described in chapters 8 and 9. 
Because oral delivery remains the most important and most commonly used 
route for drug delivery, suitable oral delivery forms that offer the possibility 
of customized dosing are urgently needed40. Sustained-release mini-tablets 
provide several distinct advantages over other conventional pediatric dos-
age forms; for example, mini-tablets can minimize dysphagia-related issues, 
they can be designed to mask unpleasant taste (thereby improving palatabil-
ity and patient compliance), and they can be modified to release the active 
ingredient slowly41. In addition, mini-tablets can provide multiparticulate 
dosing, which is needed for global pediatric drug therapy42. In a recent study, 
mini-tablets were the best accepted oral formulation in infants and pre-
school children and were significantly more often fully swallowed than the 
other oral formulations43. Therefore, the new, age-appropriate prolonged-re-
lease melatonin mini-tablets (Circadin) described in chapter 8 may provide 
important advantages over the currently licensed 2-mg tablets. In this study, 
we evaluated the pk profile, short-term safety, and acceptability of this for-
mulation in 16 children and adolescents with both autism spectrum disorder 
(asd) and a sleep disorder. In order to avoid interrupting the subject’s sleep 
due to repeated nighttime saliva sampling, the melatonin was administered 
in the morning (rather than in the evening); this also minimized study-re-
lated burden. Melatonin concentrations were measured non-invasively in 
saliva samples, and the level of sedation was evaluated using the Observer‘s 
Assessment of Alertness/Sedation (oaa/s) scale. This validated scale was orig-
inally developed to more objectively measure the level of alertness in sedated 
subjects, and it has been shown to be both reliable and sensitive to the effects 
of drugs such as midazolam44. In addition, the oaa/s scale is comparable to 
the Ramsey scale, which is commonly used in pediatric intensive care units to 
assess the patient’s level of consciousness45. The concentration of melatonin 
in the saliva peaked within two hours of receiving either a dose of 2-mg or 
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the subject to spontaneously report adverse events is often not appropriate in 
this age group, and third-party reporting of adverse events is often needed57. 
Therefore, more proactive, objective measures must be taken, for example by 
incorporating the oaa/s scale as reported in chapter 8. 
A second important step, particularly considering that most neurologi-
cal and psychiatric disorders are either chronic or recurrent, is to determine 
whether early treatment translates into an acute improvement in symp-
tom-related cns functions as well as improved function and improved 
long-term outcome. To achieve this goal, the predictive value of putative 
functional cns biomarkers should be investigated in long-term trials. Given 
that many neurological and psychiatric disorders are highly heterogenous, a 
combination of tests should be included in such a trial, as combined testing 
can yield a more precise and robust prediction of the drug’s effect. These stud-
ies should also include tolerability biomarkers, given that adverse events can 
reduce compliance or even cause the subject to discontinue treatment.
Finally, as anesthetics and analgesics are among the most common-
ly cited therapeutic subgroups with a pediatric research need on the ema 
Needs Lists2 (as reported in chapter 2), more experience should be gained in 
the field of pediatric pain research, especially as children are particularly 
prone to unfair exclusion from pain research58. Pupillometry may be a use-
ful non-invasive method to objectively quantitate pain response/intensity in 
children59. However, there are some important questions in pain and anal-
gesia research that cannot be answered without an evoked pain stimulus, 
and therefore the use of evoked pain modalities should also be expanded for 
use in pediatric clinical trials. Evoked pain offers important control over the 
environment and provides standardization of pain stimuli, thereby enabling 
a more rigorous exploration of individual differences or the environmental 
factors that can affect the subjective pain experience. In general, it is ethically 
preferable to avoid causing pain for research purposes, especially in minors. 
In addition, because the induction of pain can lack direct benefit, it is usually 
not deemed appropriate for use in either therapeutic pediatrich research or 
non-therapeutic pediatric research. However, as the factors that can affect the 
as the development of non-invasive drug monitoring generally follows an 
incremental ‘top-down’ approach, with adolescents studied first, followed by 
younger age groups. Adolescents are often overlooked in clinical trials that lead 
to drug registration48. Changes in physical parameters such as height, weight, 
and lean body mass occur during puberty, and these changes can strongly 
influence hepatic drug elimination and clearance during adolescence. Age-
dependent changes in liver size and/or functional capacity can also contribute 
significantly to changes in clearance49. In addition, many adolescents are 
more amendable to certain medications due to neurochemical differences, 
and the presence or absence of significant side-effects can strongly influence 
whether the subjects comply with the drug administration regimen50. Recent 
studies found that adolescence is a unique developmental period of transition 
in which specific brain regions undergo highly dynamic growth and prun-
ing51. Changing the levels of catecholamine neurotransmitters can have the 
strongest effect during the transition from childhood to adolescence, when 
synaptic selection peaks52. Because adolescents are rarely waived for pedi-
atric development under the Pediatric Regulation, this age group will likely 
be involved in more studies in the near future. However, preschoolers have 
historically been the most neglected age group with respect to psychophar-
macological research53, and this age group is also likely to be included in more 
trials performed under the Regulation. Currently, the youngest age at which 
a child is treated by a child psychiatrist is 2-3 years (e.g., in the case of a young 
child with irritability or aggressive behavior, for example in asd). Children with 
disorders such as pain or epilepsy may also require drug therapy at a younger 
age. Importantly, younger children may be more sensitive than older children 
to the adverse effects of certain medications. Pre-school children with adhd 
may have lower effect sizes with mph, and they may have a higher prevalence 
of adverse events54, including increased insomnia or other sleep-related 
problems, reduced appetite55, increased emotional levels, social withdrawal, 
nausea, and stomach ache56. Therefore, age-appropriate non-verbal cns tests 
that do not require a long attention span should be developed and validated 
in order to evaluate cns effects in preschool children. In addition, relying upon 
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homes. Adult studies of novel drugs that could potentially be measured in 
saliva samples should include measurements of the s/p concentration ratio. 
Because considerable pk variability has been reported for several neuropsy-
chiatric drugs, sensitive non-invasive or minimally invasive pd measurements 
should be assessed longitudinally. In addition, pediatric studies should ideally 
include a means to compare the results with adult studies. Finally, to expand 
our knowledge regarding the acceptability and tolerability of measurement 
methods, whenever possible the study participants should be asked to com-
plete a questionnaire in order to collect information regarding the reasons 
why children and adolescents participate, as well as their perceived burden 
associated with the study.
relationship between drug concentration and pain relief can differ between 
children and adults, findings obtained from adult studies may not necessar-
ily translate directly to children or even adolescents. For example, a study of 
school-age children who underwent a tonsillectomy found that paracetamol 
can have a robust placebo effect in this age group60 and a child’s thoughts and 
attitudes regarding pain can change with age, thereby contributing to more 
intense feelings of pain during adolescence than in childhood61. In addition, 
developmental changes in endogenous analgesic mechanisms and develop-
mental modulation have been proposed in animals62. Reaction time and late 
laser-evoked brain potentials decrease from childhood to adulthood, which 
may reflect aspects of maturation in sensory processing by the thermoalgesic 
system63. Because our current understanding of age-dependent effects and 
side effects is based largely on data collected from animal studies, evaluating 
age-dependent differences in pk and pd in pediatric clinical trials will be an 
important step forward. Therefore, it is necessary to include adolescents and 
children in pain studies. We predict that evoked pain will be used increasingly 
in children and adolescents. Therefore, additional knowledge and experience 
should be gained in the pediatric field of evoked pain modalities, again fol-
lowing an incremental ‘top-down’ approach, with adolescents studied first, 
followed by younger age groups.
Conclusions
The clinical studies included in this thesis show that non-invasive drug profil-
ing for cns stimulants and depressants is feasible in healthy adolescents and 
children and adolescents with asd. In addition, non-invasive drug profiling 
may help researchers both evaluate age-dependent pk and pd and compare 
the effect profiles of various formulations. Importantly, this approach may 
also facilitate the execution of studies included in Pediatric Investigation 
Plans under the Pediatric Regulation, thus representing an important step 
forward, particularly given the high need for pediatric research with respect 
to cns drugs. The ideal pediatric study should be executable in the subjects’ 
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Several challenges have emerged when working within the framework of this 
new legislation and there is an urgent need for validated assessment tools that 
are suitable for evaluating the efficacy and safety of cns drugs in the pediat-
ric population. In addition, researchers should attempt to reduce the burden 
placed on participating children and adolescents by using non-invasive or 
minimally invasive measurement methods. 
The most accessible and non-invasive means to measure drug activity in 
the brain is to measure drug-related cns functional activity using methods 
that provide sufficient sensitivity and specificity. To relate drug-related chang-
es in cns functional activity to changes in pk, drug concentrations must be 
measured. Traditional pk protocols – with multiple samples and indwelling 
catheters or multiple venipunctures – are undesirable in therapeutic pediatric 
drug research. To overcome some of these limitations, other sample collection 
methods for determining drug concentration (for example, saliva sampling) 
have been developed and validated. Saliva sampling has the added benefit of 
allowing on-site testing without the need for medical personnel or complicat-
ed post-collection sample processing, thereby further decreasing the burden 
placed on the children. Unfortunately, however, the usefulness of determin-
ing the saliva concentration of several drugs has been questioned because of 
variability in the saliva:plasma concentration (s/p) ratio. We propose that if the 
sources of variability in the s/pratio can be quantified or minimized, measuring 
the saliva drug concentration might be a meaningful alternative to measuring 
plasma drug concentration. 
chapter 2: the european pediatric regulation: will  
it provide children with the medicines they need?
In this chapter, a study is described in which the impact of the European 
Pediatric Regulation on the development of pediatric medicines  – including 
cns drugs – is evaluated. The Regulation requires the pharmaceutical indus-
try to plan clinical trials in children in an early stage during drug development 
in adults or in case a new indication, formulation or administration route 
is investigated for adults for on-patent medicines. The so-called Pediatric 
This thesis describes the potential role of non-invasive measurement of 
pharmacokinetics (pk) and pharmacodynamics (pd) in the research and 
development of central nervous system (cns) stimulants or depressants for 
children and adolescents. First, we evaluated the feasibility of using saliva 
as an alternative to plasma in two studies on psychostimulants (caffeine 
and methylphenidate). Second, neuropsychological and neurophysiologi-
cal functions were measured longitudinally using the NeuroCart, a battery 
of tests developed at the Centre for Human Drug Research (chdr, Leiden, 
The Netherlands) that includes non-invasive tests for alertness, visuomotor 
coordination, motor control, memory, and subjective drug effects. Using a 
non-invasive approach, age-dependent differences in alcohol pk and pd were 
evaluated between healthy adolescents and adults. This thesis concludes with 
the report of two clinical trials that were designed to evaluate age-appropriate 
formulations of sedative drugs that have the potential for use in children.
chapter 1: introduction
The pharmacological treatment of children and adolescents with diseas-
es of the cns has traditionally followed the development program in adults. 
However, because of differences in neuropsychopathology and develop-
ment-specific differences in pk and/or pd, the relationships between drug 
action and drug exposure in children cannot be understood fully by simply 
extrapolating information from adult patients. Therefore, it is important to 
investigate age-dependent differences in pk and pd. Unfortunately, our under-
standing of these differences is based almost entirely on animal models. In 
addition, the registration of cns drugs for use in children and adolescents has 
lagged behind new developments in adults. The situation has been compli-
cated even further by a decrease in the number of new drug registrations for 
psychiatric and neurological indications in adults. 
Despite these factors, the number of treated children and adolescents, 
as well as the duration of exposure to cns drugs, has increased substantial-
ly over the past few decades. Recent European legislation (the eu Pediatric 
Regulation) will likely drive an increase in pediatric trials and specific label 
changes, dosing recommendations, and age-appropriate formulations. 
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need. Our analysis also indicates that the percentage and number of children 
and adolescents who are treated using cns drugs continues to rise, reflected 
by an annual increase in out-patient use of neurologicals in Dutch children 
and adolescents from 2005 through 2011 (the end of the study period).
We conclude that the Regulation’s key strategy does not necessarily lead to 
the increased pediatric development of drug classes for which there may be a 
(unmet) pediatric need. Instead, the Regulation’s output is in line with expen-
diture data, most likely as a result of the ‘adult-driven’ approach. In addition, 
given the high number of granted deferrals it is likely that the registration of 
cns drugs for use in children and adolescents still lags behind new develop-
ments in adults. We propose that important refinements in implementation 
are needed in order to ensure that the Regulation will provide children and 
adolescents with the medicines they actually need. For example, evaluation of 
any proposal for a pip (or request for a waiver) should be based on the potential 
pediatric relevance of the mechanism of action or drug target, and new incen-
tives should be considered for first-in-children indications.
chapter 3: biomarkers of acute methylphenidate  
effects in children and adolescents with attention-
deficit/hyperactivity disorder 
The psychostimulant methylphenidate (mph) is the most commonly pre- 
scribed medication for treating pediatric attention-deficit/hyperactivity dis- 
order (adhd). Previously published studies investigating the effects of immedi-
ate-release mph (mph-ir) yielded contradictory results due to several sources 
of variability, for example a lack of standardized biomarkers for drug-effect 
measurements. 
In the study described in chapter 3, we performed a systematic literature 
review to identify sensitive and useful non-invasive biomarkers for monitor-
ing the effects of mph-ir in children and adolescents with adhd. We identified 
78 randomized placebo-controlled clinical studies (published until December 
2009) that investigated cns effects following a single dose of mph-ir in pedi-
atric adhd patients. Outcome measures were clustered to groups of related 
Investigational Plan (pip) describes how a medicine should be investigated in 
children. This plan should be presented by the company early in the develop-
ment of a medicine and subsequently agreed with the Pediatric Committee 
of the ema. In this study, we evaluated the drug classes for which pediatric 
development was either agreed for development or was waived by the ema 
from 2007 until March 2012. In addition, we evaluated whether the Regulation 
is likely to lead to the development of drug classes for which there exists a 
(unmet) pediatric need, or for which pharmaceutical expenditure is high. 
In addition, Dutch physicians working in pediatric healthcare indicated if 
they find that the pediatric medicines (developed and researched under the 
Regulation) are actually needed.
From 2007 until March 2012, approximately two-thirds of the medicines 
were agreed by the ema for pediatric development; deferral of the start or 
completion of measures in the pip until after authorization for adults was 
granted for 83% percentage of these medicines. Drug classes and thera-
peutic subgroups with a high need for pediatric research and development 
on the ema Needs Lists, like cns drugs, are either researched infrequently or 
often waived from pediatric development. In addition, medicines that are 
frequently prescribed (pharmo Database Network, 2005-2011), but are not 
always readily available (and that therefore represent an unmet pediatric 
need) are researched relatively rarely under the Regulation. The drug classes 
in our evaluation with the lowest number of medicines with agreed pediat-
ric development had the lowest pharmaceutical expenditure (gip databank, 
2007-2011). Finally, fifty Dutch physicians working in pediatric healthcare were 
not convinced that medicines for which pediatric development was agreed are 
needed for their clinical practice. Our analysis confirms the increased need for 
researching and developing cns drugs for use in pediatric patients, as drugs 
acting on the nervous system (the so-called neurologicals) had the highest 
number of off-label active substances for which the ema Needs Lists identified 
a need2. Nearly half of all neurologicals listed were indicated to need full pedi-
atric development. Anesthetics, analgesics, antiepileptics, and psycholeptics 
(such as antipsychotics, anxiolytics, hypnotics, and sedatives) were among the 
therapeutic subgroups with the highest number of medicines with a pediatric 
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pd factors. In adults, clinical monitoring of mph therapy is usually performed 
by measuring plasma mph concentrations. In children, however, blood sam-
pling is undesirable. Saliva may be an alternative matrix for monitoring mph 
concentrations; however, several potential complicating factors have been 
encountered in previous studies. Complicating factors included indications of 
oral contamination in the first few saliva samples after taking mph tablets and 
considerable – yet unexplained – variation in the s/p ratio throughout the time 
course of both tablet and capsule formulations. 
Obtaining an accurate s/p ratio is essential for realizing the full potential 
of using saliva sampling to monitor plasma mph concentrations. Therefore, 
we developed an analytical method for accurate and precise quantification of 
mph in both plasma and saliva. In this chapter, we present the validation of a 
liquid chromatography – tandem mass spectrometric method using a hydro-
philic interaction liquid chromatography column (hilic). In a 100 µl sample, 
proteins were precipitated with 750 µl acetonitrile/methanol 84/16 (v/v) con-
taining d9-methylphenidate as the internal standard. Standard curves were 
prepared over the mph concentration range of 0.5 – 100.0 µg/l. The total anal-
ysis time was 45 seconds. Accuracy and within- and between-run imprecision 
were in the range of 98-108% and less than 7.0%, respectively. Matrix effects 
were greater for plasma than saliva with 46% and 8% ionization suppression. 
The matrix effects were adequately compensated by the use of deuterated 
mph as internal standard. mph significantly degraded in plasma and saliva at 
room temperature and 5°C. Stability experiments demonstrated that samples 
should be stored at temperatures of -20°C or below directly after sampling, 
and that samples should be processed immediately after thawing. Samples 
were stable at -20°C for at least 4 weeks. The method was successfully applied 
for the determination of mph concentrations in plasma and saliva samples 
from an adult healthy volunteer. 
We conclude that using protein precipitation and hydrophilic interaction 
liquid chromatography coupled to tandem mass spectrometry, this method 
allows fast, accurate and precise quantification of mph in both plasma and 
saliva.
tests or test variants (referred to as ‘clusters’) in order to generate a reasonable 
degree of standardization across studies and tests. We performed a progres-
sive condensation of the results into logical clusters, thus providing a more 
general assessment of the drug’s effects on groups of comparable tests or func-
tional domains. Neurocognitive clusters and individual tests that were used in 
five or more studies were evaluated for reporting consistent mph effects. 
The results of our review revealed that a wide variety of biomarkers are 
currently being used to evaluate the effect of mph-ir in adhd. The following 
outcomes showed a consistent response to a therapeutic mph dose across 
studies based on different cohorts: Continuous Performance Test, Go/no-go 
Task, Visual Evoked Potentials, and several observation scales (including 
Following Rules Observations, Oppositional Behavior Observations, On-Task 
Behavior Observations, and Impulsivity Behavior Observations). mph’s effect 
was best detected in tests and observations regarding motor control, sustained 
attention, divided attention, and impulsivity (inhibitory control), indicating 
that mph has acute effects on all three core symptoms of adhd (inattention, 
hyperactivity, and impulsivity) among mph-responsive children with adhd.
We propose that the potential biomarkers identified in this review might 
help identify responders versus non-responders following a test dose of mph. 
Because dose-effect relationships could not be quantified, these tests and 
clusters should be investigated further in order to thoroughly evaluate the 
dose-response relationships, including effect size, and establish clinically rele-
vant changes. Ideally, these studies should include concentration- (in addition 
to dose-) effect relationships at several time points in order to profile the effect 
of mph treatment in children and adolescents with adhd.
chapter 4: determination of methylphenidate in  
plasma and saliva by liquid chromatography/tandem  
mass spectrometry 
Monitoring mph concentrations can help determine whether a lack of observed 
efficacy and/or the presence of unexpected adverse effects are related to pk or 
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chapter 6: caffeine pharmacokinetics and effects on 
central and autonomous nervous system parameters  
in adolescents
Children and adolescents frequently use caffeine as a psychostimulant. 
Despite prevalent use of caffeine among adolescents, remarkably little 
research has been conducted regarding the physiological and behavioral 
effects of caffeine in this age group. Data obtained from animal studies suggest 
that the effects of caffeine reported in adults cannot be extrapolated simply to 
adolescents. 
Therefore, in chapter 6, we evaluated the effect profile of caffeine on cen-
tral and autonomic nervous system parameters following the consumption 
of a low dose caffeinated beverage by healthy adolescents; the results were 
compared with data obtained following the consumption of a non-caffein-
ated beverage. Caffeine concentrations were measured from saliva samples. 
In a separate study using adult volunteers, we determined the extent of oral 
contamination with caffeine after consuming a caffeinated beverage ver-
sus swallowing a caffeine capsule (200 mg). Both saliva and plasma samples 
were collected simultaneously in order to measure the s/p ratio of caffeine 
concentration. Based on the data collected from this kinetic study, a popu-
lation pk model was built to estimate plasma drug levels in adolescents; this 
model could be used to develop a pharmacokinetic-pharmacodynamic (pk/pd) 
model. 
In adolescents, caffeine had significant effects on task parameters relat-
ed to attention and visuomotor coordination (adaptive tracking task) and 
alertness (saccadic peak velocity). In addition, an increase in error rate in the 
attention switch task was observed after caffeine. Plasma caffeine concen-
trations in adults were described best as a two-compartment model with a 
dose depot, first-order absorption kinetics, and first-order elimination kinet-
ics. The plasma model identified a dose of 90 mg in the caffeinated beverage. 
Lean body mass-dependent variability was identified for the volume of the 
central compartment. This pk model was expanded to a population model 
chapter 5: population pharmacokinetics modeling  
of two methylphenidate formulations in plasma  
and saliva of healthy subjects 
In this chapter, a study is described in which a first attempt was made to quan-
tify sources of variability in mph plasma and saliva concentrations, and to 
describe the relationship between mph concentration in saliva and mph con-
centration in plasma using a population pk modeling approach.
In this randomized, open-label study, mph-ir (tablet) and osmotic release 
oral system mph (mph-oros, capsule) were administered in a crossover design 
to 12 healthy adult subjects (six men and six women). Paired blood and saliva 
samples were collected pre-dose and at regular intervals for 6 (mph-ir) or 11 
(mph-oros) hours following drug administration. Population pk analysis was 
performed using nonlinear mixed-effect modeling. 
A one-compartmental structure model with first-order absorption (with 
separate compartments for mph-ir and mph-oros) and first-order elimina-
tion provided the best description of estimated mph plasma pk. The estimated 
clearance was 6.0 liters/hour and the volume of distribution was 7.5 liters. The 
derived terminal half-life was 0.9 hours. Inter-individual variability was identi-
fied on clearance, the volume of distribution, and the absorption rate constant 
for mph-oros. The s/p ratio was 2.44 from 2.5 hours onward. Inter-individual 
variability was identified in the s/p ratio. 
With proper allometric scaling techniques, we expect that this pk model 
can used in children to predict the concentration-time profile in the plasma 
using mph concentrations measured in saliva samples. Further studies are 
needed to determine the predictive performance of the model in children with 
adhd.
non-inva sive monitoring of pharmacokinetics and pharmacodynamics  





variability in central compartment volume, and height-dependent and age- 
dependent variability in intercompartment clearance. 
Smooth pursuit performance and vas Alertness were selected as biomark-
ers for pk/pd modelling based on an exploratory meta-analysis of all relevant 
alcohol data. The relationship between alcohol concentration and the effects 
of alcohol on baseline smooth pursuit performance and vas Alertness score 
was described best as being dose-dependent, with no indications of delay or 
tolerance. Higher baseline performance for smooth pursuit was correlated 
with a larger absolute decrease in performance. No covariates were identified 
for the relationship between alcohol concentration and effect with respect to 
smooth pursuit performance or vas Alertness score. 
The covariates that were identified in our pk model may be (in)directly relat-
ed to differences between adolescents and adults, as considerable age-related 
and maturity-related changes in body composition occur during adolescence. 
vas Alertness and smooth pursuit eye movements may not necessarily repre-
sent all of the alcohol-related effects on the cns, and we cannot exclude the 
possibility that sensitivity to other alcohol-related pharmacodynamics effects 
change with age. Unfortunately, other sensitive functional biomarkers for 
alcohol effects were less suitable for developing a pk/pd model, as the small 
effect in adolescents and the high number of non-responders precluded our 
ability to quantify the adolescent data and evaluate an age-dependent effect. 
Therefore, whether sensitivity to other alcohol-related pharmacodynamics 
effects changes with age remains to be determined. 
chapter 8: pharmacokinetics of prolonged-release 
melatonin mini-tablets in children with both autism 
spectrum disorder and a sleep disorder 
Melatonin is one of the cns drugs identified by the ema as having a pediatric 
therapeutic need. This includes the need to develop an age-appropriate sus-
tained-release formulation and the need to collect data regarding melatonin’s 
that described saliva caffeine concentrations in adults >1 hour after adminis-
tration as a fraction (0.68) of plasma concentration (i.e., the s/p ratio was 0.68). 
Before 1 hour after administration, saliva caffeine concentrations could not be 
described as a linear fraction; therefore, caffeine’s early effects in adolescents 
were not suitable for inclusion in a pk/pd model. 
We conclude that in healthy, alert adolescents, 90 mg caffeine has signif-
icant effects on parameters regarding alertness and reaction speed, despite 
the relatively low dose and the expected ceiling effect in this healthy and alert 
population. Whether these effects observed in adolescents are larger in ado-
lescents than in adults remains to be determined. 
chapter 7: comparison of the pharmacokinetics and 
effects of alcohol on objective and subjective biomarkers 
between healthy adolescents and adults
Our understanding of age-dependent differences in pk and pd of cns drugs 
is based almost entirely on animal models. In this study, we used a pk/pd 
modeling approach to compare the objective and subjective responses to 
alcohol between adolescent and adult subjects. The acute effect of consum-
ing a socially accepted dose of alcohol (two standard units) was determined 
in 16-18-year-old adolescents. Blood alcohol concentration was measured 
non-invasively using end-expired breath samples. A pk/pd model was then 
developed by combining the data obtained from this study in adolescents with 
data obtained from previous alcohol studies (using the clamping method) per-
formed in adults. This model was used to characterize alcohol’s pk and effects 
on an objective biomarker and a subjective biomarker and to explore potential 
sources of variability, including age. 
A two-compartment structural model with first-order absorption and 
Michaelis-Menten elimination provided the best description of estimat-
ed plasma alcohol pk. Inter-individual variability was identified for several 
kinetics parameters, with lean body weight-dependent variability in periph-
eral compartment volume and maximum elimination, weight-dependent 
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about the burden and duration of the study. Nearly all subjects (69%) and care-
givers (88%) stated that they would consider (consent for) participating in a 
similar trial again.
We conclude that this study demonstrates the short-term safety, accept-
ability, and prolonged-release profile of Circadin mini-tablets in 16 school-age 
children and adolescents with asd. 
chapter 9: pharmacokinetics and pharmacodynamics 
of a new highly concentrated intranasal midazolam 
formulation for conscious sedation
Because of its rapid onset and rapid recovery profile, midazolam is the med-
ication of choice for providing conscious sedation and management of 
epileptic seizures. Nasal delivery of midazolam is a non-invasive alternative 
to intravenous administration. However, previous formulations for delivering 
midazolam nasally have not been very successful due to the lack of solvents 
that can dissolve midazolam at therapeutic dosages without causing nasal 
mucosa damage.
In the study described in chapter 9, the pharmacokinetics of two doses 
of a novel highly concentrated aqueous intranasal midazolam formulation 
(Nazolam) was characterized. In this four-way crossover, double-blind, dou-
ble-dummy, randomized, placebo-controlled study, 16 subjects received 2.5 mg 
Nazolam, 5.0 mg Nazolam, 2.5 mg intravenous midazolam or placebo on dif-
ferent occasions. Pharmacokinetics of midazolam and _-hydroxy-midazolam 
were characterized and related to outcome variables for sedation (saccadic 
peak velocity, the Bond and Lader Visual Analogue Scale for sedation, the sim-
ple reaction time task and the Observer’s Assessment of Alertness/Sedation). 
The onset and duration of the pharmacological effect were evaluated and 
compared to intravenous midazolam using the biomarker saccadic peak 
velocity (spv), as a relationship between spv reduction and clinical efficacy has 
been described. Nasal tolerance was evaluated through subject reporting and 
ent examination.
pk, efficacy, and safety in children with autism spectrum disorder (asd) 
and a sleep disorder. The study described in chapter 8 is part of a Pediatric 
Investigation Plan (pip) under the Pediatric Regulation. This was a cross-over 
ascending dose study of Circadin (1 mg 3-mm diameter mini-tablets), a pro-
longed-release melatonin formulation. In this study, the pk profile, safety, and 
acceptability of Circadin were evaluated in 16 children and adolescents with 
autism and a sleep disorder. We tested 2-mg and 10-mg doses of Circadin based 
on the dose range we will use in an upcoming efficacy trial, which is also part 
of the development plan. To minimize the number of samples taken during 
the night, Circadin was administered in the early morning. The first occasion 
included a 24-hour baseline measurement day. Whole-saliva samples were 
collected non-invasively from passive drool, and melatonin concentration was 
measured. Urine samples were collected for determination of the metabolite 
6-sulphatoxymelatonin (6-smt). Adverse events were monitored throughout 
the study, and sedative effects were assessed using the Observer’s Assessment 
of Alertness/Sedation (oaa/s) scale for 10 hours after administration. pk param-
eters for melatonin were estimated using non-compartmental modeling. 
All 16 subjects (12 male, 4 female; age range: 7-15 years) had a clinical diag-
nosis of autism spectrum disorder (based on dsm-iv-tr criteria). All reported 
side effects were consistent with known side effects. Mini-tablets were found 
to be both safe (i.e., none of the children choked) and acceptable to the chil-
dren. The melatonin concentration peaked within two hours of administration 
and remained elevated for several hours thereafter. Circadin exposure was 
dose-linear, and clearance (1,000 l/hr) was similar between the dose groups. 
The median apparent terminal half-life was comparable between dosages. 
The mean total 6-smt recovered from urine during the baseline period was 4.2 
µg/12 daytime hours and 13.5 µg/12 nighttime hours. Following administration 
with Circadin 2 mg, the mean amount of total 6-smt recovered from urine was 
989.5 µg/12 daytime hours and 95.3 µg/12 nighttime hours. The highest levels of 
sedation (assessed using the oaa/s) were observed between 2 and 3 hours after 
administration of Circadin 2 mg and between 2 and 6 hours after administra-
tion of Circadin 10 mg. Overall, the subjects and their caregivers were positive 
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in chapters 5 and 6 attempted to investigate and quantify the sources of this 
variability using a population pk modeling approach. We showed that the rela-
tionship between plasma and saliva concentrations of mph is stable beyond 
2.5 hours and of caffeine beyond one hour after administration. Prior to these 
time points, the relationship between plasma and saliva concentrations was 
not linear; unfortunately, our efforts to correct for factors that potentially con-
tribute to variability in the s/p ratio were unsuccessful. The number of saliva 
samples that can be collected to measure the absorption phase of compounds 
with a short Tmax (such as mph and caffeine) is limited, thus hampering the 
ability to determine the magnitude of contamination, the s/p ratio, and sourc-
es of variability in the s/p ratio directly following administration. For these 
drug types, only cns effects that occur relatively late are suitable for develop-
ing a pk/pd model using measured saliva concentrations or predicted plasma 
concentrations. However, because the pharmacological cns action of most 
compounds is delayed relative to changes in plasma concentration, saliva 
sampling may still be a viable option for this type of research. Therefore, our 
results support the further exploration of using saliva as a non-invasive meth-
od for drug profiling cns drugs. 
The non-invasive cns tests that are included in the NeuroCart battery 
are sensitive enough to detect effects of low doses of caffeine and alcohol in 
healthy adolescents, as shown by the studies described in chapters 6 and 7. 
Significant effects on parameters regarding alertness (saccadic peak veloc-
ity) and reaction time (adaptive tracking) were observed after caffeine was 
administered, despite the relatively low dose and the expected ceiling effect 
on several parameters in this cohort of healthy, alert adolescents. Because 
caffeine has been reported to produce behavioral effects (including motor 
activation and arousal) similar to the effect of classic psychostimulants such 
as cocaine and amphetamine, we proposed that these tasks could be valu-
able in pediatric studies using other cns stimulants. In the study described 
in chapter 7, a low dose of alcohol induced significant changes in smooth 
pursuit eye movements, vas Alertness score, the vas alcohol effect score, body 
sway, systolic blood pressure, and heart rate. Animal studies have revealed 
Bio-availability of Nazolam was 75%. Maximal plasma concentrations of 31 
ng/ml (cv, 42.3%) were reached after 11 minutes (2.5 mg Nazolam), and of 66 
ng/ml (cv, 31.5%) after 14 minutes (5.0 mg Nazolam). Sedation onset (based 
on -2sd spv change) occurred 1 minute after administration of 2.5 mg intrave-
nous midazolam, 7 minutes after 2.5 mg Nazolam, and 4 minutes after 5 mg 
Nazolam. Sedation duration was 85 minutes for 2.5 mg intravenous midaz-
olam, 47 minutes for 2.5 mg Nazolam, and 106 minutes for 5.0 mg Nazolam. 
clinically relevant levels of sedation (as measured using oaa/s) were achieved 
within minutes after administration. In addition, single administration was 
well tolerated and safe, and did not lead to nasal mucosa damage. 
We conclude that this study demonstrates the nasal tolerance, short-term 
safety and efficacy of this novel formulation in 16 healthy adult subjects. 
When considering the preparation time needed for obtaining venous access, 
conscious sedation can be achieved in the same time span as needed for 
intravenous midazolam. This non-invasive formulation may offer important 
advantages in conscious sedation and epilepsy and has potential for use in 
children.
chapter 10: general discussion
cns drugs are researched infrequently under the Regulation, despite the 
high need for pediatric research and development, and despite the ongoing 
increase in the use of these medicines among pediatric patients. Based on our 
data, it is unlikely that the Regulation will have a positive impact on the abil-
ity of children and adolescents to access new cns drugs (as only few new cns 
drugs are developed for adults), or on the delay in pediatric registration of cns 
drugs as described in the Introduction to this thesis. Given the high number 
of cns drugs with deferred pediatric studies, clinical trial strategies should be 
revised in a timely fashion. 
In the Introduction to this thesis, we proposed that if variability in the s/p 
ratio can be minimized or quantified, measuring the saliva drug concentration 
might be a meaningful alternative (to measuring plasma drug concentration) 
for more drug types than has seemed feasible until now. The studies described 
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be evaluated in younger age groups and in subjects with other neuropsychi-
atric disorders. A second important step, particularly considering that most 
neurological and psychiatric disorders are either chronic or recurrent, is to 
determine whether early treatment translates into an acute improvement 
in symptom-related cns functions as well as improved long-term outcome. 
Finally, as there is a need to study the effects of anesthetics and analgesics 
in children and adolescents, more experience should be gained in the field of 
pediatric pain research.
conclusion
The clinical studies included in this thesis show that non-invasive drug pro-
filing for cns stimulants or depressants is feasible in healthy adolescents and 
children and adolescents with asd. In addition, non-invasive drug profiling 
may help researchers both evaluate age-dependent pk and pd and compare 
the effect profiles of various formulations. Importantly, this approach may 
also facilitate the execution of studies included in Pediatric Investigation 
Plans under the Pediatric Regulation, thus representing an important step 
forward, particularly given the high need for pediatric research with respect 
to cns drugs. The ideal pediatric study should be executable in the subjects’ 
homes. Adult studies of novel drugs that could potentially be measured in 
saliva samples should include measurements of the s/p concentration ratio. 
Because considerable pk variability has been reported for several neuropsy-
chiatric drugs, sensitive non-invasive or minimally invasive pd measurements 
should be assessed longitudinally. In addition, pediatric studies should ideally 
include a means to compare the results with adult studies. Finally, to expand 
our knowledge regarding the acceptability and tolerability of measurement 
methods, whenever possible the study participants should be asked to com-
plete a questionnaire in order to collect information regarding the reasons 
why children and adolescents participate, as well as their perceived burden 
associated with the study.
developmental changes in the pharmacological sensitivity of gabaa-recep-
tor-mediated currents to several drugs. Therefore, these tasks could be used 
to study age-related differences in the cns effects of gaba-ergic compounds 
in pediatric drug research. Importantly, the cns tests and their duration were 
tolerated by the majority of adolescent subjects in these clinical studies. 
In the Introduction to this thesis, we raised several issues with respect to 
pediatric neuropsychopharmacology. First, the differences in neuropsychopa-
thology and pharmacology between children and adults must be recognized. 
In addition, researchers need validated tools that are appropriate for assess-
ing the efficacy and safety of cns drugs in children. Finally, special emphasis 
should be placed on formulation research. We propose that cns drug profiling 
has the potential to address all of these issues. First, cns drug profiling enables 
researchers to evaluate age-dependent effects by drawing comparisons with 
existing data collected in adults, as demonstrated by the study described 
in chapter 7. Second, several drug classes have a unique cns drug profile on 
the NeuroCart test battery, which corresponds to the drug class’ mechanism 
of action. We have demonstrated previously that these ‘‘fingerprints’ can be 
used to differentiate a drug’s stimulant and sedative properties, for example 
by evaluating effects on saccadic peak velocity. As mentioned already, the cns 
tests that are included in the NeuroCart battery are sensitive enough to detect 
low doses of caffeine and alcohol in adolescents. Functional biomarkers could 
be used to determine whether a specific drug exerts a pharmacological effect 
at a specific dose in children, and they could also be used to monitor (un)want-
ed sedative or stimulant properties of drugs in children. Third, non-invasive 
monitoring of pk and pd could facilitate the evaluation of age-appropriate for-
mulations of cns drugs for use in children, as illustrated by the clinical studies 
described in chapters 8 and 9. The ‘proof-of-pharmacology’ strategy described 
in chapter 9 may perhaps also be followed in pediatric studies on drugs for 
which extensive data exist on efficacy and safety, but for which there is only a 
need for an age-appropriate formulation.
In parallel with further refining the methods described in this thesis, sev-
eral other steps must be taken. First, non-invasive drug monitoring should 
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Dit proefschrift beschrijft de mogelijke rol van het non-invasief meten van 
farmacokinetiek en farmacodynamiek tijdens het onderzoek naar en de ont-
wikkeling van geneesmiddelen met een stimulerend of onderdrukkend effect 
op het centrale zenuwstelsel bij kinderen en adolescenten. Allereerst heb-
ben wij in twee studies met psychostimulantia (cafeïne en methylfenidaat) 
de uitvoerbaarheid van het gebruiken van speeksel als een alternatief voor 
plasma onderzocht. Ten tweede zijn neuropsychologische en neurofysiolo-
gische functies longitudinaal gemeten met de NeuroCart, een testbatterij 
die door het Centre for Human Drug Research (chdr, Leiden, Nederland) is 
ontwikkeld en non-invasieve testen bevat voor alertheid, visuomotore coör-
dinatie, motorische controle, geheugen en subjectieve geneesmiddeleffecten. 
Gebruikmakend van non-invasieve methoden zijn leeftijdsafhankelijke ver-
schillen tussen gezonde adolescenten en volwassenen in de farmacokinetiek 
en farmacodynamiek van alcohol onderzocht. Dit proefschrift sluit af met de 
rapportage van de resultaten van twee klinische studies gericht op het evalu-
eren van leeftijdsgeschikte toedieningsvormen van sedativa die mogelijk bij 
kinderen toegepast kunnen worden. 
hoofdstuk 1: introductie
De medicamenteuze behandeling van kinderen en adolescenten met aandoe-
ningen van het centrale zenuwstelsel heeft vanouds het ontwikkelprogramma 
bij volwassenen gevolgd. Vanwege verschillen in de neuropsychopathologie en 
ontwikkelingsspecifieke verschillen in de farmacokinetiek en/of farmacodyna-
miek kan de relatie tussen geneesmiddeleffect en geneesmiddelblootstelling 
bij kinderen echter niet altijd volledig worden begrepen door extrapolatie 
van informatie die is verkregen bij volwassen patiënten. Om deze reden is het 
belangrijk om leeftijdsafhankelijke verschillen in de farmacokinetiek en farma-
codynamiek nader te onderzoeken. Helaas is ons begrip van deze verschillen 
bijna volledig gebaseerd op diermodellen. Bovendien loopt de registratie van 
geneesmiddelen met een effect op het centrale zenuwstelsel bij kinderen en 
adolescenten achter bij nieuwe ontwikkelingen bij volwassenen. Deze situatie 
wordt nog verder gecompliceerd door het dalen van het aantal registraties van 
nieuwe geneesmiddelen voor psychiatrische en neurologische indicaties bij 
volwassenen. 
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Ondanks bovengenoemde factoren is het aantal kinderen en adolescenten 
dat wordt behandeld met geneesmiddelen met een effect op het centrale 
zenuwstelsel alsmede de duur van blootstelling aan deze geneesmiddelen de 
afgelopen decennia fors toegenomen. Recente Europese wetgeving (de ‘eu 
Pediatric Regulation’, de Europese pediatrische Verordening) zal waarschijnlijk 
leiden tot een toename in het aantal studies bij kinderen en tot specifieke aan-
passingen in de productbeschrijving van geneesmiddelen, doseringsadviezen 
en leeftijdsgeschikte toedieningsvormen. Er zijn verschillende uitdagin-
gen naar voren gekomen tijdens het werken binnen het raamwerk van deze 
nieuwe wetgeving en er bestaat een dringende behoefte aan gevalideerde 
meetmethoden voor het evalueren van effectiviteit en veiligheid van genees-
middelen met een effect op het centrale zenuwstelsel in de pediatrische 
populatie. Bovendien is het wenselijk dat onderzoekers proberen om de belas-
ting van kinderen en adolescenten tijdens het deelnemen aan een studie te 
verminderen door gebruik te maken van non-invasieve of minimaal-invasieve 
meetmethoden. 
De meest toegankelijke en non-invasieve manier om een geneesmiddel- 
effect in de hersenen te meten is door het bepalen van geneesmiddel-gere-
lateerde functionele activiteit van het centrale zenuwstelsel waarbij gebruik 
gemaakt wordt van methoden die voldoende sensitief en specifiek zijn. Om 
deze geneesmiddel-gerelateerde functionele activiteit te relateren aan ver-
anderingen in farmacokinetiek dienen geneesmiddelconcentraties gemeten 
te worden. Traditionele protocollen voor het meten van de farmacokinetiek 
– bijvoorbeeld door middel van meerdere afnames en verblijfskatheters of 
meerdere venapuncties – zijn ongewenst in therapeutisch geneesmiddelon-
derzoek bij kinderen. 
Om een aantal van deze beperkingen te boven te komen, zijn er andere 
verzamelmethoden voor het bepalen van de geneesmiddelconcentratie ont-
wikkeld en gevalideerd. Een voorbeeld van een dergelijke verzamelmetho de 
is speekselverzameling. Speekselverzameling heeft het bijkomende voordeel 
dat het op locatie gedaan kan worden zonder de noodzaak voor medisch-ge-
schoold personeel of gecompliceerde verrichtingen na afname van het 
monster, waardoor de belasting voor het kind nog verder wordt verminderd. 
Helaas is door variabiliteit in de speeksel:plasma concentratie (s/p) ratio het 
nut van het bepalen van speekselconcentraties van verschillende geneesmid-
delen in twijfel getrokken. Wij stellen voor dat wanneer de variabiliteit in de s/p 
ratio kan worden gekwantificeerd of geminimaliseerd, het meten van speek-
selconcentraties van een geneesmiddel een zinvol alternatief kan zijn voor het 
meten van plasmaconcentraties. 
hoofdstuk 2: de europese pediatrische verordening: 
zal het leiden tot geneesmiddelen die kinderen nodig 
hebben? 
In dit hoofdstuk wordt een studie beschreven waarin het effect van de Europese 
pediatrische Verordening (European Pediatric Regulation) is onderzocht op de 
ontwikkeling van geneesmiddelen voor kinderen, waaronder ook geneesmid-
delen met een effect op het centrale zenuwstelsel. De Verordening verplicht 
farmaceutische bedrijven om klinische studies bij kinderen te plannen tijdens 
een vroeg stadium van de ontwikkeling van nieuwe geneesmiddelen of in die 
gevallen waarin een nieuwe indicatie, toedieningsvorm of toedieningsweg 
wordt onderzocht voor volwassenen voor gepatenteerde geneesmiddelen. 
Het Pediatrische Onderzoeksplan (Pediatric Investigational Plan, pip) beschrijft 
hoe een geneesmiddel bij kinderen onderzocht moet worden. Dit plan moet 
door het bedrijf in een vroeg stadium worden aangeboden aan het Pediatrisch 
Comité (Pediatric Committee, pdco) van de ema (European Medicines Agency, 
het Europese Geneesmiddelen Agentschap), die vervolgens het plan beoor-
deelt. In deze studie hebben wij onderzocht voor welke geneesmiddelklassen 
de ema het plan voor pediatrisch onderzoek heeft goedgekeurd en voor welke 
klassen de ema akkoord is gegaan met ontheffing van de noodzaak tot het doen 
van pediatrisch onderzoek in de periode 2007 tot maart 2012. Wij zijn tevens 
nagegaan of de Verordening leidt tot de ontwikkeling van geneesmiddelklas-
sen waarvoor een (niet voldane) behoefte bestaat voor pediatrisch onderzoek 
(‘(unmet) pediatric need’) of tot de ontwikkeling van klassen met de hoogste far-
maceutische uitgaven. Bovendien hebben vijftig Nederlandse artsen die met 
kinderen werken aangegeven of zij vinden dat de geneesmiddelen (die onder 
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de Verordening voor kinderen worden ontwikkeld) daadwerkelijk nodig zijn. 
In de periode 2007 tot maart 2012 werd ongeveer tweederde van de genees-
middelen door de ema goedgekeurd voor pediatrisch onderzoek; uitstel van de 
start of afronding van maatregelen in het onderzoeksplan tot na de autorisatie 
van het geneesmiddel voor volwassenen werd door de ema gehonoreerd voor 
83% van deze geneesmiddelen. Geneesmiddelklassen en therapeutische sub-
groepen met een hoge noodzaak tot pediatrisch onderzoek op de ema Needs 
Lists, zoals geneesmiddelen met een effect op het centrale zenuwstelsel, 
werden of weinig frequent goedgekeurd voor pediatrisch onderzoek of regel-
matig ontheven van deze noodzaak. Bovendien werden geneesmiddelen die 
regelmatig worden voorgeschreven aan kinderen of adolescenten (pharmo 
Database Network, 2005-2011), maar niet altijd goed beschikbaar zijn (en hier-
door een ‘unmet pediatric need’ hebben) relatief zelden onder de Verordening 
goedgekeurd voor pediatrisch onderzoek. Geneesmiddelklassen met het laag-
ste aantal geneesmiddelen waarvoor pediatrisch onderzoek was goedgekeurd 
waren klassen met de laagste farmaceutische uitgaven. Tenslotte waren de 
vijftig Nederlandse artsen er niet van overtuigd dat de geneesmiddelen waar-
voor pediatrisch onderzoek was goedgekeurd noodzakelijk waren voor de 
klinische praktijk. 
Wij concluderen dat de belangrijkste maatregel van de Verordening niet 
noodzakelijkerwijs leidt tot toename van geneesmiddelonderzoek bij kinde-
ren van geneesmiddelklassen waarvoor een (unmet) pediatric need bestaat. De 
output van de Verordening komt overeen met farmaceutische uitgaven, waar-
schijnlijk door de ‘adult-driven’ aanpak. Door het hoge aantal geneesmiddelen 
waarvoor uitstel van onderzoek door de ema werd gehonoreerd blijft de regis-
tratie van geneesmiddelen met een effect op het centrale zenuwstelsel bij 
kinderen en adolescenten nog altijd achter bij die bij volwassenen. Wij stellen 
daarom een aantal belangrijke verbeteringen voor die nodig zijn in de imple-
mentatie van de regelgeving om ervoor te zorgen dat de Verordening leidt tot 
geneesmiddelen die kinderen en adolescenten daadwerkelijk nodig hebben. 
Bijvoorbeeld, evaluatie door de ema van een Pediatrische Onderzoeksplan (of 
verzoek om ontheffing van deze verplichting) dient te worden gebaseerd op 
de mogelijke pediatrische relevantie van het werkingsmechanisme of genees-
middelentarget en er kunnen nieuwe stimuleringsmaatregelen worden 
overwogen voor first-in-children indicaties.
hoofdstuk 3: biomarkers van acute effecten van 
methylfenidaat bij kinderen en adolescenten met 
attention-deficit/hyperactivity disorder 
Methylfenidaat (mph) is het meest frequent voorgeschreven geneesmiddel 
voor de behandeling van attention-deficit/hyperactivity disorder (adhd) bij 
kinderen. Eerder gepubliceerde studies die het effect van immediate-release 
methylfenidaat (mph-ir) onderzochten, hebben tot tegengestelde resultaten 
geleid, onder ander door verschillende bronnen van variabiliteit zoals het 
gebrek aan gestandaardiseerde biomarkers voor het meten van een genees - 
middel effect. 
De studie die wordt beschreven in hoofdstuk 3 was een systematische lite-
ratuur reviewstudie waarin sensitieve en bruikbare non-invasieve biomarkers 
werden geïdentificeerd voor het monitoren van effecten van mph-ir bij kin-
deren en adolescenten met adhd. In publicaties tot december 2009 werden 78 
gerandomiseerde, placebo-gecontroleerde klinische studies gevonden die de 
effecten op het centrale zenuwstelsel onderzochten van een enkele dosis van 
mph-ir bij kinderen of adolescenten met adhd. Om tot een redelijke mate van 
standaardisering tussen studies en testen te komen, werden de uitkomstma-
ten geclusterd in groepen van gerelateerde testen of testvarianten (‘clusters’). 
Door de progressieve bundeling van de resultaten in logische clusters kon een 
meer algemene beoordeling worden gedaan van het geneesmiddeleffect op 
groepen van vergelijkbare testen of functionele domeinen. Neurocognitieve 
clusters en individuele testen die in vijf of meer studies waren onderzocht wer-
den geëvalueerd voor consistentie in de gemeten mph effecten. 
De resultaten van deze review toonden aan dat er veel verschillende 
biomarkers worden toegepast om de effecten van mph-ir bij adhd te eva-
lueren. De volgende uitkomstmaten toonden een consistente respons op 
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een therapeutische dosis van mph in verschillende studies en verschillende 
cohorten: Continuous Performance Test, Go/no-go Task, Visual Evoked Potentials 
en verschillende observatieschalen (inclusief Following Rules Observations, 
Oppositional Behavior Observations, On-Task Behavior Observations en 
Impulsivity Behavior Observations). Het effect van mph was het best te detecte-
ren in testen en observaties gerelateerd aan motorische controle, volgehouden 
aandacht, gedeelde aandacht en impulsiviteit (controle van inhibitie); dit 
betekent dat mph acute effecten heeft op de drie kernsymptomen van adhd 
(aandachtstekort, hyperactiviteit en impulsiviteit) bij kinderen met adhd die 
een effect ondervinden van mph. 
Wij stellen voor dat de potentiële biomarkers die in deze review zijn geïden-
tificeerd mogelijk kunnen bijdragen aan de identificatie van responders versus 
non-responders na een testdosis met mph. Omdat het niet mogelijk was om 
dosis-effect relaties vast te stellen, dienen deze testen en clusters verder te 
worden onderzocht op dosis-respons relaties, inclusief de effectgrootte, en 
op klinisch relevante veranderingen. Idealiter worden in deze studies naast 
dosis-effect relaties ook concentratie-effect relaties onderzocht op verschil-
lende tijdspunten na toediening van mph, zodat het effectprofiel van mph bij 
kinderen en adolescenten met adhd kan worden vastgesteld. 
hoofdstuk 4: bepaling van methylfenidaat in plasma 
en speeksel door liquid chromatography/tandem mass 
spectrometry 
Door het monitoren van mph-concentraties kan een bijdrage worden gele-
verd aan het bepalen of de afwezigheid van een effect of de aanwezigheid van 
onverwachte bijwerkingen gerelateerd zijn aan farmacokinetische of farma-
codynamische factoren. Therapeutisch monitoren van mph-behandeling bij 
volwassenen wordt meestal gedaan door het meten van mph-concentraties 
in plasma. Bij kinderen is het afnemen van bloedmonsters echter ongewenst. 
Speeksel is mogelijk een alternatieve matrix voor het monitoren van mph-con-
centraties; echter, er zijn verschillende potentieel complicerende factoren 
naar voren gekomen in eerdere studies. Complicerende factoren waren onder 
andere indicaties van orale contaminatie in de eerste speekselsamples na 
inname van mph en een aanzienlijke – nog onverklaarde – variatie in de s/p 
ratio na toediening van zowel de tablet als de capsule. 
Het verkrijgen van een betrouwbare s/p ratio is essentieel voor het behalen 
van het volledige potentiaal van het gebruik van speekselmonsters voor het 
monitoren van mph-concentraties. Om deze reden hebben wij een analytische 
methode ontwikkeld voor het nauwkeurig kwantificeren van mph in zowel 
plasma als speeksel. In dit hoofdstuk presenteren wij de validatie van een liquid 
chromatography-tandem mass spectrometriemethode waarbij gebruik wordt 
gemaakt van een hydrophilic interaction liquid chromatography column (hilic). 
Eiwitten werden geprecipiteerd in een 100 µl monster met 750 µl acetonitri-
le/methanol 84/16 (v/v) dat d9-methylfenidaat bevatte als interne standaard. 
Er werden standaardcurves geplot over een mph-concentratiebereik van 0.5 
– 100.0 µg/l. De totale analysetijd was 45 seconden. De accuraatheid bevond 
zich in het bereik van 98-108% en de within- en between-run onnauwkeurig-
heid was minder dan 7.0%. De matrixeffecten waren groter voor plasma dan 
voor speeksel met 46% and 8% ionisatiesuppressie. De matrixeffecten werden 
adequaat gecompenseerd door het gebruik van gedeutereerd mph als interne 
standaard. mph degradeerde significant in plasma en speeksel op kamertem-
peratuur en bij een temperatuur van 5°C. Stabiliteitsexperimenten toonden 
aan dat de monsters direct na afname bij een temperatuur van -20°C of lager 
moeten worden bewaard en dat de monsters direct na ontdooien moeten 
worden verwerkt. De monsters waren voor tenminste 4 weken stabiel bij een 
temperatuur van -20°C. De methode werd met succes toegepast voor de bepa-
ling van mph-concentraties in plasma en speeksel van een volwassen gezonde 
vrijwilliger. 
Wij concluderen dat door het gebruik van eiwitprecipitatie en hydrophilic 
interaction liquid chromatography gecombineerd met tandem mass spectro-
metrie, deze methode tot een snelle, betrouwbare en correcte kwantificatie 
van mph leidt in zowel plasma als speeksel. 
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hoofdstuk 5: populatiefarmacokinetisch model van twee 
toedieningsvormen van methylfenidaat in plasma en 
speeksel van gezonde vrijwilligers 
In dit hoofdstuk wordt een studie beschreven waarin een eerste aanzet is 
gedaan om de bronnen van variabiliteit in mph plasma- en speekselconcen-
traties te kwantificeren en om de relatie tussen mph-concentratie in speeksel 
en mph-concentratie in plasma te beschrijven door middel van een populatie-
farmacokinetisch model. 
In deze gerandomiseerde, open-label studie werden 10 mg mph-ir (tablet) 
en 18 mg osmotic release oral system mph (mph-oros, capsule) gekruist toe-
gediend aan 12 volwassen gezonde vrijwilligers (zes mannen en zes vrouwen). 
Zowel bloed- als speekselmonsters werden voorafgaand aan en regelmatig 
na toediening van mph afgenomen tot 6 (mph-ir) of 11 (mph-oros) uur na 
toediening. De farmacokinetische analyses zijn uitgevoerd met het populatie-
farmacokinetieksoftwarepakket nonmem (nonlinear mixed-effect modeling). 
Farmacokinetiek van mph in plasma werd het best beschreven door een 
1-compartimentenmodel met eerste-orde-absorptie (met aparte com-
partimenten voor mph-ir en mph-oros) en eerste-orde-eliminatie. De 
geschatte klaring was 6.0 liter/uur en het distributievolume was 7.5 liter. De 
terminale halfwaardetijd was 0.9 uur. Interindividuele variabilititeit werd 
geïdentificeerd voor klaring, distributievolume en de absorptiesnelheids-
constante van mph-oros. De s/p ratio was 2.44 vanaf 2.5 uur na toediening. 
Interindividuele variabiliteit werd geïdentificeerd voor de s/p ratio. 
Wij verwachten dat dit pk model met juiste allometrische schalingstech-
nieken bij kinderen gebruikt kan worden om het concentratie/tijdsprofiel in 
plasma te voorspellen op basis van gemeten mph-concentraties in speeksel. 
De voorspellende prestatie van het model bij kinderen met adhd behoeft nog 
verder onderzoek. 
hoofdstuk 6: farmacokinetiek en effecten van cafeïne op 
parameters van het centrale and autonome zenuwstelsel 
bij adolescenten
Kinderen en adolescenten gebruiken regelmatig cafeïne als psychostimulans. 
Ondanks het veelvuldige gebruik van cafeïne door adolescenten, is er relatief 
weinig onderzoek gedaan naar de fysiologische en gedragsmatige effecten 
van cafeïne in deze leeftijdsgroep. Data uit dierstudies suggereren dat de 
effecten van cafeïne bij volwassenen niet eenvoudig geëxtrapoleerd kunnen 
worden naar adolescenten. 
Om deze reden hebben wij in deze studie het effect van cafeïne op para-
meters van het centrale en autonome zenuwstelsel onderzocht bij gezonde 
adolescenten na inname van een cafeïnehoudende drank (met een lage dosis); 
de resultaten werden vergeleken met data verkregen na inname van een cafe-
inevrije drank. Cafeïneconcentraties werden gemeten in speekselmonsters. 
In een aparte studie bij gezonde volwassenen hebben wij de mate van orale 
contaminatie met cafeïne bepaald na inname van cafeïnehoudende drank 
versus een cafeïnehoudende capsule (200 mg). Speeksel- en plasmamonsters 
werden tegelijkertijd afgenomen om de s/p ratio van de cafeïneconcentraties 
te bepalen. Een populatiefarmacokinetisch model werd opgesteld gebaseerd 
op data uit deze kinetische studie om zo de plasmaconcentraties bij de eerdere 
studie bij adolescenten te schatten; dit model kon vervolgens worden gebruikt 
om een farmacokinetiek-farmacodynamiek (pk/pd) model op te stellen. 
Cafeïne had bij adolescenten een significant effect op testparameters 
gerelateerd aan aandacht en visuomotore coördinatie (adaptive tracking task) 
en alertheid (saccadic peak velocity). Na inname van cafeïne werd bovendien 
een toename in de error rate van de attention switch task waargenomen. 
Plasmaconcentraties van cafeïne werden bij volwassenen het best beschreven 
door een 2-compartimentenmodel met een dosisdepot, eerste-orde-absorp-
tie- en eerste-orde-eliminatiekinetiek. Het plasmamodel identificeerde een 
dosis van 90 mg in de cafeïnehoudende drank. Vetvrije massa (lean body mass) 
-afhankelijke variabiliteit werd geïdentificeerd voor het volume van het 
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centrale compartiment. Het farmacokinetische model werd uitgebreid naar 
een populatiemodel waarin cafeïneconcentraties in speeksel bij volwassenen 
als een fractie (0,68) van de plasmaconcentraties werden beschreven vanaf 
1 uur na toediening; in andere woorden, de s/p ratio was vanaf 1 uur na toe-
diening 0,68. Tot 1 uur na toedining kon de speekselconcentratie niet als een 
fractie worden beschreven; om deze reden waren effecten van cafeïne die 
binnen 1 uur na toediening optraden niet geschikt voor inclusie in een pk/pd 
model. 
Wij concluderen dat 90 mg cafeïne bij gezonde adolescenten een signifi-
cant effect heeft op parameters gerelateerd aan alertheid en reactiesnelheid, 
ondanks de relatief lage dosis en het verwachte plafondeffect bij deze gezonde 
en alerte populatie. Verder onderzoek is nodig om te achterhalen of deze effec-
ten bij adolescenten groter zijn dan bij volwassenen. 
hoofdstuk 7: vergelijking tussen gezonde adolescenten 
en volwassenen van de farmacokinetiek en de effecten  
op objectieve en subjectieve biomarkers van alcohol
Ons begrip van leeftijdsafhankelijke verschillen in de farmacokinetiek en de 
farmacodynamiek van geneesmiddelen met een effect op het centrale zenuw-
stelsel is bijna volledig gebaseerd op diermodellen. In dit hoofdstuk wordt een 
studie beschreven waarin wij een pk/pd model hebben opgesteld om de objec-
tieve en subjectieve effecten van alcohol tussen adolescenten en volwassenen 
te vergelijken. Het acute effect van inname van een sociaal-geaccepteerde 
dosis alcohol (2 standaardeenheden) werd bepaald bij 16-18 jarige adoles-
centen. Alcoholconcentraties werden non-invasief gemeten door middel van 
eind-expiratoire ademmonsters. Vervolgens is een pk/pd model opgesteld aan 
de hand van data van deze studie en data van eerder uitgevoerde alcoholstu-
dies (met de clamping methode) bij volwassenen. Dit model werd gebruikt om 
de farmacokinetiek en effecten op een objectieve en op een subjectieve bio-
marker te karakteriseren en mogelijke bronnen van variabiliteit, zoals leeftijd, 
te onderzoeken. 
Alcoholkinetiek in plasma werd het beste beschreven door een 2-comparti-
mentenmodel met eerste-orde-absorptie en Michaelis-Menten-eliminatie. 
Interindividuele variabiliteit werd geïdentificeerd voor verschillende 
kinetische parameters. Er was sprake van vetvrije massa (lean body weight)-af-
hankelijke variabiliteit in het volume van het perifere compartiment en de 
maximale eliminatie, gewichtsafhankelijke variabiliteit in het volume van 
het centrale compartiment en lengte- en leeftijdsafhankelijke variabiliteit in 
intercompartimentele klaring. 
Gebaseerd op een verkennende meta-analyse van alle relevante alco-
holdata werden smooth pursuit performance en vas Alertness geselecteerd 
als biomarkers voor het opstellen van het pk/pd model. De relatie tussen 
alcoholconcentratie en de effecten van alcohol op baseline smooth pursuit 
performance and vas Alertness score werd het best beschreven als een dosis-af-
hankelijke relatie, zonder indicaties van vertraging of tolerantie. Hogere 
baseline smooth pursuit performance was gecorreleerd met een grotere abso-
lute afname in uitvoering. Voor smooth pursuit performance en vas Alertnes 
werden geen covariaten geïdentificeerd voor de relatie tussen alcoholconcen-
tratie en -effect. 
De covariaten die in ons pk-model werden geïdentificeerd kunnen (in-)
direct gerelateerd zijn aan verschillen tussen adolescenten en volwassenen, 
aangezien aanzienlijke leeftijdsafhankelijke en rijpingsafhankelijke ver-
schillen in lichaamssamenstelling optreden gedurende de adolescentie. vas 
Alertness en smooth pursuit eye movements vertegenwoordigen niet nood-
zakelijkerwijs alle alcoholgerelateerde effecten op het centrale zenuwstelsel 
en wij kunnen niet uitsluiten dat de gevoeligheid voor andere alcoholgerela-
teerde farmacodynamische effecten met de leeftijd verandert. Helaas waren 
andere gevoelige functionele biomarkers voor het effect van alcohol minder 
geschikt voor het opstellen van een pk/pd model, doordat het kleine effect bij 
adolescenten en het hoge aantal non-responders ons belette om de data bij 
adolescenten te kwantificeren en een leeftijdseffect te onderzoeken. Om deze 
reden moet nog worden vastgesteld of de gevoeligheid voor andere alcoholge-
relateerde effecten verandert met de leeftijd. 
non-inva sive monitoring of pharmacokinetics and pharmacodynamics  
for pharmacological drug profiling in children and adolescents
– 318 –
 
samenvat ting / summary in dutch 
– 319 –
hoofdstuk 8: farmacokinetiek van melatonine 
minitabletten met verlengde afgifte bij kinderen met  
een autisme spectrum stoornis en een slaapstoornis 
Melatonine is één van de middelen met een effect op het centrale zenuwstel-
sel waarvoor de ema een pediatrische therapeutische noodzaak tot onderzoek 
heeft geïdentificeerd. Dit omvat de noodzaak tot het ontwikkelen van een leef-
tijdsgeschikte toedieningsvorm met verlengde afgifte en de noodzaak tot het 
verzamelen van data over de farmacokinetiek, werkzaamheid en veiligheid bij 
kinderen met autisme en een slaapstoornis. 
De studie beschreven in hoofdstuk 8 maakt onderdeel uit van een Pe - 
diatrisch Ontwikkelplan (pip) onder de Europese pediatrische Verordening. 
Deze studie was een gekruiste studie met oplopende doseringen van Circadin 
(1 mg minitabletten met een diameter van 3 mm), een toedieningsvorm met 
verlengde afgifte. In deze studie zijn het farmacokinetische profiel, de vei-
ligheid en aanvaardbaarheid van Circadin geëvalueerd bij 16 kinderen en 
adolescenten met autisme spectrum stoornis en een slaapstoornis. Gebaseerd 
op de dosisrange in een toekomstige studie waarin de werkzaamheid zal wor-
den onderzocht (die ook onderdeel is van de pip) werden doseringen van 2 en 
10 mg getest. Om afname van monsters gedurende de nacht zoveel mogelijk 
te beperken, namen de kinderen Circadin ‘s ochtends in. De eerste studie-
dag werd voorafgegaan door een 24-uur baseline meting van melatonine. 
Speekselmonsters werden non-invasief verkregen door passief kwijlen en de 
melatonineconcentratie in de monsters werd gemeten. Urinemonsters wer-
den verzameld voor de bepaling van de metaboliet 6-sulfatoxymelatonine 
(6-smt). Gedurende de studie werd gemonitord voor het optreden van bijwer-
kingen en sedatieve effecten werden geëvalueerd door middel van afname van 
de Observer’s Assessment of Alertness/Sedation (oaa/s) schaal tot 10 uur na toe-
diening. De farmacokinetische analyses zijn uitgevoerd met nonmem. 
Alle 16 deelnemers (12 man, 4 vrouw; leeftijd: 7-15 jaar) hadden de klinische 
diagnose autisme spectrum stoornis (gebaseerd op dsm-iv-tr criteria). Alle 
gerapporteerde bijwerkingen waren bekende bijwerkingen van melatonine. 
De minitabletten waren veilig (geen van de kinderen verslikte zich) en wer-
den door de kinderen geaccepteerd. De piekconcentratie trad binnen 2 uur 
op en melatonineconcentraties bleven gedurende enkele uren hierna ver-
hoogd. Blootstelling aan Circadin was dosis-lineair en de klaring (1.000 l/u) 
was vergelijkbaar tussen de dosisgroepen. De terminale halfwaardetijd was 
vergelijkbaar tussen de doseringen. De gemiddelde hoeveelheid urine 6-smt 
tijdens de baseline periode was 4,2 µg (gedurende de eerste 12 uren overdag) 
en 13,5 µg (gedurende de volgende 12 uren ’s nachts). Na toediening van 2 mg 
Circadin was de gemiddelde hoeveelheid urine 6-smt 989,5 µg (gedurende de 
eerste 12 uren overdag) en 95,3 µg (gedurende de volgende 12 uren ’s nachts). 
De hoogste sedatiescores (oaa/s) traden op tussen 2 en 3 uur na toediening van 
2 mg Circadin en tussen 2 en 6 uur na toediening van 10 mg Circadin. De deel-
nemers en hun verzorgers waren in het algemeen positief over de belasting en 
duur van de studie. Bijna alle deelnemers (69%) en verzorgers (88%) zouden 
(toestemming voor) deelname aan een vergelijkbare studie weer overwegen. 
Wij concluderen dat deze studie de korte termijn veiligheid en aan-
vaardbaarheid aantoont en het farmacokinetische profiel van verlengde 
afgifte demonstreert van Circadin minitabletten bij 16 schoolgaande kinderen 
en adolescenten met autisme spectrum stoornis. 
hoofdstuk 9: farmacokinetiek en farmacodynamiek 
van een nieuwe hoog-geconcentreerde intranasale 
toedieninsgvorm van midazolam voor matige sedatie
Vanwege de snelle werking en het snelle herstel is midazolam het genees-
middel van eerste keus voor het verkrijgen van matige sedatie (voorheen ook 
wel conscious sedation genoemd) en de management van epileptische aan-
vallen. Nasale toediening van midazolam is een non-invasief alternatief voor 
intraveneuze toediening. Eerder ontwikkelde nasale toedieningsvormen van 
midazolam zijn weinig succesvol gebleken door het gebrek aan solvens waarin 
midazolam in therapeutische doseringen kan worden opgelost zonder dat er 
schade ontstaat aan de nasale mucosa. 
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In de studie die wordt beschreven in hoofdstuk 9 is de farmacokinetiek van 
twee doseringen van een nieuwe hoog-geconcentreerde waterige intranasale 
toedieningsvorm van midazolam (Nazolam) gekarakteriseerd. In dit vier-weg 
gekruiste, dubbelblinde, dubbel-dummy, gerandomiseerde, placebo-gecon-
troleerde onderzoek ontvingen 16 volwassen deelnemers 2,5 mg Nazolam, 
5,0 mg Nazolam, 2,5 mg intraveneuze midazolam of placebo op verschillende 
studiedagen. De farmacokinetiek van midazolam en _-hydroxy-midazolam 
werden gekarakteriseerd en gerelateerd aan uitkomstvariabelen voor seda-
tie (saccadic peak velocity, Bond and Lader Visual Analogue Scale for sedation, 
simple reaction time task en de Observer’s Assessment of Alertness/Sedation). 
De aanvang en duur van het farmacologische effect werden geëvalueerd en 
vergeleken met intraveneus toegediende midazolam door middel van de 
biomarker saccadic peak velocity (spv), aangezien er een relatie is beschreven 
tussen afname in de spv en klinische werking. Nasale tolerantie werd geëva-
lueerd op basis van spontane rapportage door deelnemers en onderzoek van 
de neus. 
De biologische beschikbaarheid van Nazolam was 75%. Maximale plasma-
concentraties van 31 ng/ml (cv, 42.3%) werden bereikt na 11 minuten (2,5 mg 
Nazolam) en van 66 ng/ml (cv, 31.5%) na 14 minuten (5,0 mg Nazolam). De aan-
vang van sedatie (gebaseerd op een -2sd verandering in spv) trad 1 minuut na 
toediening van 2,5 mg intraveneuze midazolam, 7 minuten na 2,5 mg Nazolam, 
en 4 minuten na 5 mg Nazolam op. Duur van de sedatie was 85 minuten voor 
2,5 mg intraveneuze midazolam, 47 minuten voor 2,5 mg Nazolam en 106 
minuten voor 5,0 mg Nazolam. Klinisch relevante levels van sedatie (gemeten 
door middel van de oaa/s) werden binnen minuten na toediening bereikt. De 
eenmalige toediening werd bovendien goed verdragen, was veilig en leidde 
niet tot beschadiging van de nasale mucosa. 
Wij concluderen dat deze studie de nasale tolerantie, korte-termijn vei-
ligheid en werkzaamheid van deze nieuwe formulering aantoont bij 16 
volwassen gezonde deelnemers. Matige sedatie kan in hetzelfde tijdbestek 
worden behaald indien de voorbereidingstijd die nodig is voor het verkrijgen 
van een intraveneuze toegangsweg overwogen wordt. Deze non-invasieve 
toedieningsvorm heeft potentieel belangrijke voordelen voor matige sedatie 
en epilepsie en heeft een mogelijke toepassing bij kinderen.
hoofdstuk 10: algemene discussie
Geneesmiddelen met een effect op het centrale zenuwstelsel worden onder 
de Verordening relatief weinig frequent onderzocht, ondanks de noodzaak tot 
pediatrisch onderzoek en de aanhoudende toename in het gebruik van deze 
geneesmiddelen bij kinderen en adolescenten. Afgaande op onze data is het 
onwaarschijnlijk dat de Verordening een positieve uitwerking zal hebben op 
de toegang van kinderen en adolescenten tot nieuwe geneesmiddelen met 
een effect op het centrale zenuwstelsel (aangezien er weinig van dit soort 
nieuwe geneesmiddelen voor volwassenen wordt ontwikkeld) of op de vertra-
ging in pediatrische registratie van deze geneesmiddelen, zoals beschreven in 
de Introductie van dit proefschrift. Aangezien de meerderheid van de ontwik-
kelplannen voor geneesmiddelen met een effect op het centrale zenuwstelsel 
uitgestelde onderdelen bevat, is het belangrijk om clinical trial strategies tijdig 
te herzien. 
In de Introductie van dit proefschrift stelden wij voor dat wanneer de vari-
abilititeit in de s/p ratio gekwantificeerd of geminimaliseerd kan worden, het 
meten van geneesmiddelconcentraties in speeksel een zinvol alternatief kan 
zijn voor het meten van geneesmiddelconcentraties in plasma voor meer 
geneesmiddelen dan tot op heden is aangenomen. De studies beschreven in 
hoofdstuk 5 en 6 zijn een aanzet om deze bronnen van variabiliteit te onder-
zoeken en te kwantificeren door middel van een populatiefarmacokinetische 
model. Wij toonden aan dat de relatie tussen plasma- en speekselconcentra-
ties voor mph stabiel is vanaf 2,5 uur na toediening en voor cafeïne vanaf 1 uur 
na toediening. Voorafgaand aan deze tijdspunten was de relatie niet lineair; 
helaas waren onze pogingen om te corrigeren voor factoren die mogelijk bij-
dragen aan de variabiliteit in de s/pratio niet succesvol. Voor geneesmiddelen 
met een korte Tmax (zoals mph en cafeïne) is het aantal speekselmonsters dat 
verzameld kan worden om de absorptiefase vast te stellen beperkt, waar-
door de bepaling van de mate van contaminatie, de s/pratio en bronnen van 
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variabiliteit in de eerste periode na toediening wordt belemmerd. Voor dit type 
geneesmiddelen zijn alleen effecten die relatief laat optreden geschikt voor 
het opstellen van een pk/pd model gebaseerd op gemeten speekselconcentra-
ties of geschatte plasmaconcentraties. Speekselafname is echter mogelijk nog 
steeds een nuttige optie voor dit type onderzoek, omdat het farmacologische 
effect op het centrale zenuwstelsel van de meeste geneesmiddelen vertraagd 
is ten opzichte van veranderingen in de plasmaconcentratie. Om deze reden 
ondersteunen onze resultaten het verder onderzoeken van het gebruik van 
speeksel als een non-invasieve methode voor het profileren van geneesmidde-
len met een effect op het centrale zenuwstelsel. 
De non-invasieve testen die opgenomen zijn in de NeuroCart testbatte-
rij zijn voldoende gevoelig om effecten van lage doseringen van cafeïne en 
alcohol bij gezonde adolescenten te detecteren (zoals wij aantoonden in 
hoofdstuk 5 en 6). Na toediening van cafeïne werden significante effecten 
gezien op parameters gerelateerd aan alertheid (saccadic peak velocity) en 
reactietijd (adaptive tracking), ondanks de relatief lage dosering en het ver-
wachtte plafondeffect in dit cohort van gezonde en alerte adolescenten. 
Omdat gerapporteerd is dat cafeïne vergelijkbare effecten heeft op het gedrag 
(zoals motorische activatie en arousal) als klassieke psychostimulantia zoals 
cocaïne en amfetamine, zijn deze testen mogelijk van toegevoegde waarde in 
pediatrische studies met andere stimulantia. Een lage dosering alcohol leidde 
tot significante veranderingen in smooth pursuit eye movements, vas Alertness 
score, vas alcohol effect score, body sway, systolische bloeddruk en hartfre-
quentie. In diermodellen zijn ontwikkelingsgerelateerde veranderingen 
beschreven in de farmacologische gevoeligheid van gabaa-receptor-geme-
dieerde currents in reactie op verschillende geneesmiddelen. Om deze reden 
kunnen deze taken wellicht gebruikt worden om leeftijdsafhankelijke veran-
deringen te onderzoeken in de effecten van geneesmiddelen die aangrijpen op 
gaba. De meerderheid van de adolescente deelnemers verdroeg de testen en 
de testduur goed. 
In de Introductie van dit proefschrift brachten wij een aantal punten naar 
voren ten aanzien van neuropsychofarmacologie. Ten eerste is het belangrijk 
om de verschillen in neuropsychopathologie en –farmacologie tussen kin-
deren en volwassenen te erkennen. Bovendien bestaat bij onderzoekers de 
behoefte aan gevalideerde methoden die geschikt zijn voor de evaluatie 
van de werkzaamheid en veiligheid van geneesmiddelen met een effect op 
het centrale zenuwstelsel. Tenslotte moet er nadruk worden gelegd op het 
onderzoek naar toedieningsvormen. Wij stellen voor dat het profileren van 
geneesmiddelen met een effect op het centrale zenuwstelsel het potentiaal 
heeft om een bijdrage te leveren aan al deze punten. Ten eerste kunnen leef-
tijdsafhankelijke effecten worden geëvalueerd door het geneesmiddelprofiel 
bij kinderen of adolescenten te vergelijken met een (reeds eerder vastgesteld) 
profiel bij volwassenen, zoals gedemonstreerd is door de studie beschreven in 
hoofdstuk 7. Ten tweede laten verschillende geneesmiddelklassen een uniek 
effectprofiel zien op de testen uit de NeuroCart testbatterij dat overeenkomt 
met het werkingsmechanisme van het middel. Wij hebben eerder voorgesteld 
dat deze ‘vingerafdrukken’ gebruikt kunnen worden om te differentiëren tus-
sen een stimulerende en sedatieve geneesmiddeleigenschap, bijvoorbeeld 
door het effect op saccadic peak velocity te onderzoeken. Zoals reeds genoemd, 
zijn de testen in de NeuroCart voldoende gevoelig om de effecten van een lage 
dosering cafeïne of alcohol bij adolescenten te detecteren. Functionele bio-
markers kunnen worden gebruikt om te bepalen of een specifiek geneesmiddel 
bij kinderen of adolescenten in een bepaalde dosering tot een farmacologisch 
effect leidt. Deze biomarkers kunen ook worden gebruikt om (on)gewenste 
sedatieve of stimulerende eigenschappen van geneesmiddelen bij kinderen 
en adolescenten te onderzoeken. Ten derde kan het non-invasief monitoren 
van de farmacokinetiek en farmacodynamiek onderzoek naar toedienings-
vormen bij kinderen en adolescenten vereenvoudigen, zoals geïllustreerd door 
de studies die zijn beschreven in hoofdstuk 8 en 9. De ‘proof-of-pharmacology’ 
strategie die is beschreven in hoofdstuk 9 kan wellicht ook worden gevolgd bij 
pediatrische studies waarin een leeftijdsgeschikte toedieningsvorm wordt 
onderzocht voor een geneesmiddel waarvoor reeds veel data bestaan over de 
werkzaamheid en veiligheid. 
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Verschillende stappen moeten worden ondernomen in aanvulling op verdere 
verfijning van de methoden die in dit proefschrift zijn beschreven. Allereerst 
moet non-invasieve monitoring van geneesmiddelen worden geëvalueerd 
bij jongere kinderen en bij kinderen met andere neuropsychiatrische aandoe-
ningen. Een tweede belangrijke stap, met name gezien het feit dat de meest 
neurologische en psychatrische aandoeningen een chronisch of recidiverend 
karakter hebben, is het bepalen of vroege behandeling leidt tot acute ver-
betering van symptoomgerelateerde functies van het centrale zenuwstelsel 
en verbeterde lange-termijn uitkomsten. Tenslotte, vanwege de noodzaak 
om de effecten van anesthetica en analgetica te onderzoeken bij kinderen en 
adolescenten, dient er meer ervaring te worden op gedaan op het gebied van 
pediatrisch pijnonderzoek. 
Conclusie
De klinische studies beschreven in dit proefschrift tonen aan dat het non-in-
vasief vaststellen van een geneesmiddelprofiel van geneesmiddelen die het 
centrale zenuwstelsel stimuleren of onderdrukken uitvoerbaar is bij gezon-
de adolescenten en bij kinderen en adolescenten met een autisme spectrum 
stoornis. Deze aanpak draagt bij aan de evaluatie van leeftijdsafhankelijke 
verschillen in farmacokinetiek en farmacodynamiek en de vergelijking van 
effectprofielen van verschillende toedieningsvormen van hetzelfde genees-
middel. Deze aanpak vergemakkelijkt mogelijk bovendien de uitvoering 
van studies die onderdeel zijn van een Pediatrisch Ontwikkelplan onder de 
Verordening; gezien de noodzaak voor pediatrisch onderzoek op het gebied 
van geneesmiddelen met een effect op het centrale zenuwstelsel zou dit 
een belangrijke stap zijn. De ideale pediatrische studie dient zo opgesteld te 
zijn dat deze in de thuissituatie kan plaatsvinden. De s/p ratio moet worden 
bepaald in studies bij volwassenen met nieuwe geneesmiddelen waarvan 
de concentraties mogelijk in speekselmonsters kunnen worden gemeten. 
Omdat aanzienlijke variabiliteit in de farmacokinetiek is beschreven voor ver-
schillende geneesmiddelen voor neuropsychiatrische aandoeningen, dienen 
gevoelige non-invasieve of minimaal-invasieve farmacodynamische metin-
gen longitudinaal te worden verricht. Pediatrische studies dienen bovendien 
zo te zijn opgesteld dat een vergelijking met studies bij volwassenen mogelijk 
is. Tenslotte, om onze kennis over de aanvaardbaarheid van verschillende 
meetmethoden te vergroten is het nodig (indien mogelijk) deelnemers te vra-
gen een vragenlijst in te vullen om zo informatie te verzamelen over de redenen 
van deelname en over de ervaren onderzoeksbelasting.
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